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Short running head: Circulating methylated biomarkers for colorectal cancer monitoring
2What is already known about this subject?
► Cancer mutations (eg, BRAF, KRAS, TP53), in cell-free circulating DNA could be used
as markers of treatment response or disease relapse in patients with colorectal cancer but
require prior knowledge of individual gene variants.
► DNA methylation alteration is a common early event in colorectal carcinogenesis and is
detectable in cell-free circulating DNA; hence it was studied for early detection (eg, SEPT9)
or tumour monitoring (eg, NPY,WIF1).
► Previous identification of methylated markers most often relied on assessment of few
samples with low genome coverage methods and might have omitted important putative
cancer-specific markers.
What are the new findings?
► Genome-wide DNA methylation analysis from stroma-free colorectal cancer cells
identifies highly prevalent and specific methylated loci (EYA4, GRIA4, ITGA4, MAP3K14-
AS1 and MSC).
► Assessment of methylated markers in cell-free circulating DNA allows non-invasive
monitoring of disease.
► DNA shedding of methylated markers is not impaired by treatment type or duration.
► Methylation changes over time correlate with tumour response evaluated by CT scan in
patients with metastatic colorectal cancer treated with chemotherapy or targeted agents.
How might it impact on clinical practice in the foreseeable future?
► This panel of methylated markers was able to monitor tumour burden in patients with
colorectal cancer treated with different conventional treatment regimens, including
chemotherapy, anti-angiogenic agents and targeted agents. Liquid biopsy based on
methylated markers could be coupled with imaging to improve timely therapeutic changes.




Objective Mutations in cell-free circulating DNA (cfDNA) have been studied for tracking
disease relapse in colorectal cancer (CRC). This approach requires personalised assay
design due to the lack of universally mutated genes. In contrast, early methylation
alterations are restricted to defined genomic loci allowing comprehensive assay design for
population studies. Our objective was to identify cancer-specific methylated biomarkers
which could be measured longitudinally in cfDNA (liquid biopsy) to monitor therapeutic
outcome in patients with metastatic CRC (mCRC).
Design Genome-wide methylation microarrays of CRC cell lines (n=149) identified five
cancer-specific methylated loci (EYA4, GRIA4, ITGA4, MAP3K14-AS1, MSC). Digital PCR
assays were employed to measure methylation of these genes in tumour tissue DNA
(n=82) and cfDNA from patients with mCRC (n=182). Plasma longitudinal assessment was
performed in a patient subset treated with chemotherapy or targeted therapy.
Results Methylation in at least one marker was detected in all tumour tissue samples and
in 156 mCRC patient cfDNA samples (85.7%). Plasma marker prevalence was 71.4% for
EYA4, 68.5% for GRIA4, 69.7% for ITGA4, 69.1% for MAP3K14-AS1% and 65.1% for
MSC. Dynamics of methylation markers was not affected by treatment type and correlated
with objective tumour response and progression-free survival.
Conclusion This five-gene methylation panel can be used to circumvent the absence of
patient-specific mutations for monitoring tumour burden dynamics in liquid biopsy under
different therapeutic regimens. This method might be proposed for assessing
pharmacodynamics in clinical trials or when conventional imaging has limitations.
4Introduction
Tumours release fragments of nucleic acids into circulation, which could provide a
minimally invasive surrogate for tissue biopsy as well as offering the opportunity of serial
sampling over time.1 2 Recent liquid biopsy studies have evaluated tumour-specific
mutations or gene copy number changes in cell-free circulating DNA (cfDNA) derived from
patients with digestive tract cancer for early diagnosis3 and for monitoring the emergence
of disease relapse.1 4–7 This approach usually relied on alterations in oncogenic drivers
such as RAS and BRAF—up to 50% of the colorectal cancer (CRC) population—or
mutations within oncosuppressor genes (usually with no variant hotspots), therefore
requiring specific assay design for each mutation. Studies mainly focused on follow-up
after surgery5 6 8 or on patients with CRC treated with epidermal growth factor receptor
(EGFR) targeted therapies,4 9 10 in which detection of oncogenic RAS alterations is
associated with impaired treatment response. Changes in epigenetic patterns are often
associated with alterations in physiological or pathological conditions triggering cell death
and release of DNA with specific epigenetic marks,11 which prompted exploring liquid
biopsy tests as a surrogate of liver fibrosis severity in individuals affected by non-alcoholic
fatty liver disease.12 Changes in DNA methylation are considered an early event in
carcinogenesis13 and have already been proposed for early tumour detection in different
settings (including CRC), allowing non-invasive population screening using stool14 15 or
blood.16–21 The Food and Drug Administration recently approved the first blood test
exclusively based on SEPT9 methylation, which might lead to improvements in CRC
screening uptake.16 17 Here we propose the evaluation of DNA methylation markers in
cfDNA, not as an early detection method, but rather as a non-invasive treatment-
monitoring assay. Review of methylation markers for early detection of CRC identified
genes which were highly tumour specific (not found in normal adjacent mucosa), but rarely
validated in large cohorts.22 While using innovative approaches and being very
5informative, studies which aimed at identifying cancer-specific methylated markers usually
relied on platforms with low genomic coverage,21 or small sample datasets,23 or
exclusively assessed patient tissue18 24 which might have been partially infiltrated with
stroma. We therefore employed genome-wide assessment of DNA methylation in a large
collection of 149 CRC cell lines and identified a fivegene panel that was validated in tissue
and cfDNA from patients with metastatic CRC (mCRC) using digital PCR-based assays
(methyl-BEAMing19 25). Longitudinal assessment of this panel in cfDNA was performed to
monitor disease burden in patients with mCRC over diverse treatment courses.
Materials and methods
Additional details are available in online supplementary file 1.
Cell lines and genome-wide DNA methylation data processing and retrieval
A collection of 149 cell lines of intestinal origin (see online supplementary file 2A) was
assembled, as described.26 Infinium HumanMethylation450 BeadChip arrays were
prepared according to manufacturer’s protocol. Cell line methylation profiles are available
on Gene Expression Omnibus (http:// www. ncbi. nlm. nih. gov/ geo/; accession number:
GSE86078). After removing ulcerative colitis cases, cancer unrelated normal mucosa
samples from GSE32146 were used as a control set. GSE41169 was employed as a blood
control dataset (ie, healthy donors). GSE4275223 was used as a test cohort for
establishing an in silico validation threshold. Level 1 data from the TCGA colorectal
adenocarcinoma (COAD/READ) (https:// gdc- portal. nci. nih. gov) were used for the in
silico validation. Further validation in normal tissues was performed using GSE48684.24
Data preprocessing and marker discovery analysis
All raw data (IDAT files) were preprocessed in R Bioconductor (minfi27). Probe signal was
removed when the detection p value was above 0.05, or >1% of the dataset contained no
6data, or if probes contained single nucleotide polymorphisms,28 demonstrated sexual
dimorphism29 or were located on sex chromosomes. Our dataset was then merged with
the other publicly available cohorts. Differential methylation analysis was performed at
probe (lmFit from limma; adjusted p≤1×10-35; minimum delta beta-value of 0.8) or region
level (bumphunter from minfi; threshold=0.8; regions represented by at least two probes
with L≥2). Methylation in leucocytes was excluded (GSE41169; maximum beta-value
allowed=0.1) to minimise the risk of false positivity in blood tests. Differentially methylated
probes were limited to those overlapping differentially methylated regions, and ‘liquid
biopsy’ assessable loci were defined as regions represented by at least two selected
probes distant of a maximum 150 bp, the average fragment size reported in cfDNA30 and
not located in centromeres or telomeres (see online Supplementary file 2B). Receiver
operating characteristic analyses were performed in GSE42752 with the pROC package in
R Bioconductor31 to establish thresholds, considering normal and adjacent mucosa as
positive outcome and cancer as negative; only loci showing a threshold below 0.35 were
kept. Each threshold was used to stratify the TCGA COAD/READ cohort, defining a
positive predictive value (PPV) and negative predictive value (NPV) for discriminating
normal adjacent from tumour tissue. Normal healthy and peritumoural samples from
GSE4868424 were also controlled for absence of methylation above the threshold. All data
used for the in silico analyses were from DNA derived from fresh frozen samples.
Methylation and genetic alteration assays for cfDNA evaluation
Assays were designed and optimised as described25 to allow methylation independent
amplification. Full details are given in online supplementary file 2C and 3. In silico
validation was performed using solely the probes which were located within the amplicon;
results for the five markers of interest are displayed in online supplementary file 4.
Evaluation of genetic alterations (KRAS, BRAF mutations and MET gene copy number) in
7cfDNA was performed as reported.4 32 Assays, commercially available (Bio-Rad), are
listed in online supplementary file 2C.
Tissue collection and DNA isolation
Formalin-fixed paraffin-embedded (FFPE) tissues originated from two different cohorts.
The first consisted of macro-dissected tumour and normal adjacent tissues (n=31 cases;
originating from several local hospitals), which were controlled for tumour purity and
assembled at Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda (Milan,
Italy) and from which DNA was newly extracted (average DNA concentration: 689 ng/μL
(59–1844)). A second dataset of independent FFPE tumour tissues (n=51) was assembled
from remaining DNA extracted during the enrolment of the DETECT-01 (EudraCT number
2011-002080- 21)33 or TEMECT (EudraCT number 2012-003338-17)34 trials (average
DNA concentration: 163 ng/μL (10–776)).
Plasma collection and DNA isolation
De-identified plasma samples (average volume 1.5 mL (0.8–1.9)) from self-declared
healthy donors (n=50) were purchased from the Brigham and Women’s Hospital specimen
bank (Boston, USA). One hundred and eighty-two mCRC cases were retrospectively
enrolled in the study. One hundred and thirty-seven cases were selected for plasma time-
points based on blood sample availability at a time when patients were presenting
radiological evidence of disease. The remaining 45 cases were treatment baseline
specimens, selected for availability of longitudinal follow-up samples (additional total of
132 longitudinal samples). The plasma volume obtained from patients with mCRC for the
study was on average 1 mL (0.5–1.4). Summary of the clinicopathological features of the
two cohorts can be found in online supplementary file 2D and patient clinical features are
presented in online supplementary file 2E. mCRC plasma samples were collected at
Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda (Milan, Italy) or at San
Giovanni Battista Hospital (Turin, Italy). The study was conducted according to Good
8Clinical Practices and was approved by the local ethics committee. Circulating DNA was
extracted as previously described25 from 1 mL of plasma or less due to limited amount
availability.
Statistics and data analyses
All methylation microarray analyses and figures were generated in R Bioconductor as
previously mentioned. Prevalence and longitudinal representations were assembled in
GraphPad. Wilcoxon test (for matched tissues analysis), Mann-Whitney U test and
Kruskall-Wallis test (for group prevalence analyses) and Mantel-Cox log rank test (for
survival analysis) were performed in GraphPad. Scatter matrix for marker correlation was
obtained using OriginPro 2016 (OriginLab). All expressed p values were calculated with
two-tailed tests and were considered significant when p≤0.05, unless otherwise specified.
Results
Marker selection and assay optimisation
Differential methylation analysis between CRC cell lines and normal mucosa identified 162
CpG dinucleotides representative of a larger genomic region controlled to be unmethylated
in blood cells which represent the main contaminant source of cfDNA (figure 1,
Supplementary file 2B and 5). Among the markers previously proposed for liquid biopsy
assessment of CRC, SEPT9 was discarded for few differentially methylated probes too
distant from each other; WIF1 was removed because of low differential methylation
between normal and tumour tissue; while NPY demonstrated positivity in normal mucosa
samples and blood cells (see online supplementary file 6). Thirty- nine loci defined by 93
probes, were selected as liquid biopsy assessable regions (see online supplementary file
5). An in silico validation (see online supplementary file 4), confirmed that the selected
methylated loci were cancer specific and not a consequence of cell line establishment and
identified six loci (five genes: EYA4, GRIA4, ITGA4, MAP3K14-AS1, MSC) capable of
9discriminating cancer from normal mucosa with a PPV of 1 and a NPV above 0.5. Short
methylation independent amplification was considered feasible for the five genes. Digital
PCR (Methyl- BEAMing) assays were designed and their sensitivity and specificity were
reassessed in silico using the probes located within the amplicon (see online
supplementary file 4). The quantitative aspect of the assay was privileged over sensitivity,
for better serving the purpose of monitoring tumour burden in advanced disease patients.
Digital MIQE checklist can be found in online supplementary file 3.
Assessment of methylation markers in tissue from patients with CRC
Methylation status was evaluated in FFPE tissue DNA for the five markers defined above
(EYA4, GRIA4, ITGA4, MAP3K14-AS1, MSC). Amplification was successful in all cases.
Significantly higher methylation levels were observed in tumour tissue compared with their
normal counterpart (p<0.0001), and remained high in an independent set of non-macro-
dissected tumour specimens (figure 2). Average methylation (and range) for normal
tissues was 0.6% (0–3), 7.9% (0–28), 0.5% (0–9), 0.3% (0–2) and 2.3% (0–12) for EYA4,
GRIA4, ITGA4, MAP3K14-AS1, MSC, respectively. Average methylation (and range) for
matched tumour tissues was 42.2% (0–92), 67.1% (18–97), 51.7% (2–96), 43.5% (0–97)
and 71.5% (31–97) for EYA4, GRIA4, ITGA4, MAP3K14-AS1, MSC, respectively.
Detection of methylation markers in cfDNA of healthy individuals and patients with
CRC
Plasma samples were obtained from a cohort of self-declared healthy individuals
deliberately chosen above age 40 (n=50), and from a cohort of patients with mCRC
(n=182). Methylation status was evaluated in a total of 364 cfDNA samples for the five
markers (Figure 1 and online supplementary file 2G). Amplification was successful in all
samples but one for GRIA4 (0.3%), four cases for ITGA4 (1.1%) and seven for MSC (1.9%)
(online supplementary file 2G).
Marker prevalence in cfDNA
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Considering only non-longitudinal mCRC samples from individual patients for prevalence
purpose (figure 1), all markers showed significant differences in methylation distribution
between self-declared healthy donors and patients with mCRC (U test: p<0.0001, Figure
3A–E and online supplementary file 2G). Average methylation (and range) for self-
declared healthy donors was 0.5% (0–7.8), 0.5% (0–17), 0.2% (0–2.2), 0% (0–0.2) and 0%
(0–0.6) for EYA4, GRIA4, ITGA4, MAP3K14-AS1, MSC, respectively. Average methylation
(and range) for non-longitudinal mCRC samples was 26.2% (0–98.4), 33.5% (0–99.7),
33.2% (0–99), 26.3% (0–100) and 37.9% (0–100) for EYA4, GRIA4, ITGA4, MAP3K14-
AS1, MSC, respectively. Receiver operating characteristic curve (ROC) analyses were
performed for each marker in order to evaluate their performance and establish a clinically
relevant positivity threshold to discriminate self-declared healthy donors from patients with
mCRC (see online Supplementary file 7). Cut-off values were 0.7% for EYA4, 0.79% for
GRIA4, 1.06% for ITGA4, 0.24% for MAP3K14-AS1, 0.9% for MSC and 0.68% when
averaging the five markers. Only two plasma samples from healthy donors showed an
average methylation above the threshold (Figure 3G). This was due to high methylation
values in GRIA4 and EYA4 for one individual (aged 43 years), and in EYA4 for the second
(aged 62 years). One hundred and thirty-nine (76%) patients with mCRC displayed an
average methylation above the threshold. Positivity, defined as the methylation value over
cut-off thresholds and number of methylated events above the limit of blank (LOB), was
observed in 71.4% for EYA4, 68.5% for GRIA4, 69.7% for ITGA4, 68.1% for MAP3K14-
AS1, 65.1% for MSC, respectively. Considering that positivity in a single marker would be
enough to track tumour burden, we evaluated that 156 cases (86%) showed positivity in at
least one marker. When methylation values were positive, all markers were correlated
(figure 3H and online Supplementary file 8). Total DNA amount assessed by genome
equivalent per millilitre also significantly discriminated self-declared healthy donors from
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patients with mCRC, although with lower specificity (Figure 3F and online Supplementary
file 7).
Marker prevalence in tumour tissue and matched metachronous cfDNA samples
Tumour tissue DNA and matched metachronous cfDNA samples were available for a small
subset of patients for which primary tumour had been resected (n=39). Marker negativity in
cfDNA samples was not explained by absence of methylation in the matched tumour
tissue counterpart (see online Supplementary file 9).
Association between cfDNA methylation and clinicopathological features
Using univariate analyses, age, treatment status and BRAF or RAS oncogenic mutations
were not associated with different methylation values (see online Supplementary file 10;
Supplementary file 2). High carcinoembryonic antigen (CEA) level (>5 ng/mL) showed a
non-significant trend for higher methylation values in cfDNA (p=0.11). Male gender was
significantly associated with lower methylation values (p=0.029), while the presence of
unresected primary tumour (p=0.002), bulky disease (defined as massive tumour
involvement of >50% of liver or lungs; p=0.012) or multiple metastatic lesions (p=0.023)
were significantly associated with higher methylation values. The sum of target lesions as
per Response Evaluation Criteria for Solid Tumours (RECIST)35 from available CT scans
was also associated with high methylation in the highest quartiles. Altogether these
findings strongly suggest an association between release of methylated cfDNA and tumour
burden.
Longitudinal assessment
Among the 182 patients with mCRC, 45 were followed-up longitudinally (figure 1); of those,
seven were excluded due to absence of any positive marker at baseline (n=6) or
inadequate follow-up (n=1). Methylation changes, between baseline and longitudinal
plasma samples (obtained within 20 days from the first radiological evaluation) were
annotated with the tumour response status to therapy (see online Supplementary file 11).
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Significant lower methylation values were detected in samples collected close to
radiological assessment of clinical benefit (defined as objective disease stabilisation or
partial response as per RECIST criteria) for all markers but EYA4. In comparison, samples
collected close to documented objective tumour progression showed a non-significant
trend towards increased methylation values for all markers. This suggests that cfDNA
methylation changes could be associated with tumour burden dynamics. Therefore, we
investigated whether longitudinal follow-up of methylation could track tumour burden over
time. For this purpose, for each longitudinal time-point an average of selected markers
(ASM) was calculated based exclusively on the loci which displayed positive methylation in
the baseline.
Monitoring of mCRC response to conventional chemotherapy
Ten cases received conventional chemotherapy regimens (FOLFOX, FOLFIRI, with or
without bevacizumab). Two cases were excluded because they were negative at baseline.
All patients carried KRAS or BRAF mutated tumours (considered as early events in
tumourigenesis) allowing correlative assessment with methylation (figure 4). ASM was
used for longitudinal monitoring. For most time-points, ASM dynamics recapitulated
tumour burden changes as assessed by imaging, with a decrease preceding partial
response or stable disease, while an increase or stable ASM anticipated progression. For
all cases with known mutations in the corresponding tissue, KRAS or BRAF mutant levels
in cfDNA paralleled the ASM. At a few time-points negative for mutation detection and
displaying low DNA amount, ASM was around 1%, which could reflect either higher
sensitivity of multiple methylated marker testing or possible overestimation of the current
assays (see online Supplementary file 12).
Monitoring of mCRC response to targeted therapy
Additional six cases with longitudinal follow-up were treated with the EGFR targeted
antibody panitumumab based on RAS wild-type status (figure 1). One case displaying a
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baseline sample negative for methylation was excluded. Four out of five cases (figure 5)
demonstrated emergence of a resistance causative alteration at progression which could
be retrospectively analysed over time. In three individuals, progression was associated
with the emergence of KRAS alterations (figure 5A-C),4 in one by MET gene
amplification32 (figure 5D). In all cases, ASM increased in parallel with the emergence of
the resistance causative alteration. However, ASM values in plasma were much more
abundant than the percentage of mutant KRAS alleles in two cases. In two patients,
panitumumab was followed at progression by standard chemotherapy (irinotecan) that was
associated with decrease of KRAS cfDNA level independently of the methylation dynamics.
The remaining case for which the molecular mechanism of resistance to EGFR target
therapy remained unexplained could still be monitored in cfDNA with an increase in the
ASM value at progression (figure 5E).
Application of methylated circulating DNA monitoring in a clinical trial with
temozolomide in chemorefractory mCRC with MGMT hypermethylation
We investigated the use of methylated cfDNA in 29 cases from the TEMECT trial
(EudraCT number 2012-003338-17), which assessed efficacy of temozolomide treatment
in patients with chemorefractory mCRC selected based on their O-6-methylguanine- DNA
methyltransferase (MGMT) methylated status in the primary tumour tissue.34 Three cases
without any positive methylated marker at baseline and one case without longitudinal
collection were excluded (figure 1). To explore whether methylated markers in liquid
biopsy could be used as a surrogate to imaging, we considered the best methylation
change over time, similarly to what is usually performed with imaging-based RECIST
criteria. To this aim, the ASM at a longitudinal timepoint was subtracted from the ASM
value at baseline, and the best methylation change (lowest) over the course of treatment
was selected for correlative assessment with radiological response (see online
supplementary file 2I). A decrease in methylation was associated with clinical benefit as
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evaluated by RECIST (stable disease or partial response; figure 6A, PPV=0.82; NPV=0.79,
p=0.0048). Considering the best ASM change over time, a decrease in ASM was
associated with improved progression-free survival (p=0.039, HRrelapse=0.48 (0.17–0.87);
figure 6B).
Discussion
The current use of imaging for follow-up in CRC suffers from limitations potentially leading
to overtreatment, delays in treatment reorientation and potential side effects of exposure to
imaging contrast agents. The evaluation of serum protein levels such as CEA offers a
rapid and cost-effective way to measure disease evolution, but is impaired by limited
sensitivity and specificity, the latter especially during treatment courses due to
inflammation and release of protein in the bloodstream.36 Furthermore, a fraction of
patients with mCRC does not show detectable plasmatic CEA levels during the natural
history of the disease.37 Longitudinal evaluation of cancer-specific mutations in cfDNA has
been exploited to identify relapse after surgery5 or during treatment with both standard
chemotherapies and targeted agents,1 4 and it demonstrated great specificity and
sensitivity. However, these studies must rely on either mutational hotspots with partial
prevalence (only up to 50% considering all alterations of KRAS and BRAF) or on
personalised assay design after identification of a variant through massive parallel
sequencing.4 5 Alterations in methylation patterns present an advantage, as they are
limited to specific regions of the genome, allowing for a universal assay design compatible
for population studies. Moreover, their prevalence is usually high, which triggered their
implementation as early diagnostic assays.38 We confirmed the proof-of-concept work
from Garrigou et al39 that DNA methylation in cfDNA may be employed to track response
during therapy in mCRC, enabling non-invasive monitoring of tumour burden. To go
beyond previous efforts in this area, we decided to perform a marker discovery analysis
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using CRC cell lines. This strategy allowed removal of background signal coming from
stroma, which has recently been described to impair cancer signal specificity in genome-
wide analyses.40 Further validation in independent cohorts (in silico) or in tissue samples
confirmed that these markers were cancer specific and not a consequence of cell line
establishment. To our knowledge, only two studies from the same group evaluated
methylation markers dynamics in mCRC cases on treatment.39 41 In their manuscript,
Garrigou et al detected methylation of WIF1 and NPY by liquid biopsy in 80% mCRC, and
evaluated their levels over time in cfDNA from three mCRC cases under chemotherapy
treatment.39 In a follow-up study, combining WIF1 and NPY methylation Garlan et al
showed 69.2% positivity in KRAS/BRAF/TP53 wild-type mCRC.41 While these markers
were identified by Roperch et al21 using the Illumina GoldenGate methylation arrays
(lower coverage than the Illumina Infinium), they were sorted out from our pipeline. NPY
was discarded due to positivity in normal mucosa and in whole blood samples which
contain white blood cells as the main contaminant of cfDNA. WIF1 instead did not satisfy
our stringent threshold criteria due to limited differential methylation between normal
healthy/normal adjacent mucosa and tumour. Methylation of WIF1 in normal mucosa was
previously described in a small dataset42 warranting further investigation to verify the
specificity of this marker. Among other established liquid biopsy markers for CRC, SEPT9
was also filtered out from the analysis due to distance between the significantly
differentially methylated probes above the 150 bp threshold. Among the methylated loci
identified in our work, EYA4 and ITGA4 are known or putative tumour suppressor
genes,43–46 while the functional role of the other markers -GRIA4, MSC and MAP3K14-
AS1- in carcinogenesis remains to be elucidated; however, their in silico validation in
independent cohorts as well as in tissue demonstrated their reliability in identifying tumour
cells. Comparing cfDNA samples from self-declared healthy donors to patients with mCRC,
all markers showed specificity above 0.85. The less efficient marker was EYA4, which
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demonstrated low methylated values in all donor samples. Since the signal was higher
than the LOB of the assay, we hypothesised that this could be attributed to age-related
methylation in normal tissue. When evaluating plasma samples of patients with cancer, we
established positivity as methylation value above a ROC threshold (allowing the best
discrimination between healthy individuals and patients with cancer) and signal with
positive events above the LOB. While these detection thresholds efficiently define the
marker(s) to be followed over time, these assays are still suboptimal for other purposes
such as early detection or minimal residual disease assesment. Despite heterogeneity
among patients, the high prevalence of at least one methylated marker warrants including
these loci in a panel as a blood test for detection of plasma DNA of tumour origin in
patients with stage IV CRC. In our setting, all cases with intact primary CRC in situ
displayed at least one positive methylation marker, confirming that cases in which primary
lesions were not resected could be more efficiently tracked through liquid biopsy. As seen
for SEPT9,47 there was a positive correlation between cfDNA concentrations—here
measured by genome equivalent per millilitre of plasma—and average methylation.
However, in some samples with low total DNA content (below 20 000 genome equivalent),
high methylation values were recorded; on the other hand, a subset of samples with high
genome equivalent did not display detectable methylation in the selected loci. We
hypothesise that these discrepancies could be explained by haemolysis during sample
preparation and consequent contamination of plasma by leucocyte DNA, or by release of
DNA from non-cancerous tissues during treatment, possibly due to inflammation or
hepatotoxicity. Individual markers had prevalence around 65%, and only combining the
positivity of all five methylated loci resulted in 86% overall prevalence, which is slightly
higher but similar to what previously reported when both NPY and WIF1 were assessed in
the metastatic setting.39 Yet, there were still 14% of mCRC cfDNA samples with
undetectable circulating DNA methylation, which warrants further studies investigating
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possible biological or technical bases. None of the recorded clinicopathological features
correlated with lack of detectable methylation levels in cfDNA. Indeed, in our limited subset
of matched tissue and plasma samples, marker negativity in cfDNA was not related to low
methylation value in tumour tissue DNA. Consequently, we speculate that this discordance
between sample types could be attributed to spatial or temporal intratumour epigenetic
heterogeneity, 48 limited DNA shedding into circulation or suboptimal plasma specimen
handling. Since tissue and microarray data displayed very low rate of non-methylated
template (0% in our tissue dataset; 1.1% in microarray data), we expect that technical
improvements at the detection level as well as at the DNA isolation level (eg, using higher
plasma volume), will be required to achieve full penetrance of the assay. In addition to
NPY and WIF1, other previously identified methylated loci in genes such as SEPT9,16 49
VIM19 or C9ORF5018 are amenable to liquid biopsy analyses, and their use in
combination with our panel might also improve the positivity of cfDNA detection. One self-
declared healthy donor displayed positivity in two markers and high GE content, possibly
suggesting either a false-positive result or that this individual had an asymptomatic
neoplastic lesion. However, the sample collection process (ie, de-identification) prevented
us from verifying this hypothesis. It should be acknowledged that our digital PCR-based
approach was not designed as a cancer diagnostic test, but rather optimised for its
linearity and quantification ability of methylated DNA in advanced disease. Nevertheless,
future studies are warranted to establish the methylation status and prevalence of the
markers identified by our study in the earlier stages of colorectal neoplastic disease. This
knowledge together with the development of assays that would privilege sensitivity over
quantification are key to establish whether these findings could be relevant also in the
setting of early detection. There was good correlation (above 0.55) between levels of
circulating DNA methylation and early genetic events in colorectal tumourigenesis such as
KRAS or BRAF mutations, which validates the possibility to use methylation without prior
18
knowledge of the tumour genetic pattern, as previously shown.39 41 Of note, four samples
involved in the study were also assessed by massive parallel sequencing (data not shown)
and presented genetic mutations at an allelic frequency comparable to the percentage of
methylated markers, which highlights a possible role of our panel for plasma quality
assessment prior to sequencing. In fact, massive parallel sequencing sometimes fails to
detect tumour-specific somatic mutations due to low tumour content in cfDNA and
methylation assay could therefore be used for checking tumour DNA enrichment in plasma
as a quality control step. Methylation markers in cfDNA of patients treated with EGFR
inhibitors, paralleled the emergence of resistance causative genetic alterations. This
finding suggests the possibility to use these methylation markers as whole tumour DNA
content normaliser in plasma. This will be of particular importance when qualitative
assessment (presence or absence) of individual mutation variants in the blood is not
enough to predict response. Interestingly, in two cases, the likely resistance mechanism
(KRAS alteration) showed very low mutant allelic frequency in comparison to the estimated
amount of tumour derived cfDNA (as judged by ASM). We hypothesised that either the
tumour harboured additional unknown mechanisms of resistance or a small fraction of
KRAS altered cells was enough to protect the main bulk of the neoplastic lesion via
paracrine effectors as previously demonstrated.50 In two cases that progressed through
emergence of a KRAS mutation, levels of mutant alleles decreased on treatment with
irinotecan, independently of methylation, suggesting that the fitness of KRAS mutant
clones is dependent on the presence of anti-EGFR antibodies, as previously proposed.4
To our knowledge, very few studies evaluated longitudinally methylated cfDNA,39 41 51
and most works essentially focused on analysis of pretreatment samples to find predictive
markers of response. Here, we showed that evolution of the methylation abundance over
time demonstrated good prediction of response status during treatment with conventional
therapies for mCRC. This suggests that longitudinal assessment of methylation could be
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used in between radiological assessments for more accurate follow-up of the disease. We
were also able to retrospectively assess a batch of samples that were collected in a clinical
trial with temozolomide for the treatment of chemorefractory mCRC. Samples were not
collected with the aim to directly compare cfDNA with CT scans. Imaging was not usually
performed at the very same time-points when blood was drawn. Despite this limitation and
the low response rate of mCRC on temozolomide treatment, dynamics of methylation
could predict clinical benefit. This implicates that the monitoring of methylated circulating
DNA might be used as a surrogate to imaging in order to evaluate treatment efficacy and
might help reducing delays in therapeutic reorientation. In fact, with the emergence of
concepts such as early tumour shrinkage associated with long-term outcome,52 53 short-
term evaluation of pharmacodynamic response using liquid biopsy might become common
practice. In summary, we presented here a panel of five methylated universal markers of
circulating DNA of tumour origin that can be efficiently used to monitor advanced CRC on
most currently available treatments. We hypothesise that combining radiological and
repetitive cfDNA assessments will improve monitoring of patients with mCRC and would
help clinicians to adjust treatment more efficiently by adopting more timely surgical
intervention or early therapeutic reorientation.
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Figure 1 Workflow of the study. A multistep marker discovery analysis was first performed
to identify highly prevalent cancer-specific markers. After design, assay probes were
further validated in silico. Assays were optimised to achieve linear quantification over a
wide methylation range (0.09%– 100%). Marker prevalence was first evaluated in tissue
samples from 82 subjects with CRC. Then marker prevalence was evaluated in cfDNA in a
total of 232 donors enrolled in the study among which 50 were de-identified self-declared
healthy donors, and 182 patients with mCRC. Among mCRC cases, 45 were followed
longitudinally and treated either with conventional chemotherapy, targeted therapy
regimen or with temozolomide (TMZ) as part of a clinical trial. Methylation was analysed
longitudinally for cases with positivity in at least one marker at baseline sample.
Methylation dynamics was then compared with additional available clinical or molecular
features. In green: unpublished data; in blue: bench experiments; in orange: bioinformatics
or statistical analyses with clinical correlates; in grey: sample exclusion. *GSE32146 was
used after removal of ulcerative colitis cases. **In silico validation was performed again
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restricting the analysis to the probes included in the assay amplicon. ***Only normal
healthy and peritumoural tissues were used from GSE48684.
Figure 2 Prevalence of methylated markers in tissue DNA from patients with metastatic
colorectal cancer (CRC). (A): EYA4, (B): GRIA4, (C): ITGA4, (D): MAP3K14-AS1, (E):
MSC, (F): average of the five markers. Samples from 82 patients with CRC were analysed.
A first set was composed of 31 cases from which tumour and peritumoural tissue DNA
were available. A second set of independent 51 tumour tissue specimens was assembled
from remaining DNA extracted during the enrolment of two clinical trials.
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Figure 3 Prevalence of methylated markers in cell-free circulating DNA (cfDNA) and total
amount of cfDNA. Plasma samples from 50 self-declared healthy donors (blue) and 182
patients with metastatic colorectal cancer (red) were analysed for the five selected
markers. Group mean is represented by a horizontal bar. Mann-Whitney U test was
performed to compare distribution in healthy patients and patients with cancer, which were
all significantly different (with p<0.0001). Representation of individual markers: (A): EYA4,
(B): GRIA4, (C): ITGA4, (D): MAP3K14-AS1, (E): MSC, (F): genome equivalent/mL
(GE/mL). (G): Representation of average methylation signal. Self-declared healthy donor
plasma samples presenting more than one outlying value were indicated by coloured
arrows; the dashed line corresponds to the threshold established by receiver operating
characteristic curve (ROC) analyses available in online Supplementary file 7. (H):
Heatmap of methylation values sorted by average methylation.
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Figure 4 Average of selected markers (ASM) in cell-free circulating DNA dynamics in eight
metastatic colorectal cancer (CRC) patients treated with conventional chemotherapy
regimens. ASM is plotted in blue, while KRAS mutations are plotted in pink and BRAF in
red. Methylation and genetic mutations evolve in parallel demonstrating the possibility to
use methylation instead of genetic alterations for tracking response. Response status is
indicated with arrows. PR, partial response; SD, stable disease; PD, progressive disease.
Treatment periods are indicated as horizontal black arrows with corresponding
chemotherapy regimens.
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Figure 5 Average of selected markers (ASM) in cell-free circulating DNA dynamics in five
metastatic colorectal cancer (CRC) patients treated with panitumumab for whom
resistance causative mutations were discovered at progression and retrospectively
assessed longitudinally. (A–C): Resistance was acquired through the emergence of a
KRAS alteration; (D): resistance was acquired through the emergence of MET gene
amplification. In each case, increase in ASM parallels the appearance of resistance
alterations. (E): A case in which resistance mechanism remained unidentified but for which
ASM could detect relapse.
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Figure 6 Average of selected markers (ASM) in cell-free circulating DNA dynamics
assessment in patients with metastatic colorectal cancer treated with temozolomide within
a clinical trial. (A): Comparison of ASM changes to response status evaluated by RECIST.
The best ASM changes were plotted as a waterfall plot. Response status of patients
evaluated by RECIST is plotted as a heatmap. (B): Progression-free survival according to
best ASM change. Negative ASM change is associated with improved PFS. HR was
estimated by log rank approach.
Supplementary File 1 - Supplementary Material and Methods 
Cell lines and genome wide DNA methylation data processing and retrieval 
A collection of 149 cell lines of intestinal origin (Supplemental File 2A) was assembled 
from different worldwide cell line banks or academic laboratories, as described previously 
[1].  
DNA samples were extracted by Wizard SV Genomic DNA Purification System (Promega), 
and cell identity was confirmed using the Gene Print 10 System (Promega). DNA samples 
were checked for integrity by 1% agarose gel, and quantity via Picogreen quantification. All 
samples were bisulfite converted using the EZ DNA methylation Gold kit (Zymo Research) 
with a minimum input of 500 ng of gDNA following the manufacturer’s instructions. Infinium 
HumanMethylation450 BeadChip arrays were carried out according to the Illumina Infinium 
HD methylation protocol. Raw methylation profiles have been deposited on Gene 
Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/; accession number: 
GSE86078). 
GSE32146 was downloaded from GEO and considered as a control set (i.e. cancer 
unrelated normal mucosa, after removing the ulcerative colitis cases), for comparison with 
the cell lines. GSE41169 was downloaded from GEO and considered as a blood control 
(i.e. healthy donors) for verification of tissue specificity of the loci of interest. 
GSE42752 [2] was downloaded from GEO and considered as a test cohort for the 
establishment of the beta-value threshold used for the in-silico validation. Level 1 data 
from the TCGA colorectal adenocarcinoma (COAD/READ) (http://cancergenome.nih.gov/; 
https://gdc.cancer.gov/) were downloaded and defined the validation cohort used for the 
in-silico validation. Further validation in normal tissues was performed GSE48684 [3] 
 
 
Data Preprocessing and Marker Discovery Analysis 
All raw data (IDAT files) were preprocessed in R Bioconductor using the minfi package [4] 
via the preprocessIllumina function (using background correction and control 
normalization) to achieve data normalized similarly to GEO downloaded datasets. The 
individual probe signal was removed when the detection p-value was above 0.05, and 
probes were removed from the dataset if more than 1% of the dataset contained no data. 
Our dataset was then merged with the other publically available cohorts before removal of 
probes containing SNPs [5], demonstrating sexual dimorphism [6] or located on sex 
chromosomes.  
Differential probe analysis was performed using the lmFit function from limma package 
(choosing an adjusted p-value threshold of 1x10-35 and a minimum delta beta-value of 0.8). 
Probes were verified to not display any methylation in leukocytes (GSE41169; maximum 
beta-value allowed =0.1) insuring absence of false positivity in blood tests due to the high 
methylation value of blood cells. Differential region analysis was performed using the 
bumphunter function from the minfi package choosing a threshold of 0.8 and restricting the 
region to those represented by at least two probes (L  2). Differentially methylated probes 
were limited to those overlapping differentially methylated regions, and “liquid biopsy” 
assessable loci were defined. 
GSE42752 data were averaged for each of the genomic regions defined in the previous 
step according to sample type (normal and normal adjacent versus adenocarcinoma). 
Thresholds were calculated using Receiver operating characteristic analyses performed 
with the pROC package in R Bioconductor [7] considering normal and adjacent mucosa as 
positive outcome and cancer as negative; only loci showing a threshold below 0.35 were 
kept. Each characterized threshold were used to stratify the TCGA COREAD cohort, 
defining a positive predictive value (PPV) and negative predictive value (NPV) for 
discriminating normal adjacent from tumor tissue. Normal healthy and peri-tumoral 




Tissue collection and DNA isolation 
Formalin fixed paraffin embedded tissues originated from two different cohorts. One 
containing macro-dissected tumor and normal adjacent tissues (N=31 cases; originating 
from several local hospitals) which were controlled for tumor purity and assembled at 
Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda (Milan, Italy) and from 
which DNA was newly extracted. A second cohort of independent tumor tissues (N=51) 
was assembled from remaining DNA extracted during the enrollement of the DETECT 




Plasma Collection and DNA preparation 
De-identified whole blood samples from healthy donors were purchased from the Brigham 
and Women’s Hospital specimen bank (Boston, USA). Collection was performed in 
K2EDTA tubes between November 2009 and April 2010 from self-declared healthy donors 
aged 40 years and above who visited the hospital for an annual routine examination. The 
donors’ sex and age was maintained in the datafile. Plasma was isolated after 10 minutes 
of centrifugation at 1600 RCF, and stored at -80°C.  
One hundred and eighty two cases of mCRC were enrolled in the study. One hundred and 
thirty-seven cases were selected for plasma timepoints based on plasma sample 
availability at a time when patients were presenting radiological evidence of disease. The 
remaining 45 cases were treatment baselines, selected for availability of longitudinal 
follow-up (additional total of 132 longitudinal samples). Summary of the clinico-pathological 
features of the two cohorts can be found in Supplementary File 2D (mCRC patients 
clinical features are presented in Supplementary File 2E). mCRC plasma samples were 
collected in K2EDTA tubes at Ospedale Niguarda Ca' Granda (Milan, Italy) between 
September 2009 and December 2015 or at Ospedale Molinette (Turin, Italy) between June 
2013 to July 2015. Plasma was isolated in a two-step protocol (10 minutes at 1600 RCF, 
10 minutes at 3000 RCF) and stored at -80°C until processing. The study was conducted 
according to Good Clinical Practices and was approved by the local ethics committee. One 
milliliter of plasma was processed for DNA extraction with the QIAamp Circulating Nucleic 
Acid Kit (Qiagen) or with the Maxwell® RSC ccfDNA Plasma Kit (Promega) following the 
manufacturer’s protocol. Change in extraction kit (from Qiagen to Promega) was decided 
to improve the experimental throughput in a semi-automated fashion using the Maxwell® 
RSC ccfDNA Plasma Kit with no major change in extraction quality or yield. Twenty 
microliters of DNA were used for bisulfite conversion using the EZ DNA methylation Gold 
kit (Zymo Research), following the manufacturer’s protocol, with final elution in 40 µl. 
 
Methylation and genetic alteration assays for cfDNA evaluation 
Selected loci were investigated for possible methylation independent amplification. Primers 
were designed using the PyroMark® Assay Design SW 2.0 (Qiagen) with custom settings. 
Primers and probes are available in Supplemental Table 2C. In-silico validation of the 
assays was performed using the same steps as previously described: threshold estimation 
in GSE42752 and stratification in TCGA COREAD, using solely the probes which were 
located within the amplicon Supplementary File 5. Optimization and evaluation of Methyl-
BEAMing assays was performed as previously described [10], with the difference that 
beads were run on a BD C6 Accuri system (Becton-Dickinson). In-silico validation results 
display for the five markers of interest are available in Supplementary File 4. 
Digital Miqe checklist including limit of detection, limit of blank, quantification ability 
(linearity and sensitivity) is available in Supplementary File 3.  
Evaluation of genetic alterations (KRAS, BRAF mutations and MET gene copy number) in 
cfDNA was performed as previously described [11, 12]. Primers and probes are either 
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List of samples used in the marker discovery analysis
SAMPLES USED FOR THE MARKER DISCOVERY
Sample_Name Tissue_type Donor_type Dataset Sentrix_ID Sentrix_Position Official_name
C10 Cell_line Colon_Adenocarcinoma_cell GSE86078 3998998097 R02C02 C10
C106 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455219 R03C02 C106
C125PM Cell_line Colon_Adenocarcinoma_cell GSE86078 3999875059 R06C02 C125PM
C146 Cell_line Colon_Adenocarcinoma_cell GSE86078 3999876007 R02C01 C146
C170 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455225 R05C01 C170
C32 Cell_line Colon_Adenocarcinoma_cell GSE86078 3998426028 R06C01 C32
C70 Cell_line Colon_Adenocarcinoma_cell GSE86078 3998426028 R06C02 C70
C75 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647450147 R05C02 C75
C80 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455207 R01C01 C80
C84 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455254 R05C02 C84
C99 Cell_line Colon_Adenocarcinoma_cell GSE86078 3999002152 R06C01 C99
CACO2 Cell_line Colon_Adenocarcinoma_cell GSE86078 3998426003 R06C01 CACO-2
CaR1 Cell_line Colon_Adenocarcinoma_cell GSE86078 200486890054 R06C01 CAR-1
CCK81 Cell_line Colon_Adenocarcinoma_cell GSE86078 3999002152 R02C01 CCK81
CL11 Cell_line Colon_Adenocarcinoma_cell GSE86078 3998426028 R01C02 CL-11
CL14 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455235 R06C01 CL-14
CL34 Cell_line Colon_Adenocarcinoma_cell GSE86078 3999875081 R01C02 CL-34
CL40 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455254 R02C01 CL-40
Co115 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455235 R05C01 Co-115
COCM1 Cell_line Colon_Adenocarcinoma_cell GSE86078 3999002152 R04C02 COCM-1
COGA1 Cell_line Colon_Adenocarcinoma_cell GSE86078 10011071041 R01C01 COGA-1
COGA12 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455255 R06C01 COGA-12
COGA2 Cell_line Colon_Adenocarcinoma_cell GSE86078 10011071041 R02C02 COGA-2
COGA3 Cell_line Colon_Adenocarcinoma_cell GSE86078 10011071041 R03C02 COGA-3
COGA5 Cell_line Colon_Adenocarcinoma_cell GSE86078 3999875059 R01C01 COGA-5
COGA5L Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455197 R01C02 COGA-5L
COGA8 Cell_line Colon_Adenocarcinoma_cell GSE86078 3999875129 R03C02 COGA-8
COLO201 Cell_line Colon_Adenocarcinoma_cell GSE86078 10011071041 R04C01 COLO-201
COLO205 Cell_line Colon_Adenocarcinoma_cell GSE86078 200486890054 R01C02 COLO-205
COLO320DM Cell_line Colon_Adenocarcinoma_cell GSE86078 10011071041 R06C02 COLO-320DM
COLO320HSR Cell_line Colon_Adenocarcinoma_cell GSE86078 200486890054 R02C02 COLO-320HSR
COLO60H Cell_line Colon_Adenocarcinoma_cell GSE86078 3999875129 R06C01 COLO-60H
COLO678 Cell_line Colon_Adenocarcinoma_cell GSE86078 3998426028 R01C01 COLO-678
COLO94H Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455197 R01C01 COLO-94H
CX1 Cell_line Colon_Adenocarcinoma_cell GSE86078 3999875081 R03C01 CX1
DiFi Cell_line Colon_Adenocarcinoma_cell GSE86078 10011071041 R05C02 DiFi
DLD1 Cell_line Colon_Adenocarcinoma_cell GSE86078 200486890054 R03C02 DLD1
FET Cell_line Colon_Adenocarcinoma_cell GSE86078 3999002152 R05C02 FET
GEO Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455251 R04C01 GEO
GP2d Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455255 R05C02 GP2d
Gp5D Cell_line Colon_Adenocarcinoma_cell GSE86078 200693590020 R01C01 Gp5d
HCA24 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455172 R02C01 HCA24
HCA46 Cell_line Colon_Adenocarcinoma_cell GSE86078 3998998097 R02C01 HCA46
HCA7 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455255 R04C02 HCA7
HCC2998 Cell_line Colon_Adenocarcinoma_cell GSE86078 3998426003 R05C02 HCC2998
HCT116 Cell_line Colon_Adenocarcinoma_cell GSE86078 200486890054 R04C02 HCT-116
HCT15 Cell_line Colon_Adenocarcinoma_cell GSE86078 200486890054 R05C02 HCT-15
HCT8 Cell_line Colon_Adenocarcinoma_cell GSE86078 10011071041 R06C01 HCT-8
HDC114 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455164 R05C01 HDC114
HDC135 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455255 R03C01 HDC135
HDC142 Cell_line Colon_Adenocarcinoma_cell GSE86078 10006823050 R02C01 HDC142
HDC143 Cell_line Colon_Adenocarcinoma_cell GSE86078 3999875089 R06C01 HDC143
HDC54 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455235 R03C02 HDC54
HDC8 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455199 R03C01 HDC8
HDC82 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455172 R06C02 HDC82
HDC9 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455199 R02C01 HDC9
HRA16 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647450147 R06C02 HRA16
HROC18 Cell_line Colon_Adenocarcinoma_cell GSE86078 10006823050 R04C02 HROC18
HROC24 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455172 R02C02 HROC24
HROC32 Cell_line Colon_Adenocarcinoma_cell GSE86078 3998998097 R05C02 HROC32
HROC39 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455255 R02C01 HROC39
HROC46 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455235 R01C01 HROC46
HROC69 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455251 R04C02 HROC69
HROC80 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455219 R06C01 HROC80
HROC87 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647450134 R05C01 HROC87
HT115 Cell_line Colon_Adenocarcinoma_cell GSE86078 200486890054 R06C02 HT-115
HT29 Cell_line Colon_Adenocarcinoma_cell GSE86078 200693590019 R01C01 HT-29
HT55 Cell_line Colon_Adenocarcinoma_cell GSE86078 200693590020 R02C01 HT-55
HUTU80 Cell_line Colon_Adenocarcinoma_cell GSE86078 200693590019 R02C01 HuTu80
KM12 Cell_line Colon_Adenocarcinoma_cell GSE86078 200693590020 R03C01 KM-12
KM12C Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455172 R03C01 KM-12C
KM12SM Cell_line Colon_Adenocarcinoma_cell GSE86078 3999875089 R05C01 KM-12SM
KM20 Cell_line Colon_Adenocarcinoma_cell GSE86078 3999875081 R06C01 KM-20
LIM1215 Cell_line Colon_Adenocarcinoma_cell GSE86078 10011071041 R02C01 LIM-1215
LIM1899 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647450134 R04C01 LIM-1899
LIM2099 Cell_line Colon_Adenocarcinoma_cell GSE86078 3998998097 R06C01 LIM-2099
LIM2405 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455199 R02C02 LIM-2405
LIM2412 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647450134 R02C01 LIM-2412
LIM2537 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455251 R05C02 LIM-2537
LIM2550 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455172 R05C02 LIM-2550
LIM2551 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455172 R01C01 LIM-2551
LoVo Cell_line Colon_Adenocarcinoma_cell GSE86078 3998426003 R03C02 LoVo
LS1034 Cell_line Colon_Adenocarcinoma_cell GSE86078 3998426003 R06C02 LS1034
LS123 Cell_line Colon_Adenocarcinoma_cell GSE86078 200693590020 R04C01 LS123
LS174T Cell_line Colon_Adenocarcinoma_cell GSE86078 3998998097 R06C02 LS174T
LS180 Cell_line Colon_Adenocarcinoma_cell GSE86078 200693590019 R03C01 LS180
LS411N Cell_line Colon_Adenocarcinoma_cell GSE86078 3998426003 R03C01 LS411N
LS513 Cell_line Colon_Adenocarcinoma_cell GSE86078 200693590020 R02C02 LS513
MDST8 Cell_line Colon_Adenocarcinoma_cell GSE86078 200693590019 R04C01 MDST8
MIP101 Cell_line Colon_Adenocarcinoma_cell GSE86078 10006823050 R01C02 MIP101
NCIH498 Cell_line Colon_Adenocarcinoma_cell GSE86078 3999875081 R04C01 NCI-H498
NCIH508 Cell_line Colon_Adenocarcinoma_cell GSE86078 10006823050 R05C01 NCI-H508
Supplementary File 2A
NCIH630 Cell_line Colon_Adenocarcinoma_cell GSE86078 200693590020 R05C01 NCI-H630
NCIH684 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455255 R01C02 NCI-H684
NCIH716 Cell_line Colon_Adenocarcinoma_cell GSE86078 200693590019 R05C01 NCI-H716
NCIH747 Cell_line Colon_Adenocarcinoma_cell GSE86078 200693590019 R06C01 NCI-H747
OUMS23 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455199 R01C01 OUMS-23
OXCO1 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455235 R01C02 OXCO1
OXCO2 Cell_line Colon_Adenocarcinoma_cell GSE86078 10006823050 R03C02 OXCO2
OXCO3 Cell_line Colon_Adenocarcinoma_cell GSE86078 3999875118 R03C01 OXCO3
RCM1 Cell_line Colon_Adenocarcinoma_cell GSE86078 200693590019 R01C02 RCM1
RKO Cell_line Colon_Adenocarcinoma_cell GSE86078 3998426003 R01C01 RKO
RW7213 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455123 R04C01 RW7213
SKCO1 Cell_line Colon_Adenocarcinoma_cell GSE86078 3998426028 R02C02 SKCO-1
SNU1033 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455172 R01C02 SNU-1033
SNU1040 Cell_line Colon_Adenocarcinoma_cell GSE86078 3998426028 R04C02 SNU-1040
SNU1047 Cell_line Colon_Adenocarcinoma_cell GSE86078 3998426028 R02C01 SNU-1047
SNU1181 Cell_line Colon_Adenocarcinoma_cell GSE86078 3999875118 R04C01 SNU-1181
SNU1235 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647450147 R04C01 SNU-1235
SNU1406 Cell_line Colon_Adenocarcinoma_cell GSE86078 10006823050 R04C01 SNU-1406
SNU1411 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647450147 R05C01 SNU-1411
SNU1460 Cell_line Colon_Adenocarcinoma_cell GSE86078 10006823050 R06C02 SNU-1460
SNU1544 Cell_line Colon_Adenocarcinoma_cell GSE86078 10006823050 R06C01 SNU-1544
SNU1684 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455225 R04C01 SNU-1684
SNU1746 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455225 R03C02 SNU-1746
SNU175 Cell_line Colon_Adenocarcinoma_cell GSE86078 3998426028 R05C02 SNU-175
SNU254 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455254 R03C02 SNU-254
SNU283 Cell_line Colon_Adenocarcinoma_cell GSE86078 3998426003 R04C01 SNU-283
SNU407 Cell_line Colon_Adenocarcinoma_cell GSE86078 3998426003 R01C02 SNU-407
SNU479 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455123 R04C02 SNU-479
SNU503 Cell_line Colon_Adenocarcinoma_cell GSE86078 3999875089 R02C02 SNU-503
SNU61 Cell_line Colon_Adenocarcinoma_cell GSE86078 3998426003 R02C01 SNU-61
SNU769B Cell_line Colon_Adenocarcinoma_cell GSE86078 3998998097 R03C01 SNU-769B
SNU81 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455164 R01C01 SNU-81
SNU977 Cell_line Colon_Adenocarcinoma_cell GSE86078 3998998097 R03C02 SNU-977
SNUC1 Cell_line Colon_Adenocarcinoma_cell GSE86078 3998426003 R05C01 SNU-C1
SNUC2A Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455164 R01C02 SNU-C2A
SNUC2B Cell_line Colon_Adenocarcinoma_cell GSE86078 200693590019 R02C02 SNU-C2B
SNUC4 Cell_line Colon_Adenocarcinoma_cell GSE86078 3999876007 R04C01 SNU-C4
SNUC5 Cell_line Colon_Adenocarcinoma_cell GSE86078 3998426003 R02C02 SNU-C5
SW1116 Cell_line Colon_Adenocarcinoma_cell GSE86078 200693590019 R03C02 SW1116
SW1222 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647450134 R06C01 SW1222
SW1417 Cell_line Colon_Adenocarcinoma_cell GSE86078 3998426028 R05C01 SW1417
SW1463 Cell_line Colon_Adenocarcinoma_cell GSE86078 200693590019 R04C02 SW1463
SW403 Cell_line Colon_Adenocarcinoma_cell GSE86078 10006823050 R03C01 SW403
SW48 Cell_line Colon_Adenocarcinoma_cell GSE86078 6042324140 R02C01 SW48
SW480 Cell_line Colon_Adenocarcinoma_cell GSE86078 200693590019 R05C02 SW480
SW620 Cell_line Colon_Adenocarcinoma_cell GSE86078 200693590019 R06C02 SW620
SW837 Cell_line Colon_Adenocarcinoma_cell GSE86078 3998426003 R04C02 SW-837
SW948 Cell_line Colon_Adenocarcinoma_cell GSE86078 200693590020 R06C01 SW-948
T84 Cell_line Colon_Adenocarcinoma_cell GSE86078 200693590020 R01C02 T84
V411 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455207 R03C02 V411
V457 Cell_line Colon_Adenocarcinoma_cell GSE86078 3999002152 R03C02 V457
V481 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455251 R02C01 V481
V703 Cell_line Colon_Adenocarcinoma_cell GSE86078 3999002152 R04C01 V703
VACO432 Cell_line Colon_Adenocarcinoma_cell GSE86078 3998426028 R03C01 VACO-432
VACO5 Cell_line Colon_Adenocarcinoma_cell GSE86078 3999875081 R06C02 VACO-5
VACO6 Cell_line Colon_Adenocarcinoma_cell GSE86078 9647455255 R01C01 VACO-6
WiDR Cell_line Colon_Adenocarcinoma_cell GSE86078 3998426028 R04C01 WiDR
PUBLICALLY AVAILABLE DATA USED IN THE STUDY
Sample_Name Tissue_type Donor_type Dataset Sentrix_ID Sentrix_Position
GSM796576 Normal_mucosa Healthy GSE32146
GSM796577 Normal_mucosa Healthy GSE32146
GSM796578 Normal_mucosa Healthy GSE32146
GSM796579 Normal_mucosa Healthy GSE32146
GSM796580 Normal_mucosa Healthy GSE32146
GSM796581 Normal_mucosa Healthy GSE32146
GSM796582 Normal_mucosa Healthy GSE32146
GSM796583 Normal_mucosa Healthy GSE32146
GSM796584 Normal_mucosa Healthy GSE32146
GSM796585 Normal_mucosa Healthy GSE32146
GSM796586 Normal_mucosa Crohn's_disease GSE32146
GSM796587 Normal_mucosa Crohn's_disease GSE32146
GSM796588 Normal_mucosa Crohn's_disease GSE32146
GSM796589 Normal_mucosa Crohn's_disease GSE32146
GSM796590 Normal_mucosa Crohn's_disease GSE32146
GSM796591 Normal_mucosa Crohn's_disease GSE32146
GSM796592 Normal_mucosa Crohn's_disease GSE32146
GSM796593 Normal_mucosa Crohn's_disease GSE32146
GSM796594 Normal_mucosa Crohn's_disease GSE32146
GSM796598 Normal_mucosa Crohn's_disease GSE32146
GSM1009660 Whole_Blood Healthy_Blood GSE41169
GSM1009666 Whole_Blood Healthy_Blood GSE41169
GSM1009667 Whole_Blood Healthy_Blood GSE41169
GSM1009668 Whole_Blood Healthy_Blood GSE41169
GSM1009673 Whole_Blood Healthy_Blood GSE41169
GSM1009674 Whole_Blood Healthy_Blood GSE41169
GSM1009677 Whole_Blood Healthy_Blood GSE41169
GSM1009681 Whole_Blood Healthy_Blood GSE41169
GSM1009685 Whole_Blood Healthy_Blood GSE41169
GSM1009686 Whole_Blood Healthy_Blood GSE41169
GSM1009687 Whole_Blood Healthy_Blood GSE41169
GSM1009688 Whole_Blood Healthy_Blood GSE41169
GSM1009689 Whole_Blood Healthy_Blood GSE41169
GSM1009690 Whole_Blood Healthy_Blood GSE41169
GSM1009691 Whole_Blood Healthy_Blood GSE41169
GSM1009692 Whole_Blood Healthy_Blood GSE41169
GSM1009693 Whole_Blood Healthy_Blood GSE41169
GSM1009694 Whole_Blood Healthy_Blood GSE41169
GSM1009695 Whole_Blood Healthy_Blood GSE41169
GSM1009697 Whole_Blood Healthy_Blood GSE41169
GSM1009723 Whole_Blood Healthy_Blood GSE41169
GSM1009727 Whole_Blood Healthy_Blood GSE41169
GSM1009729 Whole_Blood Healthy_Blood GSE41169
GSM1009739 Whole_Blood Healthy_Blood GSE41169
GSM1009742 Whole_Blood Healthy_Blood GSE41169
GSM1009743 Whole_Blood Healthy_Blood GSE41169
GSM1009744 Whole_Blood Healthy_Blood GSE41169
GSM1009745 Whole_Blood Healthy_Blood GSE41169
GSM1009746 Whole_Blood Healthy_Blood GSE41169
GSM1009747 Whole_Blood Healthy_Blood GSE41169
GSM1009748 Whole_Blood Healthy_Blood GSE41169
GSM1009749 Whole_Blood Healthy_Blood GSE41169
GSM1009892 Whole_Blood Healthy_Blood GSE41169
GSM1009893 Whole_Blood Healthy_Blood GSE41169
GSM1049367 Normal_mucosa Healthy GSE42752
GSM1049368 Normal_mucosa Healthy GSE42752
GSM1049369 Normal_mucosa Healthy GSE42752
GSM1049370 Normal_mucosa Healthy GSE42752
GSM1049371 Normal_mucosa Healthy GSE42752
GSM1049372 Normal_mucosa Healthy GSE42752
GSM1049373 Normal_mucosa Healthy GSE42752
GSM1049374 Normal_mucosa Healthy GSE42752
GSM1049375 Normal_mucosa Healthy GSE42752
GSM1049376 Normal_mucosa Healthy GSE42752
GSM1049377 Normal_mucosa Healthy GSE42752
GSM1049378 Normal_mucosa Healthy GSE42752
GSM1049379 Normal_mucosa Healthy GSE42752
GSM1049380 Normal_mucosa Healthy GSE42752
GSM1049381 Normal_mucosa Healthy GSE42752
GSM1049382 Normal_mucosa Healthy GSE42752
GSM1049383 Normal_mucosa Healthy GSE42752
GSM1049384 Normal_mucosa Healthy GSE42752
GSM1049385 Normal_mucosa Healthy GSE42752
GSM1049386 Normal_mucosa Colon_Adenocarcinoma_norm GSE42752
GSM1049387 Normal_mucosa Colon_Adenocarcinoma_norm GSE42752
GSM1049388 Normal_mucosa Colon_Adenocarcinoma_norm GSE42752
GSM1049389 Normal_mucosa Colon_Adenocarcinoma_norm GSE42752
GSM1049390 Normal_mucosa Colon_Adenocarcinoma_norm GSE42752
GSM1049391 Normal_mucosa Colon_Adenocarcinoma_norm GSE42752
GSM1049392 Normal_mucosa Colon_Adenocarcinoma_norm GSE42752
GSM1049393 Normal_mucosa Colon_Adenocarcinoma_norm GSE42752
GSM1049394 Normal_mucosa Colon_Adenocarcinoma_norm GSE42752
GSM1049395 Normal_mucosa Colon_Adenocarcinoma_norm GSE42752
GSM1049396 Normal_mucosa Colon_Adenocarcinoma_norm GSE42752
GSM1049397 Normal_mucosa Colon_Adenocarcinoma_norm GSE42752
GSM1049398 Normal_mucosa Colon_Adenocarcinoma_norm GSE42752
GSM1049399 Normal_mucosa Colon_Adenocarcinoma_norm GSE42752
GSM1049400 Normal_mucosa Colon_Adenocarcinoma_norm GSE42752
GSM1049401 Normal_mucosa Colon_Adenocarcinoma_norm GSE42752
GSM1049402 Normal_mucosa Colon_Adenocarcinoma_norm GSE42752
GSM1049403 Normal_mucosa Colon_Adenocarcinoma_norm GSE42752
GSM1049404 Normal_mucosa Colon_Adenocarcinoma_norm GSE42752
GSM1049405 Normal_mucosa Colon_Adenocarcinoma_norm GSE42752
GSM1049406 Normal_mucosa Colon_Adenocarcinoma_norm GSE42752
GSM1049407 Normal_mucosa Colon_Adenocarcinoma_norm GSE42752
GSM1049408 Tumor Colon_Adenocarcinoma GSE42752
GSM1049409 Tumor Colon_Adenocarcinoma GSE42752
GSM1049410 Tumor Colon_Adenocarcinoma GSE42752
GSM1049411 Tumor Colon_Adenocarcinoma GSE42752
GSM1049412 Tumor Colon_Adenocarcinoma GSE42752
GSM1049413 Tumor Colon_Adenocarcinoma GSE42752
GSM1049414 Tumor Colon_Adenocarcinoma GSE42752
GSM1049415 Tumor Colon_Adenocarcinoma GSE42752
GSM1049416 Tumor Colon_Adenocarcinoma GSE42752
GSM1049417 Tumor Colon_Adenocarcinoma GSE42752
GSM1049418 Tumor Colon_Adenocarcinoma GSE42752
GSM1049419 Tumor Colon_Adenocarcinoma GSE42752
GSM1049420 Tumor Colon_Adenocarcinoma GSE42752
GSM1049421 Tumor Colon_Adenocarcinoma GSE42752
GSM1049422 Tumor Colon_Adenocarcinoma GSE42752
GSM1049423 Tumor Colon_Adenocarcinoma GSE42752
GSM1049424 Tumor Colon_Adenocarcinoma GSE42752
GSM1049425 Tumor Colon_Adenocarcinoma GSE42752
GSM1049426 Tumor Colon_Adenocarcinoma GSE42752
GSM1049427 Tumor Colon_Adenocarcinoma GSE42752
GSM1049428 Tumor Colon_Adenocarcinoma GSE42752
GSM1049429 Tumor Colon_Adenocarcinoma GSE42752
TCGA-A6-2671-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 5775041068 R01C02
TCGA-A6-2675-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 6042316001 R03C01
TCGA-A6-2679-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 5775041068 R04C01
TCGA-A6-2680-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 5775041068 R06C01
TCGA-A6-2681-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 5775041068 R02C02
TCGA-A6-2682-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 5775041068 R03C02
TCGA-A6-2684-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 5775041068 R01C01
TCGA-A6-2685-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 5775041068 R02C01
TCGA-A6-2686-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 5775041068 R03C01
TCGA-A6-4107-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 5775041068 R05C01
TCGA-A6-5667-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 6042316015 R05C01
TCGA-AA-3488-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 5775041088 R04C01
TCGA-AA-3492-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 5775041084 R05C02
TCGA-AA-3494-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 5775041065 R02C02
TCGA-AA-3495-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 5775041088 R02C02
TCGA-AA-3502-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 5775041065 R04C02
TCGA-AA-3506-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 5775041007 R01C02
TCGA-AA-3509-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 5775041084 R06C02
TCGA-AA-3510-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 5775041084 R03C02
TCGA-AA-3655-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 6042316015 R06C02
TCGA-AA-3660-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 6042308165 R05C01
TCGA-AA-3663-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 6042316001 R05C02
TCGA-AA-3697-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 6042308165 R04C02
TCGA-AA-3712-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 6042316011 R03C01
TCGA-AA-3713-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 6042308165 R04C01
TCGA-AG-3725-11 Normal_mucosa Rectal_Adenocarcinoma_norm TCGA COREAD 6055424097 R02C02
TCGA-AG-3731-11 Normal_mucosa Rectal_Adenocarcinoma_norm TCGA COREAD 6055424075 R04C01
TCGA-AG-A01W-11 Normal_mucosa Rectal_Adenocarcinoma_norm TCGA COREAD 5775041086 R02C01
TCGA-AG-A01Y-11 Normal_mucosa Rectal_Adenocarcinoma_norm TCGA COREAD 5775041086 R05C01
TCGA-AG-A020-11 Normal_mucosa Rectal_Mucinous_Adenocarcinoma_norm TCGA COREAD 5775041086 R01C02
TCGA-AG-A02N-11 Normal_mucosa Rectal_Adenocarcinoma_norm TCGA COREAD 5775041086 R04C02
TCGA-AG-A036-11 Normal_mucosa Rectal_Adenocarcinoma_norm TCGA COREAD 5775041086 R06C02
TCGA-AZ-6598-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 6057825035 R06C02
TCGA-AZ-6599-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 6057825028 R03C02
TCGA-AZ-6600-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 6057825020 R04C01
TCGA-AZ-6601-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 6057825002 R01C02
TCGA-G4-6295-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 6042308165 R06C02
TCGA-G4-6297-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 6042316015 R05C02
TCGA-G4-6298-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 6042308159 R02C01
TCGA-G4-6302-11 Normal_mucosa Colon_Mucinous_Adenocarcinoma_norm TCGA COREAD 6042316001 R02C01
TCGA-G4-6311-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 6042308159 R02C02
TCGA-G4-6314-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 6042316015 R01C02
TCGA-G4-6320-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 6042308165 R02C01
TCGA-G4-6322-11 Normal_mucosa Colon_Mucinous_Adenocarcinoma_norm TCGA COREAD 6042308159 R01C01
TCGA-G4-6625-11 Normal_mucosa Colon_Adenocarcinoma_norm TCGA COREAD 6057825028 R04C02
TCGA-3L-AA1B-01 Tumor Colon_Adenocarcinoma TCGA COREAD 9702496157 R02C02
TCGA-4N-A93T-01 Tumor Colon_Adenocarcinoma TCGA COREAD 9702496157 R06C01
TCGA-4T-AA8H-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 3999492120 R06C01
TCGA-5M-AAT4-01 Tumor Colon_Adenocarcinoma TCGA COREAD 3999492115 R06C02
TCGA-5M-AAT5-01 Tumor NA TCGA COREAD 3999492120 R05C01
TCGA-5M-AAT6-01 Tumor Colon_Adenocarcinoma TCGA COREAD 3999492120 R02C02
TCGA-5M-AATA-01 Tumor NA TCGA COREAD 3999492115 R05C02
TCGA-5M-AATE-01 Tumor Colon_Adenocarcinoma TCGA COREAD 3999492120 R06C02
TCGA-A6-2671-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041065 R01C02
TCGA-A6-2675-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316015 R04C01
TCGA-A6-2677-01 Tumor Colon_Adenocarcinoma TCGA COREAD 9305216012 R01C02
TCGA-A6-2677-01-2 Tumor Colon_Adenocarcinoma TCGA COREAD 9305216012 R02C02
TCGA-A6-2679-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041065 R04C01
TCGA-A6-2680-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041084 R01C01
TCGA-A6-2681-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041088 R03C02
TCGA-A6-2682-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041084 R06C01
TCGA-A6-2684-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041007 R02C01
TCGA-A6-2684-01-2 Tumor Colon_Adenocarcinoma TCGA COREAD 9305216012 R03C02
TCGA-A6-2684-01-3 Tumor Colon_Adenocarcinoma TCGA COREAD 9305216012 R04C02
TCGA-A6-2685-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041088 R06C01
TCGA-A6-2686-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041007 R04C01
TCGA-A6-3809-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 9305216012 R05C02
TCGA-A6-3809-01-2 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 9305216012 R06C02
TCGA-A6-3810-01 Tumor Colon_Adenocarcinoma TCGA COREAD 9305216015 R01C01
TCGA-A6-3810-01-2 Tumor Colon_Adenocarcinoma TCGA COREAD 9305216015 R02C01
TCGA-A6-4105-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825020 R03C02
TCGA-A6-4107-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041065 R01C01
TCGA-A6-5656-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718065 R06C01
TCGA-A6-5656-01-2 Tumor Colon_Adenocarcinoma TCGA COREAD 9305216015 R03C01
TCGA-A6-5656-01-3 Tumor Colon_Adenocarcinoma TCGA COREAD 9305216015 R04C01
TCGA-A6-5657-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625037 R04C02
TCGA-A6-5659-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625037 R01C01
TCGA-A6-5659-01-2 Tumor Colon_Adenocarcinoma TCGA COREAD 9305216015 R05C01
TCGA-A6-5659-01-3 Tumor Colon_Adenocarcinoma TCGA COREAD 9305216015 R06C01
TCGA-A6-5660-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625037 R01C02
TCGA-A6-5661-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625011 R06C01
TCGA-A6-5661-01-2 Tumor Colon_Adenocarcinoma TCGA COREAD 7796806109 R05C02
TCGA-A6-5662-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625011 R01C01
TCGA-A6-5664-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718079 R04C02
TCGA-A6-5665-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625057 R02C02
TCGA-A6-5665-01-2 Tumor Colon_Adenocarcinoma TCGA COREAD 7796806109 R03C02
TCGA-A6-5666-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625057 R01C02
TCGA-A6-5667-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316015 R03C02
TCGA-A6-6137-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825028 R01C01
TCGA-A6-6138-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825020 R01C02
TCGA-A6-6140-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825002 R03C02
TCGA-A6-6141-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825020 R02C01
TCGA-A6-6142-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825028 R01C02
TCGA-A6-6648-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825020 R03C01
TCGA-A6-6649-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825020 R06C02
TCGA-A6-6650-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825028 R05C02
TCGA-A6-6650-01-2 Tumor Colon_Adenocarcinoma TCGA COREAD 9305216015 R01C02
TCGA-A6-6650-01-3 Tumor Colon_Adenocarcinoma TCGA COREAD 9305216015 R02C02
TCGA-A6-6651-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718053 R05C01
TCGA-A6-6652-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825028 R06C01
TCGA-A6-6653-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825028 R06C02
TCGA-A6-6654-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718065 R02C01
TCGA-A6-6780-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 6929718053 R04C01
TCGA-A6-6780-01-2 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 9305216015 R03C02
TCGA-A6-6780-01-3 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 9305216015 R04C02
TCGA-A6-6781-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 6264509018 R01C01
TCGA-A6-6781-01-2 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 6264509087 R05C02
TCGA-A6-6781-01-3 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 9305216015 R05C02
TCGA-A6-6781-01-4 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 9305216015 R06C02
TCGA-A6-6782-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718053 R03C02
TCGA-A6-A565-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 9296931074 R02C01
TCGA-A6-A566-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 9296931073 R05C01
TCGA-A6-A567-01 Tumor Colon_Adenocarcinoma TCGA COREAD 9296931074 R04C01
TCGA-A6-A56B-01 Tumor Colon_Adenocarcinoma TCGA COREAD 9296931073 R04C01
TCGA-A6-A5ZU-01 Tumor Colon_Adenocarcinoma TCGA COREAD 9296931073 R03C02
TCGA-AA-3488-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041084 R04C01
TCGA-AA-3489-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718053 R06C02
TCGA-AA-3492-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041065 R06C01
TCGA-AA-3494-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041088 R01C01
TCGA-AA-3495-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041007 R01C01
TCGA-AA-3496-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718065 R06C02
TCGA-AA-3502-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041088 R06C02
TCGA-AA-3506-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041065 R03C02
TCGA-AA-3509-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041088 R04C02
TCGA-AA-3510-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041065 R02C01
TCGA-AA-3511-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718065 R05C01
TCGA-AA-3655-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042308165 R01C01
TCGA-AA-3660-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042308158 R06C02
TCGA-AA-3662-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042308159 R05C02
TCGA-AA-3663-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316001 R04C02
TCGA-AA-3697-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316015 R02C02
TCGA-AA-3712-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042308165 R02C02
TCGA-AA-3713-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316001 R01C01
TCGA-AD-5900-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 6285625011 R02C02
TCGA-AD-6548-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718054 R05C01
TCGA-AD-6888-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6264509018 R05C01
TCGA-AD-6888-01-2 Tumor Colon_Adenocarcinoma TCGA COREAD 6264509087 R03C02
TCGA-AD-6889-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6264509018 R03C02
TCGA-AD-6889-01-2 Tumor Colon_Adenocarcinoma TCGA COREAD 6264509087 R04C02
TCGA-AD-6890-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6264509018 R02C02
TCGA-AD-6890-01-2 Tumor Colon_Adenocarcinoma TCGA COREAD 6264509087 R01C01
TCGA-AD-6895-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6264509087 R05C01
TCGA-AD-6899-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 6264509087 R01C02
TCGA-AD-6901-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6264496026 R06C02
TCGA-AD-6963-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6264509087 R03C01
TCGA-AD-6963-01-2 Tumor Colon_Adenocarcinoma TCGA COREAD 6264509127 R03C01
TCGA-AD-6964-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6264509018 R02C01
TCGA-AD-6964-01-2 Tumor Colon_Adenocarcinoma TCGA COREAD 6264509087 R06C02
TCGA-AD-6965-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6264509018 R05C02
TCGA-AD-6965-01-2 Tumor Colon_Adenocarcinoma TCGA COREAD 6264509018 R06C01
TCGA-AD-A5EJ-01 Tumor Colon_Adenocarcinoma TCGA COREAD 9296931073 R06C01
TCGA-AD-A5EK-01 Tumor Colon_Adenocarcinoma TCGA COREAD 9296931073 R02C02
TCGA-AF-2687-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6055424097 R04C02
TCGA-AF-2690-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6055424097 R01C02
TCGA-AF-2693-01 Tumor NA TCGA COREAD 6055424075 R04C02
TCGA-AF-3911-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6055424097 R05C02
TCGA-AF-4110-01 Tumor NA TCGA COREAD 6055424097 R04C01
TCGA-AF-6136-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718081 R03C01
TCGA-AF-6655-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718081 R02C01
TCGA-AF-6672-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718081 R06C02
TCGA-AF-A56K-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 9828653044 R03C02
TCGA-AF-A56L-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 9828653044 R04C02
TCGA-AF-A56N-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 9828653044 R05C02
TCGA-AG-3591-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6055424075 R03C01
TCGA-AG-3592-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6055424075 R03C02
TCGA-AG-3725-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6055424075 R01C01
TCGA-AG-3731-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6055424040 R04C02
TCGA-AG-3732-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718058 R01C01
TCGA-AG-3742-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718058 R02C02
TCGA-AG-4021-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6055424097 R03C02
TCGA-AG-4022-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6055424097 R06C02
TCGA-AG-A01W-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 5775041086 R01C01
TCGA-AG-A01Y-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 5775041086 R04C01
TCGA-AG-A020-01 Tumor Rectal_Mucinous_Adenocarcinoma TCGA COREAD 5775041086 R06C01
TCGA-AG-A026-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 5775041086 R02C02
TCGA-AG-A02N-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 5775041086 R03C02
TCGA-AG-A036-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 5775041086 R05C02
TCGA-AH-6544-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718058 R06C02
TCGA-AH-6547-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718061 R05C02
TCGA-AH-6549-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718081 R05C01
TCGA-AH-6643-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718061 R06C02
TCGA-AH-6644-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718081 R04C02
TCGA-AH-6897-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718114 R05C01
TCGA-AH-6903-01 Tumor Rectal_Mucinous_Adenocarcinoma TCGA COREAD 6929718114 R02C01
TCGA-AM-5820-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625037 R03C02
TCGA-AM-5821-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625037 R02C01
TCGA-AU-3779-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316001 R04C01
TCGA-AU-6004-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042308159 R01C02
TCGA-AY-5543-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625037 R06C02
TCGA-AY-6196-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 6042308165 R06C01
TCGA-AY-6197-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042308159 R06C02
TCGA-AY-6386-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042308165 R01C02
TCGA-AY-A54L-01 Tumor Colon_Adenocarcinoma TCGA COREAD 9296931073 R01C02
TCGA-AY-A69D-01 Tumor Colon_Adenocarcinoma TCGA COREAD 9702496157 R05C01
TCGA-AY-A71X-01 Tumor Colon_Adenocarcinoma TCGA COREAD 9702496157 R03C02
TCGA-AY-A8YK-01 Tumor Colon_Adenocarcinoma TCGA COREAD 3999492120 R03C01
TCGA-AZ-4308-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041065 R03C01
TCGA-AZ-4313-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041065 R05C02
TCGA-AZ-4315-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041084 R02C02
TCGA-AZ-4323-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718079 R06C01
TCGA-AZ-4614-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041084 R01C02
TCGA-AZ-4615-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041007 R03C01
TCGA-AZ-4616-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718054 R03C01
TCGA-AZ-4681-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041088 R01C02
TCGA-AZ-4682-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041065 R05C01
TCGA-AZ-4684-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041088 R05C02
TCGA-AZ-5403-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625057 R02C01
TCGA-AZ-5407-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042308158 R04C02
TCGA-AZ-6598-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825020 R04C02
TCGA-AZ-6599-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825020 R05C01
TCGA-AZ-6600-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825020 R02C02
TCGA-AZ-6601-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825002 R05C01
TCGA-AZ-6603-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718053 R01C02
TCGA-AZ-6605-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718054 R01C02
TCGA-AZ-6606-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718065 R01C02
TCGA-AZ-6607-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718079 R03C02
TCGA-AZ-6608-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718065 R05C02
TCGA-BM-6198-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6055424075 R01C02
TCGA-CA-5254-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718065 R01C01
TCGA-CA-5255-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718053 R04C02
TCGA-CA-5256-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041084 R05C01
TCGA-CA-5796-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 6285625037 R05C01
TCGA-CA-5797-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625057 R06C01
TCGA-CA-6715-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718054 R05C02
TCGA-CA-6716-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718054 R02C01
TCGA-CA-6717-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 6929718079 R05C01
TCGA-CA-6718-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718054 R01C01
TCGA-CA-6719-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718079 R01C02
TCGA-CI-6619-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718081 R01C01
TCGA-CI-6620-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718058 R03C02
TCGA-CI-6621-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718061 R01C01
TCGA-CI-6622-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718061 R06C01
TCGA-CI-6623-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718061 R01C02
TCGA-CI-6624-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718058 R04C02
TCGA-CK-4947-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625037 R04C01
TCGA-CK-4948-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625068 R06C01
TCGA-CK-4950-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042308165 R03C01
TCGA-CK-4951-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 5775041084 R04C02
TCGA-CK-4952-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 6042308158 R03C01
TCGA-CK-5912-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625057 R01C01
TCGA-CK-5913-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625057 R05C01
TCGA-CK-5914-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625011 R05C02
TCGA-CK-5915-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625011 R01C02
TCGA-CK-5916-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625037 R02C02
TCGA-CK-6746-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718079 R02C02
TCGA-CK-6747-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718053 R03C01
TCGA-CK-6748-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 6929718079 R04C01
TCGA-CK-6751-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 6929718054 R06C01
TCGA-CL-4957-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6055424040 R03C02
TCGA-CL-5917-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718042 R01C02
TCGA-CL-5918-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718058 R05C01
TCGA-CM-4743-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316001 R06C02
TCGA-CM-4744-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041065 R06C02
TCGA-CM-4746-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041007 R05C01
TCGA-CM-4747-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041088 R02C01
TCGA-CM-4748-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 5775041084 R03C01
TCGA-CM-4750-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041007 R06C01
TCGA-CM-4751-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718053 R02C02
TCGA-CM-4752-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041088 R03C01
TCGA-CM-5341-01 Tumor Colon_Adenocarcinoma TCGA COREAD 5775041088 R05C01
TCGA-CM-5344-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316001 R06C01
TCGA-CM-5348-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316015 R06C01
TCGA-CM-5349-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316011 R06C01
TCGA-CM-5860-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625037 R05C02
TCGA-CM-5861-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625011 R04C01
TCGA-CM-5862-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625068 R04C01
TCGA-CM-5863-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 6929718053 R01C01
TCGA-CM-5864-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625068 R05C01
TCGA-CM-5868-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625057 R04C01
TCGA-CM-6161-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625037 R06C01
TCGA-CM-6162-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 6285625068 R01C02
TCGA-CM-6163-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929671148 R03C01
TCGA-CM-6164-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625068 R03C01
TCGA-CM-6165-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929671148 R06C01
TCGA-CM-6166-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625011 R05C01
TCGA-CM-6167-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929671148 R05C01
TCGA-CM-6168-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929671148 R04C01
TCGA-CM-6169-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625057 R04C02
TCGA-CM-6170-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625057 R03C01
TCGA-CM-6171-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625037 R03C01
TCGA-CM-6172-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625068 R01C01
TCGA-CM-6674-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718054 R03C02
TCGA-CM-6675-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718054 R04C01
TCGA-CM-6676-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718053 R02C01
TCGA-CM-6677-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718065 R04C01
TCGA-CM-6678-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718054 R04C02
TCGA-CM-6679-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718079 R05C02
TCGA-CM-6680-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718054 R06C02
TCGA-D5-5537-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6264509018 R04C02
TCGA-D5-5537-01-2 Tumor Colon_Adenocarcinoma TCGA COREAD 6264509127 R02C01
TCGA-D5-5538-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929671148 R02C01
TCGA-D5-5539-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 6285625011 R04C02
TCGA-D5-5540-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625011 R03C01
TCGA-D5-5541-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625011 R02C01
TCGA-D5-6529-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825028 R04C01
TCGA-D5-6530-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316011 R04C01
TCGA-D5-6531-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042308158 R05C02
TCGA-D5-6532-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042308165 R03C02
TCGA-D5-6533-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042308158 R02C01
TCGA-D5-6534-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 6264509087 R02C01
TCGA-D5-6534-01-2 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 6264509127 R05C01
TCGA-D5-6535-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316011 R01C01
TCGA-D5-6536-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042308159 R04C01
TCGA-D5-6537-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042308158 R03C02
TCGA-D5-6538-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316015 R01C01
TCGA-D5-6539-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316011 R05C01
TCGA-D5-6540-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 6042316001 R01C02
TCGA-D5-6541-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042308158 R01C01
TCGA-D5-6898-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6264509087 R04C01
TCGA-D5-6898-01-2 Tumor Colon_Adenocarcinoma TCGA COREAD 6264509087 R06C01
TCGA-D5-6922-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6264509127 R01C01
TCGA-D5-6923-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6264509127 R04C01
TCGA-D5-6924-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6264509018 R03C01
TCGA-D5-6924-01-2 Tumor Colon_Adenocarcinoma TCGA COREAD 6264509018 R06C02
TCGA-D5-6926-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6264509018 R01C02
TCGA-D5-6930-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 6264509087 R02C02
TCGA-D5-7000-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 6264509018 R04C01
TCGA-DC-4745-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6055424040 R06C01
TCGA-DC-4749-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6055424040 R06C02
TCGA-DC-5337-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718042 R06C01
TCGA-DC-5869-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718058 R06C01
TCGA-DC-6154-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718113 R03C02
TCGA-DC-6155-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718042 R03C02
TCGA-DC-6156-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718042 R02C02
TCGA-DC-6157-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718058 R02C01
TCGA-DC-6158-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718042 R04C02
TCGA-DC-6160-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718058 R01C02
TCGA-DC-6681-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718081 R03C02
TCGA-DC-6682-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718081 R01C02
TCGA-DC-6683-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718081 R05C02
TCGA-DM-A0X9-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316010 R04C02
TCGA-DM-A0XD-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316010 R06C02
TCGA-DM-A0XF-01 Tumor NA TCGA COREAD 6042316008 R02C01
TCGA-DM-A1D0-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316008 R04C01
TCGA-DM-A1D4-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316008 R06C01
TCGA-DM-A1D6-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 6042316008 R02C02
TCGA-DM-A1D7-01 Tumor NA TCGA COREAD 6042316008 R03C02
TCGA-DM-A1D8-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316010 R05C02
TCGA-DM-A1D9-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316008 R01C01
TCGA-DM-A1DA-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316008 R03C01
TCGA-DM-A1DB-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316008 R05C01
TCGA-DM-A1HA-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316008 R01C02
TCGA-DM-A1HB-01 Tumor NA TCGA COREAD 6929718086 R01C02
TCGA-DM-A280-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 6285625085 R04C02
TCGA-DM-A282-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929671163 R04C01
TCGA-DM-A285-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 6285625085 R02C01
TCGA-DM-A288-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 6285625085 R01C01
TCGA-DM-A28A-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625085 R05C02
TCGA-DM-A28C-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625085 R05C01
TCGA-DM-A28E-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625085 R01C02
TCGA-DM-A28F-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625085 R04C01
TCGA-DM-A28G-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625085 R06C02
TCGA-DM-A28H-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625085 R06C01
TCGA-DM-A28K-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 6285625085 R03C01
TCGA-DM-A28M-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6285625076 R06C02
TCGA-DT-5265-01 Tumor Rectal_Mucinous_Adenocarcinoma TCGA COREAD 6929718081 R04C01
TCGA-DY-A0XA-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6264509055 R02C01
TCGA-DY-A1DC-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6264509055 R03C01
TCGA-DY-A1DD-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6264509055 R04C01
TCGA-DY-A1DE-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6264509055 R05C01
TCGA-DY-A1DF-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6264509055 R06C01
TCGA-DY-A1DG-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6264509055 R01C02
TCGA-DY-A1H8-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6264509055 R02C02
TCGA-EF-5830-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718042 R05C02
TCGA-EF-5831-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718042 R06C02
TCGA-EI-6506-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6055424097 R06C01
TCGA-EI-6507-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6055424097 R03C01
TCGA-EI-6508-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6055424040 R04C01
TCGA-EI-6509-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6055424040 R02C02
TCGA-EI-6510-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6055424075 R06C01
TCGA-EI-6511-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6055424075 R02C02
TCGA-EI-6512-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6055424097 R01C01
TCGA-EI-6513-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6055424075 R05C01
TCGA-EI-6514-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6055424075 R02C01
TCGA-EI-6881-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718114 R05C02
TCGA-EI-6882-01 Tumor Rectal_Mucinous_Adenocarcinoma TCGA COREAD 6929718114 R03C02
TCGA-EI-6883-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718114 R06C01
TCGA-EI-6884-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718114 R02C02
TCGA-EI-6885-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718114 R04C01
TCGA-EI-6917-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718114 R01C02
TCGA-EI-7002-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718113 R05C02
TCGA-EI-7004-01 Tumor Rectal_Mucinous_Adenocarcinoma TCGA COREAD 6929718113 R04C02
TCGA-F4-6459-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825028 R03C01
TCGA-F4-6460-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825035 R05C02
TCGA-F4-6461-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825020 R05C02
TCGA-F4-6463-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 6042308159 R03C01
TCGA-F4-6569-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825028 R02C02
TCGA-F4-6570-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825020 R06C01
TCGA-F4-6703-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718054 R02C02
TCGA-F4-6704-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 6929718065 R03C02
TCGA-F4-6805-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718079 R01C01
TCGA-F4-6806-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718079 R02C01
TCGA-F4-6807-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718079 R03C01
TCGA-F4-6808-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718053 R06C01
TCGA-F4-6809-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718065 R02C02
TCGA-F4-6854-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6264509127 R06C01
TCGA-F5-6464-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6055424040 R05C02
TCGA-F5-6465-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6055424097 R05C01
TCGA-F5-6571-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718061 R03C01
TCGA-F5-6702-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718061 R04C01
TCGA-F5-6810-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718058 R05C02
TCGA-F5-6811-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718061 R04C02
TCGA-F5-6812-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718081 R02C02
TCGA-F5-6813-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718081 R06C01
TCGA-F5-6814-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718113 R06C02
TCGA-F5-6861-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718114 R01C01
TCGA-F5-6863-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718114 R03C01
TCGA-F5-6864-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718114 R04C02
TCGA-G4-6293-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042308159 R06C01
TCGA-G4-6294-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825035 R04C02
TCGA-G4-6295-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042308165 R05C02
TCGA-G4-6297-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316001 R05C01
TCGA-G4-6298-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316015 R02C01
TCGA-G4-6299-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825002 R04C01
TCGA-G4-6302-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 6042308158 R05C01
TCGA-G4-6303-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825002 R01C01
TCGA-G4-6306-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825028 R05C01
TCGA-G4-6307-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042308158 R04C01
TCGA-G4-6309-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718053 R05C02
TCGA-G4-6310-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316001 R03C02
TCGA-G4-6311-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042308159 R04C02
TCGA-G4-6314-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316011 R02C01
TCGA-G4-6315-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042308158 R06C01
TCGA-G4-6317-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316015 R04C02
TCGA-G4-6320-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316015 R03C01
TCGA-G4-6321-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042308158 R01C02
TCGA-G4-6322-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 6042308158 R02C02
TCGA-G4-6323-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6042316001 R02C02
TCGA-G4-6586-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825020 R01C01
TCGA-G4-6588-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825002 R06C01
TCGA-G4-6625-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825028 R02C01
TCGA-G4-6626-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825002 R03C01
TCGA-G4-6627-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6057825002 R02C01
TCGA-G4-6628-01 Tumor Colon_Adenocarcinoma TCGA COREAD 6929718065 R04C02
TCGA-G5-6233-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6055424097 R02C01
TCGA-G5-6235-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6055424040 R05C01
TCGA-G5-6572-01 Tumor Rectal_Adenocarcinoma TCGA COREAD 6929718061 R03C02
TCGA-G5-6641-01 Tumor Rectal_Mucinous_Adenocarcinoma TCGA COREAD 6929718061 R02C01
TCGA-NH-A50T-01 Tumor Colon_Adenocarcinoma TCGA COREAD 9296931074 R03C01
TCGA-NH-A50U-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 9702496157 R05C02
TCGA-NH-A50V-01 Tumor Colon_Adenocarcinoma TCGA COREAD 9296931073 R02C01
TCGA-NH-A5IV-01 Tumor Colon_Adenocarcinoma TCGA COREAD 9702496157 R06C02
TCGA-NH-A6GA-01 Tumor Colon_Adenocarcinoma TCGA COREAD 9702496157 R01C02
TCGA-NH-A6GB-01 Tumor Colon_Adenocarcinoma TCGA COREAD 9702496157 R04C01
TCGA-NH-A6GC-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 3999492120 R04C01
TCGA-NH-A8F7-01 Tumor Colon_Adenocarcinoma TCGA COREAD 3999492120 R05C02
TCGA-NH-A8F8-01 Tumor Colon_Adenocarcinoma TCGA COREAD 3999492120 R01C02
TCGA-QG-A5YV-01 Tumor Colon_Adenocarcinoma TCGA COREAD 9296931074 R05C01
TCGA-QG-A5YW-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 9296931073 R04C02
TCGA-QG-A5YX-01 Tumor Colon_Adenocarcinoma TCGA COREAD 9296931073 R03C01
TCGA-QG-A5Z1-01 Tumor Colon_Adenocarcinoma TCGA COREAD 9296931074 R01C01
TCGA-QG-A5Z2-01 Tumor Colon_Adenocarcinoma TCGA COREAD 9296931073 R05C02
TCGA-QL-A97D-01 Tumor Colon_Adenocarcinoma TCGA COREAD 3999492120 R02C01
TCGA-RU-A8FL-01 Tumor Colon_Adenocarcinoma TCGA COREAD 9702496157 R02C01
TCGA-SS-A7HO-01 Tumor NA TCGA COREAD 9702496157 R03C01
TCGA-T9-A92H-01 Tumor Colon_Adenocarcinoma TCGA COREAD 9702496157 R04C02
TCGA-WS-AB45-01 Tumor Colon_Mucinous_Adenocarcinoma TCGA COREAD 3999492120 R01C01
3331 Normal_mucosa Healthy GSE48684
3332 Normal_mucosa Healthy GSE48684
3333 Normal_mucosa Healthy GSE48684
3999 Normal_mucosa Healthy GSE48684
4000 Normal_mucosa Healthy GSE48684
4001 Normal_mucosa Healthy GSE48684
4002 Normal_mucosa Healthy GSE48684
4003 Normal_mucosa Healthy GSE48684
4004 Normal_mucosa Healthy GSE48684
4005 Normal_mucosa Healthy GSE48684
4006 Normal_mucosa Healthy GSE48684
3325 Normal_mucosa Healthy GSE48684
3326 Normal_mucosa Healthy GSE48684
3327 Normal_mucosa Healthy GSE48684
3328 Normal_mucosa Healthy GSE48684
3329 Normal_mucosa Healthy GSE48684
3330 Normal_mucosa Healthy GSE48684
CCR141 Normal_mucosa Colon_Adenocarcinoma_norm GSE48684
CCR169 Normal_mucosa Colon_Adenocarcinoma_norm GSE48684
5802 Normal_mucosa Colon_Adenocarcinoma_norm GSE48684
9043 Normal_mucosa Colon_Adenocarcinoma_norm GSE48684
9579 Normal_mucosa Colon_Adenocarcinoma_norm GSE48684
11827 Normal_mucosa Colon_Adenocarcinoma_norm GSE48684
11839 Normal_mucosa Colon_Adenocarcinoma_norm GSE48684
11879 Normal_mucosa Colon_Adenocarcinoma_norm GSE48684
3212 Normal_mucosa Colon_Adenocarcinoma_norm GSE48684
9047 Normal_mucosa Colon_Adenocarcinoma_norm GSE48684
11831 Normal_mucosa Colon_Adenocarcinoma_norm GSE48684
CCR221 Normal_mucosa Colon_Adenocarcinoma_norm GSE48684
CCR209 Normal_mucosa Colon_Adenocarcinoma_norm GSE48684
CCR281 Normal_mucosa Colon_Adenocarcinoma_norm GSE48684
CCR289 Normal_mucosa Colon_Adenocarcinoma_norm GSE48684
CCR253 Normal_mucosa Colon_Adenocarcinoma_norm GSE48684
CCR197 Normal_mucosa Colon_Adenocarcinoma_norm GSE48684
CCR193 Normal_mucosa Colon_Adenocarcinoma_norm GSE48684
CCR217 Normal_mucosa Colon_Adenocarcinoma_norm GSE48684
CCR185 Normal_mucosa Colon_Adenocarcinoma_norm GSE48684
CCR181 Normal_mucosa Colon_Adenocarcinoma_norm GSE48684
CCR233 Normal_mucosa Colon_Adenocarcinoma_norm GSE48684
CCR139 Normal_mucosa Colon_Adenocarcinoma_norm GSE48684
CCR277 Normal_mucosa Colon_Adenocarcinoma_norm GSE48684
Probe_ID CHR MAPINFO arm gene distancetoGene feature cgi feat.cgi conserved_tfbs Exclusion criteria
cg09248054 1 969257 p AGRN NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg27541454 1 975551 p AGRN NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg22497741 1 1475644 p C1orf70 NA Body shore Body - shore NA Within telomer region
cg16306898 1 1475675 p C1orf70 NA 1stExon shore 1stExon - shore NA Within telomer region
cg16601494 1 1475737 p C1orf70 NA 5'UTR shore 5'UTR - shore V$P53_01 Positivity in blood
cg15487867 1 1475742 p C1orf70 NA TSS200 shore TSS200 - shore V$P53_01 Within telomer region
cg24368383 1 1565856 p MIB2 NA Body island Body - island V$MYOGNF1_01 Not overlapping Differentially Methylated Region
cg04021697 1 3567303 p WDR8 NA TSS1500 island TSS1500 - island NA Positivity in blood
cg15472784 1 3663531 p KIAA0495 NA 1stExon island 1stExon - island NA Within telomer region
cg25467973 1 3663705 p KIAA0495 NA 1stExon island 1stExon - island NA Within telomer region
cg05121790 1 12123554 p TNFRSF8 NA 5'UTR island 5'UTR - island NA Not overlapping Differentially Methylated Region
cg21819468 1 13910569 p PDPN NA TSS1500 island TSS1500 - island NA Not overlapping Differentially Methylated Region
cg17456100 1 22140859 p LDLRAD2 NA Body shore Body - shore NA Too far from other differentially methylated probes (>150bp)
cg15467646 1 22141014 p LDLRAD2 NA Body island Body - island NA Too far from other differentially methylated probes (>150bp)
cg24685006 1 36043014 p TFAP2E NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg08599259 1 38510933 p POU3F1 NA 3'UTR island 3'UTR - island NA Not overlapping Differentially Methylated Region
cg23671221 1 44031300 p PTPRF NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg04023150 1 44873064 p RNF220 NA 5'UTR island 5'UTR - island NA Too far from other differentially methylated probes (>150bp)
cg10224098 1 44873229 p RNF220 NA 5'UTR island 5'UTR - island NA Positivity in blood
cg16732616 1 50886782 p DMRTA2 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg19166660 1 57889035 p DAB1 NA 5'UTR island 5'UTR - island NA Not overlapping Differentially Methylated Region
cg05375728 1 58715539 p DAB1 NA 5'UTR island 5'UTR - island NA Selected probes
cg27510182 1 58715553 p DAB1 NA 5'UTR island 5'UTR - island NA Selected probes
cg02283366 1 63785544 p FOXD3 -3186 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg25339566 1 67218165 p TCTEX1D1 NA 5'UTR island 5'UTR - island NA Not overlapping Differentially Methylated Region
cg14520424 1 70034491 p PIN1P1 -191367 IGR island IGR - island NA Too far from other differentially methylated probes (>150bp)
cg08146483 1 75602412 p LHX8 NA Body island Body - island NA Positivity in blood
cg13463054 1 77333159 p ST6GALNAC5 NA TSS200 island TSS200 - island NA Not overlapping Differentially Methylated Region
cg04077662 1 77333229 p ST6GALNAC5 NA 1stExon island 1stExon - island NA Not overlapping Differentially Methylated Region
cg25026529 1 91183051 p BARHL2 NA TSS1500 shore TSS1500 - shore V$USF_C Not overlapping Differentially Methylated Region
cg24884703 1 91185422 p BARHL2 7843 IGR island IGR - island V$E2F_02 Not overlapping Differentially Methylated Region
cg22333214 1 98511789 p MIR137 NA TSS200 shore TSS200 - shore NA Not overlapping Differentially Methylated Region
cg14991984 1 99470129 p LPPR5 NA 1stExon island 1stExon - island NA Not overlapping Differentially Methylated Region
cg06543087 1 108508548 p VAV3 NA TSS1500 shore TSS1500 - shore NA Not overlapping Differentially Methylated Region
cg20302133 1 111217194 p KCNA3 NA 1stExon island 1stExon - island NA Within centromer region
cg26013553 1 111217406 p KCNA3 NA 1stExon island 1stExon - island NA Within centromer region
cg11595545 1 111217497 p KCNA3 NA 1stExon island 1stExon - island NA Within centromer region
cg01423964 1 111217575 p KCNA3 NA 1stExon island 1stExon - island V$NRSF_01 Within centromer region
cg06750832 1 111217691 p KCNA3 NA TSS200 island TSS200 - island NA Within centromer region
cg07808555 1 111217712 p KCNA3 NA TSS200 island TSS200 - island NA Within centromer region
cg14175690 1 119527638 p TBX15 NA 5'UTR shore 5'UTR - shore NA Positivity in blood
cg01439876 1 119543336 p WARS2 -30503 IGR island IGR - island NA Positivity in blood
cg01959730 1 119548825 p WARS2 -25014 IGR shore IGR - shore NA Positivity in blood
cg02457680 1 154475139 q TDRD10 NA 5'UTR island 5'UTR - island NA Not overlapping Differentially Methylated Region
cg23089825 1 170630558 q PRRX1 -2755 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg16993043 1 200008026 q NR5A2 NA Body shore Body - shore NA Not overlapping Differentially Methylated Region
cg09557387 1 207818395 q CR1L NA TSS200 island TSS200 - island NA Positivity in blood
cg07914084 1 237205999 q RYR2 NA Body island Body - island NA Positivity in blood
cg02328010 1 237206482 q RYR2 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg18863333 2 5833195 p SOX11 NA 1stExon island 1stExon - island NA Not overlapping Differentially Methylated Region
cg04043795 2 5836366 p SOX11 NA 3'UTR island 3'UTR - island NA Not overlapping Differentially Methylated Region
cg06333058 2 29338077 p CLIP4 NA TSS1500 island TSS1500 - island NA Selected probes
cg25737323 2 29338100 p CLIP4 NA TSS1500 island TSS1500 - island V$SPZ1_01 Selected probes
cg23428985 2 29338113 p CLIP4 NA TSS200 island TSS200 - island NA Selected probes
cg23255835 2 29338121 p CLIP4 NA TSS200 island TSS200 - island NA Selected probes
cg03135351 2 29338258 p CLIP4 NA TSS200 island TSS200 - island NA Selected probes
cg08808128 2 29338432 p CLIP4 NA 1stExon island 1stExon - island NA Too far from other differentially methylated probes (>150bp)
cg16439198 2 38302674 p CYP1B1 NA 5'UTR island 5'UTR - island NA Not overlapping Differentially Methylated Region
cg14411266 2 40679582 p SLC8A1 NA 5'UTR shore 5'UTR - shore NA Not overlapping Differentially Methylated Region
cg22884656 2 45157296 p SIX3 -11741 IGR shore IGR - shore NA Not overlapping Differentially Methylated Region
cg23325963 2 45160093 p SIX3 -8944 IGR island IGR - island NA Positivity in blood
cg03714619 2 45160445 p SIX3 -8592 IGR shore IGR - shore NA Positivity in blood
cg02155398 2 45160490 p SIX3 -8547 IGR shore IGR - shore NA Positivity in blood
cg00097146 2 45171818 p SIX3 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg17526573 2 50574708 p NRXN1 NA Body island Body - island NA Positivity in blood
cg27364741 2 63281069 p OTX1 NA Body island Body - island NA Selected probes
cg25622366 2 63281139 p OTX1 NA Body island Body - island NA Selected probes
cg04654530 2 63282702 p OTX1 NA Body island Body - island NA Positivity in blood
cg07974511 2 63283013 p OTX1 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg21472506 2 63283967 p OTX1 NA 3'UTR island 3'UTR - island NA Selected probes
cg23229261 2 63284066 p OTX1 NA 3'UTR island 3'UTR - island NA Selected probes
cg10122865 2 63284132 p OTX1 NA 3'UTR island 3'UTR - island NA Selected probes
cg11536474 2 63286049 p OTX1 8112 IGR island IGR - island NA Positivity in blood
cg11573679 2 68546467 p CNRIP1 NA 1stExon island 1stExon - island NA Selected probes
cg07080358 2 68546507 p CNRIP1 NA 1stExon island 1stExon - island NA Selected probes
cg24171907 2 68546579 p CNRIP1 NA 1stExon island 1stExon - island NA Selected probes
cg19656282 2 74742786 p TLX2 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg21185289 2 74743437 p TLX2 NA 3'UTR island 3'UTR - island NA Not overlapping Differentially Methylated Region
cg08189989 2 105459164 q POU3F3 -12805 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg17529832 2 105461096 q POU3F3 -10873 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg21858380 2 119916486 q C1QL2 NA TSS200 island TSS200 - island NA Positivity in blood
cg07212778 2 119916510 q C1QL2 NA TSS200 island TSS200 - island NA Too far from other differentially methylated probes (>150bp)
cg15975865 2 127413831 q GYPC NA 5'UTR island 5'UTR - island NA Not overlapping Differentially Methylated Region
cg19484420 2 127414108 q GYPC NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg26820055 2 131721099 q ARHGEF4 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg26210445 2 162273326 q TBR1 NA 1stExon island 1stExon - island NA Positivity in blood
cg20935165 2 172972840 q DLX2 8674 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg06952671 2 182322268 q ITGA4 NA 5'UTR island 5'UTR - island NA Selected probes
cg21995919 2 182322279 q ITGA4 NA 5'UTR island 5'UTR - island NA Selected probes
cg25024074 2 182322501 q ITGA4 NA 1stExon island 1stExon - island NA Too far from other differentially methylated probes (>150bp)
cg11947981 2 182322749 q ITGA4 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg16918905 2 220361609 q GMPPA -1978 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg00793935 2 234847769 q TRPM8 NA Body island Body - island NA Positivity in blood
cg10429608 2 238864632 q UBE2F-SCLY -10955 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg23141355 3 44063593 p MIR138-1 -92111 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg22702772 3 48699012 p CELSR3 NA 1stExon island 1stExon - island NA Not overlapping Differentially Methylated Region
cg20072171 3 62356962 p FEZF2 NA Body island Body - island V$FAC1_01 Not overlapping Differentially Methylated Region
cg08668199 3 127795571 q RUVBL1 -4229 IGR island IGR - island NA Positivity in blood
cg11940285 3 129693385 q TRH NA 5'UTR island 5'UTR - island NA Positivity in blood
cg22512438 3 129693489 q TRH NA 5'UTR island 5'UTR - island NA Selected probes
cg02700891 3 129693586 q TRH NA 5'UTR island 5'UTR - island NA Selected probes
cg17373442 3 142839991 q CHST2 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg12892506 3 147113918 q ZIC4 NA Body island Body - island NA Positivity in blood
cg14768785 3 172166517 q GHSR NA TSS1500 island TSS1500 - island NA Not overlapping Differentially Methylated Region
cg07393736 3 172167810 q GHSR 2477 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg02119363 3 179754603 q PEX5L NA TSS200 island TSS200 - island NA Selected probes
cg13473356 3 179754613 q PEX5L NA TSS200 island TSS200 - island NA Selected probes
cg18780412 3 179755086 q PEX5L NA TSS1500 island TSS1500 - island NA Not overlapping Differentially Methylated Region
cg24000814 3 184301730 q EPHB3 22143 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg16376000 3 192127330 q FGF12 NA TSS1500 island TSS1500 - island NA Positivity in blood
cg17393267 3 192127356 q FGF12 NA TSS1500 island TSS1500 - island NA Within telomer region
cg08002883 3 192127457 q FGF12 NA TSS1500 island TSS1500 - island NA Within telomer region
cg22834653 3 192232077 q FGF12 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg17128947 4 779480 p CPLX1 NA 3'UTR island 3'UTR - island NA Positivity in blood
cg17397631 4 779880 p CPLX1 NA 3'UTR island 3'UTR - island NA Positivity in blood
cg27655158 4 1396593 p CRIPAK 11253 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg14602530 4 4859772 p MSX1 -1620 IGR island IGR - island V$IK1_01;V$IK3_01 Positivity in blood
cg15092343 4 4860061 p MSX1 NA TSS1500 island TSS1500 - island NA Positivity in blood
Supplementary File 2B
Differentially methylated probes identified with exclusion criteria
cg23300732 4 5053496 p STK32B NA TSS200 island TSS200 - island NA Within telomer region
cg08323075 4 5053504 p STK32B NA TSS200 island TSS200 - island NA Within telomer region
cg04575395 4 5892072 p CRMP1 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg18790597 4 17783331 p FAM184B NA TSS200 island TSS200 - island NA Too far from other differentially methylated probes (>150bp)
cg07696699 4 17783502 p FAM184B NA TSS1500 island TSS1500 - island NA Positivity in blood
cg07907386 4 41749443 p PHOX2B NA Body island Body - island NA Positivity in blood
cg24657817 4 42153708 p BEND4 NA Body island Body - island V$MYOGNF1_01 Not overlapping Differentially Methylated Region
cg23209990 4 55097576 q PDGFRA NA 5'UTR island 5'UTR - island NA Not overlapping Differentially Methylated Region
cg05754435 4 55992155 q KDR NA TSS1500 island TSS1500 - island NA Not overlapping Differentially Methylated Region
cg13139972 4 107957430 q DKK2 NA 1stExon island 1stExon - island NA Not overlapping Differentially Methylated Region
cg04188273 4 110223830 q COL25A1 NA TSS200 island TSS200 - island NA Not overlapping Differentially Methylated Region
cg21077559 4 122686319 q TMEM155 NA 1stExon island 1stExon - island NA Not overlapping Differentially Methylated Region
cg04638468 4 122686453 q TMEM155 NA TSS200 island TSS200 - island NA Selected probes
cg08553437 4 122686456 q TMEM155 NA TSS200 island TSS200 - island NA Selected probes
cg07978472 4 122686493 q TMEM155 NA TSS200 island TSS200 - island NA Selected probes
cg23901852 4 126238384 q FAT4 NA 1stExon island 1stExon - island V$TAXCREB_01 Not overlapping Differentially Methylated Region
cg10196720 4 134069593 q PCDH10 NA TSS1500 island TSS1500 - island NA Positivity in blood
cg17504999 4 134072723 q PCDH10 NA 1stExon island 1stExon - island NA Not overlapping Differentially Methylated Region
cg03112087 4 142053720 q RNF150 NA 1stExon island 1stExon - island NA Not overlapping Differentially Methylated Region
cg15042811 4 144621971 q FREM3 NA TSS200 island TSS200 - island NA Not overlapping Differentially Methylated Region
cg24199834 4 147560126 q POU4F2 NA 1stExon island 1stExon - island NA Positivity in blood
cg16887264 4 147561775 q POU4F2 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg00699993 4 158141570 q GRIA2 NA TSS200 island TSS200 - island NA Positivity in blood
cg26814276 4 172734266 q GALNTL6 NA TSS1500 island TSS1500 - island NA Not overlapping Differentially Methylated Region
cg15707093 4 174450353 q NBLA00301 NA TSS1500 island TSS1500 - island NA Not overlapping Differentially Methylated Region
cg14732324 5 528621 p MIR4456 -7334 IGR island IGR - island NA Within telomer region
cg14564616 5 1876337 p IRX4 -1204 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg06585708 5 3602413 p IRX1 6245 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg08466792 5 3603227 p IRX1 7059 IGR shore IGR - shore NA Not overlapping Differentially Methylated Region
cg25092681 5 16180033 p MARCH11 NA TSS200 island TSS200 - island NA Selected probes
cg00339556 5 16180048 p MARCH11 NA TSS200 island TSS200 - island NA Selected probes
cg01791874 5 16180055 p MARCH11 NA TSS200 island TSS200 - island NA Selected probes
cg17030173 5 16180062 p MARCH11 NA TSS200 island TSS200 - island NA Positivity in blood
cg17712694 5 16180068 p MARCH11 NA TSS200 island TSS200 - island NA Positivity in blood
cg16150752 5 16180072 p MARCH11 NA TSS200 island TSS200 - island NA Selected probes
cg21901718 5 16180076 p MARCH11 NA TSS200 island TSS200 - island NA Selected probes
cg23065934 5 16180266 p MARCH11 NA TSS1500 island TSS1500 - island NA Positivity in blood
cg10932018 5 54516487 q MCIDAS 1062 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg18456523 5 54516805 q MCIDAS 1380 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg14608384 5 54516879 q MCIDAS 1454 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg18250028 5 71015523 q CARTPT NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg17448335 5 76249776 q CRHBP NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg04502985 5 77268452 q AP3B1 -29698 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg23180938 5 115152485 q CDO1 NA TSS200 island TSS200 - island NA Not overlapping Differentially Methylated Region
cg08516516 5 115152492 q CDO1 NA TSS200 island TSS200 - island NA Not overlapping Differentially Methylated Region
cg11036833 5 115152494 q CDO1 NA TSS200 island TSS200 - island NA Not overlapping Differentially Methylated Region
cg22488797 5 134363324 q PITX1 -100 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg18443359 5 134374693 q PITX1 11269 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg01283246 5 135266135 q FBXL21 NA 1stExon island 1stExon - island NA Not overlapping Differentially Methylated Region
cg24847829 5 136834464 q SPOCK1 NA 5'UTR island 5'UTR - island NA Selected probes
cg14650610 5 136834492 q SPOCK1 NA 5'UTR island 5'UTR - island NA Selected probes
cg23445461 5 140864733 q PCDHGA4 NA Body island Body - island NA Positivity in blood
cg20755170 5 145720024 q POU4F3 NA 3'UTR island 3'UTR - island NA Not overlapping Differentially Methylated Region
cg07136998 5 168728081 q SLIT3 NA 5'UTR island 5'UTR - island NA Positivity in blood
cg18705773 5 170743564 q TLX3 7276 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg05560435 5 172671526 q NKX2-5 12419 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg17228900 6 391764 p IRF4 NA 5'UTR island 5'UTR - island NA Within telomer region
cg06392169 6 391936 p IRF4 NA 5'UTR island 5'UTR - island NA Within telomer region
cg21277995 6 393239 p IRF4 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg00110654 6 10385489 p TFAP2A-AS1 -11427 IGR island IGR - island NA Positivity in blood
cg24452128 6 10390919 p TFAP2A-AS1 -5997 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg17754510 6 10391412 p TFAP2A-AS1 -5504 IGR shore IGR - shore NA Not overlapping Differentially Methylated Region
cg05452406 6 10881891 p GCM2 NA Body island Body - island NA Positivity in blood
cg10903903 6 27647843 p LINC01012 -13971 IGR island IGR - island NA Positivity in blood
cg15490715 6 29521568 p UBD -1821 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg22617773 6 29521751 p UBD -1638 IGR island IGR - island NA Selected probes
cg14278853 6 29521756 p UBD -1633 IGR island IGR - island NA Selected probes
cg17394649 6 29760164 p HCG4 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg27011480 6 30228083 p HLA-L NA Body island Body - island NA Positivity in blood
cg27200446 6 41606439 p MDFI NA 5'UTR island 5'UTR - island NA Not overlapping Differentially Methylated Region
cg01883425 6 41606770 p MDFI NA Body shore Body - shore NA Not overlapping Differentially Methylated Region
cg18884037 6 62996214 q KHDRBS2 NA TSS200 island TSS200 - island NA Not overlapping Differentially Methylated Region
cg05447008 6 73331114 q KCNQ5 NA TSS1500 island TSS1500 - island NA Not overlapping Differentially Methylated Region
cg00852573 6 73331405 q KCNQ5 NA TSS200 island TSS200 - island NA Not overlapping Differentially Methylated Region
cg16334314 6 84418789 q SNAP91 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg14367020 6 99292286 q POU3F2 9706 IGR shore IGR - shore NA Positivity in blood
cg17386213 6 108488335 q NR2E1 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg05085230 6 133562461 q EYA4 NA TSS200 island TSS200 - island NA Selected probes
cg08712932 6 133562463 q EYA4 NA TSS200 island TSS200 - island NA Selected probes
cg11664500 6 133562479 q EYA4 NA TSS200 island TSS200 - island NA Selected probes
cg14287112 6 133562485 q EYA4 NA TSS200 island TSS200 - island NA Selected probes
cg22871668 6 133562492 q EYA4 NA TSS200 island TSS200 - island NA Selected probes
cg00356183 7 751833 p PRKAR1B NA 5'UTR island 5'UTR - island NA Not overlapping Differentially Methylated Region
cg08558397 7 752149 p PRKAR1B NA 5'UTR island 5'UTR - island NA Within telomer region
cg16305865 7 752180 p PRKAR1B NA 5'UTR shore 5'UTR - shore NA Within telomer region
cg20381963 7 752238 p PRKAR1B NA 5'UTR shore 5'UTR - shore NA Positivity in blood
cg18601167 7 752286 p PRKAR1B NA 5'UTR shore 5'UTR - shore NA Within telomer region
cg13895235 7 752292 p PRKAR1B NA 5'UTR shore 5'UTR - shore NA Within telomer region
cg23244488 7 19146032 p TWIST1 -9059 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg02400740 7 19157938 p TWIST1 NA TSS1500 island TSS1500 - island NA Not overlapping Differentially Methylated Region
cg24885417 7 24323764 p NPY NA TSS200 island TSS200 - island NA Positivity in blood
cg16964348 7 24323799 p NPY NA TSS200 island TSS200 - island NA Positivity in blood
cg25884711 7 24323840 p NPY NA 5'UTR island 5'UTR - island NA Positivity in blood
cg21097881 7 24323939 p NPY NA 5'UTR island 5'UTR - island NA Positivity in blood
cg24245418 7 24324976 p NPY NA Body island Body - island NA Positivity in blood
cg21773872 7 30722320 p CRHR2 NA TSS200 island TSS200 - island NA Not overlapping Differentially Methylated Region
cg05809668 7 35301188 p TBX20 30076 IGR island IGR - island NA Positivity in blood
cg17093995 7 49815502 p VWC2 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg19868631 7 54609776 p VSTM2A NA TSS1500 island TSS1500 - island NA Not overlapping Differentially Methylated Region
cg02300154 7 70597058 q WBSCR17 NA TSS1500 island TSS1500 - island NA Too far from other differentially methylated probes (>150bp)
cg03044249 7 70597065 q WBSCR17 NA TSS1500 island TSS1500 - island NA Positivity in blood
cg05223720 7 71801793 q CALN1 NA 5'UTR island 5'UTR - island NA Not overlapping Differentially Methylated Region
cg12973591 7 93519473 q TFPI2 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg20230721 7 93519855 q TFPI2 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg16934178 7 93520074 q TFPI2 NA TSS200 island TSS200 - island NA Not overlapping Differentially Methylated Region
cg01307939 7 98467571 q TMEM130 NA 5'UTR island 5'UTR - island NA Not overlapping Differentially Methylated Region
cg07697895 7 116963259 q WNT2 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg04153784 7 127672235 q SND1 NA Body island Body - island NA Too far from other differentially methylated probes (>150bp)
cg12628196 7 127672458 q SND1 NA Body island Body - island NA Positivity in blood
cg09087503 7 127672473 q SND1 NA Body island Body - island NA Selected probes
cg09296001 7 127672564 q SND1 NA Body island Body - island NA Selected probes
cg12345672 7 127672658 q SND1 NA Body island Body - island NA Selected probes
cg03514404 7 143579665 q FAM115A NA 5'UTR shelf 5'UTR - shelf NA Selected probes
cg01030534 7 143579698 q FAM115A NA 5'UTR shelf 5'UTR - shelf NA Selected probes
cg03225210 7 143579951 q FAM115A NA 5'UTR shelf 5'UTR - shelf NA Too far from other differentially methylated probes (>150bp)
cg02864844 7 149917263 q ACTR3C -27038 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg21532325 7 151107400 q WDR86 NA TSS1500 island TSS1500 - island NA Not overlapping Differentially Methylated Region
cg19814400 7 158936632 q VIPR2 NA Body island Body - island NA Within telomer region
cg21038156 7 158936739 q VIPR2 NA Body island Body - island NA Within telomer region
cg18349835 7 158937107 q VIPR2 NA Body island Body - island NA Within telomer region
cg03976877 7 158937610 q VIPR2 NA 1stExon island 1stExon - island NA Not overlapping Differentially Methylated Region
cg01200640 8 687384 p ERICH1 73184 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg26777883 8 688417 p ERICH1 74217 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg04218812 8 9763263 p MIR124-1 2365 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg18577280 8 16884549 p EFHA2 NA TSS200 island TSS200 - island NA Too far from other differentially methylated probes (>150bp)
cg19677607 8 24772270 p NEFM NA TSS200 island TSS200 - island V$LMO2COM_01 Not overlapping Differentially Methylated Region
cg04118306 8 24772350 p NEFM NA TSS200 island TSS200 - island NA Selected probes
cg03169018 8 24772435 p NEFM NA TSS200 island TSS200 - island NA Selected probes
cg04555373 8 31497042 p NRG1 NA TSS1500 island TSS1500 - island NA Not overlapping Differentially Methylated Region
cg24946597 8 31497464 p NRG1 NA 5'UTR island 5'UTR - island NA Positivity in blood
cg21517947 8 41167107 p SFRP1 NA TSS200 island TSS200 - island NA Not overlapping Differentially Methylated Region
cg05166490 8 41754172 p ANK1 NA 1stExon island 1stExon - island NA Within centromer region
cg17331296 8 41754181 p ANK1 NA 1stExon island 1stExon - island NA Within centromer region
cg15531403 8 53852184 q NPBWR1 NA TSS1500 island TSS1500 - island NA Positivity in blood
cg07770968 8 53852422 q NPBWR1 NA TSS200 island TSS200 - island NA Not overlapping Differentially Methylated Region
cg16491617 8 54164391 q OPRK1 NA TSS200 island TSS200 - island NA Not overlapping Differentially Methylated Region
cg11071231 8 57069907 q PLAG1 -3561 IGR island IGR - island NA Selected probes
cg16504626 8 57070013 q PLAG1 -3455 IGR island IGR - island NA Selected probes
cg04612444 8 57358713 q PENK NA 5'UTR island 5'UTR - island NA Positivity in blood
cg25260137 8 65282185 q LINC00966 -3590 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg25900085 8 65291513 q MIR124-2 NA TSS200 shore TSS200 - shore NA Positivity in blood
cg18065361 8 67344588 q ADHFE1 NA TSS200 island TSS200 - island NA Not overlapping Differentially Methylated Region
cg20295442 8 67344665 q ADHFE1 NA TSS200 island TSS200 - island NA Selected probes
cg20912169 8 67344720 q ADHFE1 NA 5'UTR island 5'UTR - island NA Selected probes
cg14353137 8 67873799 q TCF24 15063 IGR island IGR - island NA Too far from other differentially methylated probes (>150bp)
cg20980783 8 67874178 q TCF24 15442 IGR island IGR - island NA Selected probes
cg26618965 8 67874206 q TCF24 15470 IGR island IGR - island NA Selected probes
cg22001496 8 69243486 q MIR548H4 529 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg21479226 8 69244510 q MIR548H4 1553 IGR shore IGR - shore NA Not overlapping Differentially Methylated Region
cg25832771 8 72756058 q MSC NA 1stExon island 1stExon - island NA Selected probes
cg09734791 8 72756155 q MSC NA 1stExon island 1stExon - island V$E47_01 Selected probes
cg05690644 8 97158015 q GDF6 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg13211683 8 97171827 q GDF6 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg00421139 8 97172961 q GDF6 NA 1stExon island 1stExon - island NA Not overlapping Differentially Methylated Region
cg18233405 8 98290148 q TSPYL5 NA 1stExon island 1stExon - island NA Not overlapping Differentially Methylated Region
cg16462462 8 117950825 q C8orf85 NA Body shore Body - shore NA Positivity in blood
cg13912117 8 132054555 q ADCY8 262008 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg17698295 8 145106299 q OPLAH NA Body island Body - island NA Within telomer region
cg17301223 8 145106438 q OPLAH NA Body island Body - island NA Within telomer region
cg22882523 8 145107012 q OPLAH NA Body island Body - island NA Positivity in blood
cg14058647 9 88137909 q AGTPBP1 -23545 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg24393316 9 100616469 q FOXE1 NA 1stExon island 1stExon - island V$TAXCREB_01 Positivity in blood
cg24039697 10 8094534 p FLJ45983 NA Body island Body - island NA Positivity in blood
cg18794404 10 22542024 p LOC100130992 1023 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg05099508 10 22634432 p SPAG6 NA 1stExon island 1stExon - island NA Selected probes
cg24031355 10 22634439 p SPAG6 NA 1stExon island 1stExon - island NA Selected probes
cg23068913 10 23463377 p PTF1A -18083 IGR island IGR - island NA Positivity in blood
cg24487076 10 23983496 p KIAA1217 NA TSS200 island TSS200 - island NA Selected probes
cg13882278 10 23983498 p KIAA1217 NA TSS200 island TSS200 - island NA Selected probes
cg08539841 10 23983538 p KIAA1217 NA TSS200 island TSS200 - island V$AHRARNT_01 Not overlapping Differentially Methylated Region
cg07825347 10 43600497 q RET NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg06365057 10 50323706 q C10orf72 NA TSS200 island TSS200 - island NA Not overlapping Differentially Methylated Region
cg20744625 10 64578469 q EGR2 NA 5'UTR island 5'UTR - island NA Not overlapping Differentially Methylated Region
cg06419761 10 72043661 q LRRC20 -15068 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg11036831 10 82116382 q DYDC2 NA TSS200 island TSS200 - island NA Too far from other differentially methylated probes (>150bp)
cg03701427 10 82117089 q DYDC1 NA TSS1500 island TSS1500 - island NA Positivity in blood
cg05316043 10 83634974 q NRG3 NA TSS200 island TSS200 - island NA Not overlapping Differentially Methylated Region
cg17538572 10 94834763 q CYP26A1 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg17863743 10 100993587 q HPSE2 NA Body shore Body - shore NA Not overlapping Differentially Methylated Region
cg12118269 10 102893980 q TLX1 NA Body island Body - island NA Selected probes
cg24812837 10 102894120 q TLX1 NA Body island Body - island NA Selected probes
cg14861089 10 102895043 q TLX1 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg05482942 10 102899285 q TLX1 8224 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg14038391 10 102900130 q TLX1 9069 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg17101450 10 102900365 q TLX1 9304 IGR shore IGR - shore NA Not overlapping Differentially Methylated Region
cg25209842 10 103536342 q FGF8 NA TSS1500 island TSS1500 - island NA Not overlapping Differentially Methylated Region
cg23095743 10 104000831 q PITX3 NA 5'UTR island 5'UTR - island NA Positivity in blood
cg21384402 10 105036701 q INA NA TSS1500 island TSS1500 - island NA Selected probes
cg24680586 10 105036727 q INA NA TSS200 island TSS200 - island NA Selected probes
cg18932798 10 105037503 q INA NA 1stExon island 1stExon - island NA Not overlapping Differentially Methylated Region
cg02320740 10 106400259 q SORCS3 NA TSS1500 island TSS1500 - island NA Too far from other differentially methylated probes (>150bp)
cg14752336 10 106400454 q SORCS3 NA TSS1500 island TSS1500 - island NA Too far from other differentially methylated probes (>150bp)
cg03958798 10 106400686 q SORCS3 NA TSS200 island TSS200 - island NA Not overlapping Differentially Methylated Region
cg13320291 10 118030970 q GFRA1 NA Body island Body - island V$OLF1_01;V$ROAZ_01 Not overlapping Differentially Methylated Region
cg05667348 10 118892581 q VAX1 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg24390913 10 118899788 q VAX1 6987 IGR island IGR - island NA Positivity in blood
cg19912142 10 119494671 q EMX2OS 192715 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg14072515 10 125732604 q CHST15 -34578 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg08701047 10 130085199 q MKI67 190274 IGR open sea IGR - open sea NA Not overlapping Differentially Methylated Region
cg27513573 10 131768098 q CTAGE7P -94064 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg03109827 10 133110349 q TCERG1L NA TSS1500 island TSS1500 - island NA Not overlapping Differentially Methylated Region
cg02886408 10 133796164 q BNIP3 NA TSS1500 island TSS1500 - island NA Not overlapping Differentially Methylated Region
cg12816961 10 134598927 q NKX6-2 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg25774643 11 627175 p SCT NA TSS200 island TSS200 - island NA Not overlapping Differentially Methylated Region
cg12928379 11 637175 p DRD4 NA TSS200 island TSS200 - island NA Within telomer region
cg09607276 11 637491 p DRD4 NA 1stExon island 1stExon - island NA Within telomer region
cg25098208 11 8190659 p RIC3 NA TSS200 island TSS200 - island NA Not overlapping Differentially Methylated Region
cg02027945 11 20618230 p SLC6A5 -2716 IGR island IGR - island NA Positivity in blood
cg01642521 11 20618250 p SLC6A5 -2696 IGR island IGR - island NA Positivity in blood
cg14749465 11 20690720 p NELL1 NA TSS1500 island TSS1500 - island NA Selected probes
cg02510267 11 20690807 p NELL1 NA TSS1500 island TSS1500 - island NA Selected probes
cg23861668 11 20691126 p NELL1 NA 5'UTR island 5'UTR - island NA Selected probes
cg14689623 11 20691161 p NELL1 NA 5'UTR island 5'UTR - island NA Selected probes
cg01563031 11 20691429 p NELL1 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg09537620 11 31826574 p PAX6 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg18372607 11 31827084 p PAX6 NA Body shore Body - shore NA Not overlapping Differentially Methylated Region
cg26848718 11 32454975 p WT1 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg15556502 11 43602845 p MIR129-2 NA TSS200 island TSS200 - island NA Selected probes
cg14416371 11 43602847 p MIR129-2 NA TSS200 island TSS200 - island NA Selected probes
cg14944647 11 43602857 p MIR129-2 NA TSS200 island TSS200 - island NA Selected probes
cg01939477 11 43602879 p MIR129-2 NA TSS200 island TSS200 - island NA Selected probes
cg05376374 11 43602920 p MIR129-2 NA TSS200 island TSS200 - island NA Not overlapping Differentially Methylated Region
cg09802835 11 71952131 q PHOX2A NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg04543008 11 71955332 q PHOX2A NA TSS200 island TSS200 - island NA Not overlapping Differentially Methylated Region
cg03225817 11 105481317 q GRIA4 NA 5'UTR island 5'UTR - island NA Selected probes
cg04747226 11 105481319 q GRIA4 NA 5'UTR island 5'UTR - island NA Selected probes
cg07972135 11 105481322 q GRIA4 NA 5'UTR island 5'UTR - island NA Selected probes
cg22879515 11 111383515 q MIR34B NA TSS200 island TSS200 - island NA Not overlapping Differentially Methylated Region
cg09657963 11 124790875 q HEPACAM NA 3'UTR island 3'UTR - island NA Positivity in blood
cg03419885 11 125036385 q PKNOX2 NA 5'UTR island 5'UTR - island NA Not overlapping Differentially Methylated Region
cg23727983 11 125774082 q DDX25 NA TSS200 shore TSS200 - shore NA Selected probes
cg01736784 11 125774092 q DDX25 NA TSS200 shore TSS200 - shore NA Selected probes
cg11017065 11 128564874 q FLI1 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg07072722 11 131781246 q NTM NA 1stExon island 1stExon - island NA Not overlapping Differentially Methylated Region
cg06947913 12 50297793 q FAIM2 NA TSS200 island TSS200 - island NA Too far from other differentially methylated probes (>150bp)
cg00817367 12 52401214 q GRASP NA Body island Body - island NA Too far from other differentially methylated probes (>150bp)
cg09597070 12 54088972 q CALCOCO1 -15930 IGR shore IGR - shore NA Not overlapping Differentially Methylated Region
cg08190858 12 54321346 q HOXC13-AS -7766 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg27277463 12 62585031 q FAM19A2 NA 5'UTR island 5'UTR - island NA Not overlapping Differentially Methylated Region
cg26272220 12 81471884 q ACSS3 NA 1stExon island 1stExon - island NA Not overlapping Differentially Methylated Region
cg22538054 12 95941988 q USP44 NA 5'UTR island 5'UTR - island NA Not overlapping Differentially Methylated Region
cg03308628 12 95942287 q USP44 NA 5'UTR island 5'UTR - island NA Positivity in blood
cg22802813 12 95942761 q USP44 NA TSS200 island TSS200 - island NA Positivity in blood
cg01857475 12 104697193 q TXNRD1 NA 5'UTR shore 5'UTR - shore NA Positivity in blood
cg03817911 12 104697389 q TXNRD1 NA 5'UTR island 5'UTR - island NA Not overlapping Differentially Methylated Region
cg10790429 12 106974623 q LOC100287944 -2062 IGR island IGR - island NA Positivity in blood
cg11213520 12 113901529 q LHX5 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg04569082 12 127940323 q FLJ37505 -425839 IGR shore IGR - shore NA Not overlapping Differentially Methylated Region
cg09170112 12 132102188 q SFSWAP -93444 IGR open sea IGR - open sea NA Positivity in blood
cg04865180 13 23734385 q SGCG -20675 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg19937061 13 25320133 q RNF17 -18168 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg25366582 13 25621027 q PABPC3 -49249 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg20194314 13 28503060 q PDX1 8892 IGR island IGR - island NA Positivity in blood
cg17200768 13 28503373 q PDX1 9205 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg02478448 13 37006063 q CCNA1 NA 1stExon island 1stExon - island NA Positivity in blood
cg18348647 13 37006107 q CCNA1 NA 1stExon island 1stExon - island NA Too far from other differentially methylated probes (>150bp)
cg08866608 13 58203798 q PCDH17 -1991 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg20634967 13 58204224 q PCDH17 -1565 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg23766591 13 78493205 q EDNRB NA TSS1500 island TSS1500 - island NA Not overlapping Differentially Methylated Region
cg24236409 13 78493282 q EDNRB NA TSS1500 island TSS1500 - island NA Not overlapping Differentially Methylated Region
cg26132774 13 79170146 q RNF219-AS1 -3084 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg00295794 13 100641409 q ZIC2 7383 IGR island IGR - island NA Positivity in blood
cg18115507 13 102069169 q NALCN NA TSS1500 island TSS1500 - island NA Not overlapping Differentially Methylated Region
cg11437784 13 112710823 q SOX1 -11090 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg13692446 13 112759719 q SOX1 37806 IGR island IGR - island NA Within telomer region
cg25570913 13 112759893 q SOX1 37980 IGR island IGR - island NA Within telomer region
cg15384598 14 24045549 q JPH4 NA Body island Body - island V$ER_Q6 Not overlapping Differentially Methylated Region
cg08217024 14 48145108 q MDGA2 NA TSS1500 island TSS1500 - island NA Not overlapping Differentially Methylated Region
cg19871940 14 57264287 q OTX2 -3138 IGR shore IGR - shore NA Not overlapping Differentially Methylated Region
cg21026830 14 60973517 q SIX6 -2421 IGR shore IGR - shore NA Not overlapping Differentially Methylated Region
cg06785999 14 60975964 q SIX6 NA 1stExon island 1stExon - island NA Not overlapping Differentially Methylated Region
cg19456540 14 60976285 q SIX6 NA 1stExon island 1stExon - island NA Not overlapping Differentially Methylated Region
cg04281464 14 70014873 q CCDC177 -21658 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg23241781 14 70653964 q SLC8A3 NA 5'UTR shore 5'UTR - shore NA Not overlapping Differentially Methylated Region
cg22916722 14 76605056 q GPATCH2L -13203 IGR island IGR - island NA Too far from other differentially methylated probes (>150bp)
cg17410236 14 85996495 q FLRT2 NA 1stExon island 1stExon - island NA Not overlapping Differentially Methylated Region
cg02874376 14 101193397 q DLK1 NA 1stExon island 1stExon - island NA Not overlapping Differentially Methylated Region
cg03419058 15 26108391 q ATP10A NA TSS200 island TSS200 - island NA Not overlapping Differentially Methylated Region
cg10652393 15 27112430 q GABRA5 NA 1stExon island 1stExon - island V$TAXCREB_01 Not overlapping Differentially Methylated Region
cg04803843 15 28351906 q HERC2 -4277 IGR island IGR - island NA Too far from other differentially methylated probes (>150bp)
cg03061682 15 28352098 q HERC2 -4085 IGR island IGR - island NA Too far from other differentially methylated probes (>150bp)
cg00330492 15 28352558 q HERC2 -3625 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg17741501 15 29077493 q MIR5009 -12614 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg13800209 15 37390284 q MEIS2 NA 1stExon island 1stExon - island NA Not overlapping Differentially Methylated Region
cg02018277 15 65116255 q PIF1 NA Body island Body - island NA Positivity in blood
cg09193347 15 79381867 q RASGRF1 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg20973720 15 79383167 q RASGRF1 NA 5'UTR island 5'UTR - island V$TAXCREB_02 Not overlapping Differentially Methylated Region
cg11167100 15 83776269 q TM6SF1 NA TSS200 island TSS200 - island NA Selected probes
cg08452658 15 83776271 q TM6SF1 NA TSS200 island TSS200 - island NA Selected probes
cg26460092 15 83776420 q TM6SF1 NA 5'UTR island 5'UTR - island NA Selected probes
cg03063639 15 83776422 q TM6SF1 NA 5'UTR island 5'UTR - island NA Positivity in blood
cg02318926 15 83952345 q BNC1 NA Body island Body - island NA Selected probes
cg23989963 15 83952420 q BNC1 NA Body island Body - island NA Selected probes
cg17124224 15 83953880 q BNC1 NA TSS1500 island TSS1500 - island NA Too far from other differentially methylated probes (>150bp)
cg06523224 15 83953883 q BNC1 NA TSS1500 island TSS1500 - island NA Positivity in blood
cg19288904 15 98836248 q FAM169B -144143 IGR open sea IGR - open sea NA Positivity in blood
cg05915293 16 2041512 p SYNGR3 NA Body shore Body - shore NA Not overlapping Differentially Methylated Region
cg07642043 16 10276674 p GRIN2A NA TSS1500 island TSS1500 - island NA Not overlapping Differentially Methylated Region
cg00133595 16 31228059 p TRIM72 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg02809746 16 49312033 q CBLN1 204 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg04698114 16 51184379 q SALL1 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg08806408 16 51185001 q SALL1 NA TSS1500 island TSS1500 - island NA Selected probes
cg00124695 16 51185039 q SALL1 NA TSS1500 island TSS1500 - island NA Selected probes
cg08439930 16 51185060 q SALL1 NA TSS1500 island TSS1500 - island NA Positivity in blood
cg06653699 16 51185082 q SALL1 NA TSS1500 island TSS1500 - island NA Selected probes
cg07502439 16 51185461 q SALL1 NA TSS1500 island TSS1500 - island NA Not overlapping Differentially Methylated Region
cg01064265 16 55363058 q IRX6 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg09849405 16 66612955 q CMTM1 NA 3'UTR island 3'UTR - island NA Not overlapping Differentially Methylated Region
cg08032924 16 66613096 q CMTM2 NA TSS1500 island TSS1500 - island NA Not overlapping Differentially Methylated Region
cg16626067 16 66613266 q CMTM2 NA TSS200 island TSS200 - island NA Positivity in blood
cg06666025 16 66613278 q CMTM2 NA TSS200 island TSS200 - island NA Positivity in blood
cg07816687 16 67197186 q HSF4 NA TSS200 island TSS200 - island NA Not overlapping Differentially Methylated Region
cg00748373 16 68676741 q CDH3 NA TSS1500 island TSS1500 - island NA Not overlapping Differentially Methylated Region
cg16801887 16 86541480 q FOXF1 -2653 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg16202470 17 8907213 p NTN1 -17646 IGR island IGR - island V$AP2_Q6 Not overlapping Differentially Methylated Region
cg13291283 17 10101195 p GAS7 NA Body island Body - island NA Too far from other differentially methylated probes (>150bp)
cg25116216 17 10101581 p GAS7 NA 1stExon island 1stExon - island NA Too far from other differentially methylated probes (>150bp)
cg08358166 17 18538271 p TBC1D28 -571 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg18686527 17 27044685 q RAB34 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg21101720 17 27940509 q ANKRD13B NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg14603098 17 32484259 q ACCN1 NA TSS1500 island TSS1500 - island NA Not overlapping Differentially Methylated Region
cg15790037 17 37321490 q ARL5C NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg13001868 17 43339223 q C17orf46 NA Body island Body - island NA Selected probes
cg04992638 17 43339328 q C17orf46 NA Body island Body - island NA Selected probes
cg03048083 17 43339497 q LOC100133991 NA Body island Body - island NA Selected probes
cg01627847 17 43339512 q LOC100133991 NA Body island Body - island NA Selected probes
cg08124910 17 43339515 q LOC100133991 NA Body island Body - island NA Selected probes
cg24542751 17 43339589 q LOC100133991 NA Body island Body - island NA Selected probes
cg02081266 17 59529618 q TBX4 -4189 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg20275528 17 75369484 q SEPT9 NA 5'UTR island 5'UTR - island NA Too far from other differentially methylated probes (>150bp)
cg12783819 17 75369657 q SEPT9 NA 5'UTR island 5'UTR - island NA Too far from other differentially methylated probes (>150bp)
cg12865552 17 77721631 q ENPP7 16749 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg11771234 18 908396 p ADCYAP1 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg22455914 18 7116977 p LAMA1 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg03117976 18 11149435 p FAM38B NA TSS1500 island TSS1500 - island NA Not overlapping Differentially Methylated Region
cg25958283 18 11752089 p GNAL NA 5'UTR island 5'UTR - island NA Not overlapping Differentially Methylated Region
cg21114773 18 12254452 p CIDEA NA Body island Body - island NA Positivity in blood
cg12395205 18 12254469 p CIDEA NA Body island Body - island NA Within centromer region
cg16727201 18 12254556 p CIDEA NA Body island Body - island NA Positivity in blood
cg05700339 18 12254566 p CIDEA NA Body island Body - island NA Within centromer region
cg27641522 18 53447560 q MIR4529 301108 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg07519816 18 53447596 q MIR4529 301144 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg27189087 18 56941246 q RAX NA TSS1500 island TSS1500 - island NA Not overlapping Differentially Methylated Region
cg12799689 18 67067893 q DOK6 NA TSS1500 island TSS1500 - island NA Not overlapping Differentially Methylated Region
cg18596362 18 70210955 q CBLN2 NA 5'UTR island 5'UTR - island NA Not overlapping Differentially Methylated Region
cg18448581 18 70534767 q NETO1 NA 1stExon island 1stExon - island NA Not overlapping Differentially Methylated Region
cg05884032 18 76740088 q SALL3 NA TSS200 island TSS200 - island V$MYOGNF1_01 Positivity in blood
cg14007067 18 76740258 q SALL3 NA TSS200 island TSS200 - island NA Not overlapping Differentially Methylated Region
cg11616651 19 2251837 p AMH NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg22963915 19 3785855 p MATK NA 5'UTR island 5'UTR - island NA Not overlapping Differentially Methylated Region
cg25936054 19 15090242 p SLC1A6 29251 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg04704053 19 15090275 p SLC1A6 29284 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg18652900 19 15580445 p PGLYRP2 NA Body island Body - island NA Positivity in blood
cg16206460 19 15580700 p PGLYRP2 NA Body island Body - island NA Positivity in blood
cg08607018 19 31842873 q TSHZ3 77022 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg25999442 19 34113398 q CHST8 NA 5'UTR island 5'UTR - island NA Not overlapping Differentially Methylated Region
cg04332534 19 37096487 q ZNF382 NA 5'UTR island 5'UTR - island NA Not overlapping Differentially Methylated Region
cg11957331 19 42828156 q TMEM145 NA Body island Body - island V$TAXCREB_02 Not overlapping Differentially Methylated Region
cg09489306 19 44203913 q IRGC -16301 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg15779837 19 48918116 q GRIN2D NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg22049569 19 54466538 q CACNG8 NA 1stExon island 1stExon - island NA Not overlapping Differentially Methylated Region
cg15708153 19 56879554 q ZNF542 NA TSS200 island TSS200 - island NA Not overlapping Differentially Methylated Region
cg26612735 19 56988806 q ZNF667 NA TSS200 island TSS200 - island NA Not overlapping Differentially Methylated Region
cg08063125 19 56989543 q ZNF667 NA TSS1500 island TSS1500 - island NA Not overlapping Differentially Methylated Region
cg18845189 19 57683712 q ZNF264 -19156 IGR island IGR - island NA Not overlapping Differentially Methylated Region
cg02446106 19 57751691 q ZNF805 NA TSS1500 shore TSS1500 - shore NA Not overlapping Differentially Methylated Region
cg18579862 19 58095595 q ZIK1 NA TSS200 island TSS200 - island NA Within telomer region
cg13668618 19 58446745 q ZNF418 NA TSS200 island TSS200 - island NA Within telomer region
cg12961842 19 58446758 q ZNF418 NA TSS200 island TSS200 - island NA Within telomer region
cg12028548 20 590799 p TCF15 NA 1stExon island 1stExon - island NA Not overlapping Differentially Methylated Region
cg07113642 20 2781262 p CPXM1 NA 5'UTR island 5'UTR - island NA Not overlapping Differentially Methylated Region
cg14262681 20 21084420 p KIZ -22204 IGR shore IGR - shore NA Not overlapping Differentially Methylated Region
cg17368760 20 23029287 p THBD NA 1stExon island 1stExon - island NA Selected probes
cg16339238 20 23029298 p THBD NA 1stExon island 1stExon - island NA Selected probes
cg22388634 20 25058429 p VSX1 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg14763548 20 25062447 p VSX1 NA 1stExon island 1stExon - island NA Not overlapping Differentially Methylated Region
cg10615414 20 37353096 q SLC32A1 NA TSS200 island TSS200 - island NA Selected probes
cg08313939 20 37353117 q SLC32A1 NA 5'UTR island 5'UTR - island NA Selected probes
cg24454144 20 37353126 q SLC32A1 NA 5'UTR island 5'UTR - island NA Selected probes
cg11172693 20 37434229 q PPP1R16B NA TSS200 island TSS200 - island NA Not overlapping Differentially Methylated Region
cg24033330 20 39317034 q MAFB NA 1stExon island 1stExon - island NA Not overlapping Differentially Methylated Region
cg03403065 20 41818358 q PTPRT NA 1stExon island 1stExon - island NA Not overlapping Differentially Methylated Region
cg10439765 20 44657838 q SLC12A5 NA 1stExon island 1stExon - island NA Positivity in blood
cg14060496 20 61638518 q BHLHE23 NA TSS200 island TSS200 - island NA Within telomer region
cg26492446 20 61638574 q BHLHE23 NA TSS200 island TSS200 - island NA Within telomer region
cg27501878 20 61638588 q BHLHE23 NA TSS1500 island TSS1500 - island NA Within telomer region
cg15699267 20 61809557 q MIR124-3 NA TSS1500 island TSS1500 - island NA Not overlapping Differentially Methylated Region
cg27357571 21 34398226 q OLIG2 NA TSS200 island TSS200 - island NA Not overlapping Differentially Methylated Region
cg00495860 21 38065524 q SIM2 -6467 IGR island IGR - island NA Positivity in blood
cg21697851 21 38076869 q SIM2 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg10682155 21 38077473 q SIM2 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg24080247 21 38082613 q SIM2 NA Body shore Body - shore NA Positivity in blood
cg25446076 21 38083149 q SIM2 NA Body shore Body - shore NA Not overlapping Differentially Methylated Region
cg05206884 22 33454324 q SYN3 NA 5'UTR island 5'UTR - island NA Not overlapping Differentially Methylated Region
cg04198308 22 48971959 q FAM19A5 NA Body island Body - island NA Not overlapping Differentially Methylated Region
cg03957481 22 50986962 q KLHDC7B NA 1stExon island 1stExon - island NA Not overlapping Differentially Methylated Region

































Name Catalog # Tm(°C)
BRAF V600E dHsaCP2000027 55
KRAS G13D dHsaMDV2510598 55
KRAS G12D dHsaMDV2510596 55
KRAS G12A dHsaMDV2510586 55
KRAS G12R dHsaMDV2510590 55
KRAS G12V dHsaMDV2510592 55
KRAS G12C dHsaMDV2510584 55
KRAS Q61H dHsaMDV2010131 55














2.5 50 99 chr17:43339469-43339567
chr8:72756000-72756121
chr6:133562421-13356251696542
chr2:182,322,231-182,322,306 cg06952671; cg219959192.5 50 76





mCRC cohort N (%)
Sex Male 117 (64.3)
Female 65 (35.7)
Age (years) median 64
Range [33-85]










RECIST (mm) [9-49.25[ 44 (24.3)




Primary tumor resected Yes 150 (82.9)
No 31 (17.1)
Metastatic lesions 1 49 (26.9)
2+ 128 (70.3)
NA 5 (2.7)
Bulky Disease No 122 (67)
Yes 47 (25.8)
NA 13 (7.1)
RAS wild type 107 (58.8)
mutated 75 (41.2)
NA 0 (0)
BRAF wild type 133 (73.1)
mutated 13 (7.1)
NA 36 (19.8)
Clinical data summary for the two cohorts of














































































































CRC_Monitoring_1 F 1-Jan-43 69.0 52861.4 9-Dec-11 9-Dec-11 100 0 Dacarbazina 10-Nov-11 30-Nov-11 0 -9 3 10-Nov-11 -29 158 0 0 3 1 1 0 1 0 0 1 1 0
CRC_Monitoring_2 F 17-Oct-34 76.1 60603.1 11-Nov-10 10-Nov-10 229.2 -1 PmAb 15-Sep-10 10-Nov-10 0 -1 2 16-Nov-10 5 92 0 0 2 0 0 0 0 1 1 0 0 0
CRC_Monitoring_3 F 4-Aug-67 47.2 26504.8 15-Oct-14 17-Sep-14 765.6 -28 MEK162 1-Oct-14 1-Oct-14 0 -14 2 17-Nov-14 33 115 1 0 2 1 0 1 0 0 0 0 0 0 0
CRC_Monitoring_4 M 5-Apr-45 69.4 35085.2 5-Aug-14 2-Jul-14 17.7 -34 no treatment 1 2 16-Jul-14 -20 104 1 0 2 0 1 1 0 0 0 0 1 1 0
CRC_Monitoring_5 F 25-Dec-66 48.3 35851.8 8-Apr-15 13-Apr-15 387.2 5 HERACLES 14-Apr-15 14-Apr-15 1 6 4 8-Apr-15 0 124 0 0 3 1 1 1 0 0 0 0 0
CRC_Monitoring_6 M 25-Dec-44 64.8 30699.0 9-Sep-09 18-Sep-09 45.5 9 no treatment 1 4 16-Sep-09 7 193 0 0 4 1 0 1 0 0 2 0
CRC_Monitoring_7 F 17-Aug-54 55.8 30438.3 4-May-10 3-May-10 3 -1 no treatment 1 2 4-Jun-10 31 65 1 0 3 1 0 1 0 0 1 0 0 0
CRC_Monitoring_8 M 7-Aug-29 83.0 201913.5 29-Jun-12 28-Jun-12 1738 -1 Folfiri+Beva 29-Jun-12 29-Jun-12 1 0 2 7-Jun-12 -22 109 0 0 1 1 0 0 0 0 0 0 0 0
CRC_Monitoring_9 M 31-Jul-47 64.0 88959.6 8-Jul-11 20-Jun-11 119.6 -18 Folfiri 21-May-11 20-Jun-11 0 -18 3 11-Jul-11 3 192 1 0 2 1 0 1 0 0 0 1 1 0
CRC_Monitoring_10 M 28-Jan-46 68.8 204675.3 6-Nov-14 10-Nov-14 6.4 4 Folfiri 20-Oct-14 20-Oct-14 0 -17 0 7-Nov-14 1 86 0 0 3 1 0 1 0 0 1 0 0 0 1
CRC_Monitoring_11 M 6-Jul-58 56.9 196187.1 18-May-15 7-May-15 32.9 -11 ELO 18-Mar-15 1 -61 1 7-May-15 -11 31 0 0 1 1 0 0 0 0 0 0 0 0 0
CRC_Monitoring_12 M 9-Sep-44 71.2 84931.2 23-Oct-15 23-Oct-15 9.8 0 Folfo+Beva 9-Nov-15 2-Mar-15 1 -235 1 27-Oct-15 4 28 0 0 1 0 0 0 0 0 1 1 1 0
CRC_Monitoring_13 M 23-Oct-60 51.0 449292.9 3-Oct-11 19-Sep-11 835.5 -14 GA201 10-Oct-11 15-Sep-11 0 -18 1 19-Sep-11 -14 122 1 1 2 1 0 1 0 0 0 0 0 0
CRC_Monitoring_14 F 20-Mar-43 68.2 19396.6 25-May-11 25-May-11 60.5 0 PmAb 25-May-11 24-May-11 0 -1 2 15-Apr-11 -40 43 0 0 4 1 1 0 0 0 1 0 0 1
CRC_Monitoring_15 M 17-Apr-32 80.8 181456.6 7-Jan-13 7-Jan-13 2.6 0 PmAb 5-Dec-12 20-Dec-12 0 -18 3 28-Jan-13 21 35 0 0 2 0 1 0 0 0 0 0 0 0
CRC_Monitoring_16 M 18-Feb-42 73.4 215847.9 2-Jul-15 8-Jul-15 1.1 6 PmAb+Tramet 16-Jul-15 16-Jul-15 1 14 3 9-Jul-15 7 12 0 0 2 0 1 0 0 0 0 0 0 1
CRC_Monitoring_17 M 26-Nov-40 69.6 10659.3 24-Jun-10 24-Jun-10 21 0 no treatment 1 1 3-May-10 -52 117 0 0 2 1 0 0 1 0 0 0 0 1
CRC_Monitoring_18 F 4-Oct-60 54.5 154841.2 8-Apr-15 8-Apr-15 9762 0 Irinotecan 1-Apr-15 1-Apr-15 0 -7 3 26-Mar-15 -13 226 1 1 3 1 1 1 0 0 0 0 0 0
CRC_Monitoring_19 M 30-Nov-37 72.5 120155.3 25-May-10 23-Jun-10 8.7 29 Irinotecan 22-May-10 22-May-10 0 -3 0 4-May-10 -21 117 0 1 1 1 0 0 0 0 0 0 0 0
CRC_Monitoring_20 M 3-Jul-62 49.6 47477.6 6-Feb-12 5-Dec-11 228.6 -63 Pre-Surgery - No treatment 1 1 1-Feb-12 -5 83 0 1 1 1 0 0 0 0 0 0 0 0
CRC_Monitoring_21 M 25-May-39 74.5 131904.1 18-Nov-13 18-Nov-13 858.9 0 no treatment 1 3 18-Nov-13 0 1 2 1 1 0 0 0 0 1 1 0
CRC_Monitoring_22 M 21-Jul-34 76.0 48021.2 20-Jul-10 19-Jul-10 27.7 -1 Folfo 14-May-10 19-Jul-10 0 -1 0 9-Aug-10 20 113 1 0 1 1 0 0 0 0 0 0 0 0
CRC_Monitoring_23 F 11-Feb-41 70.0 95896.7 19-Jan-11 18-Jan-11 89.3 -1 Folfiri 15-Sep-10 18-Jan-11 0 -1 1 19-Apr-11 90 44 0 0 2 0 0 0 1 0 1 1 1 0
CRC_Monitoring_24 M 24-Dec-58 56.8 21320.9 18-Sep-15 2-Sep-15 491.2 -16 PmAb+Tramet 4-Aug-15 4-Sep-15 0 -14 3 15-Oct-15 27 87 1 0 3 0 1 1 0 0 1 0 0 1
CRC_Monitoring_25 M 25-May-49 61.1 1294369.3 23-Jun-10 23-Jun-10 107.8 0 Folfo 23-Jun-10 23-Jun-10 1 0 0 4-Jun-10 -19 58 0 1 3 1 0 0 0 0 1 0 0 0
CRC_Monitoring_26 M 11-Apr-41 69.6 157496.2 19-Oct-10 28-Sep-10 1.7 -21 Folfo+Cmab 6-Aug-10 28-Sep-10 0 -21 0 27-Oct-10 8 1 1 1 0 0 0 0 0 0 0 0
CRC_Monitoring_27 F 13-Nov-34 79.8 272173.8 4-Aug-14 23-Jun-14 113.6 -42 Folfiri 14-May-14 22-Jul-14 0 -13 2 30-Jun-14 -35 84 0 1 3 1 1 0 0 1 0 1 1 0
CRC_Monitoring_28 M 11-May-51 63.6 409422.1 20-Nov-14 20-Nov-14 7.3 0 Pre-Surgery - No treatment 1 1 21-Oct-14 -30 42 0 0 1 1 0 0 0 0 0 0
CRC_Monitoring_29 F 28-Apr-40 74.2 288828.3 24-Jun-14 25-Jun-14 2.7 1 Folfo 20-May-14 23-Jun-14 0 -1 0 22-May-14 -33 167 0 0 3 0 0 1 1 0 1 0 0 0 1
CRC_Monitoring_30 M 28-Nov-45 68.7 21913.7 1-Aug-14 24-Jun-14 67.4 -38 Folfiri 16-Jul-14 16-Jul-14 0 -16 1 30-Jun-14 -32 161 0 0 3 1 0 1 0 0 1 1 0 1 0
CRC_Monitoring_31 F 12-Apr-64 49.8 214073.7 21-Jan-14 21-Jan-14 473.5 0 no treatment 1 3 15-Jan-14 -6 0 3 1 0 1 0 0 1 0 0 1
CRC_Monitoring_32 F 30-Jun-45 69.7 164095.6 11-Mar-15 8-Jan-15 5.5 -62 Pre-Surgery - No treatment 1 1 11-Mar-15 0 46 0 0 1 1 0 0 0 0 0 0 1 1 0
CRC_Monitoring_33 M 16-Nov-35 78.7 176952.6 26-Jun-14 26-Jun-14 278.2 0 Pre-Surgery - No treatment 1 1 7-Apr-14 -80 43 0 0 1 1 0 0 0 0 0 0 0
CRC_Monitoring_34 M 1-May-28 82.7 77612.2 21-Dec-10 24-Dec-10 4.3 3 Folfiri 11-Dec-10 11-Dec-10 0 -10 1 16-Dec-10 -5 57 0 1 1 1 0 0 0 0 0 1 1 0
CRC_Monitoring_35 M 26-May-42 72.3 155034.4 3-Sep-14 8-Jul-14 24.2 -57 PmAb 11-Sep-14 9-Jul-14 1 -56 2 9-Sep-14 6 81 0 0 1 1 0 0 0 0 0 0 0 0 0
CRC_Monitoring_36 F 19-Jul-40 73.8 485302.7 8-Apr-14 17-Mar-14 4189 -22 Folfo 23-Jan-14 7-Apr-14 0 -1 0 15-May-14 37 175 1 1 2 1 0 1 0 0 0 1 0 1 0
CRC_Monitoring_37 F 20-Dec-40 69.8 3718000.8 14-Sep-10 14-Sep-10 48.5 0 Mitomicina+5FU 14-Sep-10 4-Aug-10 1 -41 2 9-Aug-10 -36 61 0 0 2 1 0 0 0 0 0 1 1 0
CRC_Monitoring_38 F 19-Jan-42 72.7 517187.6 10-Sep-14 26-Aug-14 4.8 -15 no treatment 1 0 10-Sep-14 0 19 0 1 1 1 0 0 0 0 0 0 0 0 0
CRC_Monitoring_39 M 25-May-60 50.2 33734.4 28-Jul-10 13-Aug-10 3.3 16 PmAb 9-Apr-10 1-Jul-10 0 -27 2 8-Jul-10 -20 18 0 0 1 1 0 0 0 0 0 0 0 0
CRC_Monitoring_40 M 29-Apr-44 70.0 10562.6 14-Apr-14 14-Apr-14 17.2 0 no treatment 1 3 2-Apr-14 -12 72 0 0 2 0 1 1 0 0 0 0
CRC_Monitoring_41 M 20-Apr-48 67.0 6878.7 23-Mar-15 23-Mar-15 1.7 0 Pre-Surgery - No treatment 1 1 23-Mar-15 0 75 0 1 1 1 0 0 0 0 0 0
CRC_Monitoring_42 M 30-Jun-40 72.5 25247.4 11-Dec-12 11-Dec-12 2 0 PmAb 14-Aug-12 27-Nov-12 0 -14 2 14-Dec-12 3 59 0 0 2 1 0 1 0 0 0 1 1 0
CRC_Monitoring_43 M 26-Oct-36 79.0 167832.7 15-Oct-15 13-Oct-15 2 -2 Pre-Surgery - No treatment 1 0 15-Oct-15 0 25 0 0 1 1 0 0 0 0 0 0
CRC_Monitoring_44 M 20-Apr-55 59.3 103753.4 5-Aug-14 5-Aug-14 8.6 0 no treatment 1 1 11-Sep-14 37 81 1 1 4 1 1 0 1 0 1 0 0 0 1
CRC_Monitoring_45 M 16-Jul-74 40.3 818211.6 5-Nov-14 5-Nov-14 1267 0 Pre-Surgery - No treatment 1 0 6-Nov-14 1 75 1 0 1 1 0 0 0 0 0 0
CRC_Monitoring_46 M 1-Jun-29 81.0 96154.5 11-May-10 11-May-10 7.5 0 Folfo 9-May-10 9-May-10 0 -2 2 22-Apr-10 -19 41 0 0 1 0 0 1 0 0 0 0
CRC_Monitoring_47 M 21-Dec-68 46.5 28029.4 10-Jun-15 10-Jun-15 31.4 0 no treatment 1 4 16-May-15 -25 110 1 0 1 1 0 0 0 0 0 0 0
CRC_Monitoring_48 M 16-Jul-35 75.3 8874.5 12-Oct-10 9-Nov-10 27 28 Folfiri 3-Sep-10 24-Sep-10 0 -18 2 20-Jul-10 -84 10 0 0 1 0 0 0 0 0 1 0 0 0
CRC_Monitoring_49 M 29-Nov-41 73.5 39603.6 8-May-15 20-Apr-15 12.1 -18 Folfo 21-Apr-15 20-Apr-15 0 -18 0 19-Jun-15 42 32 0 0 2 1 1 0 0 0 0 0 0 0 0
CRC_Monitoring_50 F 11-Jul-56 58.1 83437.2 23-Jul-14 22-Jul-14 250 -1 Pre-Surgery - No treatment 1 0 23-Jul-14 0 55 0 1 1 1 0 0 0 0 0 1 1 0
CRC_Monitoring_51 M 23-Sep-47 67.7 41904.5 8-May-15 8-May-15 71.7 0 no treatment 1 4 14-Apr-15 -24 200 0 0 3 1 1 1 0 0 0 0 0 0
CRC_Monitoring_52 F 27-Nov-49 64.8 8307.2 2-Sep-14 14-Jul-14 13.6 -50 no treatment 1 3 18-Aug-14 -15 250 1 0 4 1 1 0 0 0 1 0 0 0 0
CRC_Monitoring_53 M 27-Mar-29 85.2 26651.3 30-May-14 30-May-14 147.3 0 PmAb 16-May-14 16-May-14 0 -14 2 9-May-14 -21 86.8 1 0 2 1 0 0 0 1 0 0 0 0 0
CRC_Monitoring_54 F 29-Mar-32 81.6 100139.2 3-Oct-13 11-Sep-13 8 -22 no treatment 1 0 12-Sep-13 -21 77 0 1 2 1 0 1 0 0 0 0
CRC_Monitoring_55 M 28-May-52 61.1 1006748.2 5-Jun-13 4-Jun-13 418.7 -1 no treatment 1 6 16-May-13 -20 0 2 1 1 0 0 0 0 0 0 1
CRC_Monitoring_56 F 2-May-31 82.8 21946.5 27-Jan-14 27-Jan-14 193.6 0 PmAb 26-Nov-13 13-Jan-14 0 -14 0 10-Sep-13 -139 15 0 0 1 1 0 0 0 0 0 0 0
CRC_Monitoring_57 F 19-Sep-74 40.1 31568.7 30-Oct-14 29-Oct-14 1085 -1 no treatment 1 2 31-Oct-14 1 141 1 0 1 1 0 0 0 0 0 1 0 1 0
CRC_Monitoring_58 M 4-Oct-76 34.7 1572.9 8-Jun-11 7-Jun-11 20543 -1 no treatment 1 3 10-Jun-11 2 210 1 0 1 1 0 0 0 0 0 1 1 0
CRC_Monitoring_59 M 23-May-33 80.6 12264.0 22-Nov-13 22-Nov-13 235.4 0 Folfiri+Cmab 22-Nov-13 6-Nov-13 0 -16 1 28-Nov-13 6 124 1 0 3 1 1 1 0 0 0 0 0 0
CRC_Monitoring_60 M 10-Jul-49 63.8 220621.9 2-Apr-13 18-Mar-13 72.1 -15 Recourse 18-Mar-13 30-Mar-13 0 -3 4 18-Mar-13 -15 36 0 0 3 1 1 0 0 0 0 0 0 0
CRC_Monitoring_61 F 9-Apr-51 60.6 12394.0 11-Nov-11 25-Oct-11 1084 -17 Folfo 26-Oct-11 26-Oct-11 0 -16 0 26-Sep-11 -46 152.5 0 1 2 1 0 1 0 0 0 1 1 0
CRC_Monitoring_62 F 28-Oct-54 55.8 7130.7 22-Jul-10 8-Jul-10 10 -14 Cmab+CPT11 3-Feb-10 8-Jul-10 0 -14 1 19-Aug-10 28 60 1 0 2 1 0 0 1 0 1 0 0 0
CRC_Monitoring_63 F 12-Feb-81 33.3 4692.3 4-Jun-14 4-Jun-14 918.4 0 no treatment 1 2 1-Apr-14 -64 0 3 1 1 1 0 0 0 1 1 0
CRC_Monitoring_64 F 17-Nov-78 35.1 32810.7 23-Dec-13 25-Nov-13 54.4 -28 Dareck 18-Nov-13 13-Dec-13 0 -10 1 6-Nov-13 -47 35 0 0 2 0 1 0 1 0 0 0 0 0
CRC_Monitoring_65 F 22-Dec-63 50.0 18510.0 29-Nov-13 25-Nov-13 8.7 -4 Lung metastasectomy 1 0 27-Nov-13 -2 20 0 0 1 0 1 0 0 0 0 1 1 0
CRC_Monitoring_66 M 6-Apr-70 43.3 32359.9 8-Jul-13 8-Jul-13 102 0 CmAb+Folfiri 30-Apr-13 25-Jun-13 0 -13 2 28-Jun-13 -10 200 0 0 2 1 0 0 0 0 0 0 0 0
CRC_Monitoring_67 F 11-Aug-62 52.5 1212.5 29-Jan-15 13-Mar-15 2 43 Pre-Surgery - No treatment 1 1 29-Dec-14 -31 20 0 0 2 1 0 1 0 0 0 0 1 1 0
CRC_Monitoring_68 M 4-Nov-64 50.7 46937.4 15-Jul-15 15-Jul-15 39.9 0 no treatment 1 1 16-Jul-15 1 139 0 0 2 1 0 0 0 1 0 0 0 1
CRC_Monitoring_69 F 15-Aug-36 77.2 6438.8 1-Oct-13 9-Sep-13 156.5 -22 Irinotecan 25-May-13 19-Jul-13 1 -74 1 9-Sep-13 -22 122 0 0 3 1 0 0 0 1 1 0 0 0
CRC_Monitoring_70 F 14-Nov-42 68.5 1193.6 20-Apr-11 20-Apr-11 8.9 0 no treatment 1 2 20-Apr-11 0 0 2 1 1 0 0 0 0 0 0
CRC_Monitoring_71 M 30-Mar-41 72.7 547401.1 18-Nov-13 27-Sep-13 11.2 -52 Above 15-Apr-13 30-Sep-13 1 -49 0 18-Sep-13 -61 51 0 1 2 1 0 0 0 0 1 1 0 1 0
CRC_Monitoring_72 F 30-Dec-73 38.1 20302.3 30-Jan-12 6-Mar-12 38.3 36 GA201 16-Dec-11 23-Jan-12 0 -7 2 14-Jan-12 -16 136 0 0 2 0 0 0 0 0 1 0 0 0
CRC_Monitoring_73 M 21-Jan-59 55.6 93202.7 1-Aug-14 18-Jul-14 88.6 -14 Folfiri 21-Jul-14 21-Jul-14 0 -11 2 30-May-14 -63 45 0 0 1 1 0 0 0 0 0 0 0 0 0
CRC_Monitoring_74 M 7-Dec-39 75.8 107551.8 2-Sep-15 2-Sep-15 43.7 0 no treatment 1 4 3-Sep-15 1 154 0 0 3 1 1 0 0 0 1 0 0
CRC_Monitoring_75 M 27-Jul-50 65.4 7137.3 25-Nov-15 14-Dec-15 24.1 19 Folfo 15-Oct-15 19-Oct-15 1 -37 0 16-Oct-15 -40 32 0 0 1 1 0 0 1 0 0 0 0 0 0
CRC_Monitoring_76 M 4-Jan-53 62.7 18897.8 19-Aug-15 19-Aug-15 46.4 0 SYM 23-Jul-15 13-Aug-15 0 -6 2 27-Aug-15 8 90 0 1 3 1 0 0 0 0 1 0 0 0 0
CRC_Monitoring_77 M 21-Jun-44 66.1 211770.7 12-Jul-10 5-Jul-10 294.4 -7 CmAb+Lenalidomide 17-May-10 20-Mar-10 1 -114 4 9-Jul-10 -3 90 0 0 3 1 1 0 0 0 0 1 1 0
CRC_Monitoring_78 M 16-Oct-56 58.2 286363.4 5-Dec-14 5-Dec-14 6.3 0 PmAb+Folfo 6-Oct-14 17-Nov-14 0 -18 0 26-Nov-14 -9 1 1 1 0 0 0 0 0 0 0 0 0
CRC_Monitoring_79 F 22-Nov-60 51.7 1087810 26-Jul-12 15-Jun-12 339 -41 Folfo 23-Jun-12 24-Jul-12 0 -2 0 27-Jun-12 -29 78 1 1 2 1 0 1 0 0 0 0 0 1
CRC_Monitoring_80 M 13-Aug-62 50.9 12622.8 25-Jun-13 25-Jun-13 0.8 0 Folfiri+MEHD7945A 15-Mar-13 12-Jun-13 0 -13 0 10-Jun-13 -15 9 0 0 2 0 1 1 0 0 1 0 0 0
CRC_Monitoring_81 F 16-Mar-57 53.3 25265.6 15-Jun-10 8-Jun-10 1184 -7 CmAb+Lenalidomide 25-May-10 8-Jun-10 0 -7 3 12-May-10 -34 99 1 0 3 1 1 1 0 0 0 0
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CRC_Monitoring_82 F 24-Oct-63 51.3 663475.4 9-Feb-15 9-Feb-15 3.3 0 PmAb+Folfo 13-Jan-15 27-Jan-15 0 -13 0 9-Jan-15 -31 90 0 1 3 1 0 1 0 0 1 0 0 0 0
CRC_Monitoring_83 M 15-Sep-63 49.6 58741.5 28-Mar-13 11-Feb-13 120.8 -45 CmAb+Irinotecan 28-Mar-13 9-Mar-13 0 -19 0 2-May-13 35 60 0 0 2 1 0 0 0 0 0 0 0 0
CRC_Monitoring_84 F 31-Jul-37 76.8 192324.6 18-Apr-14 24-Mar-14 7.5 -25 CmAb+Folfiri 3-Jan-14 8-Apr-14 0 -10 0 12-May-14 24 149 0 0 2 1 1 0 0 0 0 0 0 0 0
CRC_Monitoring_85 M 18-Feb-36 76.0 37876.5 30-Jan-12 30-Jan-12 63.5 0 Dacarbazina 9-Jan-12 9-Jan-12 0 -21 4 17-Dec-11 -44 107.3 0 0 4 1 1 1 1 0 0 1 1 0
CRC_Monitoring_86 M 8-May-54 57.6 279826.4 11-Nov-11 15-Nov-11 560.1 4 Dacarbazina 15-Nov-11 12-Oct-11 0 -30 6 14-Nov-11 3 153 1 0 3 1 1 1 0 0 0 0 0
CRC_Monitoring_87 F 27-Nov-67 44.3 18227.6 15-Mar-12 15-Mar-12 1.1 0 Dacarbazina 15-Mar-12 15-Mar-12 1 0 6 15-Mar-12 0 38.4 0 0 1 0 0 1 0 0 0 0 0
CRC_Monitoring_88 M 4-Nov-56 54.9 88515.9 31-Aug-11 25-Aug-11 11.4 -6 Dacarbazina 29-Aug-11 1-Jul-11 1 -61 4 26-Aug-11 -5 98.3 0 0 2 1 1 0 0 0 0 0 0
CRC_Monitoring_89 F 23-Dec-35 75.7 48028.9 9-Aug-11 8-Aug-11 66.1 -1 Dacarbazina 9-Aug-11 15-Jun-11 1 -55 3 8-Aug-11 -1 75.9 0 0 2 1 0 1 0 0 0 1 1 0
CRC_Monitoring_90 M 27-Nov-44 67.2 31252.6 16-Jan-12 16-Jan-12 12.3 0 Dacarbazina 23-Jan-12 15-Oct-11 1 -93 3 26-Jan-12 10 97.1 0 0 2 1 0 1 0 0 0 0 0
CRC_Monitoring_91 M 6-Apr-58 53.8 12879.9 9-Jan-12 9-Jan-12 161.9 0 Dacarbazina 12-Jan-12 15-Nov-11 1 -55 4 11-Jan-12 2 79.3 0 0 4 1 1 1 0 0 1 0 0
CRC_Monitoring_92 F 14-Jul-36 75.1 44150.3 28-Jul-11 22-Aug-11 102.5 25 Dacarbazina 29-Jul-11 28-Jun-11 0 -30 3 28-Jul-11 0 64 0 0 1 0 0 1 0 0 0 1 1 0
CRC_Monitoring_93 M 5-Jan-38 74.0 16070.5 5-Dec-11 5-Dec-11 101.1 0 Dacarbazina 4-Oct-11 13-Nov-11 0 -22 4 3-Oct-11 -63 64 1 0 2 0 1 1 0 0 0 1 1 0
CRC_Monitoring_94 M 6-Sep-52 58.9 14936.5 15-Jul-11 15-Jul-11 30.3 0 Dacarbazina 15-Jul-11 10-Jun-11 1 -35 4 16-Jun-11 -29 39.5 0 0 2 1 1 0 0 0 0 1 1 0
CRC_Monitoring_95 F 19-May-55 56.1 168268.6 9-Jun-11 9-Jun-11 443.8 0 Dacarbazina 11-Jun-11 9-Feb-11 1 -120 4 10-Jun-11 1 29 1 0 2 1 1 0 0 0 0 0 0
CRC_Monitoring_96 M 1-Jun-75 36.5 74046.0 5-Dec-11 5-Dec-11 2057 0 Dacarbazina 6-Dec-11 28-Oct-11 1 -38 2 6-Dec-11 1 93.2 1 0 1 1 0 0 0 0 0 0 0 0
CRC_Monitoring_97 M 30-Sep-41 70.1 124077.1 24-Oct-11 24-Oct-11 4.2 0 Dacarbazina 25-Oct-11 15-Aug-11 1 -70 4 24-Oct-11 0 63.1 1 0 2 1 1 0 0 0 0 1 1 0
CRC_Monitoring_98 F 5-Feb-52 59.9 20085.5 29-Nov-11 28-Nov-11 299.6 -1 Dacarbazina 29-Nov-11 3-Oct-11 1 -57 4 14-Nov-11 -15 69 0 0 1 0 1 0 0 0 0 0 0
CRC_Monitoring_99 M 10-Apr-52 59.2 133205.0 8-Jun-11 8-Jun-11 9.7 0 Dacarbazina 9-Jun-11 15-Feb-11 1 -113 2 8-Jun-11 0 128 0 0 3 1 1 1 0 0 0 1 1 0
CRC_Monitoring_100 F 15-Jun-44 67.4 278709.5 5-Oct-11 3-Oct-11 868.5 -2 Dacarbazina 8-Oct-11 12-Sep-11 0 -23 3 4-Oct-11 -1 53.3 0 0 2 1 1 0 0 0 0 1 1 0
CRC_Monitoring_101 F 10-Apr-39 72.8 255619.6 23-Jan-12 23-Jan-12 26.1 0 Dacarbazina 24-Jan-12 16-Dec-11 1 -38 3 27-Dec-11 -27 181 1 0 2 1 1 0 0 0 0 0 0 0
CRC_Monitoring_102 M 25-Aug-34 77.1 108563.7 28-Sep-11 28-Sep-11 968.8 0 Dacarbazina 1-Oct-11 15-Jun-11 1 -105 5 29-Sep-11 1 125.6 1 0 2 1 1 0 0 0 0 0 0
CRC_Monitoring_103 M 24-Jun-49 62.7 80164.5 14-Feb-12 14-Feb-12 241.5 0 Dacarbazina 14-Feb-12 13-Jan-12 1 -32 7 9-Feb-12 -5 191.9 0 0 2 1 1 0 0 0 0 0 0
CRC_Monitoring_104 F 21-Apr-63 48.8 29126.1 10-Feb-12 10-Feb-12 186.5 0 Dacarbazina 27-Feb-12 20-Dec-11 1 -52 4 1-Feb-12 -9 160 0 0 4 1 1 1 0 0 1 0 0
CRC_Monitoring_105 M 24-Aug-47 64.6 10282.6 14-Mar-12 14-Mar-12 12.7 0 Dacarbazina 27-Mar-12 15-Feb-12 0 -28 3 26-Mar-12 12 107.9 0 0 2 1 1 0 0 0 0 0 0 0
CRC_Monitoring_106 M 15-Jan-46 66.2 2046.3 12-Mar-12 12-Mar-12 155.4 0 Dacarbazina 20-Feb-12 20-Feb-12 0 -21 5 17-Feb-12 -24 112.8 1 0 2 1 1 0 0 0 0 0 0
CRC_Monitoring_107 M 14-May-36 75.4 28040.5 5-Sep-11 5-Sep-11 60.2 0 Dacarbazina 6-Sep-11 11-Aug-11 0 -25 6 11-Aug-11 -25 112.6 0 0 2 0 1 0 0 0 1 1 1 0
CRC_Monitoring_108 M 23-Apr-53 58.4 12029.2 19-Aug-11 19-Aug-11 10.8 0 Dacarbazina 14-Jun-11 26-Jul-11 0 -24 2 12-Aug-11 -7 24 0 0 3 1 0 1 1 0 0 1 1 0
CRC_Monitoring_109 M 15-Mar-66 45.9 3700.3 30-Jan-12 30-Jan-12 231.9 0 Dacarbazina 31-Jan-12 19-Dec-11 1 -42 2 23-Jan-12 -7 97.9 1 0 2 1 1 0 0 0 0 0 0
CRC_Monitoring_110 M 23-Apr-75 36.9 12044.0 20-Feb-12 20-Feb-12 569 0 Dacarbazina 21-Feb-12 15-Dec-11 1 -67 6 6-Feb-12 -14 174 1 0 3 1 0 1 0 0 1 0
CRC_Monitoring_111 M 15-Oct-54 57.0 28588.4 19-Sep-11 25-Aug-11 3.3 -25 Dacarbazina 29-Aug-11 29-Aug-11 0 -21 2 4-Aug-11 -46 117.6 0 0 2 1 0 1 0 0 0 1 1 0
CRC_Monitoring_112 M 27-Sep-58 53.4 32088.4 26-Jan-12 25-Jan-12 78 -1 Dacarbazina 27-Jan-12 5-Dec-11 1 -52 5 26-Jan-12 0 55 1 0 2 1 1 0 0 0 0 1 1 0
CRC_Monitoring_113 F 16-Nov-41 70.1 97321.7 29-Nov-11 28-Nov-11 2930 -1 Dacarbazina 29-Nov-11 7-Nov-11 0 -22 3 7-Nov-11 -22 65.6 1 0 2 1 1 0 0 0 0 0 0
CRC_Monitoring_114 M 30-Jan-39 72.7 27679.7 13-Sep-11 22-Aug-11 1.9 -22 Dacarbazina 11-Jul-11 23-Aug-11 0 -21 4 9-Sep-11 -4 65 0 0 1 0 1 0 0 0 0 1 1 0
CRC_Monitoring_115 F 9-Nov-69 41.9 266432.4 12-Sep-11 19-Aug-11 991.4 -24 Dacarbazina 28-Aug-11 23-Aug-11 0 -20 2 1 1 0
CRC_Monitoring_116 M 1-May-52 59.4 13431.5 2-Sep-11 19-Aug-11 45.2 -14 Dacarbazina 20-Jun-11 1-Aug-11 1 -32 3 5-Aug-11 -28 52.3 0 0 2 0 1 0 1 0 0 1 1 0
CRC_Monitoring_117 M 18-Aug-71 40.4 17440.7 17-Jan-12 17-Jan-12 44.8 0 Dacarbazina 23-Jan-12 15-Oct-11 1 -94 3 4-Jan-12 -13 70.3 0 0 2 1 0 1 0 0 0 1 1 0
CRC_Monitoring_118 M 17-Jun-57 54.6 1110.9 24-Jan-12 24-Jan-12 7.1 0 Dacarbazina 26-Jan-12 15-Dec-11 1 -40 5 26-Jan-12 2 55.5 0 0 1 0 0 0 1 0 0 1 1 0
CRC_Monitoring_119 M 15-Jul-30 81.0 350586.4 13-Jun-11 10-Jun-11 167.8 -3 Dacarbazina 11-Jun-11 11-Jun-11 0 -2 3 10-Jun-11 -3 113 0 0 2 0 1 1 0 0 0 1 1 0
CRC_Monitoring_120 M 6-Jan-35 76.9 51240.2 7-Nov-11 3-Nov-11 1600 -4 Dacarbazina 4-Nov-11 4-Nov-11 0 -3 4 3-Nov-11 -4 53.7 0 0 1 1 0 0 0 0 0 0 0 0
CRC_Monitoring_121 M 17-Jun-42 69.6 100424.6 23-Jan-12 23-Jan-12 69.3 0 Dacarbazina 24-Jan-12 12-Dec-11 1 -42 4 19-Jan-12 -4 82.1 0 0 1 1 0 0 0 0 0 0
CRC_Monitoring_122 M 25-Feb-37 74.9 83442.6 15-Dec-11 12-Dec-11 282.2 -3 Dacarbazina 13-Dec-11 13-Dec-11 0 -2 3 29-Nov-11 -16 109.6 0 0 2 1 0 0 0 0 1 0 0
CRC_Monitoring_123 M 9-Oct-37 74.2 9259907.7 14-Dec-11 18-Dec-11 34.1 4 Dacarbazina 15-Dec-11 15-Oct-11 1 -60 2 14-Dec-11 0 198 1 0 2 1 0 1 0 0 0 1 1 0
CRC_Monitoring_124 F 26-Nov-53 57.7 124284.9 8-Aug-11 4-Aug-11 82.9 -4 Dacarbazina 6-Aug-11 6-Aug-11 0 -2 4 5-Aug-11 -3 40.3 1 0 1 0 1 0 0 0 0 0 0
CRC_Monitoring_125 F 11-Nov-40 70.7 152843.3 4-Jul-11 4-Jul-11 151.7 0 Dacarbazina 4-Jul-11 15-Mar-11 1 -111 4 1-Jul-11 -3 40 1 0 2 1 1 0 0 0 0 0 0 0
CRC_Monitoring_126 M 29-May-48 63.5 10694.6 7-Nov-11 4-Nov-11 4.4 -3 Dacarbazina 8-Nov-11 7-Oct-11 1 -31 3 7-Nov-11 0 62.6 0 0 2 0 1 0 1 0 0 1 1 0
CRC_Monitoring_127 M 9-Jun-38 73.5 39522.9 11-Nov-11 11-Nov-11 211.5 0 Dacarbazina 15-Nov-11 15-Oct-11 0 -27 2 14-Nov-11 3 91 0 0 2 1 0 1 0 0 0 1 1 0
CRC_Monitoring_128 F 19-Feb-44 67.6 325832.1 26-Sep-11 26-Sep-11 2581 0 Dacarbazina 26-Sep-11 15-Aug-11 1 -42 4 10-Nov-11 45 30 1 0 1 0 1 0 0 0 0 0 0 0
CRC_Monitoring_129 M 20-Oct-45 65.8 28485.4 20-Jul-11 18-Jul-11 246.4 -2 Dacarbazina 20-Jul-11 15-Jun-11 1 -35 6 19-Jul-11 -1 113.3 0 0 3 1 1 0 0 0 1 0 0
CRC_Monitoring_130 F 5-May-71 40.8 2361.0 10-Feb-12 10-Feb-12 18.6 0 Dacarbazina 11-Feb-12 2-Dec-11 1 -70 4 10-Feb-12 0 49 0 0 2 0 1 0 0 0 1 1 1 0
CRC_Monitoring_131 M 9-Sep-42 69.0 8482.1 1-Sep-11 30-Aug-11 79.9 -2 Dacarbazina 6-Aug-11 30-Aug-11 0 -2 6 9-Aug-11 -23 37 1 0 2 0 1 1 0 0 0 0 0
CRC_Monitoring_132 M 26-Aug-36 74.7 9992.4 3-May-11 4-May-11 5.3 1 PmAb 18-May-11 4-Apr-11 0 -29 2 4-Apr-11 -29 50 0 1 1 1 0 0 0 0 0 0 0
CRC_Monitoring_133 F 20-Sep-67 45.8 4188490 11-Jul-13 11-Jul-13 3321 0 PmAb 12-Jul-13 17-Apr-13 1 -85 4 27-Jun-13 -14 65 1 1 1 1 0 0 0 0 0 0 0
CRC_Monitoring_134 M 28-Jun-59 52.7 2400999.3 16-Feb-12 16-Feb-12 8828 0 PmAb 16-Feb-12 27-Jan-12 0 -20 2 30-Jan-12 -17 123 0 1 1 1 0 0 0 0 0 0 0
CRC_Monitoring_135 M 21-Feb-41 70.5 24307 29-Jul-11 29-Jul-11 39.3 0 PmAb 2-Aug-11 20-Apr-11 1 -100 2 28-Jul-11 -1 105 0 0 2 1 1 0 0 0 0 0 0 0
CRC_Monitoring_136 M 8-Mar-54 59.0 51765 6-Mar-13 5-Mar-13 3.3 -1 PmAb 6-Mar-13 18-Dec-12 1 -78 2 1-Feb-13 -33 16 0 0 1 0 0 0 0 0 1 0 0
CRC_Monitoring_137 F 15-Sep-64 45.9 28860.0 23-Jul-10 23-Jul-10 1.3 0 PmAb 29-Mar-13 15-Jul-10 0 -8 2 14-Jul-10 -9 39 0 0 1 0 0 1 0 0 0 0 0
CRC_Monitoring_138 M 27-Jun-30 82.9 49712 30-Apr-13 16-May-13 60.4 16 PmAb 2-May-13 27-Mar-13 1 -34 2 2-Apr-13 -28 86 0 0 2 1 0 1 0 0 0 0 0
CRC_Monitoring_139 M 12-Oct-38 74.7 24183 22-May-13 22-May-13 2.6 0 PmAb 23-May-13 8-Feb-13 1 -103 2 14-Mar-13 -69 88 0 0 3 1 1 1 0 0 0 0 0 0 0
CRC_Monitoring_140 M 19-May-48 68.1 101354.8 1-Jun-16 1-Jun-16 75.8 0 FOLFOX+Beva 3-Jun-16 1 0 18-May-16 -14 153 1 1 3 1 1 1 0 0 0 1 1 0
CRC_Monitoring_141 F 12-Oct-54 61.6 20210.3 19-Apr-16 11-May-16 56.3 22 Folfox+Beva 13-May-16 1 0 12-May-16 23 86 0 1 1 1 0 0 0 0 0 0 0 1
CRC_Monitoring_142 M 29-Apr-52 60.7 44483.9 28-Dec-12 28-Dec-12 137 0 TMZ 28-Dec-12 5-Dec-12 0 -23 5 4-Dec-12 -24 141 0 0 2 1 1 0 0 0 0 0 0 0
CRC_Monitoring_143 M 28-Mar-52 60.9 48356.6 25-Jan-13 24-Jan-13 44.5 -1 TMZ 26-Jan-13 15-Nov-12 1 -71 4 23-Jan-13 -2 117 0 0 3 1 1 1 0 0 0 1 1 0
CRC_Monitoring_144 M 1-Sep-59 54.0 17574.2 23-Aug-13 23-Aug-13 13.3 0 TMZ 27-Aug-13 5-Jul-13 1 -49 3 26-Aug-13 3 97 0 0 3 0 1 1 0 0 1 1 1 0
CRC_Monitoring_145 M 2-Aug-51 62.4 11773.6 19-Dec-13 19-Dec-13 80 0 TMZ 24-Dec-13 15-Nov-13 1 -34 2 20-Dec-13 1 84 0 0 3 0 1 1 0 0 1 1 1 0
CRC_Monitoring_146 F 3-Feb-41 72.5 19981.2 5-Jul-13 5-Jul-13 147.6 0 TMZ 12-Jul-13 19-Feb-13 1 -136 3 10-Jul-13 5 126 0 0 2 1 1 0 0 0 0 1 1 0
CRC_Monitoring_147 M 9-Mar-36 77.5 34425.0 3-Sep-13 3-Sep-13 138.2 0 TMZ 4-Sep-13 18-Jun-13 1 -77 2 23-Aug-13 -11 133 0 0 3 1 1 0 0 0 1 1 1 0
CRC_Monitoring_148 M 21-Feb-50 63.0 70062.1 21-Jan-13 21-Jan-13 3389 0 TMZ 29-Jan-13 15-Nov-12 1 -67 3 21-Jan-13 0 135.6 1 0 2 1 1 0 0 0 0 1 1 0
CRC_Monitoring_149 M 16-Dec-50 62.1 35596.9 14-Jan-13 29-Jan-13 2148 15 TMZ 16-Jan-13 16-Oct-12 1 -90 5 21-Dec-12 -24 167 0 0 3 0 1 1 0 0 1 0 0 0
CRC_Monitoring_150 M 23-Apr-51 62.0 21605.5 4-Apr-13 29-Mar-13 111.3 -6 TMZ 5-Apr-13 14-Feb-13 1 -49 2 4-Apr-13 0 84 1 0 2 0 1 1 0 0 0 1 1 0
CRC_Monitoring_151 F 19-Jan-68 45.3 19489.7 6-May-13 6-May-13 11.2 0 TMZ 13-May-13 8-Apr-13 0 -28 2 6-May-13 0 53 0 0 3 1 1 1 0 0 0 1 1 0
CRC_Monitoring_152 M 9-Feb-66 47.1 23568.1 14-Mar-13 11-Mar-13 19.2 -3 TMZ 27-Mar-13 15-Oct-12 1 -150 3 11-Mar-13 -3 34 0 0 2 0 1 0 0 0 1 0 0 0
CRC_Monitoring_153 M 12-May-72 40.9 14536.3 21-Mar-13 21-Mar-13 59.1 0 TMZ 25-Mar-13 28-Dec-12 1 -83 4 12-Mar-13 -9 57 0 0 4 1 1 1 0 0 1 1 1 0
CRC_Monitoring_154 F 4-Jul-56 56.6 40464.8 25-Jan-13 25-Jan-13 496.9 0 TMZ 29-Jan-13 15-Dec-12 1 -41 3 29-Jan-13 4 105.6 0 0 2 0 0 0 0 1 1 1 1 0
CRC_Monitoring_155 M 10-Jun-58 54.9 104241.0 3-Apr-13 11-Apr-13 634.7 8 TMZ 11-Apr-13 15-Feb-13 1 -47 2 8-Apr-13 5 107 1 0 3 1 1 1 0 0 0 0 0
CRC_Monitoring_156 F 5-Mar-58 55.1 6089.3 10-Apr-13 10-Apr-13 68.4 0 TMZ 30-Apr-13 15-Jan-13 1 -85 3 12-Apr-13 2 29 0 0 1 0 1 0 0 0 0 0 0 0
CRC_Monitoring_157 F 24-Mar-49 64.1 18011.6 4-Apr-13 3-Apr-13 5 -1 TMZ 4-Apr-13 15-Dec-12 1 -110 5 18-Mar-13 -17 34.3 0 0 3 0 1 1 0 0 1 1 1 0
CRC_Monitoring_158 M 23-Mar-52 62.0 16364.5 28-Feb-14 27-Feb-14 6.8 -1 TMZ 2-Mar-14 15-Jan-14 1 -44 6 10-Feb-14 -18 29 0 0 1 1 0 0 0 0 0 0 0 0
CRC_Monitoring_159 M 7-Jan-58 56.0 32537.4 17-Dec-13 16-Dec-13 262.8 -1 TMZ 23-Dec-13 15-Jul-13 1 -155 3 18-Dec-13 1 172 1 0 3 1 1 0 0 0 1 1 1 0
CRC_Monitoring_160 M 25-Oct-40 73.4 23854.4 18-Feb-14 18-Feb-14 280 0 TMZ 21-Feb-14 15-Nov-13 1 -95 3 5-Feb-14 -13 107 1 0 2 1 1 0 0 0 0 0 0 1
CRC_Monitoring_161 F 8-Mar-46 68.0 28576.9 4-Mar-14 5-Mar-14 22 1 TMZ 6-Mar-14 14-Nov-13 1 -110 3 26-Feb-14 -6 29 0 0 1 0 1 0 0 0 0 0 0 0
CRC_Monitoring_162 F 10-May-53 60.1 35053.0 30-May-13 30-May-13 7.6 0 TMZ 31-May-13 30-Apr-13 0 -30 2 2-May-13 -28 79 0 0 2 1 1 0 0 0 0 1 1 0
CRC_Monitoring_163 M 27-May-47 65.8 40107.0 14-Feb-13 14-Feb-13 1.4 0 TMZ 18-Feb-13 17-Dec-12 1 -59 8 23-Jan-13 -22 190 1 0 3 1 1 0 0 0 1 1 1 0
CRC_Monitoring_164 F 20-Jan-60 53.1 75477.5 18-Feb-13 18-Feb-13 517.2 0 TMZ 22-Feb-13 18-Jan-13 1 -31 3 18-Feb-13 0 142 0 0 2 1 0 1 0 0 0 1 1 0
CRC_Monitoring_165 F 10-Jul-53 60.9 149958.5 14-May-14 30-Apr-14 274.2 -14 TMZ 15-May-14 15-Apr-14 0 -29 3 14-May-14 0 147 1 0 2 1 1 0 0 0 0 0 0 0
CRC_Monitoring_166 M 18-May-74 39.0 28811.0 14-May-13 14-May-13 57.5 0 TMZ 24-May-13 12-Mar-13 1 -63 3 23-May-13 9 48 0 1 3 1 1 1 0 0 0 0 0 0
CRC_Monitoring_167 M 27-Jun-60 53.0 13968.2 28-May-13 28-May-13 73 0 TMZ 31-May-13 15-Mar-13 1 -74 2 28-May-13 0 38 0 0 1 0 1 0 0 0 0 1 1 0
CRC_Monitoring_168 M 18-Nov-42 71.3 1210352.6 3-Mar-14 3-Mar-14 421.4 0 TMZ 6-Mar-14 1-Feb-14 0 -30 3 5-Feb-14 -26 85 1 0 2 1 1 0 0 0 0 1 1 0
CRC_Monitoring_169 M 1-Oct-50 63.0 306597.5 2-Oct-13 2-Oct-13 342.8 0 TMZ 10-Oct-13 14-Aug-13 1 -49 5 4-Oct-13 2 108 0 0 2 1 0 1 0 0 0 1 1 0
CRC_Monitoring_170 M 25-Dec-39 74.0 29332.6 19-Dec-13 16-Dec-13 51.6 -3 TMZ 20-Dec-13 5-Sep-13 1 -105 4 25-Nov-13 -24 69.2 0 0 2 0 1 1 0 0 0 0 0 0
CRC_Monitoring_171 M 3-Mar-48 65.4 100149.0 28-Jun-13 30-Jun-13 82.9 2 no treatment 28-Jun-13 1 0 8-May-13 -51 70 0 0 2 1 1 1 1 0
CRC_Monitoring_172 F 26-Oct-48 64.9 162360.0 19-Sep-13 19-Sep-13 78 0 no treatment 19-Sep-13 1 0 22-Jul-13 -59 113 0 1 2 1 1 1 1 0
CRC_Monitoring_173 F 1-Nov-37 76.0 37908.0 2-Oct-13 16-Sep-13 2.3 -16 no treatment 2-Oct-13 1 0 2-Aug-13 -61 40 0 1 1 0
CRC_Monitoring_174 M 17-Mar-44 70.0 9661.0 10-Feb-14 24-Oct-13 49.8 -109 no treatment 10-Feb-14 1 0 29-Oct-13 -104 47 0 1 1 0
CRC_Monitoring_175 F 13-Aug-47 66.8 341927.0 29-Apr-14 29-Apr-14 79 0 no treatment 29-Apr-14 1 0 4-Apr-14 -25 182 1 4 1 1 1 1 1 1 0
CRC_Monitoring_176 F 25-Jun-68 45.9 7014008.0 12-May-14 26-May-14 518.3 14 no treatment 12-May-14 1 0 14-Apr-14 -28 70 0 1 2 1 1 1 1 0
CRC_Monitoring_177 M 22-May-37 77.0 29728.0 13-May-14 13-May-14 455.9 0 no treatment 13-May-14 1 0 17-Apr-14 -26 110 0 0 4 1 1 1 1 1 1 0
CRC_Monitoring_178 F 5-Mar-52 61.4 95599.0 2-Jul-13 2-Jul-13 527 0 no treatment 2-Jul-13 1 0 20-Jun-13 -12 70 1 1 1 0
CRC_Monitoring_179 M 25-Jan-59 54.5 21720.0 3-Jul-13 23-May-13 1.8 -41 no treatment 3-Jul-13 1 0 20-May-13 -44 50 0 1 1 0
CRC_Monitoring_180 F 8-Apr-45 68.3 69420.0 15-Jul-13 15-Jul-13 28.9 0 no treatment 15-Jul-13 1 0 23-May-13 -53 70 0 0 1 1 1 1 0
CRC_Monitoring_181 M 12-Apr-52 64.0 13540.4 12-Apr-16 Folfox+Beva 3-May-16 1 0 11-Apr-16 -1 35 0 0 3 1 1 1 1 1 0

























































































































































































































































































Normal_Tissue_01 Matched Normal/Tumor Tissue Cohort 1.02 N 0.05 16493 9 0.40 12629 51 0.23 0.25 5.66 21551 1294 3.97 11642 481 4.82 1.20 0.00 998 0 0.04 2433 1 0.02 0.03 0.01 37353 4 0.00 46909 0 0.01 0.01 0.02 5723 1 0.00 25475 0 0.01 0.01
Tumor_Tissue_01 Matched Normal/Tumor Tissue Cohort 30.25 T 2.94 9248 280 12.41 9263 1312 7.68 6.70 47.37 7045 6341 41.10 6385 4456 44.24 4.43 6.51 2068 144 8.92 643 63 7.72 1.70 40.22 5640 3794 33.23 3980 1981 36.73 4.94 46.90 6655 5877 62.93 999 1696 54.92 11.33
Normal_Tissue_02 Matched Normal/Tumor Tissue Cohort 8.43 N 1.84 15811 297 1.93 13907 274 1.89 0.06 18.44 4759 1076 17.88 17953 3908 18.16 0.40 8.30 4760 431 8.95 12349 1214 8.63 0.46 0.75 18847 142 1.83 14964 279 1.29 0.76 18.81 9949 2305 5.60 1398 83 12.21 9.34
Tumor_Tissue_02 Matched Normal/Tumor Tissue Cohort 50.89 T 59.42 5802 8496 55.76 8596 10836 57.59 2.59 45.64 2126 1785 49.17 11865 11478 47.41 2.50 55.66 4810 6038 54.51 3278 3928 55.09 0.81 21.76 9262 2576 28.29 5451 2150 25.03 4.62 68.95 2308 5126 69.74 1541 3552 69.35 0.56
Normal_Tissue_03 Matched Normal/Tumor Tissue Cohort 1.77 N 0.29 22156 65 0.28 18236 51 0.29 0.01 6.76 20372 1476 9.72 8050 867 8.24 2.09 0.13 7640 10 0.31 1907 6 0.22 0.13 0.12 27927 34 0.12 28297 33 0.12 0.00 0.00 1041 0 0.00 4965 0 0.00 0.00
Tumor_Tissue_03 Matched Normal/Tumor Tissue Cohort 33.97 T 31.86 15986 7476 16.22 12972 2512 24.04 11.06 55.65 5038 6322 63.49 6229 10833 59.57 5.54 40.43 1292 877 42.51 11598 8577 41.47 1.47 0.04 29092 11 0.03 46836 12 0.04 0.01 44.35 1246 993 45.09 2683 2203 44.72 0.52
Normal_Tissue_04 Matched Normal/Tumor Tissue Cohort 1.95 N 0.01 72740 7 0.01 103932 10 0.01 0.00 9.83 3633 396 7.22 17755 1382 8.53 1.85 0.19 2588 5 0.14 10767 15 0.17 0.04 0.11 32980 36 0.14 24289 33 0.13 0.02 0.63 25527 161 1.18 16528 197 0.91 0.39
Tumor_Tissue_04 Matched Normal/Tumor Tissue Cohort 70.29 T 77.10 4913 16540 71.33 3786 9418 74.22 4.08 95.72 356 7954 92.46 1294 15866 94.09 2.31 93.55 1163 16865 92.92 546 7166 93.24 0.45 0.07 12764 9 0.01 18378 1 0.04 0.04 88.90 1340 10732 90.82 948 9374 89.86 1.36
Normal_Tissue_05 Matched Normal/Tumor Tissue Cohort 6.71 N 1.64 38556 642 2.15 35056 769 1.90 0.36 24.15 6434 2049 24.82 16844 5562 24.49 0.47 0.61 7450 46 1.18 2420 29 0.90 0.40 0.23 20885 48 0.26 16837 44 0.25 0.02 3.48 23600 852 8.61 6900 650 6.05 3.63
Tumor_Tissue_05 Matched Normal/Tumor Tissue Cohort 88.62 T 82.10 4067 18655 81.60 4307 19106 81.85 0.35 92.08 858 9972 90.23 1512 13968 91.16 1.31 88.78 820 6486 91.30 1049 11005 90.04 1.78 86.96 1386 9242 89.30 1654 13803 88.13 1.65 93.34 1498 20989 90.48 1804 17147 91.91 2.02
Normal_Tissue_06 Matched Normal/Tumor Tissue Cohort 5.15 N 0.50 60788 305 0.54 54522 297 0.52 0.03 22.28 7479 2144 22.07 2231 632 22.18 0.15 0.64 8048 52 0.31 32877 101 0.48 0.23 0.12 28916 34 0.14 30823 42 0.13 0.01 3.49 5054 183 1.37 2086 29 2.43 1.50
Tumor_Tissue_06 Matched Normal/Tumor Tissue Cohort 71.44 T 48.33 6066 5675 69.58 7738 17699 58.96 15.03 81.60 1735 7693 84.26 2872 15378 82.93 1.88 74.70 4519 13345 71.18 1090 2692 72.94 2.49 57.76 2298 3142 64.44 3974 7202 61.10 4.72 81.99 1510 6875 80.55 3391 14047 81.27 1.02
Normal_Tissue_07 Matched Normal/Tumor Tissue Cohort 7.39 N 0.54 46421 252 0.71 48864 347 0.63 0.12 28.22 7096 2790 27.75 11975 4599 27.99 0.33 0.75 21846 165 0.69 4890 34 0.72 0.04 0.06 31284 20 0.24 10991 26 0.15 0.13 1.62 19979 330 13.30 5934 910 7.46 8.26
Tumor_Tissue_07 Matched Normal/Tumor Tissue Cohort 36.60 T 0.17 64439 108 0.13 65699 86 0.15 0.03 74.37 3722 10802 70.67 4515 10881 72.52 2.62 36.94 7975 4672 30.69 4412 1954 33.82 4.42 16.50 7549 1492 21.34 5040 1367 18.92 3.42 60.75 2156 3337 54.43 3033 3622 57.59 4.47
Normal_Tissue_08 Matched Normal/Tumor Tissue Cohort 0.87 N 3.15 13758 447 2.24 45652 1044 2.70 0.64 2.26 260 6 0.23 3438 8 1.25 1.44 0.28 7860 22 0.28 2118 6 0.28 0.00 0.02 29586 5 0.03 10560 3 0.03 0.01 0.15 653 1 0.02 5775 1 0.09 0.09
Tumor_Tissue_08 Matched Normal/Tumor Tissue Cohort 58.85 T 55.99 4806 6114 41.91 6492 4683 48.95 9.96 80.06 1283 5151 91.24 273 2843 85.65 7.91 28.60 252 101 25.24 3350 1131 26.92 2.38 43.95 3856 3023 55.00 3349 4094 49.48 7.81 82.61 32 152 83.91 417 2175 83.26 0.92
Normal_Tissue_09 Matched Normal/Tumor Tissue Cohort 2.18 N 0.08 90345 74 0.09 89095 81 0.09 0.01 2.40 17590 433 8.77 16059 1543 5.59 4.50 0.11 28058 32 0.22 16886 37 0.17 0.08 0.26 21882 58 0.31 14937 46 0.29 0.04 0.63 3486 22 8.90 1023 100 4.77 5.85
Tumor_Tissue_09 Matched Normal/Tumor Tissue Cohort 22.97 T 16.26 7476 1452 7.51 15864 1289 11.89 6.19 43.09 8463 6407 17.13 8101 1675 30.11 18.36 20.35 8779 2243 18.05 5471 1205 19.20 1.63 12.52 11361 1626 18.21 6915 1540 15.37 4.02 45.30 2522 2089 31.23 2215 1006 38.27 9.95
Normal_Tissue_10 Matched Normal/Tumor Tissue Cohort 2.18 N 0.50 46606 234 1.41 34350 490 0.96 0.64 11.71 5784 767 6.53 24548 1716 9.12 3.66 0.16 22096 35 0.13 6373 8 0.15 0.02 0.09 28640 26 0.35 14151 50 0.22 0.18 0.87 29119 256 0.02 5623 1 0.45 0.60
Tumor_Tissue_10 Matched Normal/Tumor Tissue Cohort 83.23 T 60.01 6586 9882 78.26 4674 16821 69.14 12.90 87.93 835 6082 94.45 957 16291 91.19 4.61 84.28 2242 12019 80.70 493 2062 82.49 2.53 78.32 1757 6346 84.76 1530 8508 81.54 4.55 94.74 857 15433 88.84 1682 13396 91.79 4.17
Normal_Tissue_11 Matched Normal/Tumor Tissue Cohort 1.55 N 0.95 36001 344 0.19 20282 38 0.57 0.54 2.05 9579 200 2.28 5315 124 2.17 0.16 0.43 21297 92 0.76 3265 25 0.60 0.23 0.21 20725 43 0.10 42019 42 0.16 0.08 1.16 6980 82 7.32 15490 1224 4.24 4.36
Tumor_Tissue_11 Matched Normal/Tumor Tissue Cohort 86.77 T 61.10 6325 9933 67.45 7172 14864 64.28 4.49 90.53 1563 14945 89.14 2438 20007 89.84 0.98 91.43 578 6170 90.92 370 3705 91.18 0.36 92.93 653 8581 93.34 1285 18022 93.14 0.29 99.76 51 21628 91.11 1850 18966 95.44 6.12
Normal_Tissue_12 Matched Normal/Tumor Tissue Cohort 0.77 N 0.18 6150 11 1.11 17453 196 0.65 0.66 0.18 10134 18 0.42 15933 68 0.30 0.17 0.27 7682 21 0.33 5123 17 0.30 0.04 0.87 26301 231 0.90 18218 165 0.89 0.02 3.38 8851 310 0.02 5569 1 1.70 2.38
Tumor_Tissue_12 Matched Normal/Tumor Tissue Cohort 90.03 T 67.69 5322 11148 79.25 3000 11459 73.47 8.17 96.00 706 16946 98.81 229 19095 97.41 1.99 85.63 853 5082 84.53 975 5327 85.08 0.78 96.72 645 19035 96.95 637 20249 96.84 0.16 98.21 518 28374 96.51 746 20608 97.36 1.20
Normal_Tissue_13 Matched Normal/Tumor Tissue Cohort 0.97 N 0.97 31267 305 0.41 59230 246 0.69 0.40 1.03 6270 65 4.86 11632 594 2.95 2.71 0.23 23291 53 0.18 18749 34 0.21 0.04 0.24 14132 34 0.35 31599 110 0.30 0.08 0.06 3177 2 1.35 6511 89 0.71 0.91
Tumor_Tissue_13 Matched Normal/Tumor Tissue Cohort 42.21 T 17.17 1548 321 29.57 7493 3146 23.37 8.77 79.49 1342 5202 73.26 3914 10724 76.38 4.41 39.73 176 116 31.56 4532 2090 35.65 5.78 9.60 9220 979 9.68 11605 1244 9.64 0.06 60.47 3073 4700 71.52 1689 4241 66.00 7.81
Normal_Tissue_14 Matched Normal/Tumor Tissue Cohort 2.08 N 0.26 39826 1 0.28 21289 60 0.27 0.01 12.15 3686 510 7.16 8692 670 9.66 3.53 0.27 2927 8 0.09 8063 7 0.18 0.13 0.19 35301 67 0.00 20964 0 0.10 0.13 0.00 3943 0 0.42 4779 20 0.21 0.30
Tumor_Tissue_14 Matched Normal/Tumor Tissue Cohort 25.57 T 2.29 14454 338 4.68 18721 919 3.49 1.69 29.71 951 402 30.59 615 271 30.15 0.62 2.00 11248 230 2.79 2858 82 2.40 0.56 13.14 6341 959 7.88 11228 961 10.51 3.72 78.49 671 2449 84.09 543 2869 81.29 3.96
Normal_Tissue_15 Matched Normal/Tumor Tissue Cohort 4.06 N 0.60 28238 170 0.40 42789 173 0.50 0.14 17.86 2368 515 17.26 14716 3070 17.56 0.42 0.25 22469 57 0.30 7578 23 0.28 0.04 0.01 33625 3 0.07 17190 12 0.04 0.04 2.07 8043 170 1.82 8103 150 1.95 0.18
Tumor_Tissue_15 Matched Normal/Tumor Tissue Cohort 63.60 T 22.93 4382 1304 19.49 6623 1603 21.21 2.43 96.10 915 22518 86.53 1524 9791 91.32 6.77 30.19 481 208 36.71 967 561 33.45 4.61 81.92 739 3349 75.86 1997 6277 78.89 4.29 90.19 151 1388 96.08 26 638 93.14 4.16
Normal_Tissue_16 Matched Normal/Tumor Tissue Cohort 0.16 N 0.04 9850 4 0.01 14401 1 0.03 0.02 0.00 783 0 0.00 253 0 0.00 0.00 0.10 5167 5 0.31 1904 6 0.21 0.15 0.03 11468 3 0.01 15772 2 0.02 0.01 0.23 2205 5 0.86 28786 251 0.55 0.45
Tumor_Tissue_16 Matched Normal/Tumor Tissue Cohort 66.96 T 66.21 6023 11802 50.52 8385 8560 58.37 11.09 90.41 73 688 89.42 598 5053 89.92 0.70 57.59 687 933 59.09 369 533 58.34 1.06 33.80 6144 3137 57.40 2472 3331 45.60 16.69 91.75 675 7509 73.40 715 1973 82.58 12.98
Normal_Tissue_17 Matched Normal/Tumor Tissue Cohort 2.37 N 0.99 22494 224 0.70 16780 118 0.85 0.21 12.44 18003 2558 7.98 22901 1987 10.21 3.15 0.51 8507 44 0.09 9748 9 0.30 0.30 0.41 35205 144 0.18 18007 33 0.30 0.16 0.00 1741 0 0.40 2715 11 0.20 0.28
Tumor_Tissue_17 Matched Normal/Tumor Tissue Cohort 46.11 T 52.53 3870 4283 41.95 4579 3309 47.24 7.48 57.28 1742 2336 54.40 3245 3871 55.84 2.04 37.76 244 148 26.53 3598 1299 32.15 7.94 60.84 2737 4253 62.20 3397 5590 61.52 0.96 34.98 2392 1287 32.61 1176 569 33.80 1.68
Normal_Tissue_18 Matched Normal/Tumor Tissue Cohort 1.17 N 0.74 12544 93 0.61 19647 121 0.68 0.09 0.11 10149 11 8.29 7425 671 4.20 5.78 0.29 6563 19 0.93 3515 33 0.61 0.45 0.31 30087 94 0.36 13995 50 0.34 0.04 0.04 2365 1 0.04 2823 1 0.04 0.00
Tumor_Tissue_18 Matched Normal/Tumor Tissue Cohort 58.49 T 72.70 3401 9055 70.56 6311 15125 71.63 1.51 63.26 907 1562 68.74 562 1236 66.00 3.87 63.49 2996 5211 70.76 2625 6351 67.13 5.14 0.05 58779 28 0.26 11409 30 0.16 0.15 75.32 801 2445 99.74 10 3839 87.53 17.27
Normal_Tissue_19 Matched Normal/Tumor Tissue Cohort 2.28 N 0.29 65358 189 0.10 42991 42 0.20 0.13 2.87 10045 297 18.59 10323 2358 10.73 11.12 0.00 1567 0 0.06 9334 6 0.03 0.04 0.49 12084 60 0.18 19447 36 0.34 0.22 0.21 1917 4 0.00 2603 0 0.11 0.15
Tumor_Tissue_19 Matched Normal/Tumor Tissue Cohort 20.17 T 14.39 20830 3500 9.79 20804 2257 12.09 3.25 19.91 3186 792 16.71 11651 2337 18.31 2.26 13.45 7124 1107 11.58 9894 1296 12.52 1.32 24.54 8480 2757 30.09 3796 1634 27.32 3.92 24.01 4413 1394 37.24 5829 3459 30.63 9.36
Normal_Tissue_20 Matched Normal/Tumor Tissue Cohort 0.37 N 0.01 95626 11 0.02 71449 17 0.02 0.01 0.00 8613 0 2.08 19674 417 1.04 1.47 0.20 16785 34 0.11 6328 7 0.16 0.06 0.12 23810 29 0.15 38249 57 0.14 0.02 0.00 1457 0 1.01 1276 13 0.51 0.71
Tumor_Tissue_20 Matched Normal/Tumor Tissue Cohort 62.54 T 62.37 8062 13364 60.52 8738 13394 61.45 1.31 77.05 767 2575 78.41 3108 11287 77.73 0.96 58.74 1612 2295 59.20 2930 4251 58.97 0.33 30.98 5387 2418 35.87 3482 1948 33.43 3.46 71.44 1320 3302 90.83 1174 11632 81.14 13.71
Normal_Tissue_21 Matched Normal/Tumor Tissue Cohort 0.34 N 1.14 49922 574 0.25 41484 105 0.70 0.63 0.70 1133 8 0.64 621 4 0.67 0.04 0.10 19460 19 0.05 2008 1 0.08 0.04 0.31 11065 34 0.09 17348 16 0.20 0.16 0.11 2755 3 0.02 4900 1 0.07 0.06
Tumor_Tissue_21 Matched Normal/Tumor Tissue Cohort 32.89 T 22.23 10832 3096 17.89 20241 4409 20.06 3.07 55.61 1666 2087 49.51 2944 2887 52.56 4.31 8.65 7644 724 9.41 16666 1731 9.03 0.54 44.07 4082 3216 52.76 4103 4583 48.42 6.14 34.37 529 277 34.37
Normal_Tissue_22 Matched Normal/Tumor Tissue Cohort 2.18 N 0.54 13662 74 0.94 16394 155 0.74 0.28 5.03 13467 714 14.52 1124 191 9.78 6.71 0.06 3218 2 0.08 4916 4 0.07 0.01 0.00 24845 0 0.47 16896 80 0.24 0.33 0.00 192 0 0.11 1826 2 0.06 0.08
Tumor_Tissue_22 Matched Normal/Tumor Tissue Cohort 23.07 T 7.94 15323 1322 14.00 15384 2504 10.97 4.29 32.67 8764 4252 32.62 10186 4932 32.65 0.04 18.57 10661 2431 14.44 6917 1167 16.51 2.92 15.62 8406 1556 12.70 10539 1533 14.16 2.06 44.67 6655 5373 37.5 8461 5077 41.09 5.07
Normal_Tissue_23 Matched Normal/Tumor Tissue Cohort 5.40 N 0.19 12103 23 0.34 23271 79 0.27 0.11 19.21 8154 1939 20.20 20214 5116 19.71 0.70 0.08 4780 4 0.12 4189 5 0.10 0.03 0.12 27393 34 0.25 26013 65 0.19 0.09 3.28 6465 219 10.21 4616 525 6.75 4.90
Tumor_Tissue_23 Matched Normal/Tumor Tissue Cohort 67.66 T 28.69 8311 3343 34.96 7705 4142 31.83 4.43 75.90 2070 6518 64.91 3582 6625 70.41 7.77 70.47 686 1637 68.55 522 1138 69.51 1.36 72.26 1694 4412 73.56 1825 5078 72.91 0.92 98.22 622 34244 89.03 1915 15549 93.63 6.50
Normal_Tissue_24 Matched Normal/Tumor Tissue Cohort 0.69 N 0.45 24970 113 0.53 13481 72 0.49 0.06 0.50 38683 194 3.55 15016 552 2.03 2.16 0.07 5372 4 0.34 4063 14 0.21 0.19 0.12 41963 49 0.25 32027 80 0.19 0.09 0.48 5790 28 0.59 9032 54 0.54 0.08
Tumor_Tissue_24 Matched Normal/Tumor Tissue Cohort 86.23 T 76.03 3379 10716 76.55 4216 13762 76.29 0.37 84.95 1710 9652 84.78 2297 12794 84.87 0.12 86.85 1910 12610 88.53 1026 7916 87.69 1.19 91.17 567 5857 91.89 1640 18576 91.53 0.51 89.55 2293 19653 92.04 1825 21105 90.80 1.76
Normal_Tissue_25 Matched Normal/Tumor Tissue Cohort 0.65 N 0.40 28651 115 1.24 32851 414 0.82 0.59 0.48 24749 119 0.68 10077 69 0.58 0.14 0.11 35942 38 0.09 26736 24 0.10 0.01 0.08 23885 18 0.36 29422 105 0.22 0.20 3.02 23054 717 0.04 23549 10 1.53 2.11
Tumor_Tissue_25 Matched Normal/Tumor Tissue Cohort 58.75 T 37.39 5884 3514 40.63 10160 6953 39.01 2.29 82.31 2331 10844 77.03 2871 9627 79.67 3.73 83.34 1197 5988 81.25 568 2461 82.30 1.48 0.02 46164 8 0.07 31810 21 0.05 0.04 87.86 2839 20548 97.59 819 33199 92.73 6.88
Normal_Tissue_26 Matched Normal/Tumor Tissue Cohort 1.08 N 0.05 69572 38 0.13 68751 92 0.09 0.06 4.85 6046 308 5.30 26842 1503 5.08 0.32 0.33 6040 20 0.07 6962 5 0.20 0.18 0.09 35219 31 0.02 58066 14 0.06 0.05 0.00 11943 0 0 9540 0 0.00 0.00
Tumor_Tissue_26 Matched Normal/Tumor Tissue Cohort 45.31 T 22.57 18902 5510 8.49 16982 1575 15.53 9.96 47.62 3650 3318 51.53 9624 10230 49.58 2.76 38.02 1901 1166 38.15 5927 3656 38.09 0.09 43.39 5073 3889 48.05 3696 3418 45.72 3.30 81.40 3435 15031 73.84 3679 10383 77.62 5.35
Normal_Tissue_27 Matched Normal/Tumor Tissue Cohort 3.23 N 0.64 41935 271 0.02 50133 10 0.33 0.44 13.38 2220 343 12.08 9542 1311 12.73 0.92 0.21 17788 38 0.32 25658 83 0.27 0.08 0.22 20904 46 0.05 40975 21 0.14 0.12 4.95 8366 436 0.38 3664 14 2.67 3.23
Tumor_Tissue_27 Matched Normal/Tumor Tissue Cohort 25.27 T 18.68 9409 2162 13.55 9547 1497 16.12 3.63 18.26 10231 2285 16.76 8925 1797 17.51 1.06 16.00 10327 1967 16.73 6875 1381 16.37 0.52 17.12 8019 1656 14.56 9032 1539 15.84 1.81 54.17 1489 1760 66.89 1092 2206 60.53 8.99
Normal_Tissue_28 Matched Normal/Tumor Tissue Cohort 1.51 N 2.31 31867 755 0.78 34142 268 1.55 1.08 0.64 4007 26 1.24 28825 362 0.94 0.42 0.35 24849 87 0.21 19734 41 0.28 0.10 0.69 11437 80 0.46 9512 44 0.58 0.16 0.69 5044 35 7.76 5062 426 4.23 5.00
Tumor_Tissue_28 Matched Normal/Tumor Tissue Cohort 94.90 T 93.02 2604 34678 90.76 4130 40590 91.89 1.60 95.18 434 8574 96.44 953 25812 95.81 0.89 97.32 1017 36998 95.05 390 7482 96.19 1.61 92.96 1111 14674 93.52 495 7146 93.24 0.40 96.87 320 9892 97.92 283 13291 97.40 0.74
Normal_Tissue_29 Matched Normal/Tumor Tissue Cohort 2.29 N 0.38 34511 133 0.36 41635 151 0.37 0.01 1.96 13142 263 0.82 19058 157 1.39 0.81 0.26 38403 100 0.25 16088 41 0.26 0.01 0.23 21380 50 0.47 36399 172 0.35 0.17 16.89 7226 1468 1.31 14020 186 9.10 11.02
Tumor_Tissue_29 Matched Normal/Tumor Tissue Cohort 74.76 T 85.24 3843 22190 93.04 2286 30553 89.14 5.52 95.12 544 10600 96.11 480 11850 95.62 0.70 92.30 1192 14289 88.25 422 3171 90.28 2.86 31.97 3754 1764 38.82 4352 2761 35.40 4.84 57.33 1240 1666 69.45 1464 3328 63.39 8.57
Normal_Tissue_30 Matched Normal/Tumor Tissue Cohort 0.34 N 0.27 13919 38 0.06 9617 6 0.17 0.15 0.47 34496 164 0.69 29937 208 0.58 0.16 0.89 1007 9 0.07 8219 6 0.48 0.58 0.25 37141 94 0.59 25332 151 0.42 0.24 0.11 1880 2 0.01 6857 1 0.06 0.07
Tumor_Tissue_30 Matched Normal/Tumor Tissue Cohort 31.05 T 1.79 27615 504 2.20 26748 603 2.00 0.29 46.44 4127 3579 37.13 2274 1343 41.79 6.58 34.47 1458 767 24.20 8030 2564 29.34 7.26 37.11 9115 5378 43.59 4239 3275 40.35 4.58 36.89 14400 8418 46.68 5854 5125 41.79 6.92
Normal_Tissue_31 Matched Normal/Tumor Tissue Cohort 1.16 N 0.64 34517 224 0.57 28973 166 0.61 0.05 1.91 9792 191 3.21 5600 186 2.56 0.92 0.56 23521 133 0.21 17925 38 0.39 0.25 2.70 6117 170 1.43 18509 268 2.07 0.90 0.14 17182 24 0.25 21313 54 0.20 0.08


































































































































































































































































Tumor_Tissue_33 Independent Tumors 0.6 9.20 A01 5.06 15089 804 5.53 21860 1280 5.30 0.33 11.63 10739 1413 12.04 20425 2796 11.84 0.29 6.50 7432 520 3.00 44740 1380 4.75 2.47 4.93 18000 933 5.06 21940 1170 5.00 0.09 20.90 28908 7636 17.32 25602 5365 19.11 2.53
Tumor_Tissue_34 Independent Tumors CRC_Monitoring_88 0.4 34.23 B01 19.79 7445 1837 9.38 15076 1560 14.59 7.36 23.11 10684 3211 27.11 13181 4902 25.11 2.83 35.20 16249 8838 34.60 15246 8079 34.90 0.42 22.71 16724 4915 17.98 12972 2843 20.35 3.34 80.43 11743 48257 71.99 8466 21759 76.21 5.97
Tumor_Tissue_35 Independent Tumors 0.2 10.20 C01 13.21 9529 1450 7.98 13113 1137 10.60 3.70 31.36 6115 2794 30.11 3444 1484 30.74 0.88 8.30 9956 907 10.90 6589 802 9.60 1.84 0.01 54017 4 0.11 60884 70 0.06 0.07 0.00 2072 0 0.02 4057 1 0.01 0.01
Tumor_Tissue_36 Independent Tumors CRC_Monitoring_86 0.3 51.77 D01 38.13 5255 3239 50.80 4921 5081 44.47 8.96 77.9 3082 10866 78.17 621 2224 78.04 0.19 35.80 10722 5968 34.70 8046 4284 35.25 0.78 21.31 13441 3640 12.48 14083 2008 16.90 6.24 87.01 1658 11104 81.35 234 1021 84.18 4.00
Tumor_Tissue_37 Independent Tumors CRC_Monitoring_110 0.5 21.71 G01 4.42 3894 180 8.45 3382 312 6.44 2.85 35.84 6946 3880 37.4 7555 4514 36.62 1.10 6.00 20225 1280 6.50 16906 1176 6.25 0.35 12.28 17701 2478 5.18 6317 345 8.73 5.02 57.25 14780 19790 43.76 13276 10332 50.51 9.54
Tumor_Tissue_38 Independent Tumors CRC_Monitoring_118 0.6 28.47 H01 3.48 2164 78 11.82 2888 387 7.65 5.90 37.05 8314 4893 43.68 3055 2369 40.37 4.69 25.30 3290 1113 21.30 2202 596 23.30 2.83 1.73 27404 482 0.60 4158 25 1.17 0.80 67.78 6662 14013 72.00 953 2451 69.89 2.98
Tumor_Tissue_39 Independent Tumors CRC_Monitoring_93 0.5 70.93 D05 64.57 2358 4298 53.60 2235 2582 59.09 7.76 85.53 208 1229 67.35 1017 2098 76.44 12.86 47.70 2686 2445 52.90 840 942 50.30 3.68 60.06 4250 6390 77.57 2975 10290 68.82 12.38 99.97 12 39564 100.00 0 7999 99.99 0.02
Tumor_Tissue_40 Independent Tumors CRC_Monitoring_90 0.5 35.92 F11 47.08 3429 3050 46.77 4616 4055 46.93 0.22 66.63 1733 3461 68.68 3235 7094 67.66 1.45 32.30 6001 2863 22.80 5661 1669 27.55 6.72 30.07 9934 4271 36.08 9605 5421 33.08 4.25 3.69 548 21 5.09 1584 85 4.39 0.99
Tumor_Tissue_41 Independent Tumors CRC_Monitoring_98 42.48 D03 35.46 2777 1526 36.38 2244 1283 35.92 0.65 58.53 3159 4459 56.22 5830 7487 57.38 1.63 33.30 6293 3143 30.90 2732 1219 32.10 1.70 5.84 9423 584 9.05 19056 1897 7.45 2.27 84.39 2285 12349 74.69 3735 11022 79.54 6.86
Tumor_Tissue_42 Independent Tumors 0.1 36.86 F03 11.51 3974 517 19.74 5008 1232 15.63 5.82 41.23 2091 1467 37.15 1812 1071 39.19 2.88 29.40 3840 1601 25.80 2353 817 27.60 2.55 19.82 5141 1271 29.36 9951 4136 24.59 6.75 72.09 5821 15039 82.49 148 697 77.29 7.35
Tumor_Tissue_43 Independent Tumors CRC_Monitoring_107 0.2 46.62 G05 34.81 9773 5219 32.08 4625 2184 33.45 1.93 52.31 1353 1484 44.27 1761 1399 48.29 5.69 63.30 1404 2418 51.20 103 108 57.25 8.56 16.14 9479 1825 23.05 7887 2362 19.60 4.89 87.12 369 2497 61.87 657 1066 74.50 17.85
Tumor_Tissue_44 Independent Tumors CRC_Monitoring_119 69.55 E03 51.58 1873 1995 62.63 1942 3254 57.11 7.81 80.35 1654 6765 83.88 3509 18259 82.12 2.50 68.30 3339 7179 57.50 1675 2268 62.90 7.64 55.05 2208 2704 57.68 6952 9477 56.37 1.86 94.83 2650 48646 83.68 3664 18788 89.26 7.88
Tumor_Tissue_45 Independent Tumors CRC_Monitoring_94 14.24 H03 2.77 6202 177 4.91 7309 377 3.84 1.51 36.41 5148 2948 32.41 10390 4983 34.41 2.83 14.50 4848 822 10.40 1661 193 12.45 2.90 6.41 19787 1356 8.83 11903 1153 7.62 1.71 7.66 10894 904 18.07 8552 1886 12.87 7.36
Tumor_Tissue_46 Independent Tumors 0.4 41.86 H05 33.46 3938 1980 40.19 6297 4231 36.83 4.76 60.48 3495 5349 50.39 4346 4415 55.44 7.13 27.80 1282 493 31.70 1476 685 29.75 2.76 23.58 8099 2499 39.41 5617 3654 31.50 11.19 49.70 9125 9017 61.88 3961 6430 55.79 8.61
Tumor_Tissue_47 Independent Tumors CRC_Monitoring_97 0.6 63.27 B05 65.99 3648 7078 72.72 3825 10198 69.36 4.76 80.58 2140 8877 89.81 1002 8829 85.20 6.53 74.60 5628 16559 75.80 3334 10456 75.20 0.85 1.61 40158 658 4.10 16138 690 2.86 1.76 77.62 8462 29349 89.82 2970 26193 83.72 8.63
Tumor_Tissue_48 Independent Tumors CRC_Monitoring_108 0.5 25.02 C05 29.11 6266 2573 37.31 7505 4466 33.21 5.80 33.7 7097 3607 44.35 3154 2514 39.03 7.53 24.10 2340 745 17.70 7457 1602 20.90 4.53 14.01 15664 2552 29.07 7181 2943 21.54 10.65 5.77 16832 1030 15.11 11964 2130 10.44 6.60
Tumor_Tissue_49 Independent Tumors CRC_Monitoring_102 0.5 88.99 E05 76.82 1026 3401 87.33 1243 8564 82.08 7.43 92.4 1134 13794 92.75 1093 13980 92.58 0.25 89.00 183 1483 85.60 538 3194 87.30 2.40 88.55 1988 15377 84.18 2384 12685 86.37 3.09 99.10 693 76387 94.17 1804 29158 96.64 3.49
Tumor_Tissue_50 Independent Tumors CRC_Monitoring_100 0.5 51.19 F05 49.71 2151 2126 51.44 3264 3457 50.58 1.22 76.95 2755 9196 69.54 3984 9096 73.25 5.24 38.90 1989 1264 27.60 280 107 33.25 7.99 18.21 9698 2159 23.44 13884 4251 20.83 3.70 66.96 7870 15953 89.14 2454 20144 78.05 15.68
Tumor_Tissue_51 Independent Tumors CRC_Monitoring_112 0.6 92.02 B07 90.03 955 8623 93.52 907 13089 91.78 2.47 95.54 462 9887 85.06 3289 18726 90.30 7.41 89.50 1775 15085 83.70 54 278 86.60 4.10 95.77 1551 35074 90.02 2063 18610 92.90 4.07 99.77 127 55237 97.33 779 28372 98.55 1.73
Tumor_Tissue_52 Independent Tumors CRC_Monitoring_125 0.6 79.91 A07 81.24 1346 5829 84.15 1783 9464 82.70 2.06 65.94 1434 2776 59.64 5167 7635 62.79 4.45 78.80 5299 19700 79.30 3527 13523 79.05 0.35 85.80 2055 12417 84.18 3468 18454 84.99 1.15 93.14 2627 35667 86.95 4961 33051 90.05 4.38
Tumor_Tissue_53 Independent Tumors CRC_Monitoring_120 0.4 25.87 C03 19.91 8727 2170 26.60 12020 4355 23.26 4.73 70.62 448 1077 76.69 242 796 73.66 4.29 23.30 1026 312 15.20 268 48 19.25 5.73 9.60 11078 1177 15.75 9907 1852 12.68 4.35 0.49 7546 37 0.50 1001 5 0.50 0.01
Tumor_Tissue_54 Independent Tumors CRC_Monitoring_123 0.4 44.22 D07 32.58 2450 1184 43.69 3077 2387 38.14 7.86 60.39 4837 7375 54.76 9663 11697 57.58 3.98 33.27 10604 5288 34.20 7166 3724 33.74 0.66 7.79 7207 609 12.24 13636 1902 10.02 3.15 83.25 6524 32435 80.00 3578 14314 81.63 2.30
Tumor_Tissue_55 Independent Tumors 70.15 C07 66.20 2750 5385 74.06 2809 8021 70.13 5.56 81.21 2361 10203 79.57 5450 21224 80.39 1.16 52.40 5044 5544 46.10 7636 6524 49.25 4.45 62.36 2838 4702 57.58 6247 8479 59.97 3.38 93.17 1460 19913 88.85 2783 22174 91.01 3.05
Tumor_Tissue_56 Independent Tumors 0.4 12.35 G07 1.98 4948 100 3.82 9115 362 2.90 1.30 7.99 19005 1650 8.18 21493 1916 8.09 0.13 3.40 28719 1001 3.10 3842 122 3.25 0.21 1.79 17441 317 3.61 27421 1028 2.70 1.29 43.10 12808 9700 46.49 12263 10656 44.80 2.40
Tumor_Tissue_57 Independent Tumors CRC_Monitoring_104 0.6 61.03 H07 50.44 7499 7633 53.44 1457 1672 51.94 2.12 78.73 4041 14962 68.41 6222 13476 73.57 7.30 29.20 8693 3580 34.00 4356 2240 31.60 3.39 56.55 3363 4377 57.53 6262 8481 57.04 0.69 92.51 3239 40033 89.53 3176 27157 91.02 2.11
Tumor_Tissue_58 Independent Tumors CRC_Monitoring_101 0.6 63.27 B09 23.06 5640 1690 25.98 6356 2231 24.52 2.06 79.27 2580 9863 76.86 2647 8792 78.07 1.70 59.90 4585 6844 60.40 4069 6206 60.15 0.35 56.92 6020 7953 55.82 6933 8761 56.37 0.78 98.35 1066 63428 96.17 1375 34513 97.26 1.54
Tumor_Tissue_59 Independent Tumors CRC_Monitoring_23 0.3 55.83 C09 0.98 11811 117 1.22 17184 212 1.10 0.17 89.3 1620 13520 90.35 2151 20131 89.83 0.74 93.00 1339 17782 88.00 1156 8509 90.50 3.54 0.16 58796 96 0.12 75744 91 0.14 0.03 97.48 1434 55401 97.70 1142 48467 97.59 0.16
Tumor_Tissue_60 Independent Tumors CRC_Monitoring_103 5.20 E09 0.85 5928 51 2.83 11111 324 1.84 1.40 9.92 7904 870 1.84 7242 136 5.88 5.71 4.40 6141 281 5.11 446 24 4.76 0.50 3.36 26863 933 2.23 20374 464 2.80 0.80 11.75 3702 493 9.66 215 23 10.71 1.48
Tumor_Tissue_61 Independent Tumors CRC_Monitoring_96 0.7 16.29 F09 0.15 10314 16 0.20 13896 28 0.18 0.04 18.75 9571 2208 23.76 12745 3973 21.26 3.54 13.40 3126 482 10.20 8868 1012 11.80 2.26 1.19 25888 313 1.36 39463 545 1.28 0.12 52.72 5691 6347 41.21 7856 5507 46.97 8.14
Tumor_Tissue_62 Independent Tumors 0.6 28.59 G09 10.74 3625 436 19.40 4080 982 15.07 6.12 52.65 5216 5801 46 5904 5029 49.33 4.70 16.70 6429 1289 11.80 5463 734 14.25 3.46 14.97 14592 2569 12.47 10156 1447 13.72 1.77 56.85 7796 10273 44.29 11913 9471 50.57 8.88
Tumor_Tissue_63 Independent Tumors CRC_Monitoring_115 0.3 68.94 G03 59.79 1480 2201 66.45 623 1234 63.12 4.71 88.59 689 5348 79.19 5225 19889 83.89 6.65 66.80 2818 5661 64.50 2575 4685 65.65 1.63 51.74 3466 3716 66.11 4237 8265 58.93 10.16 67.37 1568 3238 78.88 5406 20193 73.13 8.14
Tumor_Tissue_64 Independent Tumors CRC_Monitoring_126 0.3 47.46 E07 55.08 1822 2234 68.38 1664 3598 61.73 9.40 58.04 720 996 47.54 3098 2807 52.79 7.42 22.80 5177 1529 19.80 1757 435 21.30 2.12 30.12 11389 4910 30.12 9287 4003 30.12 0.00 82.39 528 2471 60.37 7976 12149 71.38 15.57
Tumor_Tissue_65 Independent Tumors CRC_Monitoring_117 0.5 51.63 F07 43.13 2116 1605 55.24 2118 2614 49.19 8.56 72.54 4010 10595 62.3 7916 13082 67.42 7.24 45.80 4158 3517 46.40 4823 4168 46.10 0.42 9.17 8890 898 16.93 13742 2800 13.05 5.49 77.46 6875 23625 87.32 4326 29781 82.39 6.97
Tumor_Tissue_66 Independent Tumors CRC_Monitoring_109 0.3 21.25 A09 13.92 8679 1403 17.22 10736 2234 15.57 2.33 21.15 12337 3310 25.01 3425 1142 23.08 2.73 16.40 9959 1955 15.00 21279 3754 15.70 0.99 10.52 17531 2062 7.02 27219 2054 8.77 2.47 40.59 11931 8150 45.64 2274 1909 43.12 3.57
Tumor_Tissue_67 Independent Tumors CRC_Monitoring_116 0.3 89.75 D09 73.67 1500 4196 83.85 1115 5789 78.76 7.20 94.79 857 15607 94.64 1218 21494 94.72 0.11 89.20 1704 14025 87.10 1493 10089 88.15 1.48 90.75 1398 13717 91.60 1176 12828 91.18 0.60 97.06 1547 51149 94.84 1931 35477 95.95 1.57
Tumor_Tissue_68 Independent Tumors 0.4 11.64 H09 1.02 5536 57 1.66 19689 333 1.34 0.45 46.16 6330 5426 51.39 6480 6851 48.78 3.70 4.40 7416 343 5.30 4250 240 4.85 0.64 3.11 32931 1058 3.10 23696 758 3.11 0.01 0.01 44807 4 0.26 29960 78 0.14 0.18
Tumor_Tissue_69 Independent Tumors 0.4 41.89 A11 24.40 6858 2214 32.14 6395 3029 28.27 5.47 74.51 1755 5130 78 1765 6259 76.26 2.47 62.40 6284 10436 59.90 3202 4792 61.15 1.77 34.66 11513 6106 43.58 9826 7591 39.12 6.31 0.45 6821 31 8.88 19044 1856 4.67 5.96
Tumor_Tissue_70 Independent Tumors CRC_Monitoring_1 0.4 57.32 E11 53.67 3064 3549 56.53 2907 3780 55.10 2.02 74.06 3615 10319 72.43 4064 10679 73.25 1.15 58.30 767 1074 58.00 3212 4427 58.15 0.21 24.50 11948 3877 24.34 14579 4689 24.42 0.11 77.07 3675 12354 74.30 4417 12770 75.69 1.96
Tumor_Tissue_71 Independent Tumors CRC_Monitoring_142 0.5 45.51 G11 32.21 4231 2010 42.02 7475 5417 37.12 6.94 53.66 3854 4463 56.2 3836 4922 54.93 1.80 40.70 4487 3084 36.70 1468 851 38.70 2.83 34.52 9892 5216 35.16 5795 3142 34.84 0.45 64.64 4646 8493 59.24 6792 9870 61.94 3.82
Tumor_Tissue_72 Independent Tumors CRC_Monitoring_164 0.5 31.64 A01 18.23 9097 2028 24.07 4860 1541 21.15 4.13 62.39 16873 27994 58.03 6117 8459 60.21 3.08 2.32 1854 44 0.38 1308 5 1.35 1.37 15.45 2369 433 14.76 2627 455 15.11 0.49 69.85 7605 17623 50.87 24482 25353 60.36 13.42
Tumor_Tissue_73 Independent Tumors CRC_Monitoring_163 0.4 29.88 B01 18.51 12249 2783 14.43 10126 1707 16.47 2.88 27.84 15674 6047 23 3682 1100 25.42 3.42 24.78 762 251 17.66 2378 510 21.22 5.03 20.13 14596 3678 24.38 7715 2487 22.26 3.01 63.71 654 1148 64.31 14140 25475 64.01 0.42
Tumor_Tissue_74 Independent Tumors CRC_Monitoring_153 0.1 4.11 C01 1.63 16826 279 7.79 4228 357 4.71 4.36 1.44 1092 16 13.17 455 69 7.31 8.29 7.29 318 25 1.40 282 4 4.35 4.16 0.42 43639 183 4.10 7491 320 2.26 2.60 3.90 592 24 0.00 2531 0 1.95 2.76
Tumor_Tissue_75 Independent Tumors 0.5 29.84 D01 4.25 10767 478 14.14 11261 1855 9.20 6.99 20.86 9603 2531 22.8 4640 1370 21.83 1.37 15.74 1317 246 10.70 1661 199 13.22 3.56 22.39 22352 6449 14.83 11121 1937 18.61 5.35 95.27 507 10221 77.39 6607 22611 86.33 12.64
Tumor_Tissue_76 Independent Tumors CRC_Monitoring_162 0.3 14.73 E01 12.08 15723 2161 17.90 15823 3450 14.99 4.12 3.79 17126 674 3.4 19031 670 3.60 0.28 12.06 729 100 10.21 2516 286 11.14 1.31 9.22 18156 1844 1.82 15240 283 5.52 5.23 34.81 7181 3835 42.00 13312 9640 38.41 5.08
Tumor_Tissue_77 Independent Tumors CRC_Monitoring_158 40.69 F01 46.91 9642 8520 31.94 11050 5186 39.43 10.59 57.62 5816 7909 64.28 2562 4610 60.95 4.71 44.58 818 658 32.21 884 420 38.40 8.75 0.01 51414 3 0.01 38975 2 0.01 0.00 65.63 794 1516 63.66 9246 16196 64.65 1.39
Tumor_Tissue_78 Independent Tumors 0.2 69.14 G01 65.83 6812 13126 60.01 7685 11531 62.92 4.12 64.17 1231 2205 66.81 1160 2335 65.49 1.87 81.35 168 733 77.64 471 1635 79.50 2.62 63.72 4788 8409 60.30 3227 4902 62.01 2.42 73.17 9363 25536 78.43 5891 21420 75.80 3.72
Tumor_Tissue_79 Independent Tumors CRC_Monitoring_159 47.52 A03 44.53 7872 6319 34.07 8488 4387 39.30 7.40 55.02 3382 4137 47.25 19198 17195 51.14 5.49 35.29 2332 1272 50.07 1064 1067 42.68 10.45 30.71 5279 2340 25.02 9732 3247 27.87 4.02 85.74 6065 36460 67.51 5220 10846 76.63 12.89
Tumor_Tissue_80 Independent Tumors 0.6 56.12 B03 43.23 8116 6181 44.36 8996 7171 43.80 0.80 63.26 9862 16980 63.27 9978 17186 63.27 0.01 55.94 8668 11005 61.01 11550 18076 58.48 3.59 26.86 5753 2113 23.33 3901 1187 25.10 2.50 96.50 2829 77964 83.39 5740 28810 89.95 9.27
Tumor_Tissue_81 Independent Tumors CRC_Monitoring_113 0.7 47.46 A05 31.23 7319 3323 39.08 7745 4968 35.16 5.55 57.04 235 312 56.12 1844 2358 56.58 0.65 45.50 5495 4587 41.90 857 619 43.70 2.55 12.92 22420 3327 25.87 6290 2195 19.40 9.16 76.94 5815 19406 87.99 1381 10120 82.47 7.81
Tumor_Tissue_82 Independent Tumors CRC_Monitoring_85 0.6 10.57 B11 7.85 8961 763 4.62 21434 1038 6.24 2.28 15.61 7685 1421 34.26 894 466 24.94 13.19 5.20 17322 944 3.90 8587 351 4.55 0.92 0.85 35077 302 1.61 23221 380 1.23 0.54 5.28 556 31 26.48 5425 1954 15.88 14.99
Tumor_Tissue_83 Independent Tumors CRC_Monitoring_122 0.1 42.84 C11 21.32 4675 1267 31.57 8311 3834 26.45 7.25 59.47 5122 7514 55.98 6050 7694 57.73 2.47 36.30 14978 8527 29.40 9503 3964 32.85 4.88 23.48 14570 4472 27.01 10801 3996 25.25 2.50 72.99 7690 20781 70.87 7377 17944 71.93 1.50
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CRC_Monitoring_183 62 18-Nov-09 Promega 7821 Prevalence Aging 0.10 0.31 0.00 0 0.06 0.15 0.00 0.00 0.31 0 1651 0 0.12 808 1 0.06 0.08 0 3614 0 0.3 24330 74 0.15 0.21 0 9243 0 0 4179 0 0.00 0.00 0 931 0 0 4036 0 0.00 0.00 0.62 4500 28 0 870 0 0.31 0.44
CRC_Monitoring_184 60 18-Nov-09 Promega 7652 Prevalence Aging 0.24 0.98 0.00 0 0.02 0.09 0.00 0.14 0.98 0 1279 0 0.03 14696 4 0.02 0.02 0 676 0 0.17 1197 2 0.09 0.12 0 13970 0 0 1042 0 0.00 0.00 0.27 1093 3 0 642 0 0.14 0.19 0 875 0 1.95 251 5 0.98 1.38
CRC_Monitoring_185 63 16-Nov-09 Promega 38733 Prevalence Aging 0.15 0.68 0.00 0 0.07 0.68 0.00 0.01 0.00 0.01 16408 2 0.12 1698 2 0.07 0.08 1.27 24791 319 0.08 20684 16 0.68 0.84 0 22600 0 0 88519 2 0.00 0.00 0.02 16297 3 0 14431 0 0.01 0.01 0 571 0 0 213 0 0.00 0.00
CRC_Monitoring_186 40 17-Nov-09 Promega 16124 Prevalence Aging 0.13 0.50 0.00 0 0.00 0.12 0.50 0.03 0.01 0 2418 0 0 402 0 0.00 0.00 0.04 5653 2 0.19 1610 3 0.12 0.11 0.99 999 10 0 5180 0 0.50 0.70 0.05 3811 2 0 2854 0 0.03 0.04 0.02 8137 2 0 1241 0 0.01 0.01
CRC_Monitoring_187 63 17-Nov-09 Promega 35381 Prevalence Aging 0.46 2.23 0.00 1 X 0.00 0.06 0.00 0.00 2.23 0 1510 0 0 1944 0 0.00 0.00 0.04 4992 2 0.07 2848 2 0.06 0.02 0 24551 0 0 16996 0 0.00 0.00 0 12017 0 0 4437 0 0.00 0.00 2.19 134 3 2.27 388 9 2.23 0.06
CRC_Monitoring_188 62 17-Nov-09 Promega 13698 Prevalence Aging 1.60 7.87 0.00 1 X 0.00 7.87 0.05 0.06 0.00 X 0 8765 0 0 485 0 0.00 0.00 8.17 6778 603 7.56 24086 1969 7.87 0.43 0.1 2006 2 0 8998 0 0.05 0.07 0 3157 0 0.12 839 1 0.06 0.08 0 5039 0 0 2794 0 0.00 0.00
CRC_Monitoring_189 42 18-Nov-09 Promega 8156 Prevalence Aging 0.67 3.12 0.00 1 X 0.06 3.12 0.00 0.00 0.18 X 0 469 0 0.12 10642 13 0.06 0.08 5.02 3654 193 1.21 20683 254 3.12 2.69 0 7502 0 0 19626 0 0.00 0.00 0 2825 0 0 1081 0 0.00 0.00 0.36 1656 6 0 1838 0 0.18 0.25
CRC_Monitoring_190 63 18-Nov-09 Promega 13897 Prevalence Aging 0.16 0.67 0.00 0 0.00 0.12 0.02 0.00 0.67 0 4725 0 0 1372 0 0.00 0.00 0.09 15790 15 0.15 7337 11 0.12 0.04 0.03 3145 1 0.01 14382 1 0.02 0.01 0 6318 0 0 4668 0 0.00 0.00 1.33 744 10 0 264 0 0.67 0.94
CRC_Monitoring_191 60 18-Nov-09 Promega 36396 Prevalence Aging 0.49 1.68 0.00 1 X 0.13 0.49 0.00 0.16 1.68 X 0 2387 0 0.25 4390 11 0.13 0.18 0.02 9562 2 0.96 4457 43 0.49 0.66 0 15113 0 0 61900 0 0.00 0.00 0 10917 0 0.32 3440 11 0.16 0.23 2.48 1021 26 0.88 226 2 1.68 1.13
CRC_Monitoring_192 41 11-Dec-09 Promega 11494 Prevalence Aging 0.08 0.14 0.03 0 0.14 0.03 0.03 0.07 0.13 0.25 395 1 0.02 5009 1 0.14 0.16 0.06 3085 2 0 1583 0 0.03 0.04 0.05 9266 5 0 6365 0 0.03 0.04 0 2781 0 0.13 1546 2 0.07 0.09 0 635 0 0.26 381 1 0.13 0.18
CRC_Monitoring_193 61 18-Nov-09 Promega 56746 Prevalence Aging 0.18 0.70 0.00 0 0.03 0.04 0.11 0.00 0.70 0.02 13483 3 0.04 12650 5 0.03 0.01 0.04 18401 8 0.03 7893 2 0.04 0.01 0.22 4090 9 0 51063 0 0.11 0.16 0 9962 0 0 4352 0 0.00 0.00 0.83 2496 21 0.57 7123 41 0.70 0.18
CRC_Monitoring_194 63 19-Nov-09 Promega 14434 Prevalence Aging 0.04 0.08 0.00 0 0.08 0.05 0.00 0.05 0.00 0.03 2862 1 0.12 1613 2 0.08 0.06 0.07 1472 1 0.03 3471 1 0.05 0.03 0 8074 0 0 6505 0 0.00 0.00 0 2025 0 0.1 1972 2 0.05 0.07 0 1353 0 0 389 0 0.00 0.00
CRC_Monitoring_195 63 20-Nov-09 Promega 5514 Prevalence Aging 0.19 0.72 0.00 0 0.72 0.03 0.00 0.00 0.22 0.03 3833 1 1.4 212 3 0.72 0.97 0.06 1642 1 0 371 0 0.03 0.04 0 170 0 0 508 0 0.00 0.00 0 914 0 0 2376 0 0.00 0.00 0 259 0 0.43 1848 8 0.22 0.30
CRC_Monitoring_196 65 25-Nov-09 Promega 10932 Prevalence Aging 0.14 0.41 0.00 0 0.04 0.25 0.02 0.00 0.41 0 3098 0 0.08 1199 1 0.04 0.06 0.18 1090 2 0.31 2569 8 0.25 0.09 0 12126 0 0.04 2267 1 0.02 0.03 0 7800 0 0 3914 0 0.00 0.00 0.82 2057 17 0 394 0 0.41 0.58
CRC_Monitoring_197 63 1-Dec-09 Promega 13638 Prevalence Aging 0.15 0.25 0.00 0 0.09 0.21 0.18 0.00 0.25 0.01 9278 1 0.17 1175 2 0.09 0.11 0.35 3663 13 0.06 5098 3 0.21 0.21 0 14839 0 0.36 549 2 0.18 0.25 0 1864 0 0 3130 0 0.00 0.00 0 2255 0 0.5 5224 26 0.25 0.35
CRC_Monitoring_198 62 27-Nov-09 Promega 17104 Prevalence Aging 0.02 0.08 0.00 0 0.00 0.08 0.00 0.00 0.00 0 7985 0 0 3631 0 0.00 0.00 0.07 4062 3 0.08 7681 6 0.08 0.01 0 3549 0 0 32551 0 0.00 0.00 0 1491 0 0 2899 0 0.00 0.00 0 510 0 0 1963 0 0.00 0.00
CRC_Monitoring_199 41 3-Dec-09 Promega 56799 Prevalence Aging 0.01 0.03 0.00 0 0.01 0.02 0.00 0.00 0.03 0.01 37537 3 0.01 0.01 21889 3 0.02 17705 3 0.02 0.01 0 52745 1 0.00 0 14574 0 0 9243 0 0.00 0.00 0.05 43254 22 0 1804 0 0.03 0.04
CRC_Monitoring_200 43 3-Dec-09 Promega 41908 Prevalence Aging 3.84 17.02 0.00 1 X X 17.02 2.18 0.00 0.01 0.01 X X 20.44 2973 764 13.6 3482 548 17.02 4.84 0.91 12313 113 3.44 8582 306 2.18 1.79 0 29040 0 0 24625 0 0.00 0.00 0 16518 0 0.01 10932 1 0.01 0.01 0.01 16244 2 0 15790 0 0.01 0.01
CRC_Monitoring_201 45 3-Dec-09 Promega 4982 Prevalence Aging 0.02 0.05 0.00 0 0.05 0.03 0.04 0.00 0.00 0 4631 0 0.1 966 1 0.05 0.07 0 1313 0 0.05 1937 1 0.03 0.04 0.01 6963 1 0.06 3337 2 0.04 0.04 0 2145 0 0 1361 0 0.00 0.00 0 236 0 0 691 0 0.00 0.00
CRC_Monitoring_202 61 4-Dec-09 Promega 5022 Prevalence Aging 0.09 0.36 0.00 0 0.36 0.08 0.00 0.00 0.00 0 615 0 0.72 3582 26 0.36 0.51 0.05 3879 2 0.1 17300 18 0.08 0.04 0 1926 0 0 12518 0 0.00 0.00 0 2472 0 0 1873 0 0.00 0.00 0 1686 0 0 891 0 0.00 0.00
CRC_Monitoring_203 61 4-Dec-09 Promega 92951 Prevalence Aging 0.19 0.78 0.00 0 0.00 0.16 0.00 0.01 0.78 0 6151 0 0 3072 0 0.00 0.00 0.27 11252 30 0.05 16331 8 0.16 0.16 0 9741 0 0 21112 0 0.00 0.00 0.02 4614 1 0 5206 0 0.01 0.01 1.56 948 15 0 251 0 0.78 1.10
CRC_Monitoring_204 61 19-Nov-09 Promega 16922 Prevalence Aging 0.20 0.97 0.00 1 X 0.02 0.97 0.01 0.00 0.00 X 0.04 4693 2 0 4031 0 0.02 0.03 0.08 13839 11 1.85 3605 68 0.97 1.25 0 24815 0 0.02 6351 1 0.01 0.01 0 6547 0 0 6421 0 0.00 0.00 0 537 0 0 1364 0 0.00 0.00
CRC_Monitoring_205 61 14-Dec-09 Promega 4573 Prevalence Aging 0.53 2.02 0.00 1 X 0.61 2.02 0.00 0.00 0.00 X 0.04 2354 1 1.18 336 4 0.61 0.81 4.04 24880 1048 0 1442 0 2.02 2.86 0 2442 0 0 665 0 0.00 0.00 0 2334 0 0 965 0 0.00 0.00 0 3073 0 0 3666 0 0.00 0.00
CRC_Monitoring_206 41 14-Dec-09 Promega 30588 Prevalence Aging 0.13 0.40 0.00 0 0.40 0.13 0.00 0.02 0.12 0.74 538 4 0.05 6657 3 0.40 0.49 0.19 3741 7 0.06 1694 1 0.13 0.09 0 854 0 0 3896 0 0.00 0.00 0.03 3795 1 0 7914 0 0.02 0.02 0 2496 0 0.24 1646 4 0.12 0.17
CRC_Monitoring_207 45 15-Dec-09 Promega 66447 Prevalence Aging 0.03 0.09 0.00 0 0.05 0.02 0.00 0.00 0.09 0 7715 0 0.09 9196 8 0.05 0.06 0.02 9760 2 0.02 11148 2 0.02 0.00 0 1278 0 0 19406 0 0.00 0.00 0 7125 0 0 7011 0 0.00 0.00 0.17 582 1 0 464 0 0.09 0.12
CRC_Monitoring_208 62 23-Nov-09 Promega 67790 Prevalence Aging 0.19 0.61 0.00 0 0.00 0.32 0.01 0.01 0.61 0 19952 0 0 2443 0 0.00 0.00 0.55 21432 119 0.08 18953 16 0.32 0.33 0 165 0 0.02 8006 2 0.01 0.01 0 22240 1 0.01 16781 2 0.01 0.01 0.84 2700 23 0.37 4587 17 0.61 0.33
CRC_Monitoring_209 61 1-Apr-10 Promega 34482 Prevalence Aging 0.09 0.23 0.00 0 0.09 0.10 0.00 0.02 0.23 0.16 644 1 0.02 4463 1 0.09 0.10 0 5028 0 0.2 5068 10 0.10 0.14 0 855 0 0.00 0 8380 0 0.03 9457 3 0.02 0.02 0.45 671 3 0 1551 0 0.23 0.32
CRC_Monitoring_210 43 17-Dec-09 Promega 21188 Prevalence Aging 0.11 0.49 0.00 0 0.02 0.49 0.00 0.06 0.00 0.03 3881 1 0 3223 0 0.02 0.02 0.92 5406 50 0.05 13818 7 0.49 0.62 0 5388 0 0 13610 0 0.00 0.00 0 7838 0 0.11 2761 3 0.06 0.08 0 1142 0 0 157 0 0.00 0.00
CRC_Monitoring_211 62 2-Apr-10 Promega 4410 Prevalence Aging 0.16 0.60 0.00 0 0.15 0.04 0.60 0.00 0.00 0 1150 0 0.29 697 2 0.15 0.21 0.07 22951 17 0.01 84716 12 0.04 0.04 1.2 164 2 0 1545 0 0.60 0.85 0 7952 0 0 223 0 0.00 0.00 0 160 0 0 1281 0 0.00 0.00
CRC_Monitoring_212 65 1-Apr-10 Promega 7970 Prevalence Aging 0.29 1.03 0.00 1 X 0.02 1.03 0.00 0.00 0.41 X 0.03 3342 1 0 609 0 0.02 0.02 0.07 4320 3 1.98 4990 101 1.03 1.35 0 3918 0 0 1190 0 0.00 0.00 0 2803 0 0 1706 0 0.00 0.00 0 522 0 0.82 3029 25 0.41 0.58
CRC_Monitoring_213 44 8-Dec-09 Promega 5048 Prevalence Aging 0.06 0.21 0.00 0 0.21 0.05 0.00 0.04 0.00 0.41 480 2 0 570 0 0.21 0.29 0.09 4475 4 0 732 0 0.05 0.06 0 9632 0 0 609 0 0.00 0.00 0 2491 0 0.07 1473 1 0.04 0.05 0 311 0 0 1347 0 0.00 0.00
CRC_Monitoring_214 42 10-Dec-09 Promega 7149 Prevalence Aging 0.09 0.26 0.00 0 0.26 0.05 0.00 0.17 0.00 0.46 1300 6 0.05 1944 1 0.26 0.29 0.06 3511 2 0.03 3123 1 0.05 0.02 0 679 0 0 231 0 0.00 0.00 0 3080 0 0.33 1821 6 0.17 0.23 0 1353 0 0 351 0 0.00 0.00
CRC_Monitoring_215 62 16-Dec-09 Promega 8801 Prevalence Aging 0.01 0.04 0.00 0 0.00 0.04 0.00 0.00 0.00 0 2977 0 0 4929 0 0.00 0.00 0.08 2482 2 0 1049 0 0.04 0.06 0 665 0 0 403 0 0.00 0.00 0 424 0 0 1723 0 0.00 0.00 0 2535 0 0 1158 0 0.00 0.00
CRC_Monitoring_216 45 6-Apr-10 Promega 4868 Prevalence Aging 0.00 0.02 0.00 0 0.00 0.02 0.00 0.00 0.00 0 4668 0 0 3251 0 0.00 0.00 0.03 3043 1 0 2500 0 0.02 0.02 0 1386 0 0 3 0 0.00 0.00 0 1139 0 0 2140 0 0.00 0.00 0 882 0 0 1380 0 0.00 0.00
CRC_Monitoring_217 61 4-Dec-09 Promega 8264 Prevalence Aging 0.21 0.76 0.00 0 0.76 0.03 0.00 0.00 0.25 1.31 302 4 0.21 482 1 0.76 0.78 0 4243 0 0.05 2008 1 0.03 0.04 0 24429 0 0 2833 0 0.00 0.00 0 3941 0 0 715 0 0.00 0.00 0.5 599 3 0 1012 0 0.25 0.35
CRC_Monitoring_218 43 9-Dec-09 Promega 9105 Prevalence Aging 0.08 0.27 0.00 0 0.13 0.27 0.00 0.00 0.01 0 689 0 0.26 1170 3 0.13 0.18 0.5 2562 13 0.03 3202 1 0.27 0.33 0 177 0 0 150 0 0.00 0.00 0 2912 0 0 2809 0 0.00 0.00 0.01 7265 1 0 1588 0 0.01 0.01
CRC_Monitoring_219 65 3-Dec-09 Promega 19478 Prevalence Aging 0.11 0.36 0.00 0 0.36 0.12 0.04 0.04 0.00 0 1427 0 0.71 420 3 0.36 0.50 0.04 54639 21 0.19 2674 5 0.12 0.11 0.07 2702 2 0 501 0 0.04 0.05 0.07 1479 1 0 2629 0 0.04 0.05 0 4245 0 0 1104 0 0.00 0.00
CRC_Monitoring_220 40 4-Dec-09 Promega 11158 Prevalence Aging 0.62 2.85 0.00 1 X 0.12 2.85 0.00 0.09 0.06 0 565 0 0.24 410 1 0.12 0.17 0 1035 0 0.00 0 2685 0 0 3604 0 0.00 0.00 0 3491 0 0.17 1814 3 0.09 0.12 0 1809 0 0.11 2716 3 0.06 0.08
CRC_Monitoring_221 41 8-Dec-09 Promega 16463 Prevalence Aging 0.03 0.09 0.00 0 0.05 0.09 0.00 0.00 0.00 0 4443 0 0.1 976 1 0.05 0.07 0.13 8317 11 0.05 1892 1 0.09 0.06 0 1663 0 0 540 0 0.00 0.00 0 1715 0 0 3671 0 0.00 0.00 0 2187 0 0 2901 0 0.00 0.00
CRC_Monitoring_222 64 8-Dec-09 Promega 9736 Prevalence Aging 0.10 0.26 0.00 0 0.22 0.26 0.00 0.02 0.00 0 1002 0 0.43 229 1 0.22 0.30 0 1552 0 0.51 787 4 0.26 0.36 0 25595 0 0 2047 0 0.00 0.00 0.03 3758 1 0 2700 0 0.02 0.02 0 966 0 0 435 0 0.00 0.00
CRC_Monitoring_223 45 8-Dec-09 Promega 24783 Prevalence Aging 0.05 0.11 0.00 0 0.11 0.07 0.00 0.00 0.09 0.11 908 1 0.11 0.12 9504 11 0.01 9927 1 0.07 0.08 0 230 0 0 4887 0 0.00 0.00 0 3759 0 0 4534 0 0.00 0.00 0.17 1190 2 0 1281 0 0.09 0.12
CRC_Monitoring_224 64 8-Dec-09 Promega 10080 Prevalence Aging 0.03 0.13 0.00 0 0.00 0.04 0.00 0.00 0.13 0 724 0 0 765 0 0.00 0.00 0.01 9931 1 0.06 3184 2 0.04 0.04 0 6583 0 0 5643 0 0.00 0.00 0 6467 0 0 2824 0 0.00 0.00 0.26 775 2 0 148 0 0.13 0.18
CRC_Monitoring_225 43 9-Dec-09 Promega 121208 Prevalence Aging 0.18 0.47 0.03 0 0.03 0.47 0.08 0.16 0.15 0.03 29564 8 0.02 13260 3 0.03 0.01 0.03 20278 7 0.91 22964 212 0.47 0.62 0 530 0 0.15 666 1 0.08 0.11 0.29 18852 55 0.02 9865 2 0.16 0.19 0.01 25273 3 0.29 4784 14 0.15 0.20
CRC_Monitoring_226 40 10-Dec-09 Promega 8761 Prevalence Aging 0.03 0.08 0.00 0 0.05 0.08 0.00 0.01 0.00 0.09 1129 1 0 8402 0 0.05 0.06 0.09 3521 3 0.07 2839 2 0.08 0.01 0 465 0 0.00 0 5868 0 0.02 4431 1 0.01 0.01 0 4530 0 0 2226 0 0.00 0.00
CRC_Monitoring_227 43 10-Dec-09 Promega 5701 Prevalence Aging 0.04 0.12 0.00 0 0.12 0.08 0.00 0.00 0.00 0.24 1226 3 0 359 0 0.12 0.17 0.16 611 1 0 382 0 0.08 0.11 0 2009 0 0.00 0 1057 0 0 1146 0 0.00 0.00 0 542 0 0 1132 0 0.00 0.00
CRC_Monitoring_228 62 11-Dec-09 Promega 17936 Prevalence Aging 0.06 0.12 0.00 0 0.09 0.09 0.00 0.01 0.12 0.18 3315 6 0 594 0 0.09 0.13 0.05 5722 3 0.12 3257 4 0.09 0.05 0 1539 0 0 158 0 0.00 0.00 0 6567 0 0.01 7871 1 0.01 0.01 0.12 860 1 0.12
CRC_Monitoring_229 65 15-Dec-09 Promega 14304 Prevalence Aging 0.03 0.13 0.00 0 0.00 0.13 0.00 0.02 0.00 0 1455 0 0 17294 0 0.00 0.00 0.08 2567 2 0.18 1643 3 0.13 0.07 0 1557 0 0.00 0.03 5764 2 0 4253 0 0.02 0.02 0 3391 0 0 915 0 0.00 0.00
CRC_Monitoring_230 64 16-Dec-09 Promega 3507 Prevalence Aging 0.11 0.21 0.00 0 0.17 0.19 0.00 0.21 0.00 0.19 517 1 0.14 694 1 0.17 0.04 0.15 1934 3 0.22 924 2 0.19 0.05 0 179 0 0.00 0.27 738 2 0.14 716 1 0.21 0.09 0 1774 0 0 417 0 0.00 0.00
CRC_Monitoring_231 60 16-Dec-09 Promega 7265 Prevalence Aging 0.02 0.07 0.00 0 0.01 0.07 0.00 0.00 0.00 0.01 11591 1 0 8902 0 0.01 0.01 0.07 4035 3 0.06 1693 1 0.07 0.01 0 563 0 0 511 0 0.00 0.00 0 1736 0 0 1746 0 0.00 0.00 0 200 0 0 649 0 0.00 0.00
CRC_Monitoring_232 64 1-Apr-10 Promega 3902 Prevalence Aging 0.03 0.10 0.00 0 0.03 0.02 0.01 0.00 0.10 0 414 0 0.06 1602 1 0.03 0.04 0 1165 0 0.03 17615 6 0.02 0.02 0.01 22575 2 0.01 0 3247 0 0 2041 0 0.00 0.00 0 263 0 0.2 500 1 0.10 0.14
CRC_Monitoring_132 75 4-May-11 5.3 3-May-11 Promega 9992 Prevalence Prevalence 0.23 0.95 0.00 1 X 0.19 0.95 0.00 0.01 0.00 X 0 1405 0 0.38 263 1 0.19 0.27 0.08 67939 51 1.81 22440 414 0.95 1.22 0 776 0 0.00 0 54991 2 0.02 6313 1 0.01 0.01 0 374 0 0 368 0 0.00 0.00
CRC_Monitoring_85 76 30-Jan-12 63.5 30-Jan-12 Qiagen 37877 Prevalence Prevalence 21.50 31.21 10.60 1 X X X X X 20.37 20.44 24.89 10.60 31.21 X X X X X 13.65 23.85 25540 7999 16.89 1516 308 20.37 4.92 12.44 4771 678 28.43 20112 7988 20.44 11.31 14.6 51258 8760 35.17 5719 3102 24.89 14.55 13.5 3990 624 7.7 14343 1197 10.60 4.10 31.47 135 62 30.95 1490 668 31.21 0.37
CRC_Monitoring_86 57 15-Nov-11 560 11-Nov-11 Qiagen 279826 Prevalence Prevalence 80.32 92.80 66.95 1 X X X X X 79.46 66.95 92.80 75.50 86.89 X X X X X 80.01 10362 41472 78.91 8239 30818 79.46 0.78 69.49 1397 3182 64.41 9982 18067 66.95 3.59 96.3 3199 83968 89.3 3758 31357 92.80 4.95 82.4 1432 6694 68.6 3656 7987 75.50 9.76 86.19 1783 11125 87.58 994 7012 86.89 0.98
CRC_Monitoring_87 45 15-Mar-12 1.1 15-Mar-12 Qiagen 18228 Prevalence Prevalence 84.38 96.47 60.00 1 X X X X X 91.14 90.89 96.47 60.00 83.38 X X X X X 84.79 3092 17232 97.49 33 1280 91.14 8.98 89.45 632 5359 92.33 2395 28815 90.89 2.04 93.5 4513 65062 99.44 49 8761 96.47 4.20 60 1458 2185 60.00 80.49 1459 6019 86.26 966 6067 83.38 4.08
CRC_Monitoring_88 55 25-Aug-11 11.4 31-Aug-11 Qiagen 88516 Prevalence Prevalence 2.04 7.40 0.29 1 X X X X 0.29 0.71 7.40 0.41 1.39 X X X X 0.05 36804 18 0.53 10419 56 0.29 0.34 0.52 2688 14 0.9 62308 565 0.71 0.27 0.2 58900 103 14.59 6011 1027 7.40 10.18 0.6 4132 24 0.22 20589 46 0.41 0.27 2.19 5852 131 0.59 3208 19 1.39 1.13
CRC_Monitoring_89 76 8-Aug-11 66.1 9-Aug-11 Qiagen 48029 Prevalence Prevalence 66.17 77.37 45.15 1 X X X X X 60.32 74.68 77.37 45.15 73.32 X X X X X 47.29 47.26 6538 5859 73.37 1766 4865 60.32 18.46 80.12 923 3719 69.24 6205 13970 74.68 7.69 84.8 3693 20545 69.93 3815 8872 77.37 10.51 55.5 1955 2434 34.8 4874 2602 45.15 14.64 72.52 979 2583 74.11 87 249 73.32 1.12
CRC_Monitoring_90 68 16-Jan-12 12.3 16-Jan-12 Qiagen 31253 Prevalence Prevalence 12.12 26.71 2.27 1 X X X X X 2.27 9.94 17.62 4.05 26.71 X X X X X 4.46 10712 500 0.07 1364 1 2.27 3.10 8.14 2168 192 11.73 30684 4077 9.94 2.54 17.62 360 77 17.62 360 77 17.62 0.00 7.8 1090 92 0.29 9130 27 4.05 5.31 29.8 603 256 23.62 789 244 26.71 4.37
CRC_Monitoring_91 54 9-Jan-12 162 9-Jan-12 Qiagen 12880 Prevalence Prevalence 71.06 98.30 19.95 1 X X X X X 84.47 19.95 98.30 75.10 77.48 X X X X X 75.06 1999 6015 93.88 360 5525 84.47 13.31 28.6 1620 649 11.3 18953 2415 19.95 12.23 100 0 32366 96.59 28 794 98.30 2.41 75.1 628 1895 75.10 76.84 63 209 78.12 158 564 77.48 0.91
CRC_Monitoring_92 75 22-Aug-11 103 28-Jul-11 Qiagen 44150 Prevalence Prevalence 8.67 13.26 3.67 1 X X X X X 13.26 3.67 10.40 5.87 10.14 X X X X X 5.55 26091 1533 20.97 6553 1739 13.26 10.90 6.15 1359 89 1.18 41444 495 3.67 3.51 10.4 21915 2544 10.40 4.5 4006 189 7.23 8328 649 5.87 1.93 10.49 256 30 9.78 2730 296 10.14 0.50
CRC_Monitoring_93 73 5-Dec-11 101 5-Dec-11 Qiagen 16071 Prevalence Prevalence 10.74 16.60 7.06 1 X X X X X 9.00 7.06 16.60 10.11 10.93 X X X X X 5.96 11.27 3691 469 6.73 3325 240 9.00 3.21 11.9 8030 1085 2.22 61743 1403 7.06 6.84 16.6 53295 10608 16.60 2.5 3571 92 17.72 5255 1132 10.11 10.76 12.73 281 41 9.13 1204 121 10.93 2.55
CRC_Monitoring_94 59 15-Jul-11 30.3 15-Jul-11 Qiagen 14937 Prevalence Prevalence 23.38 35.59 1.86 1 X X X X X 26.41 1.86 34.14 35.59 18.91 X X X X X 2.44 34.46 1449 762 18.35 218 49 26.41 11.39 3.71 12135 468 0.01 63361 5 1.86 2.62 34.14 4634 2402 34.14 35.59 2279 1259 35.59 18.12 583 129 19.69 204 50 18.91 1.11
CRC_Monitoring_95 56 9-Jun-11 444 9-Jun-11 Qiagen 168269 Prevalence Prevalence 93.07 96.58 88.55 1 X X X X X 94.98 88.55 96.58 91.16 94.07 X X X X X 90.92 546 5468 99.03 183 18723 94.98 5.73 91.23 501 5209 85.86 2650 16095 88.55 3.80 94.2 2842 46532 98.95 150 14109 96.58 3.36 94.5 839 14507 87.82 1595 11505 91.16 4.72 92.01 1389 15996 96.13 1021 25346 94.07 2.91
CRC_Monitoring_96 36 5-Dec-11 2057 5-Dec-11 Qiagen 74046 Prevalence Prevalence 38.96 66.69 2.87 1 X X X X X 54.25 2.87 65.86 5.13 66.69 X X X X X 62.99 954 1624 45.5 5319 4440 54.25 12.37 5.65 5445 326 0.08 76777 62 2.87 3.94 64.7 8620 15793 67.01 3346 6797 65.86 1.63 9.6 3166 336 0.66 26737 178 5.13 6.32 63.23 442 760 70.15 2053 4825 66.69 4.89
CRC_Monitoring_97 70 24-Oct-11 4.2 24-Oct-11 Qiagen 124077 Prevalence Prevalence 73.53 93.24 34.28 1 X X X X X 73.47 73.72 93.24 34.28 92.93 X X X X X 0.00 77.45 797 2737 69.49 3440 7836 73.47 5.63 69.02 672 1497 78.41 3795 13783 73.72 6.64 94.6 2437 42921 91.87 2636 29801 93.24 1.93 37.3 2121 1262 31.25 8321 3783 34.28 4.28 94.06 547 8661 91.8 731 8180 92.93 1.60
CRC_Monitoring_98 59 28-Nov-11 300 29-Nov-11 Qiagen 20086 Prevalence Prevalence 10.13 18.40 1.45 1 X X X X X 1.86 18.40 12.80 1.45 16.14 X X X X X 3.69 2846 109 0.02 10726 2 1.86 2.60 21.78 3189 888 15.01 19088 3372 18.40 4.79 25.6 6789 2338 0 255 0 12.80 18.10 2.6 5866 158 0.29 18456 54 1.45 1.63 14.63 846 145 17.65 765 164 16.14 2.14
CRC_Monitoring_99 59 8-Jun-11 9.7 8-Jun-11 Qiagen 133205 Prevalence Prevalence 65.19 84.39 23.31 1 X X X X X 84.03 68.52 65.71 23.31 84.39 X X X X X 84.2 2893 15414 83.85 2279 11831 84.03 0.25 65.3 399 751 71.73 5445 13819 68.52 4.55 62.3 7837 12946 69.11 3280 7337 65.71 4.82 22.7 2930 862 23.91 9043 2841 23.31 0.86 83.61 2625 13395 85.16 2451 14063 84.39 1.10
CRC_Monitoring_100 67 3-Oct-11 869 5-Oct-11 Qiagen 278709 Prevalence Prevalence 50.78 85.38 33.56 1 X X X X X 39.18 33.56 85.38 38.25 57.52 X X X X X 37.29 38.26 213 132 40.09 7254 4855 39.18 1.29 41.9 2140 1543 25.22 9900 3339 33.56 11.79 80.3 4969 20225 90.45 2306 21846 85.38 7.18 41.1 2141 1497 35.4 5935 3252 38.25 4.03 58.94 4717 6771 56.09 4037 5156 57.52 2.02
CRC_Monitoring_101 73 23-Jan-12 26.1 23-Jan-12 Qiagen 255620 Prevalence Prevalence 85.42 95.73 67.72 1 X X X X X 91.41 67.72 95.73 79.86 92.39 X X X X X 87.26 914 6258 95.55 3153 67641 91.41 5.86 58.04 1945 2690 77.4 6309 21601 67.72 13.69 98.1 1282 64887 93.35 1320 18524 95.73 3.36 78.2 823 2950 81.52 3342 14745 79.86 2.35 92.59 651 8135 92.18 1577 18585 92.39 0.29
CRC_Monitoring_102 77 28-Sep-11 969 28-Sep-11 Qiagen 108564 Prevalence Prevalence 84.87 96.79 72.52 1 X X X X X 72.52 82.43 96.79 82.54 90.08 X X X X X 74.11 1449 4147 70.93 4133 10082 72.52 2.25 83.75 1093 5635 81.1 5016 21529 82.43 1.87 96.2 1633 41894 97.38 575 21391 96.79 0.83 88.6 842 6536 76.48 4068 13227 82.54 8.57 91.94 245 2793 88.21 915 6843 90.08 2.64
CRC_Monitoring_103 63 14-Feb-12 242 14-Feb-12 Qiagen 80164 Prevalence Prevalence 33.86 41.78 19.89 1 X X X X X 29.25 41.78 39.98 19.89 38.39 X X X X X 22.52 2374 690 35.97 8427 4734 29.25 9.51 43.62 2178 1685 39.93 8781 5838 41.78 2.61 48.7 16249 15424 31.26 2338 1063 39.98 12.33 15.8 6089 1139 23.98 11766 3712 19.89 5.78 44.48 800 641 32.29 7713 3678 38.39 8.62
CRC_Monitoring_104 49 10-Feb-12 187 10-Feb-12 Qiagen 29126 Prevalence Prevalence 30.82 41.88 18.71 1 X X X X X 41.88 18.71 24.78 29.99 38.73 X X X X X 35.96 2356 1323 47.8 5482 5019 41.88 8.37 17.31 15507 3246 20.11 12149 3058 18.71 1.98 20 30784 7678 29.56 2402 1008 24.78 6.76 40 2331 1553 19.97 13015 3247 29.99 14.16 35.75 1580 879 41.71 1223 875 38.73 4.21
CRC_Monitoring_105 65 14-Mar-12 12.7 14-Mar-12 Qiagen 10283 Prevalence Prevalence 19.10 30.94 5.85 1 X X X X X 27.57 5.85 10.29 30.94 20.83 X X X X X 31.35 519 237 23.79 993 310 27.57 5.35 11.69 6702 887 0.01 75909 4 5.85 8.26 20.5 12354 3180 0.07 3056 2 10.29 14.45 34.7 2906 1545 27.17 6631 2474 30.94 5.32 23.11 183 55 18.55 755 172 20.83 3.22
CRC_Monitoring_106 66 12-Mar-12 155 12-Mar-12 Qiagen 2046 Prevalence Prevalence 8.52 39.56 0.13 1 X X X 0.31 39.56 0.13 0.90 1.68 X X 0 2836 0 0.62 161 1 0.31 0.44 39.56 1647 1078 39.56 0 6412 2 0.26 377 1 0.13 0.18 1.8 110 2 0 4333 0 0.90 1.27 0 321 0 3.35 231 8 1.68 2.37
CRC_Monitoring_107 75 5-Sep-11 60.2 5-Sep-11 Qiagen 28040 Prevalence Prevalence 11.82 38.60 3.68 1 X X X X X 3.68 4.24 38.60 5.47 7.11 X X X X X 6.01 0 3940 0 7.36 2645 210 3.68 5.20 4.42 3701 171 4.06 30733 1302 4.24 0.25 38.6 12981 8147 38.60 0 9675 3 10.93 13670 1678 5.47 7.73 6.13 536 35 8.09 2907 256 7.11 1.39
CRC_Monitoring_108 58 19-Aug-11 10.8 19-Aug-11 Qiagen 12029 Prevalence Prevalence 0.71 2.39 0.00 1 X X 0.00 2.39 0.00 0.01 1.15 X 0.00 0 3047 0 0 8224 0 0.00 0.00 0.02 12408 3 4.76 27562 1379 2.39 3.35 0 57003 10 0 4116 0 0.00 0.00 0 18147 0 0.01 41091 5 0.01 0.01 0 1693 0 2.3 1696 40 1.15 1.63
CRC_Monitoring_109 46 30-Jan-12 232 30-Jan-12 Qiagen 3700 Prevalence Prevalence 15.56 41.57 0.08 1 X NA X X 5.94 0.08 41.57 14.65 X NA X 10.98 1548 191 0.9 329 3 5.94 7.13 0.14 10829 15 0.01 36728 3 0.08 0.09 41.57 7759 5520 41.57 14.65 338 58 14.65
CRC_Monitoring_110 37 20-Feb-12 569 20-Feb-12 Qiagen 12044 Prevalence Prevalence 26.79 38.79 11.37 1 X X X X X 24.54 11.37 38.40 38.79 20.85 X X X X X 16 1596 304 33.08 7800 3856 24.54 12.08 14.49 7252 1229 8.24 19792 1778 11.37 4.42 38.4 9809 6118 38.40 34.1 3676 1903 43.48 4246 3267 38.79 6.63 22.85 726 215 18.84 1124 261 20.85 2.84
CRC_Monitoring_111 57 25-Aug-11 3.3 19-Sep-11 Qiagen 28588 Prevalence Prevalence 2.83 6.48 0.93 1 X X X X X 6.48 1.25 0.93 1.60 3.90 X X X X 8.46 9.76 1674 181 3.19 3214 106 6.48 4.65 0 21608 1 2.49 34201 872 1.25 1.76 1.8 53723 985 0.05 5994 3 0.93 1.24 3.2 6439 216 0 6844 0 1.60 2.26 0 201 0 7.8 272 23 3.90 5.52
CRC_Monitoring_112 54 25-Jan-12 78 26-Jan-12 Qiagen 32088 Prevalence Prevalence 50.76 66.02 36.31 1 X X X X X 43.24 36.31 56.20 66.02 52.01 X X X X X 57.25 239 320 29.23 13552 5597 43.24 19.81 38.56 1694 1063 34.06 7786 4022 36.31 3.18 56.2 9628 12374 56.20 66.3 1369 2694 65.73 1565 3002 66.02 0.40 44.55 483 388 59.46 493 723 52.01 10.54
CRC_Monitoring_113 70 28-Nov-11 2930 29-Nov-11 Qiagen 97322 Prevalence Prevalence 78.98 95.79 42.30 1 X X X X X 88.14 42.30 95.79 78.55 90.11 X X X X X 87.94 413 3011 88.34 2337 17700 88.14 0.28 38.85 1253 796 45.75 3711 3130 42.30 4.88 93.34 4832 67670 98.23 654 36338 95.79 3.46 82.1 897 4119 75 2585 7757 78.55 5.02 88.93 847 6804 91.28 1439 15063 90.11 1.66
CRC_Monitoring_114 72 22-Aug-11 1.9 13-Sep-11 Qiagen 27680 Prevalence Prevalence 0.50 2.35 0.00 1 X 0.00 0.03 0.00 2.35 0.11 X 0.00 0 3170 0 0 1971 0 0.00 0.00 0.03 11940 4 0.02 18516 3 0.03 0.01 0 32105 1 0 442 0 0.00 0.00 4.7 1782 88 0 23892 0 2.35 3.32 0.21 477 1 0 1662 0 0.11 0.15
CRC_Monitoring_115 42 19-Aug-11 991 12-Sep-11 Qiagen 266432 Prevalence Prevalence 70.74 82.23 61.14 1 X X X X X 61.14 68.53 82.23 61.27 80.54 X X X X X 50.71 51.99 1014 1098 70.29 5360 12680 61.14 12.94 74.65 181 533 62.41 6491 10777 68.53 8.65 82.4 5346 25066 82.06 2666 12198 82.23 0.24 67.2 670 1374 55.34 4196 5200 61.27 8.39 79.76 2650 10441 81.32 1289 5611 80.54 1.10
CRC_Monitoring_116 59 19-Aug-11 45.2 2-Sep-11 Qiagen 13432 Prevalence Prevalence 0.02 0.06 0.00 0 0.02 0.06 0.00 0.00 0.00 0.00 0.03 3680 1 0 12813 0 0.02 0.02 0.12 14357 17 0 111045 3 0.06 0.08 0 42457 1 0.00 0 8270 0 0 14748 0 0.00 0.00 0 1774 0 0 1306 0 0.00 0.00
CRC_Monitoring_117 41 17-Jan-12 44.8 17-Jan-12 Qiagen 17441 Prevalence Prevalence 19.73 42.40 6.62 1 X X X X X 6.62 42.40 18.70 14.28 16.65 X X X X X 15.61 12.14 3118 431 1.1 9795 109 6.62 7.81 52.48 2723 3007 32.32 13164 6287 42.40 14.26 18.7 29411 6749 18.70 14.9 6142 1075 13.66 12277 1942 14.28 0.88 10.86 5620 685 22.43 377 109 16.65 8.18
CRC_Monitoring_118 55 24-Jan-12 7.1 24-Jan-12 Qiagen 1111 Prevalence Prevalence 2.36 10.73 0.00 1 X X 1.08 10.73 0.00 0.00 0.00 X X 10.00 1.08 548 6 1.08 21.46 5876 1606 0 2045 0 10.73 15.17 0 19132 2 0.00 0 7110 1 0 4926 0 0.00 0.00 0 473 0 0 253 0 0.00 0.00
CRC_Monitoring_119 81 10-Jun-11 168 13-Jun-11 Qiagen 350586 Prevalence Prevalence 0.25 0.54 0.01 0 0.48 0.54 0.06 0.01 0.14 0.10 0.41 6349 26 0.55 51622 284 0.48 0.10 0.54 7900 43 0.53 37844 202 0.54 0.01 0.1 78417 49 0.01 79422 4 0.06 0.06 0 12144 0 0.02 58876 14 0.01 0.01 0.18 20354 37 0.09 35329 31 0.14 0.06
CRC_Monitoring_120 76 3-Nov-11 1600 7-Nov-11 Qiagen 51240 Prevalence Prevalence 17.11 29.34 7.52 1 X X X X X 7.52 9.83 14.99 23.85 29.34 X X X X X 13.53 3661 573 1.51 18408 282 7.52 8.50 5.42 7551 433 14.24 16292 2705 9.83 6.24 21.6 15524 4288 8.38 5638 516 14.99 9.35 22 1189 336 25.7 8564 2963 23.85 2.62 19 597 140 39.68 1122 738 29.34 14.62
CRC_Monitoring_121 70 23-Jan-12 69.3 23-Jan-12 Qiagen 100425 Prevalence Prevalence 76.95 95.19 29.87 1 X X X X X 88.96 84.38 95.19 29.87 86.37 X X X X X 81.01 685 2922 96.91 85 2670 88.96 11.24 85.65 366 2185 83.1 2461 12098 84.38 1.80 93 1644 21827 97.38 654 24304 95.19 3.10 39.2 2367 1529 20.53 10930 2824 29.87 13.20 90.56 284 2724 82.18 36 166 86.37 5.93
CRC_Monitoring_122 74 12-Dec-11 282 15-Dec-11 Qiagen 83443 Prevalence Prevalence 18.61 27.11 6.42 1 X X X X X 16.34 18.79 27.11 6.42 24.41 X X X X X 15.37 1779 323 17.3 11369 2379 16.34 1.36 24.86 1390 460 12.72 9253 1348 18.79 8.58 32.6 5294 2566 21.61 6314 1741 27.11 7.77 7 6553 493 5.83 17247 1067 6.42 0.83 15.78 523 98 33.04 847 418 24.41 12.20
CRC_Monitoring_123 74 18-Dec-11 34.1 14-Dec-11 Qiagen 9259908 Prevalence Prevalence 96.18 99.25 90.36 1 X X X X X 96.65 90.36 99.25 95.66 98.98 X X X X X 52.27 95.8 106 2417 97.49 1629 63204 96.65 1.20 91.01 346 3501 89.71 2511 21880 90.36 0.92 99.4 209 37089 99.1 609 67103 99.25 0.21 96.5 233 6395 94.81 1064 19437 95.66 1.20 98.98 639 61798 98.98 631 61015 98.98 0.00
CRC_Monitoring_124 58 4-Aug-11 82.9 8-Aug-11 Qiagen 124285 Prevalence Prevalence 1.40 4.04 0.09 1 X X 0.34 0.09 4.04 1.62 0.91 X X 0.53 11096 59 0.15 37308 57 0.34 0.27 0 10316 0 0.18 95536 169 0.09 0.13 1.3 45133 582 6.77 33909 2462 4.04 3.87 3 22788 712 0.24 54100 131 1.62 1.95 0.36 10013 36 1.45 1287 19 0.91 0.77
CRC_Monitoring_125 71 4-Jul-11 152 4-Jul-11 Qiagen 152843 Prevalence Prevalence 87.03 94.08 78.08 1 X X X X X 78.08 81.14 94.08 88.06 93.77 X X X X X 80.04 1125 4512 76.12 3113 9923 78.08 2.77 77.91 862 3041 84.36 4758 25658 81.14 4.56 93.8 1479 22284 94.36 1922 32171 94.08 0.40 92.6 1922 24224 83.52 3659 18539 88.06 6.42 91.78 705 7875 95.76 1190 26871 93.77 2.81
CRC_Monitoring_126 63 4-Nov-11 4.4 7-Nov-11 Qiagen 10695 Prevalence Prevalence 0.22 0.74 0.00 1 X 0.00 0.23 0.74 0.01 0.11 X 0 3606 0 0 419 0 0.00 0.00 0.46 1285 6 0 58668 2 0.23 0.33 0.1 14820 22 1.38 214 3 0.74 0.91 0 12615 1 0.02 13483 3 0.01 0.01 0 653 0 0.22 902 2 0.11 0.16
CRC_Monitoring_127 73 11-Nov-11 212 11-Nov-11 Qiagen 39523 Prevalence Prevalence 30.98 82.61 13.05 1 X X X X X 20.18 16.25 82.61 13.05 22.83 X X X X X 24.86 29.23 2489 1028 11.13 5995 751 20.18 12.80 25.12 5975 2004 7.37 28673 2283 16.25 12.55 83.4 4940 24782 81.82 1669 7509 82.61 1.12 10.1 10028 1126 15.99 11031 2099 13.05 4.16 32.35 1171 560 13.3 2478 380 22.83 13.47
CRC_Monitoring_128 67 26-Sep-11 2581 26-Sep-11 Qiagen 325832 Prevalence Prevalence 83.11 96.33 51.39 1 X X X X X 91.03 89.74 51.39 96.33 87.08 X X X X X 89.52 421 3595 92.53 3801 47069 91.03 2.13 87.61 295 2086 91.86 2567 28976 89.74 3.01 48.57 8819 8329 54.21 12201 14444 51.39 3.99 97.8 76 3446 94.86 1202 22174 96.33 2.08 86.46 2718 17350 87.69 2711 19306 87.08 0.87
CRC_Monitoring_129 66 18-Jul-11 246 20-Jul-11 Qiagen 28485 Prevalence Prevalence 66.79 89.15 45.51 1 X X X X X 81.42 45.51 89.15 55.38 62.51 X X X X X 75.34 476 1454 87.49 231 1615 81.42 8.59 50.79 1815 1873 40.23 10198 6864 45.51 7.47 81.1 3789 16248 97.2 308 10707 89.15 11.38 55.9 294 372 54.86 2867 3484 55.38 0.74 58.07 686 950 66.94 1433 2901 62.51 6.27
CRC_Monitoring_1 68 9-Dec-11 100 9-Dec-11 Qiagen 52861 Prevalence Prevalence 58.13 75.59 19.55 1 X X X X X 67.41 54.03 19.55 74.06 75.59 X X X X X 63.26 377 649 71.55 3362 8457 67.41 5.86 51.33 7148 7539 56.73 6933 9090 54.03 3.82 26.11 20519 7250 12.99 3964 592 19.55 9.28 80 1171 4687 68.12 2692 5753 74.06 8.40 75.86 4054 12739 75.31 1608 4905 75.59 0.39
CRC_Monitoring_130 41 10-Feb-12 18.6 10-Feb-12 Qiagen 2361 Prevalence Prevalence 0.04 0.20 0.00 0 0.00 0.01 0.20 0.00 0.00 0 1007 0 0.00 0.01 23030 3 0.01 23030 3 0.01 0.00 0.2 3923 7 0.20 0 2186 0 0 875 0 0.00 0.00 0 1519 0 0.00
CRC_Monitoring_131 69 30-Aug-11 79.9 1-Sep-11 Qiagen 8482 Prevalence Prevalence 13.97 36.42 0.00 1 X X X X 0.00 27.83 4.35 1.25 36.42 X X X X 0 688 0 0.00 39.55 3885 2542 16.1 10473 2010 27.83 16.58 8.7 35508 3393 4.35 6.15 2.5 12560 321 0 16161 0 1.25 1.77 27.62 152 58 45.21 120 99 36.42 12.44
CRC_Monitoring_2 76 10-Nov-10 229 11-Nov-10 Promega 60603 Prevalence Prevalence 47.19 69.83 28.72 1 X X X X X 39.13 48.96 69.83 28.72 49.30 X X X X X 33.07604 14653 7242 45.17637 11377 9375 39.13 8.56 51.94 4372 4725 45.97 5037 4285 48.96 4.22 77.73 1853 6469 61.92 1520 2472 69.83 11.18 23.88 3101 973 33.55 4590 2317 28.72 6.84 34.48 2446 1287 64.11 206 368 49.30 20.95
CRC_Monitoring_3 47 17-Sep-14 766 15-Oct-14 Promega 26505 Prevalence Prevalence 18.07 59.14 0.02 1 X X X 0.90 0.11 59.14 0.02 30.17 X X 1.797943 34847 638 0 5647 0 0.90 1.27 0.12 17002 20 0.09 2278 2 0.11 0.02 59.14 1687 2442 59.14 0.02 12648 3 0.01 17632 1 0.02 0.01 30.17 588 254 30.17
CRC_Monitoring_4 69 2-Jul-14 17.7 5-Aug-14 Promega 35085 Prevalence Prevalence 9.30 31.59 0.02 1 X X X 8.98 0.02 0.03 5.89 31.59 X X X 10.30998 27516 3163 7.652303 2486 206 8.98 1.88 0.02 21646 5 0.01 28223 2 0.02 0.01 0.06 17837 10 0 7495 0 0.03 0.04 3.42 6666 236 8.35 6268 571 5.89 3.49 37.84 2060 1254 25.34 271 92 31.59 8.84
CRC_Monitoring_5 49 13-Apr-15 387 8-Apr-15 Promega 35852 Prevalence Prevalence 2.80 8.78 0.00 1 X X 0.00 5.22 0.00 8.78 0.00 X X 0 6194 0 0 10222 0 0.00 0.00 0.05 27507 13 10.39 12802 1485 5.22 7.31 0 10795 0 0 3396 0 0.00 0.00 0 4667 0 17.56 5058 1077 8.78 12.42 0 384 0 0 275 0 0.00 0.00
CRC_Monitoring_6 65 18-Sep-09 45.5 9-Sep-09 Promega 30699 Prevalence Prevalence 0.07 0.31 0.00 0 0.03 0.31 0.00 0.02 0.00 0.02553 3916 1 0.029343 10221 3 0.03 0.00 0.05 22891 12 0.57 8840 51 0.31 0.37 0 288 0 0 1717 0 0.00 0.00 0.04 2292 1 0 14769 0 0.02 0.03 0 211 0 0 236 0 0.00 0.00
CRC_Monitoring_7 56 3-May-10 3 4-May-10 Promega 30438 Prevalence Prevalence 0.01 0.03 0.00 0 0.00 0.03 0.00 0.01 0.00 0 11686 0 0.008897 11239 1 0.00 0.01 0.02 23418 4 0.03 27396 9 0.03 0.01 0 6447 0 0 3834 0 0.00 0.00 0 4924 0 0.01 16550 1 0.01 0.01 0 3883 0 0 2514 0 0.00 0.00
CRC_Monitoring_8 83 28-Jun-12 1738 29-Jun-12 Promega 201913 Prevalence Prevalence 8.31 28.23 2.36 1 X X X X X 4.07 2.36 28.23 3.06 3.82 X X X X X 5.403128 20204 1154 2.745355 26746 755 4.07 1.88 2.3 4938 116 2.42 4883 121 2.36 0.08 27.57 10627 4045 28.88 2276 924 28.23 0.93 5.13 4585 248 0.98 17304 172 3.06 2.93 3.86 3040 122 3.77 2117 83 3.82 0.06
CRC_Monitoring_9 64 20-Jun-11 120 8-Jul-11 Promega 88960 Prevalence Prevalence 25.02 59.68 9.33 1 X X X X X 9.33 9.64 59.68 15.94 30.52 X X X X X 15.87801 9351 1765 2.772964 1122 32 9.33 9.27 9.29 6916 708 9.98 10321 1144 9.64 0.49 67.06 334 680 52.3 2054 2252 59.68 10.44 18.85 4180 971 13.03 6586 987 15.94 4.12 33.53 1320 666 27.51 577 219 30.52 4.26
CRC_Monitoring_10 68 10-Nov-14 6.4 6-Nov-14 Promega 204675 Prevalence Prevalence 0.30 0.87 0.00 1 X 0.00 0.16 0.00 0.87 0.48 X 0 25478 0 0 61559 0 0.00 0.00 0.14 13067 18 0.17 10335 18 0.16 0.02 0 22678 0 0 22948 0 0.00 0.00 0 4199 0 1.74 2703 48 0.87 1.23 0.65 5539 36 0.3 16963 51 0.48 0.25
CRC_Monitoring_11 57 7-May-15 32.9 18-May-15 Promega 196187 Prevalence Prevalence 11.42 26.75 1.35 1 X X X X X 26.75 1.35 20.17 1.64 7.17 X X X X X 24.05 14147 4480 29.45 5895 2461 26.75 3.82 1.47 13572 203 1.22 10255 127 1.35 0.18 30.92 8298 3714 9.42 2039 212 20.17 15.20 1.73 3416 60 1.55 40399 638 1.64 0.13 10.82 5326 646 3.52 4874 178 7.17 5.16
CRC_Monitoring_12 71 23-Oct-15 9.8 23-Oct-15 Promega 84931 Prevalence Prevalence 0.05 0.20 0.00 0 0.03 0.20 0.01 0.00 0.01 0.05 2049 1 0.01 8976 1 0.03 0.03 0.38 16698 64 0.02 11581 2 0.20 0.25 0.02 4836 1 0 5070 0 0.01 0.01 0 2337 0 0 32627 1 0.00 0.00 0.02 12379 2 0 548 0 0.01 0.01
CRC_Monitoring_13 51 19-Sep-11 836 3-Oct-11 Promega 449293 Prevalence Prevalence 80.84 96.12 45.98 1 X X X X X 95.51 80.99 96.12 45.98 85.60 X X X X X 96.08 934 22866 94.93 1737 32496 95.51 0.81 74.16 1650 4736 87.82 540 3892 80.99 9.66 93.4 1222 17283 98.84 311 26495 96.12 3.85 41.51 434 308 50.44 4677 4760 45.98 6.31 87.41 199 1382 83.79 123 636 85.60 2.56
CRC_Monitoring_14 68 25-May-11 60.5 25-May-11 Promega 19397 Prevalence Prevalence 6.86 25.23 0.01 1 X X X 7.26 1.72 0.07 0.01 25.23 X X X 0.55 359 2 13.97 696 113 7.26 9.49 3.41 4413 156 0.02 4183 1 1.72 2.40 0.07 3023 2 0.07 0 417 0 0.02 5717 1 0.01 0.01 25.79 446 155 24.66 220 72 25.23 0.80
CRC_Monitoring_15 81 7-Jan-13 2.6 7-Jan-13 Promega 181457 Prevalence Prevalence 81.69 95.29 43.39 1 X X X X X 89.49 92.19 95.29 88.07 43.39 X X X X X 92.18 1017 11986 86.8 2022 13298 89.49 3.80 90.26 281 2605 94.12 162 2595 92.19 2.73 98.09 251 12901 92.49 196 2415 95.29 3.96 88.58 1853 14372 87.56 1757 12367 88.07 0.72 52.79 1296 1449 33.99 1398 720 43.39 13.29
CRC_Monitoring_16 73 8-Jul-15 1.1 2-Jul-15 Promega 215848 Prevalence Prevalence 69.55 94.15 21.24 1 X X X X X 93.57 59.25 94.15 21.24 79.52 X X X X X 93.56 723 10499 93.58 2510 36582 93.57 0.01 51.65 1947 2080 66.84 757 1526 59.25 10.74 98.35 119 7082 89.95 384 3437 94.15 5.94 20.49 648 167 21.99 5892 1661 21.24 1.06 73.07 1422 3858 85.97 443 2714 79.52 9.12
CRC_Monitoring_17 70 24-Jun-10 21 24-Jun-10 Promega 10659 Prevalence Prevalence 2.11 10.33 0.00 1 X 0.02 0.13 0.06 0.00 10.33 X 0.02 6504 1 0.01 34154 3 0.02 0.01 0.13 5410 7 0.13 5561 7 0.13 0.00 0.01 13866 1 0.1 1967 2 0.06 0.06 0 600 0 0 2214 0 0.00 0.00 6.32 623 42 14.33 550 92 10.33 5.66
CRC_Monitoring_18 55 8-Apr-15 9762 8-Apr-15 Promega 154841 Prevalence Prevalence 66.85 83.44 37.81 1 X X X X X 83.44 72.79 77.14 37.81 63.06 X X X X X 73.94 6169 17506 92.93 2069 27176 83.44 13.43 70.28 1683 3979 75.29 884 2694 72.79 3.54 77.58 1561 5402 76.7 2097 6904 77.14 0.62 33.88 320 164 41.73 4532 3246 37.81 5.55 59.19 2239 3247 66.92 1597 3230 63.06 5.47
CRC_Monitoring_19 73 23-Jun-10 8.7 25-May-10 Promega 120155 Prevalence Prevalence 2.07 4.56 0.01 1 X X X X 2.27 0.80 0.01 2.70 4.56 X X X X 4.54 9611 457 0 21920 1 2.27 3.21 0.22 4144 9 1.37 9348 130 0.80 0.81 0.01 12378 1 0 6186 0 0.01 0.01 5.4 963 55 0 3265 0 2.70 3.82 3.45 9799 350 5.67 2961 178 4.56 1.57
CRC_Monitoring_20 50 5-Dec-11 229 6-Feb-12 Promega 47478 Prevalence Prevalence 0.97 4.74 0.00 1 X 0.05 0.02 0.02 0.00 4.74 0.04 2483 1 0.06 7888 5 0.05 0.01 0.01 17162 2 0.03 13461 4 0.02 0.01 0.03 3728 1 0 239 0 0.02 0.02 0 1453 0 0 13756 0 0.00 0.00 0.08 1268 1 9.39 434 45 4.74 6.58
CRC_Monitoring_21 74 18-Nov-13 859 18-Nov-13 Promega 131904 Prevalence Prevalence 2.54 4.53 1.32 1 X X X X X 4.53 2.36 1.79 1.32 2.69 X X X X X 9 24583 2431 0.05 16001 8 4.53 6.33 1.37 10187 142 3.35 6875 238 2.36 1.40 3.31 2542 87 0.27 743 2 1.79 2.15 0.65 4271 28 1.99 9532 194 1.32 0.95 1 10790 109 4.37018 372 17 2.69 2.38
CRC_Monitoring_22 76 19-Jul-10 27.7 20-Jul-10 Promega 48021 Prevalence Prevalence 0.07 0.21 0.00 0 0.06 0.09 0.00 0.01 0.21 0.11 2660 3 0 3237 0 0.06 0.08 0.11 9254 10 0.07 12402 9 0.09 0.03 0 1834 0 0 4330 0 0.00 0.00 0 3983 0 0.02 5413 1 0.01 0.01 0 1043 0 0.41 488 2 0.21 0.29
CRC_Monitoring_23 70 18-Jan-11 89.3 19-Jan-11 Promega 95897 Prevalence Prevalence 3.20 15.43 0.00 1 X X 15.43 0.18 0.11 0.26 0.00 X X 10.03 4887 545 20.82 24607 6472 15.43 7.63 0.01 18950 2 0.35 8153 29 0.18 0.24 0.04 9432 4 0.17 5392 9 0.11 0.09 0 1323 0 0.52 25139 132 0.26 0.37 0 285 0 0 1081 0 0.00 0.00
CRC_Monitoring_24 57 2-Sep-15 491 18-Sep-15 Promega 21321 Prevalence Prevalence 0.04 0.08 0.00 0 0.08 0.03 0.06 0.03 0.00 0.07 4015 3 0.08 1269 1 0.08 0.01 0.02 10910 2 0.04 4722 2 0.03 0.01 0.03 3083 1 0.08 1279 1 0.06 0.04 0.05 1969 1 0.03 0 308 0 0 189 0 0.00 0.00
CRC_Monitoring_25 61 23-Jun-10 108 23-Jun-10 Promega 1294369 Prevalence Prevalence 10.73 19.86 2.94 1 X X X X X 19.86 6.37 16.99 2.94 7.52 X X X X X 20.34 18629 4758 19.38 17667 4247 19.86 0.68 4.39 3901 179 8.34 1979 180 6.37 2.79 14.92 7043 1235 19.06 24768 5834 16.99 2.93 0.96 824 8 4.91 7551 390 2.94 2.79 9.6 16867 1791 5.43 12825 737 7.52 2.95
CRC_Monitoring_26 69 28-Sep-10 1.7 19-Oct-10 Promega 157496 Prevalence Prevalence 79.25 88.26 73.01 1 X X X X X 73.01 73.79 84.55 88.26 76.62 X X X X X 68.8 83 183 77.21 3851 13046 73.01 5.95 72.69 1254 3338 74.88 541 1613 73.79 1.55 76.24 3056 9806 92.85 647 8407 84.55 11.75 91.87 81 915 84.65 1791 9875 88.26 5.11 69.11 4728 10580 84.13 389 2062 76.62 10.62
CRC_Monitoring_27 80 23-Jun-14 114 4-Aug-14 Promega 272174 Prevalence Prevalence 25.47 43.78 1.22 1 X X X X X 36.92 15.47 43.78 1.22 29.94 X X X X X 45.5 4391 3666 28.34 14170 5603 36.92 12.13 12.86 6017 888 18.08 2724 601 15.47 3.69 47.96 4537 4182 39.6 6384 4186 43.78 5.91 1.71 1552 27 0.72 27449 200 1.22 0.70 36.49 3613 2076 23.38 295 90 29.94 9.27
CRC_Monitoring_28 63 20-Nov-14 7.3 20-Nov-14 Promega 409422 Prevalence Prevalence 0.18 0.57 0.02 0 0.57 0.27 0.03 0.02 0.02 0.51 23973 123 0.62 160 1 0.57 0.08 0.33 21229 71 0.21 11085 23 0.27 0.08 0.05 1861 1 0 8131 0 0.03 0.04 0 7523 0 0.03 49386 14 0.02 0.02 0.03 31285 8 0 622 0 0.02 0.02
CRC_Monitoring_29 74 25-Jun-14 2.7 24-Jun-14 Promega 288828 Prevalence Prevalence 86.00 89.70 80.37 1 X X X X X 80.37 89.57 85.41 84.96 89.70 X X X X X 79.32 3293 12630 81.41 1547 6773 80.37 1.48 88.43 1583 12097 90.71 373 3642 89.57 1.61 88.55 1437 11116 82.27 1528 7090 85.41 4.44 86.36 93 589 83.56 1722 8751 84.96 1.98 90.32 1475 13758 89.07 1658 13511 89.70 0.88
CRC_Monitoring_30 69 24-Jun-14 67.4 1-Aug-14 Promega 21914 Prevalence Prevalence 2.22 7.86 0.00 1 X X X 1.98 0.15 0.00 7.86 1.14 X 3.95 4250 175 0 1557 0 1.98 2.79 0.06 1775 1 0.23 1322 3 0.15 0.12 0 16002 0 0 953 0 0.00 0.00 0 17398 0 7.86 0 626 0 2.28 214 5 1.14 1.61
CRC_Monitoring_31 50 21-Jan-14 474 21-Jan-14 Promega 214074 Prevalence Prevalence 59.98 88.95 33.04 1 X X X X X 88.95 41.08 70.81 33.04 66.02 X X X X X 87.19 1990 13544 90.7 2775 27065 88.95 2.48 36.81 606 353 45.35 729 605 41.08 6.04 73.37 651 1794 68.24 5523 11866 70.81 3.63 27.87 176 68 38.2 4567 2823 33.04 7.30 59.9 79 118 72.14 1137 2944 66.02 8.65
CRC_Monitoring_32 70 8-Jan-15 5.5 11-Mar-15 Promega 164096 Prevalence Prevalence 5.41 10.50 0.41 1 X X X X X 2.06 10.32 3.75 0.41 10.50 X X X X 4.05 20578 869 0.07 25568 17 2.06 2.81 5.98 6672 424 14.65 3116 535 10.32 6.13 1.03 4823 50 6.46 2188 151 3.75 3.84 0.82 364 3 0 14533 0 0.41 0.58 14.16 3637 600 6.83 2238 164 10.50 5.18
CRC_Monitoring_33 79 26-Jun-14 278 26-Jun-14 Promega 176953 Prevalence Prevalence 1.01 2.21 0.04 1 X X X 2.21 0.72 2.00 0.10 0.04 X X X 4.41 4375 202 0 45354 1 2.21 3.12 0.07 22508 15 1.36 7667 106 0.72 0.91 3.99 6444 268 0 14781 0 2.00 2.82 0 7731 0 0.19 4694 9 0.10 0.13 0 801 0 0.07 9404 7 0.04 0.05
CRC_Monitoring_34 82 24-Dec-10 4.3 21-Dec-10 Promega 77612 Prevalence Prevalence 4.70 22.49 0.00 1 X X 22.49 0.94 0.01 0.00 0.06 X X 12.56 2291 329 32.42 6617 3175 22.49 14.04 1.88 14637 280 0 18434 0 0.94 1.33 0.01 11350 1 0.01 13313 1 0.01 0.00 0 934 0 0 25283 1 0.00 0.00 0.11 933 1 0 3501 0 0.06 0.08
CRC_Monitoring_35 72 8-Jul-14 24.2 3-Sep-14 Promega 155034 Prevalence Prevalence 12.39 28.83 1.38 1 X X X X X 28.83 3.02 6.72 1.38 22.01 X X X X X 20.5 1326 342 37.16 1796 1062 28.83 11.78 3.42 11551 409 2.62 9469 255 3.02 0.57 1.69 3365 58 11.74 2999 399 6.72 7.11 2.34 1673 40 0.41 33005 136 1.38 1.36 27.58 4141 1577 16.43 4325 850 22.01 7.88
CRC_Monitoring_36 74 17-Mar-14 4189 8-Apr-14 Promega 485303 Prevalence Prevalence 79.59 88.15 69.70 1 X X X X X 75.21 80.05 88.15 69.70 84.86 X X X X X 77.46 4325 14861 72.96 3639 9820 75.21 3.18 78.12 1040 3713 81.98 637 2898 80.05 2.73 85.27 740 4283 91.02 1746 17707 88.15 4.07 63.1 224 383 76.3 2598 8362 69.70 9.33 87.97 2947 21540 81.75 1830 8195 84.86 4.40
CRC_Monitoring_37 70 14-Sep-10 48.5 14-Sep-10 Promega 3718001 Prevalence Prevalence 61.31 97.22 0.32 1 X X X X 0.32 80.65 97.22 79.98 48.39 X X X X 0.02 13139 3 0.61 33652 206 0.32 0.42 74.87 959 2857 86.43 409 2606 80.65 8.17 97.16 844 28887 97.27 592 21073 97.22 0.08 72.8 68 182 87.15 290 1966 79.98 10.15 47.09 8086 7196 49.68 4672 4613 48.39 1.83
CRC_Monitoring_38 72 26-Aug-14 4.8 10-Sep-14 Promega 517188 Prevalence Prevalence 70.35 95.62 30.39 1 X X X X X 62.51 85.39 77.86 95.62 30.39 X X X X X 52.25 1284 1405 72.76 1833 4897 62.51 14.50 82.12 760 3490 88.66 224 1752 85.39 4.62 85.89 3279 19958 69.82 8188 18945 77.86 11.36 94.5 54 928 96.73 684 20228 95.62 1.58 32.78 8177 3988 28 4827 1877 30.39 3.38
CRC_Monitoring_39 50 13-Aug-10 3.3 28-Jul-10 Promega 33734 Prevalence Prevalence 9.42 39.95 0.00 1 X X X X 39.95 1.24 4.85 1.08 0.00 X X X X 31 15038 6757 48.89 2159 2065 39.95 12.65 2.43 11258 280 0.05 6230 3 1.24 1.68 0 751 0 9.7 763 82 4.85 6.86 2.15 1550 34 0.01 21497 2 1.08 1.51 0 3178 0 0 898 0 0.00 0.00
CRC_Monitoring_40 70 14-Apr-14 17.2 14-Apr-14 Promega 10563 Prevalence Prevalence 0.02 0.06 0.00 0 0.06 0.06 0.00 0.00 0.00 0 26393 0 0.11 1781 2 0.06 0.08 0.04 4491 2 0.07 3010 2 0.06 0.02 0 1000 0 0 2017 0 0.00 0.00 0 114 0 0 8727 0 0.00 0.00 0 217 0 0 409 0 0.00 0.00
CRC_Monitoring_41 67 23-Mar-15 1.7 23-Mar-15 Promega 6879 Prevalence Prevalence 5.50 27.36 0.00 1 X 27.36 0.11 0.01 0.03 0.00 X 41.65 3644 2601 13.06 4426 665 27.36 20.22 0.21 8592 18 0 13488 0 0.11 0.15 0 1625 0 0.02 6287 1 0.01 0.01 0 678 0 0.05 21335 10 0.03 0.04 0 636 0 0 975 0 0.00 0.00
CRC_Monitoring_42 72 11-Dec-12 2 11-Dec-12 Promega 25247 Prevalence Prevalence 0.03 0.08 0.00 0 0.00 0.05 0.03 0.01 0.08 0 5521 0 0 3359 0 0.00 0.00 0.03 25254 8 0.06 10382 6 0.05 0.02 0.05 2164 1 0 6426 0 0.03 0.04 0.02 5691 1 0 3561 0 0.01 0.01 0 2254 0 0.15 672 1 0.08 0.11
CRC_Monitoring_43 79 13-Oct-15 2 15-Oct-15 Promega 167833 Prevalence Prevalence 0.15 0.60 0.00 1 X 0.04 0.07 0.00 0.60 0.04 X 0.08 9004 7 0 7666 0 0.04 0.06 0.03 25024 7 0.11 14052 16 0.07 0.06 0 2235 0 0 5956 0 0.00 0.00 0.13 4671 6 1.07 832 9 0.60 0.66 0.04 24296 9 0.04
CRC_Monitoring_44 59 5-Aug-14 8.6 5-Aug-14 Promega 103753 Prevalence Prevalence 10.50 22.46 3.76 1 X X X X X 10.66 7.58 8.02 3.76 22.46 X X X X X 10.89 14258 1743 10.42 10200 1187 10.66 0.33 10.83 8540 1037 4.33 7099 321 7.58 4.60 15.97 2641 502 0.06 8790 5 8.02 11.25 3.5 1987 72 4.02 15871 665 3.76 0.37 16.79 2408 486 28.13 327 128 22.46 8.02
CRC_Monitoring_45 40 5-Nov-14 1267 5-Nov-14 Promega 818212 Prevalence Prevalence 89.42 98.84 77.83 1 X X X X X 88.41 88.53 98.84 93.50 77.83 X X X X X 84.36 1458 7863 92.45 2385 29224 88.41 5.72 84.16 771 4095 92.89 299 3904 88.53 6.17 97.94 286 13614 99.74 65 25192 98.84 1.27 95.44 40 837 91.55 800 8670 93.50 2.75 87.16 1401 9514 68.5 132 287 77.83 13.19
CRC_Monitoring_46 81 11-May-10 7.5 11-May-10 Promega 96154 Prevalence Prevalence 0.14 0.34 0.00 0 0.34 0.08 0.00 0.00 0.27 0.17 1184 2 0.51 979 5 0.34 0.24 0.13 15980 20 0.03 7349 2 0.08 0.07 0 1442 0 0 3448 0 0.00 0.00 0 3366 0 0 125083 0 0.00 0.00 0.27 13556 37 0.27
CRC_Monitoring_47 47 10-Jun-15 31.4 10-Jun-15 Promega 28029 Prevalence Prevalence 0.07 0.17 0.00 0 0.13 0.07 0.00 0.00 0.17 0.25 1618 4 0 754 0 0.13 0.18 0.03 22465 7 0.11 6967 8 0.07 0.06 0 919 0 0 2451 0 0.00 0.00 0 1322 0 0 567 0 0.00 0.00 0.33 299 1 0 638 0 0.17 0.23
CRC_Monitoring_48 75 9-Nov-10 27 12-Oct-10 Promega 8875 Prevalence Prevalence 0.13 0.60 0.00 0 0.00 0.05 0.00 0.00 0.60 0 1372 0 0 15195 0 0.00 0.00 0.01 18326 2 0.08 4945 4 0.05 0.05 0 2654 0 0.00 0 264 0 0 423 0 0.00 0.00 0.6 497 3 0.60
CRC_Monitoring_49 74 20-Apr-15 12.1 8-May-15 Promega 39604 Prevalence Prevalence 16.77 48.62 7.61 1 X X X X X 10.40 8.85 7.61 8.38 48.62 X X X X X 20.8 9186 2412 0 10151 0 10.40 14.71 9.22 10800 1097 8.48 6239 578 8.85 0.52 15 2516 444 0.22 452 1 7.61 10.45 13.53 1534 240 3.23 15408 514 8.38 7.28 56.97 719 952 40.27 178 120 48.62 11.81
CRC_Monitoring_50 58 22-Jul-14 250 23-Jul-14 Promega 83437 Prevalence Prevalence 84.34 98.00 64.04 1 X X X X X 91.03 64.04 98.00 75.51 93.14 X X X X X 89.22 2044 16913 92.84 1551 20102 91.03 2.56 61.13 3107 4886 66.95 767 1554 64.04 4.12 96.23 103 2629 99.76 6 2541 98.00 2.50 69.43 538 1222 81.58 3080 13642 75.51 8.59 93.75 189 2834 92.52 78 965 93.14 0.87
CRC_Monitoring_51 68 8-May-15 71.7 8-May-15 Promega 41905 Prevalence Prevalence 33.73 72.29 3.03 1 X X X X X 72.29 4.73 56.86 3.03 31.76 X X X X X 65.09 5695 10617 79.48 1685 6528 72.29 10.18 6.27 10093 675 3.19 8351 275 4.73 2.18 46.85 245 216 66.86 866 1747 56.86 14.15 3.36 2416 84 2.7 59494 1650 3.03 0.47 32.33 515 246 31.18 574 260 31.76 0.81
CRC_Monitoring_52 65 14-Jul-14 13.6 2-Sep-14 Promega 8307 Prevalence Prevalence 0.08 0.32 0.00 0 NA 0.32 0.01 0.00 0.00 NA 0.61 3267 20 0.03 2985 1 0.32 0.41 0 7200 0 0.01 6720 1 0.01 0.01 0 592 0 0 5843 0 0.00 0.00 0 346 0 0 264 0 0.00 0.00
CRC_Monitoring_53 85 30-May-14 147 30-May-14 Promega 26651 Prevalence Prevalence 71.18 87.83 48.32 1 X X X X X 48.32 66.51 78.79 87.83 74.48 X X X X X 52.41 999 1100 44.23 232 184 48.32 5.78 59.22 1097 1593 73.79 1140 3210 66.51 10.30 76.74 385 1270 80.84 1169 4933 78.79 2.90 95.11 64 1246 80.54 3872 16022 87.83 10.30 80.62 88 366 68.33 140 302 74.48 8.69
CRC_Monitoring_54 81 11-Sep-13 8 3-Oct-13 Promega 100139 Prevalence Prevalence 78.86 92.89 68.27 1 X X X X X 92.89 68.66 68.27 81.53 82.97 X X X X X 92.97 2130 28160 92.81 1776 22929 92.89 0.11 76.93 1005 3351 60.39 1409 2148 68.66 11.70 58.97 128 184 77.56 267 923 68.27 13.15 80.35 1898 7763 82.71 1431 6846 81.53 1.67 85.8 47 284 80.14 87 351 82.97 4.00
CRC_Monitoring_55 61 4-Jun-13 419 5-Jun-13 Promega 1006748 Prevalence Prevalence 98.32 99.58 97.16 1 X X X X X 98.43 97.16 98.05 99.58 98.39 X X X X X 97.93 825 39115 98.92 663 60804 98.43 0.70 96.62 205 5859 97.69 141 5954 97.16 0.76 98.74 418 32825 97.35 940 34536 98.05 0.98 99.61 11 2777 99.55 158 35265 99.58 0.04 98.78 202 16330 98 225 11017 98.39 0.55
CRC_Monitoring_56 83 27-Jan-14 194 27-Jan-14 Promega 21946 Prevalence Prevalence 35.65 99.60 0.00 1 X X X X 0.82 29.07 99.60 0.00 48.74 X X X X 0.19 1029 2 1.44 5125 75 0.82 0.88 29.07 1608 659 29.07 99.25 3 395 99.94 2 3566 99.60 0.49 0 48692 0 0 10255 0 0.00 0.00 40.95 124 86 56.53 143 186 48.74 11.02
CRC_Monitoring_57 40 29-Oct-14 1085 30-Oct-14 Promega 31569 Prevalence Prevalence 0.23 1.04 0.00 1 X 1.04 0.13 0.00 0.00 0.00 X 0.01 26974 3 2.07 6526 138 1.04 1.46 0.23 29161 67 0.02 54866 11 0.13 0.15 0 22181 1 0 21989 0 0.00 0.00 0 36189 0 0 30790 0 0.00 0.00 0 454 0 0 208 0 0.00 0.00
CRC_Monitoring_58 35 7-Jun-11 #### 8-Jun-11 Promega 1573 Prevalence Prevalence 0.06 0.26 0.00 0 NA 0.00 0.26 0.00 0.00 NA 0 791 0 0 3025 0 0.00 0.00 0 1251 0 0.51 20346 105 0.26 0.36 0 10956 0 0.00 0 138 0 0 346 0 0.00 0.00
CRC_Monitoring_59 80 22-Nov-13 235 22-Nov-13 Promega 12264 Prevalence Prevalence 64.67 99.74 38.32 1 X X X X X 99.74 38.32 58.84 84.90 41.54 X X X X X 99.94 6 10644 99.53 5 1065 99.74 0.29 49.75 203 201 26.88 2658 977 38.32 16.17 47.37 2541 2287 70.31 4983 11802 58.84 16.22 80.84 2481 10468 88.95 980 7887 84.90 5.73 56.22 109 140 26.85 662 243 41.54 20.77
CRC_Monitoring_60 64 18-Mar-13 72.1 2-Apr-13 Promega 220622 Prevalence Prevalence 0.65 1.63 0.01 1 X X 0.01 1.16 0.36 0.10 1.63 X X 0 46629 0 0.02 44906 10 0.01 0.01 1.47 10989 164 0.85 18248 157 1.16 0.44 0.01 132813 12 0.71 73764 530 0.36 0.49 0.13 31613 41 0.07 41848 28 0.10 0.04 1.19 12331 149 2.07 1417 30 1.63 0.62
CRC_Monitoring_61 60 25-Oct-11 1084 11-Nov-11 Promega 12394 Prevalence Prevalence 18.65 67.60 0.00 1 X X 0.01 25.62 0.00 0.00 67.60 X X 0 4114 0 0.01 8552 1 0.01 0.01 33.69 2382 1210 17.54 3856 820 25.62 11.42 0 5951 0 0 259 0 0.00 0.00 0 38977 0 0 21440 0 0.00 0.00 67.6 104 217 67.60
CRC_Monitoring_62 56 8-Jul-10 10 22-Jul-10 Promega 7131 Prevalence Prevalence 0.05 0.14 0.00 0 0.06 0.14 0.03 0.00 0.00 0.11 1829 2 0 209 0 0.06 0.08 0.02 14253 3 0.25 1194 3 0.14 0.16 0.06 3554 2 0.03 0 33868 1 0 40354 0 0.00 0.00 0 198 0 0 439 0 0.00 0.00
CRC_Monitoring_63 33 4-Jun-14 918 4-Jun-14 Promega 4692 Prevalence Prevalence 1.06 4.09 0.00 1 X NA 4.09 0.00 0.14 0.00 X NA 0 3208 0 8.17 5362 477 4.09 5.78 0 951 0 0 951 0 0.00 0.00 0 1592 0 0.27 736 2 0.14 0.19 0 2254 0 0 352 0 0.00 0.00
CRC_Monitoring_64 35 25-Nov-13 54.4 23-Dec-13 Promega 32811 Prevalence Prevalence 0.54 2.52 0.00 1 X 0.03 2.52 0.00 0.00 0.16 X 0.04 11321 4 0.02 6089 1 0.03 0.01 4.91 13087 676 0.13 6721 9 2.52 3.38 0 75458 0 0 19169 0 0.00 0.00 0 42438 0 0 26450 0 0.00 0.00 0.31 318 1 0 207 0 0.16 0.22
CRC_Monitoring_65 50 25-Nov-13 8.7 29-Nov-13 Promega 18510 Prevalence Prevalence 15.66 39.38 0.00 1 X X X 0.01 22.08 0.00 16.85 39.38 X X X 0 1258 0 0.02 11752 2 0.01 0.01 29.68 8439 3562 14.48 4529 767 22.08 10.75 0 19172 0 0.00 15.19 10319 1848 18.51 3852 875 16.85 2.35 32.44 227 109 46.31 313 270 39.38 9.81
CRC_Monitoring_66 43 8-Jul-13 102 8-Jul-13 Promega 32360 Prevalence Prevalence 53.01 97.19 10.60 1 X X X X X 97.19 10.60 88.14 14.60 54.52 X X X X X 99.64 9 2478 94.73 103 1851 97.19 3.47 11.99 6521 888 9.2 11567 1172 10.60 1.97 86.82 2561 16867 89.45 2222 18830 88.14 1.86 18.89 9049 2108 10.3 8056 925 14.60 6.07 64.71 174 319 44.33 324 258 54.52 14.41
CRC_Monitoring_67 53 13-Mar-15 2 29-Jan-15 Promega 1213 Prevalence Prevalence 0.33 1.41 0.00 1 X 0.03 0.21 1.41 0.01 0.00 X 0.05 2202 1 0 278 0 0.03 0.04 0.2 4476 9 0.22 909 2 0.21 0.01 1.41 4822 69 1.41 0.01 17166 1 0 1545 0 0.01 0.01 0 325 0 0 483 0 0.00 0.00
CRC_Monitoring_68 51 15-Jul-15 39.9 15-Jul-15 Promega 46937 Prevalence Prevalence 1.24 6.06 0.00 1 X 0.00 0.10 0.06 0.00 6.06 0 1530 0 0 35076 0 0.00 0.00 0 2746 0 0.19 26499 50 0.10 0.13 0.12 28312 35 0 4641 0 0.06 0.08 0 51070 0 0 57075 1 0.00 0.00 0.04 2539 1 12.08 815 112 6.06 8.51
CRC_Monitoring_69 77 9-Sep-13 157 1-Oct-13 Promega 6439 Prevalence Prevalence 0.02 0.04 0.00 0 0.02 0.04 0.02 0.00 0.00 0 3864 0 0.04 2387 1 0.02 0.03 0.03 30717 10 0.04 28714 11 0.04 0.01 0.03 7983 2 0.02 0 37295 1 0 32923 0 0.00 0.00 0 481 0 0 1277 0 0.00 0.00
CRC_Monitoring_70 69 20-Apr-11 8.9 20-Apr-11 Promega 1194 Prevalence Prevalence 0.04 0.21 0.00 0 0.00 0.21 0.00 0.00 0.00 0 369 0 0 277 0 0.00 0.00 0.35 286 1 0.06 4899 3 0.21 0.21 0 45584 1 0.00 0 19664 0 0 25655 0 0.00 0.00 0 975 0 0 1707 0 0.00 0.00
CRC_Monitoring_71 72 27-Sep-13 11.2 18-Nov-13 Promega 547401 Prevalence Prevalence 89.16 91.38 82.66 1 X X X X X 90.94 82.66 91.38 90.45 90.36 X X X X X 95.22 1348 26861 86.65 2402 15594 90.94 6.06 85.21 1265 7286 80.11 1646 6631 82.66 3.61 93.85 2909 44355 88.91 1370 10986 91.38 3.49 93.74 277 4148 87.16 295 2003 90.45 4.65 89.89 1250 11111 90.82 1016 10050 90.36 0.66
CRC_Monitoring_72 39 6-Mar-12 38.3 30-Jan-12 Promega 20302 Prevalence Prevalence 11.85 58.97 0.01 1 X 0.09 0.17 0.03 0.01 58.97 X 0.07 4218 3 0.11 7375 8 0.09 0.03 0.29 2391 7 0.05 3783 2 0.17 0.17 0.06 3557 2 0 3508 0 0.03 0.04 0.01 14060 2 0 8703 0 0.01 0.01 58.97 318 457 58.97
CRC_Monitoring_73 55 18-Jul-14 88.6 1-Aug-14 Promega 93203 Prevalence Prevalence 44.37 91.48 13.96 1 X X X X X 59.26 13.96 91.48 21.67 35.47 X X X X X 57.2 6083 8131 61.32 3587 5686 59.26 2.91 9.37 15501 1602 18.54 2561 583 13.96 6.48 91.82 2833 31792 91.13 498 5117 91.48 0.49 28.82 2818 1141 14.52 1366 232 21.67 10.11 46.68 281 246 24.25 2989 957 35.47 15.86
CRC_Monitoring_74 76 2-Sep-15 43.7 2-Sep-15 Promega 107552 Prevalence Prevalence 1.54 5.67 0.00 1 X X 5.67 0.60 0.00 0.00 1.44 X X 1.41 21887 312 9.92 18607 2049 5.67 6.02 0.29 342 1 0.91 1408 13 0.60 0.44 0 7104 0 0 1039 0 0.00 0.00 0 28382 0 0 3663 0 0.00 0.00 0.58 2593 15 2.29 1705 40 1.44 1.21
CRC_Monitoring_75 65 14-Dec-15 24.1 25-Nov-15 Promega 7137 Prevalence Prevalence 0.93 4.49 0.00 1 X 0.00 0.18 0.00 0.00 4.49 0 4141 0 0 210 0 0.00 0.00 0.12 2589 3 0.24 1650 4 0.18 0.08 0 23639 0 0 2139 0 0.00 0.00 0 37675 0 0 8061 0 0.00 0.00 0 1110 0 8.98 294 29 4.49 6.35
CRC_Monitoring_76 62 19-Aug-15 46.4 19-Aug-15 Promega 18898 Prevalence Prevalence 0.86 3.90 0.00 1 X 3.90 0.38 0.01 0.00 0.00 X 3.53 383 14 4.26 6693 298 3.90 0.52 0.7 33329 236 0.05 3754 2 0.38 0.46 0.01 46096 5 0 2546 0 0.01 0.01 0 40321 0 0 9274 0 0.00 0.00 0 1849 0 0 271 0 0.00 0.00
CRC_Monitoring_77 66 5-Jul-10 294 12-Jul-10 Promega 211771 Prevalence Prevalence 42.85 66.21 18.49 1 X X X X X 57.08 19.81 66.21 18.49 52.66 X X X X X 50.66 5742 5896 63.49 3531 6139 57.08 9.07 17.88 5740 1250 21.74 1195 332 19.81 2.73 63.37 5208 9009 69.05 11538 25745 66.21 4.02 12.58 3030 436 24.39 527 170 18.49 8.35 57.94 98 135 47.38 602 542 52.66 7.47
CRC_Monitoring_78 58 5-Dec-14 6.3 5-Dec-14 Promega 286363 Prevalence Prevalence 59.00 83.43 32.92 1 X X X X X 74.68 32.92 83.43 46.22 57.77 X X X X X 83.07 4282 21005 66.28 2079 4086 74.68 11.87 37.38 4258 2542 28.45 1059 421 32.92 6.31 79.94 7956 31698 86.92 5579 37063 83.43 4.94 42.46 1813 1338 49.98 6171 6166 46.22 5.32 50.32 2657 2691 65.21 850 1593 57.77 10.53
CRC_Monitoring_79 52 15-Jun-12 339 26-Jul-12 Promega 220328 Prevalence Prevalence 99.33 99.95 98.43 1 X X X X X 99.30 98.43 99.95 99.95 99.01 X X X X X 99.43 463 80785 99.17 618 73879 99.30 0.18 98.47 290 18672 98.39 422 25841 98.43 0.06 99.96 53 142509 99.93 97 136389 99.95 0.02 99.97 6 21031 99.92 5 6605 99.95 0.04 99.15 292 34159 98.86 250 21627 99.01 0.21
CRC_Monitoring_80 51 25-Jun-13 0.8 25-Jun-13 Promega 12623 Prevalence Prevalence 0.31 1.50 0.00 1 X 0.00 0.04 1.50 0.00 0.00 X 0 4713 0 0 765 0 0.00 0.00 0.07 15033 10 0 313 0 0.04 0.05 2.59 28263 752 0.4 251 1 1.50 1.55 0 15513 0 0 2150 0 0.00 0.00 0 163 0 0 337 0 0.00 0.00
CRC_Monitoring_81 53 8-Jun-10 1184 15-Jun-10 Promega 25266 Prevalence Prevalence 68.72 94.25 45.51 1 X X X X X 94.25 79.82 72.82 51.23 45.51 X X X X X 99.99 2 20290 88.51 576 4438 94.25 8.12 82.64 1267 6031 76.99 742 2482 79.82 4.00 57.59 6864 9319 88.04 2346 17264 72.82 21.53 62.72 1972 3318 39.73 2306 1520 51.23 16.26 58.44 441 620 32.58 356 172 45.51 18.29
CRC_Monitoring_82 52 9-Feb-15 3.3 9-Feb-15 Promega 663475 Prevalence Prevalence 95.16 99.13 92.97 1 X X X X X 94.09 92.97 99.13 95.81 93.80 X X X X X 92.71 2348 29882 95.47 1790 37754 94.09 1.95 91.61 1134 12385 94.32 263 4371 92.97 1.92 99.04 752 77671 99.22 828 105374 99.13 0.13 97.43 151 5723 94.19 631 10229 95.81 2.29 94.71 1273 22775 92.88 759 9908 93.80 1.29
CRC_Monitoring_83 50 11-Feb-13 121 28-Mar-13 Promega 58742 Prevalence Prevalence 81.32 98.26 70.83 1 X X X X X 88.43 70.83 98.26 71.49 77.61 X X X X X 80.75 72 302 96.1 81 1994 88.43 10.85 71.64 266 672 70.01 535 1249 70.83 1.15 96.51 845 23345 100 0 763 98.26 2.47 69.62 750 1719 73.36 795 2189 71.49 2.64 78.75 112 415 76.46 101 328 77.61 1.62
CRC_Monitoring_84 77 24-Mar-14 7.5 18-Apr-14 Promega 192325 Prevalence Prevalence 74.94 97.55 52.77 1 X X X X X 80.22 52.77 97.55 76.76 67.42 X X X X X 78.09 5066 18057 82.34 2328 10854 80.22 3.01 48.45 14517 13643 57.08 764 1016 52.77 6.10 97.4 1523 57076 97.7 1865 79330 97.55 0.21 78.18 765 2741 75.33 1924 5876 76.76 2.02 58.45 679 955 76.39 601 1944 67.42 12.69
CRC_Monitoring_136 59 5-Mar-13 3.3 6-Mar-13 Promega 51765 Prevalence Prevalence 1.09 3.79 0.00 1 X X 0.00 3.79 0.01 0.00 1.66 X 0 3797 0 0 5895 0 0.00 0.00 3.72 19330 746 3.85 29148 1167 3.79 0.09 0.02 10889 2 0 12557 0 0.01 0.01 0 70610 0 0 19420 0 0.00 0.00 0 525 0 3.32 1079 37 1.66 2.35
CRC_Monitoring_182 76 4-May-16 2.8 19-May-16 Promega 5981 Prevalence Prevalence 3.11 9.06 0.00 1 X X 6.21 0.06 0.22 9.06 0.00 X X 12.42 395 56 0 1356 0 6.21 8.78 0.09 42220 36 0.03 65697 19 0.06 0.04 0.04 2419 1 0.39 1282 5 0.22 0.25 18.11 3215 711 0 17719 0 9.06 12.81 0 207 0 0.00
CRC_Monitoring_181 44 12-Apr-16 Promega 13540 Prevalence Prevalence 19.79 88.91 0.04 1 X X X 0.06 4.34 0.04 5.63 88.91 X X X 0 330 0 0.11 947 1 0.06 0.08 0.09 24484 23 8.58 14591 1369 4.34 6.00 0 2206 0 0.07 38798 26 0.04 0.05 11.24 4531 574 0.01 7331 1 5.63 7.94 89.31 248 2072 88.5 289 2223 88.91 0.57
CRC_Monitoring_171 65 FOLFOX4-start 1-Jul-13 28-Jun-13 82.9 28-Jun-13 Qiagen 100149 Prevalence Chemotherapy 0 78.41 78.41 95.38 72.22 1 X X X X X 72.22 75.22 95.38 72.87 76.36 X X X X X 38.00 67.1 7543 15413 77.33 1093 3728 72.22 7.23 82.49 1626 7660 67.94 2052 4348 75.22 10.29 98.73 194 15113 92.03 1353 15622 95.38 4.74 82.47 2253 10601 63.26 629 1083 72.87 13.58 84.04 506 2665 68.68 1281 2809 76.36 10.86
CRC_Monitoring_171 65 FOLFOX4-end 1-Mar-14 SD 1-Oct-13 6-Sep-13 6.8 6-Sep-13 Qiagen 15186 longitudinal Chemotherapy 70 0.78 0.78 2.80 0.02 1 X 2.80 0.04 0.02 0.12 0.90 X 0.80 5.2 23828 1317 0.39 258 1 2.80 3.40 0.01 30731 3 0.07 37185 27 0.04 0.04 0.04 5582 2 0 6063 0 0.02 0.03 0.02 37230 6 0.22 445 1 0.12 0.14 1.8 218 4 0 97 0 0.90 1.27
CRC_Monitoring_171 65 Beva-FOLFIRI-start 3-Mar-14 PD 23-Jan-14 13-Dec-13 36 13-Dec-13 Qiagen 53899 longitudinal Chemotherapy 168 57.73 57.73 82.67 45.50 1 X X X X NA 53.30 49.45 82.67 45.50 X X X X NA 32.00 53.3 15080 17205 53.30 49.45 19692 19261 49.45 82.67 567 2704 82.67 45.5 5867 4899 45.50 Exhausted Exhausted Exhausted Exhausted Exhausted Exhausted
CRC_Monitoring_171 65 Beva-FOLFIRI-end 7-May-14 Death 1-Jul-14 1-Mar-14 45 13-Feb-14 Qiagen 237271 longitudinal Chemotherapy 230 74.05 74.05 99.22 55.42 1 X X X X NA 83.30 55.42 99.22 58.24 X X X X NA 38.70 73.1 14366 39116 93.49 2248 32270 83.30 14.42 55.42 7896 9815 55.42 99.22 182 23017 99.22 58.24 266 371 58.24 266 371 58.24 0.00 Exhausted Exhausted Exhausted Exhausted Exhausted Exhausted
CRC_Monitoring_171 65 31-Mar-14 46.4 7-May-14 Qiagen 233542 longitudinal Chemotherapy 313 72.71 72.71 93.61 50.66 1 X X X X X 77.38 71.39 93.61 50.66 70.54 X X X X X 38.40 75.47 3772 11602 79.28 402 1538 77.38 2.69 68.51 8385 18246 74.26 469 1353 71.39 4.07 100 0 4760 87.21 1850 12612 93.61 9.04 53.87 1259 1470 47.44 6333 5716 50.66 4.55 65.89 162 313 75.19 994 3013 70.54 6.58
CRC_Monitoring_171 65 12-Jun-14 99.7
CRC_Monitoring_172 65 FOLFOX4-start 19-Sep-13 19-Sep-13 77.8 19-Sep-13 Qiagen 162360 Prevalence Chemotherapy 0 53.18 53.18 77.34 12.29 1 X X X X X 61.76 39.90 77.34 12.29 74.61 X X X X X 31.85 51.6 7749 8256 71.92 253 648 61.76 14.37 36.25 2924 1663 43.54 769 593 39.90 5.15 67.22 9414 19305 87.45 1286 8960 77.34 14.30 3.67 5541 211 20.91 1702 450 12.29 12.19 64.52 33 60 84.7 671 3714 74.61 14.27
CRC_Monitoring_172 65 FOLFOX4-end 15-Jan-14 Mixted Response 20-Nov-13 9-Dec-13 29.3 20-Dec-13 Qiagen 24222 longitudinal Chemotherapy 92 0.50 0.50 1.50 0.00 1 X X 0.97 1.50 0.00 0.00 0.05 X X 0.30 0.1 18258 21 1.84 480 9 0.97 1.23 0.01 92672 12 2.99 389 12 1.50 2.11 0 7881 0 0 13316 0 0.00 0.00 0 34028 0 0 418 0 0.00 0.00 0.09 3484 3 0 2462 0 0.05 0.06
CRC_Monitoring_172 65 Beva-DeGramont-start 11-Feb-14 PD 1-Jan-14 12-Mar-14 28.1 25-Mar-14 Qiagen 20231 longitudinal Chemotherapy 187 0.42 0.42 1.36 0.00 1 X 1.36 0.52 0.00 0.00 0.20 X 0.00 2.5 30969 806 0.22 906 2 1.36 1.61 1.03 15585 162 0 222 0 0.52 0.73 0 5415 0 0.00 0 37922 0 0 31976 0 0.00 0.00 0.2 509 1 0.20
CRC_Monitoring_172 65 Beva-DeGramont-end 2-Sep-14 PR 20-May-14 20-May-14 20.1 20-May-14 Qiagen 21965 longitudinal Chemotherapy 243 2.71 2.71 9.88 0.02 1 NA X 0.39 0.54 0.02 9.88 NA 3.60 0 10365 1 0.77 258 2 0.39 0.54 0.82 62041 511 0.26 386 1 0.54 0.40 0.03 6900 2 0 522 0 0.02 0.02 0 1073 0 19.76 727 179 9.88 13.97
CRC_Monitoring_172 65 Beva-FOLFIRI-start 27-Oct-14 PD 12-Jan-15 14-Jul-14 23.8 18-Aug-14 Qiagen 11887 longitudinal Chemotherapy 333 24.16 24.16 62.30 1.08 1 X X X X X 10.84 19.65 62.30 1.08 26.94 X X X X X 8.50 0.58 689 4 21.1 3859 1032 10.84 14.51 21.5 522 143 17.79 134 29 19.65 2.62 62.3 1905 3148 62.30 1.89 622 12 0.27 374 1 1.08 1.15 28.99 409 167 24.88 157 52 26.94 2.91
CRC_Monitoring_172 65 Beva-FOLFIRI-end 21-Jan-15 2-Oct-14 29 11-Nov-14 Qiagen 14493 longitudinal Chemotherapy 418 4.20 4.20 17.60 0.00 1 X X 17.60 0.14 0.02 3.24 0.00 X X 3.95 17.6 426 91 17.60 0 709 0 0.28 352 1 0.14 0.20 0 1714 0 0.03 3122 1 0.02 0.02 6.47 1706 118 0 15624 0 3.24 4.57 0 261 0 0 444 0 0.00 0.00
CRC_Monitoring_172 65 Beva-FOLFIRI-start 2-Mar-15 12-Jan-15 20.9 22-Dec-14 Qiagen 9301 longitudinal Chemotherapy 459 1.49 1.49 6.92 0.00 1 X 6.92 0.48 0.02 0.01 0.00 X 0.00 13.83 698 112 0 374 0 6.92 9.78 0 543 0 0.96 311 3 0.48 0.68 0.04 9937 4 0.02 0.01 38423 2 0 379 0 0.01 0.01 0 330 0 Exhausted Exhausted Exhausted 0.00
CRC_Monitoring_172 65 Beva-FOLFIRI-end 11-Aug-15 2-Mar-15 24.6 21-Jan-15 Qiagen 14050 longitudinal Chemotherapy 489 1.77 1.77 8.23 0.00 1 X 0.59 0.05 0.00 0.00 8.23 X 5.55 1.11 356 4 0.07 4056 3 0.59 0.74 0.1 1013 1 0 600 0 0.05 0.07 0 14888 0 0.00 0 785 0 0 719 0 0.00 0.00 8.56 972 91 7.89 642 55 8.23 0.47
CRC_Monitoring_172 65 Palliative 12-Aug-15 7-Apr-15 45.8 23-Mar-15 Qiagen 26548 longitudinal Chemotherapy 550 29.51 29.51 53.99 2.07 1 X X X X X 29.81 29.70 31.98 2.07 53.99 X X X X X 21.50 39.77 206 136 19.85 105 26 29.81 14.09 28.76 1090 440 30.64 9433 4168 29.70 1.33 35.9 923 517 28.06 364 142 31.98 5.54 0.46 1505 7 3.68 602 23 2.07 2.28 53.7 419 486 54.27 477 566 53.99 0.40
CRC_Monitoring_172 65 29-Jun-15 97.5 15-Jun-15 Qiagen 29845 longitudinal Chemotherapy 634 20.73 20.73 54.52 0.00 1 X X X 14.78 54.52 0.00 0.01 34.32 X X X 13.00 6.91 310 23 22.64 1473 431 14.78 11.12 54.78 7272 8810 54.26 693 822 54.52 0.37 0 5849 0 0.00 0.01 72691 7 0 1283 0 0.01 0.01 39.26 2013 1301 29.38 125 52 34.32 6.99
CRC_Monitoring_172 65 15-Jul-15 Qiagen 22107 longitudinal Chemotherapy 664 42.02 42.02 97.02 8.06 1 X X X X X 24.29 25.27 97.02 8.06 55.46 X X X X X 24.00 21.69 491 136 26.88 710 261 24.29 3.67 27.17 2480 925 23.36 817 249 25.27 2.69 94.16 419 6759 99.87 18 14102 97.02 4.04 10.56 1126 133 5.56 730 43 8.06 3.54 67.84 805 1698 43.08 2748 2080 55.46 17.51
CRC_Monitoring_173 16-Sep-13 2.3 2-Oct-13 Qiagen 37908 Prevalence Chemotherapy 0 2.56 1.02 2.99 0.00 1 X X 0.00 0.01 2.12 0.00 2.99 X X 0 9823 2 0.00 0.02 25664 5 0 76461 3 0.01 0.01 4.17 17938 780 0.06 4840 3 2.12 2.91 0 23695 0 0 19392 0 0.00 0.00 2.97 1634 50 3 2655 82 2.99 0.02
CRC_Monitoring_174 24-Oct-13 49.8 10-Feb-14 Qiagen 9661 Prevalence Chemotherapy 0 0.04 0.14 0.00 0 0.00 0.05 0.02 0.00 0.14 0 7084 0 0.00 0.05 10265 5 0.05 0.04 2522 1 0.02 0 15192 0 0.00 0.28 353 1 0 168 0 0.14 0.20
CRC_Monitoring_175 67 29-Apr-14 79 29-Apr-14 Qiagen 341927 Prevalence Chemotherapy 0 52.28 52.28 87.17 0.78 1 X X X X X 53.60 48.01 87.17 0.78 71.84 X X X X X 52.50 53.6 6682 7724 53.60 48.01 1373 1268 48.01 82.24 3645 16879 92.09 1554 18090 87.17 6.97 0.78 16951 133 0.78 63.2 913 1568 80.48 644 2655 71.84 12.22
CRC_Monitoring_176 45 FOLFIRI-start 14-May-14 26-May-14 518 12-May-14 Qiagen 7014008 Prevalence Chemotherapy 0 95.50 95.50 97.75 93.45 1 X X X X X 93.86 93.45 97.75 96.70 95.76 X X X X X 72.00 92.2 6598 78365 95.51 1628 34624 93.86 2.34 90.59 326 3139 96.31 3042 79344 93.45 4.04 98.81 520 43205 96.68 4567 132864 97.75 1.51 96.4 295 7895 96.99 52 1677 96.70 0.42 95.56 1191 25631 95.95 889 21066 95.76 0.28
CRC_Monitoring_176 45 FOLFIRI-end 17-Jul-14 Mixed Response 25-Jun-14 9-Jun-14 Qiagen 84081 longitudinal Chemotherapy 28 44.82 44.82 80.92 2.00 1 X X X X X 77.80 2.00 80.92 29.67 33.70 X X X X X 36.50 73.49 1600 4436 82.1 97 445 77.80 6.09 1.11 2666 30 2.88 439 13 2.00 1.25 87.21 188 1282 74.63 1431 4209 80.92 8.90 21.56 12279 3375 37.78 359 218 29.67 11.47 44.04 6771 5328 23.35 325 99 33.70 14.63
CRC_Monitoring_176 45 PD 9-Jul-14 26-Jun-14 308 25-Jun-14 Qiagen 58684 longitudinal Chemotherapy 44 44.10 44.10 66.24 21.70 1 X X X X X 52.39 21.70 66.24 53.42 26.74 X X X X X 30.00 44.8 548 445 59.97 15343 22989 52.39 10.73 11.66 23340 3081 31.74 243 113 21.70 14.20 66.24 973 1909 66.24 55.48 2824 3519 51.36 303 320 53.42 2.91 17.86 3007 654 35.62 188 104 26.74 12.56
CRC_Monitoring_176 45 Death 1-Aug-14 9-Jul-14 Qiagen 397544 longitudinal Chemotherapy 58 77.41 77.41 93.62 66.84 1 X X X X X 66.84 74.21 93.62 76.41 75.99 X X X X X 56.80 69.5 650 1484 64.18 792 1419 66.84 3.76 74.32 6626 19172 74.09 277 792 74.21 0.16 93.62 1147 16841 93.62 84.2 2278 12143 68.61 1172 2562 76.41 11.02 70.46 2034 4852 81.52 216 953 75.99 7.82
CRC_Monitoring_177 77 Beva-FOLFIRI-start 13-May-14 13-May-14 455 13-May-14 Qiagen 29728 Prevalence Chemotherapy 0 37.84 30.30 66.44 0.12 1 X X X X 66.44 33.56 0.12 35.90 15.48 X X X X 53.00 66.43841 8822 17464 66.44 24.16 656 209 42.95 6921 5210 33.56 13.29 0.12 4038 5 0.12 36.91 4787 2800 34.88 323 173 35.90 1.44 14.97 1642 289 15.99 394 75 15.48 0.72
CRC_Monitoring_177 77 Beva-FOLFIRI-end 15-Jul-14 SD dimensional / PD clinic 6-Aug-14 27-May-14 Qiagen 30848 longitudinal Chemotherapy 14 20.92 16.12 62.70 0.01 1 X X NA 62.70 0.05 1.71 0.01 X NA 9.50 62.70136 1204 2024 62.70 0.05 72376 35 0.05 3.41 170 6 0 821 0 1.71 2.41 0.01 43835 3 0.01 Exhausted Exhausted Exhausted Exhausted Exhausted Exhausted
CRC_Monitoring_177 77 Palliative 16-Jul-14 10-Jun-14 362.4 10-Jun-14 Qiagen 27968 longitudinal Chemotherapy 28 8.04 6.50 13.69 0.11 1 X X X 10.79 7.59 0.30 13.69 0.11 X X X 2.70 21.09431 3288 879 0.49 203 1 10.79 14.57 0.03 154612 41 15.15 3887 694 7.59 10.69 0.57 2286 13 0.02 6092 1 0.30 0.39 15.23 13633 2450 12.14 9781 1351 13.69 2.18 0.22 1375 3 0 270 0 0.11 0.16
CRC_Monitoring_177 77 25-Jun-14 Qiagen 42135 longitudinal Chemotherapy 43 8.86 26.16 95.35 0.03 1 X X X X 21.68 0.03 95.35 6.47 7.26 X X X X 28.50 27.72 3582 1374 15.63 286 53 21.68 8.55 0.01 172170 22 0.05 22349 12 0.03 0.03 94.46 267 4551 96.24 719 18406 95.35 1.26 4.61 1489 72 8.33 22715 2064 6.47 2.63 7.26 281 22 Exhausted Exhausted Exhausted 7.26
CRC_Monitoring_177 77 15-Jul-14 1070 15-Jul-14 Qiagen 36197 longitudinal Chemotherapy 63 34.44 33.62 57.77 8.73 1 X X X X X 43.30 57.77 30.34 27.94 8.73 X X X X X 36.75 50.34 3728 3779 36.26 3916 2228 43.30 9.96 60.82 7894 12256 54.72 259 313 57.77 4.31 24.71 4995 1639 35.96 1115 626 30.34 7.95 25.72 2585 895 30.16 5106 2205 27.94 3.14 7.02 1352 102 10.43 206 24 8.73 2.41
CRC_Monitoring_177 77 6-Aug-14 3278 19-Aug-14 Qiagen 7881452 longitudinal Chemotherapy 98 29.75 36.38 62.89 2.22 1 X X X X X 51.12 20.80 62.89 44.88 2.22 X X X X X 39.73 45.29639 15753 13044 56.95 10346 13684 51.12 8.24 20.27 20204 5137 21.32 8597 2330 20.80 0.74 60.64 5006 7714 65.13 8526 15922 62.89 3.17 35.12 3732 2020 54.64 7706 9282 44.88 13.80 1.82 2862 53 2.61 4658 125 2.22 0.56
CRC_Monitoring_178 62 Beva-FOLFOX-start 2-Jul-13 2-Jul-13 527 2-Jul-13 Qiagen 95599 Prevalence Chemotherapy 0 43.64 43.64 64.39 15.39 1 X X X X X 51.20 39.51 64.39 47.73 15.39 X X X X X 32.50 51.2 22127 23204 51.20 49.84 1730 1719 29.18 301 124 39.51 14.61 64.39 5555 10045 64.39 47.73 2966 2708 47.73 21.01 109 29 9.77 314 34 15.39 7.95
CRC_Monitoring_178 62 Beva-FOLFOX-end 18-Dec-13 PR 1-Sep-13 10-Sep-13 14.9 10-Sep-13 Qiagen 9759 longitudinal Chemotherapy 70 0.03 0.03 0.15 0.00 0 0.00 0.15 0.00 0.01 0.00 0.00 0 8750 1 0.00 0.01 155799 19 0.29 1034 3 0.15 0.20 0 663 0 0 6817 0 0.00 0.00 0.01 14829 1 0 536 0 0.01 0.01 0 190 0 0 1311 0 0.00 0.00
CRC_Monitoring_178 62 FOLFIRI-start 4-Feb-14 PD 1-Jan-14 9-Dec-13 81.5 14-Jan-14 Qiagen 47443 longitudinal Chemotherapy 196 24.52 24.52 39.78 12.46 1 X X X X X 29.34 25.76 15.28 12.46 39.78 X X X X X 25.95 29.1 12283 5034 29.58 4636 1947 29.34 0.34 21.75 20169 5607 29.77 17263 7316 25.76 5.67 6.25 30 2 24.3 2782 893 15.28 12.76 5.43 61820 3551 19.48 24555 5941 12.46 9.93 34.64 417 221 44.91 395 322 39.78 7.26
CRC_Monitoring_178 62 FOLFIRI-end 2-Apr-14 3-Feb-14 791 14-Apr-14 Qiagen 38313 longitudinal Chemotherapy 286 64.44 64.44 78.94 49.17 1 X X X X X 49.17 78.94 63.37 72.18 58.53 X X X X X 42.50 46.7 8162 7158 51.63 357 381 49.17 3.49 78.47 5173 18852 79.4 296 1141 78.94 0.66 59.43 6543 9584 67.3 5701 11732 63.37 5.56 70.21 6193 14595 74.15 3178 9116 72.18 2.79 56.65 388 507 60.4 40 61 58.53 2.65
CRC_Monitoring_178 62 18-Mar-14 878
CRC_Monitoring_178 62 31-Mar-14 1197
CRC_Monitoring_179 54 3-Jul-13 Qiagen 21720 Prevalence Chemotherapy 0 1.58 9.99 48.35 0.00 1 X X 0.00 1.58 0.01 0.01 48.35 X 0 22051 1 0.00 2.76 21539 612 0.4 251 1 1.58 1.67 0.01 13529 1 0.01 0.01 19317 1 0.01 Exhausted Exhausted Exhausted 48.35 376 352 48.35
CRC_Monitoring_180 68 Beva-FOLFOX-start 23-Jul-13 15-Jul-13 28.9 15-Jul-13 Qiagen 69420 Prevalence Chemotherapy 0 59.93 59.93 76.80 41.67 1 X X X X X 76.80 42.69 41.67 74.96 63.53 X X X X X 35.50 78.2 4475 16058 75.39 1251 3832 76.80 1.99 50.01 2821 2822 35.37 254 139 42.69 10.35 46.55 13812 12029 36.78 9691 5638 41.67 6.91 67.05 2103 4279 82.87 142 687 74.96 11.19 66.67 146 292 60.38 891 1358 63.53 4.45
CRC_Monitoring_180 68 Beva-FOLFOX-end 5-Mar-14 PR 1-May-14 9-Oct-13 7.3 21-Oct-13 Qiagen 23076 longitudinal Chemotherapy 98 1.34 1.34 3.01 0.00 1 X X 0.70 3.01 0.00 2.96 0.04 X X 0.00 1.4 63029 884 0 255 0 0.70 0.99 5.62 21912 1306 0.39 511 2 3.01 3.70 0 2925 0 0 10660 0 0.00 0.00 5.91 58079 3647 0 23624 0 2.96 4.18 0 2350 0 0.08 1176 1 0.04 0.06
CRC_Monitoring_180 68 Beva-DeGramont-start 1-Apr-14 PD 1-Sep-14 30-Dec-13 4.5 3-Feb-14 Qiagen 52987 longitudinal Chemotherapy 203 0.50 0.50 2.34 0.00 1 X 0.00 0.11 0.04 2.34 0.00 X 0.00 0 20286 0 0 6844 0 0.00 0.00 0.22 40402 88 0 1363 0 0.11 0.16 0 1120 0 0.08 9879 8 0.04 0.06 4.15 2240 97 0.52 383 2 2.34 2.57 0 222 0 0 1909 0 0.00 0.00
CRC_Monitoring_180 68 Beva-DeGramont-end 27-May-14 15-Feb-14 4.7 12-May-14 Qiagen 26961 longitudinal Chemotherapy 301 11.11 11.11 41.79 0.03 1 X X 0.12 0.03 0.03 41.79 13.57 X X 8.90 0 759 0 0.24 834 2 0.12 0.17 0.02 55026 13 0.03 32741 9 0.03 0.01 0.06 1754 1 0.03 39.39 5451 3543 44.19 1964 1555 41.79 3.39 21.43 264 72 5.7 496 30 13.57 11.12
CRC_Monitoring_180 68 FOLFIRI-start 16-Sep-14 28-May-14 4.9 3-Jul-14 Qiagen 38802 longitudinal Chemotherapy 353 39.15 39.15 75.20 13.75 1 X X X X X 23.70 13.75 59.67 75.20 23.44 X X X X X 24.90 23.74 845 263 23.65 2089 647 23.70 0.06 17.35 1210 254 10.14 1134 128 13.75 5.10 73.35 3835 10557 45.99 25872 22032 59.67 19.35 78.56 7145 26184 71.83 5605 14291 75.20 4.76 21.88 4198 1176 25 357 119 23.44 2.21
CRC_Monitoring_180 68 FOLFIRI-end 13-May-15 29-Oct-14 5.1 15-Sep-14 Qiagen 13961 longitudinal Chemotherapy 427 10.63 10.63 30.30 0.02 1 X X X 0.63 15.17 0.02 7.05 30.30 X X X 4.50 0.27 3330 9 0.98 303 3 0.63 0.50 13.39 485 75 16.94 201 41 15.17 2.51 0 10420 0 0.03 7542 2 0.02 0.02 6.04 8978 577 8.05 274 24 7.05 1.42 27.27 104 39 33.33 174 87 30.30 4.29
CRC_Monitoring_140 68 Beva-FOLFOX-start 3-Jun-16 SD 6-Sep-16 1-Jun-16 75.8 1-Jun-16 Promega 101355 Prevalence Chemotherapy 0 81.80 65.46 96.53 0.09 1 X X X X 78.19 85.25 96.53 67.25 0.09 X X X X 63.57 75.01 1143 3430 81.37 1034 4517 78.19 4.50 83.28 2212 11015 87.21 5161 35182 85.25 2.78 94.23 714 11651 98.82 1204 100762 96.53 3.25 67.19 1458 2986 67.3 5058 10411 67.25 0.08 0 250 0 0.17 603 1 0.09 0.12
CRC_Monitoring_140 68 21-Jun-16 Promega 44388 longitudinal Chemotherapy 20 51.87 41.51 67.95 0.10 1 X X X X 40.79 55.19 67.95 43.55 0.10 X X X X 39.00 44.53 2443 1961 37.04 476 280 40.79 5.30 54.74 8323 10067 55.63 2906 3643 55.19 0.63 77.52 294 1014 58.37 495 694 67.95 13.54 41.97 7130 5156 45.12 2504 2059 43.55 2.23 0 2303 0 0.2 2005 4 0.10 0.14
CRC_Monitoring_140 68 18-Jul-16 Promega 45691 longitudinal Chemotherapy 47 1.66 1.78 2.32 1.09 1 X X X X X 1.70 2.32 1.54 1.09 2.23 X X X X X 2.33 3.34 636 22 0.06 3387 2 1.70 2.32 3.81 17540 695 0.83 19868 167 2.32 2.11 0 28402 0 3.08 15718 499 1.54 2.18 0.46 22905 107 1.72 7650 134 1.09 0.89 2.56 912 24 1.9 2484 48 2.23 0.47
CRC_Monitoring_140 68 21-Jun-16 149 1-Aug-16 Promega 24586 longitudinal Chemotherapy 61 0.93 12.69 59.73 0.01 1 X X X 2.45 0.56 0.01 0.71 59.73 X X X 0.90 4.89 993 51 0 1621 0 2.45 3.46 1.07 38130 413 0.04 25456 11 0.56 0.73 0.01 36621 2 0 70891 0 0.01 0.01 1.42 12173 175 0 10489 0 0.71 1.00 63.43 839 1455 56.02 1311 1670 59.73 5.24
CRC_Monitoring_140 68 25-Oct-16 56 17-Aug-16 Promega 44081 longitudinal Chemotherapy 77 0.56 0.88 2.20 0.00 1 X X 0.00 1.77 0.33 0.12 2.20 X X 0.33 0 5899 0 0 574 0 0.00 0.00 2.34 40859 980 1.2 28265 342 1.77 0.81 0.65 6748 44 0.01 68854 9 0.33 0.45 0 30629 0 0.24 9437 23 0.12 0.17 0.57 1038 6 3.82 252 10 2.20 2.30
CRC_Monitoring_140 68 30-Aug-16 Promega 42876 longitudinal Chemotherapy 90 0.12 0.39 1.43 0.00 1 X 0.00 0.49 0.00 0.01 1.43 X 0.00 0 7158 0 0.00 0.52 34059 179 0.46 31413 145 0.49 0.04 0 32004 0 0 66683 0 0.00 0.00 0 26507 1 0.01 9743 1 0.01 0.01 1.1 719 8 1.75 1456 26 1.43 0.46
CRC_Monitoring_141 62 Beva-FOLFOX-start 13-May-16 PR 19-Jul-16 11-May-16 56.3 19-Apr-16 Promega 20210 Prevalence Chemotherapy 0 78.24 78.24 97.78 52.36 1 X X X X X 97.78 62.77 94.89 52.36 83.41 X X X X X 32.33 99.93 5 7162 95.62 39 852 97.78 3.05 61.49 3174 5068 64.04 2060 3668 62.77 1.80 91.85 418 4713 97.93 410 19410 94.89 4.30 62.04 2189 3577 42.68 2071 1542 52.36 13.69 85.83 102 618 80.98 113 481 83.41 3.43
CRC_Monitoring_141 62 PR 1-Sep-16 4-Jul-16 Promega 44711 longitudinal Chemotherapy 76 0.02 0.02 0.05 0.00 0 0.00 0.05 0.05 0.02 0.00 0.70 0 4068 0 0 1356 0 0.00 0.00 0.08 87043 71 0.02 28167 6 0.05 0.04 0.01 11494 1 0.09 10398 9 0.05 0.06 0.03 17821 5 0 9498 0 0.02 0.02 0 6474 0 0 202 0 0.00 0.00
CRC_Monitoring_141 62 19-Jul-16 Promega 47809 longitudinal Chemotherapy 91 0.60 0.60 2.39 0.04 1 X X 0.20 0.14 0.04 0.26 2.39 X X 0.00 0.03 3400 1 0.36 274 1 0.20 0.23 0.26 60543 160 0.01 50756 5 0.14 0.18 0 9975 0 0.07 18280 12 0.04 0.05 0 24300 0 0.51 22325 114 0.26 0.36 2.98 4824 148 1.8 3212 59 2.39 0.83
CRC_Monitoring_141 62 2-Aug-16 Promega 33231 longitudinal Chemotherapy 105 0.16 0.16 0.71 0.00 1 X 0.04 0.04 0.00 0.71 0.00 X 0.23 0 3521 0 0.07 9501 7 0.04 0.05 0.04 43843 19 0.03 38613 11 0.04 0.01 0 6157 0 0 18555 0 0.00 0.00 0 1292 0 1.41 4465 64 0.71 1.00 0 6313 0 0 298 0 0.00 0.00
CRC_Monitoring_141 62 16-Aug-16 Promega 15860 longitudinal Chemotherapy 119 0.05 0.05 0.13 0.00 0 0.00 0.13 0.05 0.00 0.09 0.00 0 2023 0 0 2325 0 0.00 0.00 0.05 47600 24 0.21 17945 37 0.13 0.11 0.1 33878 33 0 77199 1 0.05 0.07 0 11765 0 0 6438 0 0.00 0.00 0.09 1056 1 0.08 1200 1 0.09 0.01
CRC_Monitoring_141 62 29-Aug-16 Promega 27284 longitudinal Chemotherapy 132 0.71 0.71 3.14 0.00 1 X 0.06 3.14 0.15 0.20 0.00 X 0.00 0 5250 0 0.11 947 1 0.06 0.08 4.09 23647 1009 2.19 15415 345 3.14 1.34 0.29 24734 73 0 67549 2 0.15 0.21 0.01 16959 1 0.38 11574 44 0.20 0.26 0 2087 0 0 2952 0 0.00 0.00
CRC_Monitoring_133 46 Panitumumab - start 11-Jul-13 PR 10-Jan-14 11-Jul-13 3321 11-Jul-13 Promega 133064 Prevalence EGFRi 0 38.46 30.85 83.65 0.41 1 X X X X 45.20 1.03 0.41 83.65 23.98 X X X X 16.11 2.00 36.96 1501 880 53.44 1738 1995 45.20 11.65 2.05 85370 1787 0.01 65089 8 1.03 1.44 0.05 23656 13 0.76 28540 219 0.41 0.50 88.71 1021 8024 78.58 2623 9624 83.65 7.16 22.81 3198 945 25.14 13746 4616 23.98 1.65
CRC_Monitoring_133 46 Panitumumab - end 11-Apr-14 PD 11-Apr-14 26-Jul-13 Qiagen 23597 longitudinal EGFRi 15 2.27 1.94 9.03 0.00 1 X 0.00 0.06 0.62 0.00 9.03 X 6.60 1.75 0 5349 0 0 17708 0 0.00 0.00 0.07 27338 19 0.05 61721 29 0.06 0.01 1.17 1950 23 0.06 3290 2 0.62 0.78 0 87185 0 0 13523 0 0.00 0.00 9.03 443 44 9.03
CRC_Monitoring_133 46 20-Aug-13 Qiagen 22726 longitudinal EGFRi 40 1.46 1.17 5.75 0.00 1 X 0.00 0.07 0.01 0.00 5.75 X 3.42 1.90 0 4136 0 0 1976 0 0.00 0.00 0.12 12904 15 0.02 22751 5 0.07 0.07 0.01 17027 1 0 9277 0 0.01 0.01 0 104889 0 0 3569 0 0.00 0.00 11.49 231 30 0 1591 0 5.75 8.12
CRC_Monitoring_133 46 3-Sep-13 Qiagen 24621 longitudinal EGFRi 54 0.05 0.04 0.19 0.00 0 0.00 0.19 0.00 0.00 0.00 3.15 1.45 0 268 0 0 162 0 0.00 0.00 0.35 15036 53 0.03 48729 17 0.19 0.23 0 1121 0 0 12405 0 0.00 0.00 0 99760 0 0 62926 0 0.00 0.00 0 322 0 0.00
CRC_Monitoring_133 46 3-Oct-13 Promega 12837 longitudinal EGFRi 84 0.36 0.32 1.33 0.00 1 X 0.00 0.09 0.20 0.01 1.33 X 0.82 1.80 0 3256 0 0 508 0 0.00 0.00 0.12 28792 34 0.05 27476 13 0.09 0.05 0 335 0 0.39 766 3 0.20 0.28 0 8991 0 0.01 18062 1 0.01 0.01 1.07 4236 46 1.58 1246 20 1.33 0.36
CRC_Monitoring_133 46 30-Dec-13 71 16-Jan-14 Promega 24798 longitudinal EGFRi 189 28.73 22.99 76.79 0.00 1 X X X X 4.68 8.41 0.00 76.79 25.06 X X X X 34.80 2.60 9.36 1182 122 0 4114 0 4.68 6.62 16.63 56912 11355 0.18 83262 150 8.41 11.63 0 2267 0 0 378 0 0.00 0.00 69.25 2394 5391 84.32 2747 14775 76.79 10.66 26.04 693 244 24.07 4007 1270 25.06 1.39
CRC_Monitoring_133 46 3-Apr-14 Promega 2532635 longitudinal EGFRi 266 50.31 40.46 90.00 0.06 1 X X X X 80.86 0.06 1.09 90.00 30.32 X X X X 83.99 5.00 72.46 1314 3458 89.26 363 3018 80.86 11.88 0.07 20274 14 0.04 84364 34 0.06 0.02 0.91 8692 80 1.26 76764 982 1.09 0.25 91.15 1297 13354 88.84 1619 12893 90.00 1.63 30.54 2220 976 30.09 3552 1529 30.32 0.32
CRC_Monitoring_134 53 Panitumumab - start 5-Nov-13 PR 12-Apr-12 16-Feb-12 8828 16-Feb-12 Promega 2400999 Prevalence EGFRi 0 87.13 87.13 97.41 69.75 1 X X X X X 93.25 69.75 97.41 91.33 83.93 X X X X X 65.00 0.00 0.00 0.00 0.00 0.00 0.00 93.14 822 11164 93.35 1000 14033 93.25 0.15 71.71 12544 31802 67.79 3555 7482 69.75 2.77 96.91 741 23213 97.91 586 27433 97.41 0.71 89.78 915 8037 92.88 1743 22746 91.33 2.19 78.27 151 544 89.59 2094 18015 83.93 8.00
CRC_Monitoring_134 53 Panitumumab - end 20-Mar-14 PD 14-Sep-12 15-Mar-12 Qiagen 176978 longitudinal EGFRi 28 0.88 0.88 3.76 0.00 1 X 0.38 3.76 0.10 0.00 0.14 X 0.25 0.00 0.01 0.00 0.00 0.00 0.00 0 2540 0 0.75 4907 37 0.38 0.53 7.49 11442 927 0.02 56761 13 3.76 5.28 0.2 3908 8 0 19494 0 0.10 0.14 0 62819 0 0 75097 0 0.00 0.00 0.09 1114 1 0.18 2202 4 0.14 0.06
CRC_Monitoring_134 53 Irinotecan - start 1-Sep-14 29-Mar-12 360 12-Apr-12 Promega 177880 longitudinal EGFRi 56 0.65 0.65 2.24 0.00 1 X 0.08 2.24 0.00 0.01 0.90 X 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.11 869 1 0.04 2758 1 0.08 0.05 0.11 92253 103 4.37 24286 1111 2.24 3.01 0 3822 0 0 277 0 0.00 0.00 0.01 71926 8 0 17929 0 0.01 0.01 1.8 1584 29 0 154 0 0.90 1.27
CRC_Monitoring_134 53 21-Jun-12 Qiagen 334573 longitudinal EGFRi 126 0.80 0.80 1.87 0.00 1 X X X 1.87 0.71 0.27 0.00 1.14 X X 0.32 0.00 0.00 0.00 0.00 0.00 0.00 0.71 13648 98 3.02 8359 260 1.87 1.63 1.4 27876 397 0.02 64136 12 0.71 0.98 0.04 39420 17 0.5 47079 235 0.27 0.33 0 75039 0 0 45485 0 0.00 0.00 0.09 2193 2 2.19 4373 98 1.14 1.48
CRC_Monitoring_134 53 5-Jul-12 Promega 24850 longitudinal EGFRi 140 6.47 6.47 14.66 0.25 1 X X X X 0.59 14.66 8.82 0.25 8.03 X X X X 2.34 0.17 1.26 0.57 0.08 0.00 0.00 0.59 3551 21 0.59 29.22 4601 1899 0.09 19217 17 14.66 20.60 6.41 21841 1496 11.23 9188 1162 8.82 3.41 0.01 48638 4 0.48 12272 59 0.25 0.33 8.03 859 75 8.03
CRC_Monitoring_134 53 2-Aug-12 Promega 200639 longitudinal EGFRi 168 57.07 57.07 89.54 11.04 1 X X X X X 86.89 11.04 89.54 26.57 71.32 X X X X X 9.08 0.42 0.46 0.00 0.00 0.00 0.00 84.29 229 1229 89.49 966 8228 86.89 3.68 16.25 22740 4413 5.82 21911 1355 11.04 7.38 81.65 476 2118 97.43 98 3717 89.54 11.16 24.53 5496 1786 28.61 8449 3386 26.57 2.88 64.95 238 441 77.68 6529 22726 71.32 9.00
CRC_Monitoring_134 53 16-Aug-12 Qiagen 196545 longitudinal EGFRi 182 54.54 54.54 75.11 35.47 1 X X X X X 75.11 35.47 72.05 49.39 40.68 X X X X X 4.27 0.46 1.21 0.41 0.26 0.25 0.04 66.09 2744 5348 84.12 3580 18967 75.11 12.75 40.23 9908 6670 30.71 15748 6981 35.47 6.73 78.41 209 759 65.69 7372 14117 72.05 8.99 56.48 6590 8552 42.29 4506 3302 49.39 10.03 45.86 784 664 35.5 7790 4288 40.68 7.33
CRC_Monitoring_134 53 31-Aug-12 Qiagen 414699 longitudinal EGFRi 197 55.77 55.77 83.57 43.14 1 X X X X X 47.83 43.98 83.57 60.34 43.14 X X X X X 20.20 0.09 0.84 0.25 0.00 0.00 0.00 44.4 6427 5132 51.25 5734 6028 47.83 4.84 45.96 4256 3620 41.99 5635 4079 43.98 2.81 81.8 5160 23196 85.34 4197 24426 83.57 2.50 56.78 7455 9793 63.89 7418 13122 60.34 5.03 36.84 1010 589 49.44 3358 3283 43.14 8.91
CRC_Monitoring_134 53 14-Sep-12 Promega 324263 longitudinal EGFRi 211 52.78 52.78 83.12 26.42 1 X X X X X 52.54 26.42 83.12 56.61 45.23 X X X X X 12.40 0.13 0.28 0.40 0.00 0.00 0.00 58.65 2397 3400 46.42 4272 3701 52.54 8.65 32.39 25177 12063 20.44 11305 2904 26.42 8.45 82.03 858 3917 84.2 582 3102 83.12 1.53 60.31 5509 8371 52.91 5714 6419 56.61 5.23 50.66 634 651 39.79 7760 5129 45.23 7.69
CRC_Monitoring_135 70 Panitumumab - start 2-Aug-11 SD 17-Aug-11 29-Jul-11 39.3 29-Jul-11 Qiagen 11590 Prevalence EGFRi 0 48.81 39.05 59.04 0.00 1 X X X X 0.00 28.04 58.31 49.86 59.04 X X X X 2.01 0 14438 0 0 286 0 0.00 0.00 34.97 4423 2378 21.1 9837 2631 28.04 9.81 58.31 9467 13239 58.31 49.86 1230 1223 49.86 59.04 111 160 59.04
CRC_Monitoring_135 70 SD 28-Sep-11 17-Aug-11 Qiagen 7866 longitudinal EGFRi 19 2.28 2.14 8.90 0.00 1 X X 1.57 0.21 0.00 0.01 8.90 X X 0.19 3.07 5055 160 0.07 9501 7 1.57 2.12 0.33 62798 206 0.09 47929 43 0.21 0.17 0 2571 0 0 491 0 0.00 0.00 0.01 15643 1 0.01 7170 1 0.01 0.00 17.75 417 90 0.05 2166 1 8.90 12.52
CRC_Monitoring_135 70 PD 6-Dec-11 28-Sep-11 Qiagen 22098 longitudinal EGFRi 61 0.79 0.68 3.03 0.00 1 X 0.23 0.04 0.00 3.03 0.08 X 0.10 0.1 2870 3 0.36 274 1 0.23 0.18 0.03 75132 21 0.05 34774 17 0.04 0.01 0 5722 0 0 834 0 0.00 0.00 6.06 16419 1059 0 4662 0 3.03 4.29 0 792 0 0.16 627 1 0.08 0.11
CRC_Monitoring_135 70 11-Oct-11 Qiagen 12698 longitudinal EGFRi 74 1.76 1.47 7.02 0.00 1 X 0.31 0.03 0.01 7.02 0.00 X 0.25 0.31 639 2 0.31 0.02 8343 2 0.04 25752 11 0.03 0.01 0.01 8998 1 0 6808 0 0.01 0.01 14.03 13954 2278 0 7668 0 7.02 9.92 0 551 0 0 122 0 0.00 0.00
CRC_Monitoring_135 70 6-Dec-11 Qiagen 14734 longitudinal EGFRi 130 25.77 25.77 43.17 0.00 1 NA X X X 29.79 0.00 43.17 30.12 NA X X X 3.46 28.41 9719 3856 31.17 10369 4695 29.79 1.95 0 3400 0 0 634 0 0.00 0.00 56.17 4147 5315 30.16 4991 2155 43.17 18.39 32.26 147 70 27.98 888 345 30.12 3.03
CRC_Monitoring_135 71 6-Feb-12 Qiagen 13984 longitudinal EGFRi 192 73.11 72.29 100.00 54.53 1 X X X X X 69.00 54.53 100.00 76.20 61.72 X X X X X 60.91 464 723 77.08 5794 19485 69.00 11.43 43.43277 2541 1951 65.62 1626 3104 54.53 15.69 100 1 31884 100 0 351 100.00 0.00 76.2 775 2481 76.2 76.20 0.00 60.65 205 316 62.78 329 555 61.72 1.51
CRC_Monitoring_137 46 23-Jul-10 1.3 23-Jul-10 Promega 28860 Prevalence EGFRi 0 0.02 0.06 0.00 0 0.00 0.06 0.05 0.00 0.00 0 748 0 0 261 0 0.00 0.00 0.07 8355 6 0.04 42023 16 0.06 0.02 0 4605 0 0.09 14878 13 0.05 0.06 0 72299 0 0 3146 0 0.00 0.00 0 1107 0 0 105 0 0.00 0.00
CRC_Monitoring_138 83 Panitumumab - start 2-May-13 16-May-13 60.4 30-Apr-13 Promega 80205 Prevalence EGFRi 0 1.96 1.26 2.79 0.00 1 X X X 0.42 2.79 0.75 0.00 2.34 X X X 0.00 0.81 18447 150 0.03 7116 2 0.42 0.55 1.7 22211 385 3.87 26507 1067 2.79 1.53 0 84444 1 1.49 16673 253 0.75 1.05 0 56559 0 0 47577 1 0.00 0.00 2.71 12171 339 1.96 1598 32 2.34 0.53
CRC_Monitoring_138 83 Panitumumab - end 28-Oct-13 PD 28-Oct-13 19-Jul-13 Qiagen 51181 longitudinal EGFRi 80 6.50 4.04 9.78 0.00 1 X X X 0.34 9.78 0.00 0.36 9.71 X X X 0.20 0 3235 0 0.67 7269 49 0.34 0.47 18.77 9403 2173 0.78 34141 268 9.78 12.72 0 29656 0 0 8715 0 0.00 0.00 0.71 8583 61 0 30095 0 0.36 0.50 11.4 793 102 8.01 517 45 9.71 2.40
CRC_Monitoring_138 83 Irinotecan - start 4-Jan-14 18-Oct-13 29.7 6-Nov-13 Promega 1012589 longitudinal EGFRi 190 9.84 6.47 18.33 0.00 1 X X X X 0.00 4.24 6.96 2.83 18.33 X X X X 7.30 0 1119 0 0 1678 0 0.00 0.00 6 23738 1516 2.47 34418 871 4.24 2.50 6.61 26596 1883 7.31 9003 710 6.96 0.49 2.68 14359 396 2.98 30067 922 2.83 0.21 29.89 617 263 6.77 2714 197 18.33 16.35
CRC_Monitoring_138 83 14-Jan-14 Promega 489943 longitudinal EGFRi 259 39.62 37.47 50.24 20.20 1 X X X X X 41.94 20.20 50.24 26.58 48.41 X X X X X 3.60 40.24 597 402 43.63 9628 7451 41.94 2.40 23.78 10863 3390 16.62 8701 1734 20.20 5.06 39.89 11969 7944 60.59 12904 19841 50.24 14.64 20.86 6007 1583 32.3 9956 4749 26.58 8.09 46.26 906 780 50.56 351 359 48.41 3.04
CRC_Monitoring_138 83 29-Jan-14 Promega 449804 longitudinal EGFRi 274 11.15 14.57 25.72 7.80 1 X X X X X 25.72 7.80 8.34 13.67 17.32 X X X X X 1.60 27.85 2660 1027 23.58 5964 1840 25.72 3.02 6.24 21203 1412 9.36 16959 1752 7.80 2.21 13.73 9007 1433 2.95 4316 131 8.34 7.62 12.83 5338 786 14.5 12439 2110 13.67 1.18 14.17 1127 186 20.46 1991 512 17.32 4.45
CRC_Monitoring_139 75 Panitumumab - start 23-May-13 22-May-13 2.6 22-May-13 Qiagen 24183 Prevalence EGFRi 0 2.41 1.93 6.97 0.00 1 X X X X 1.18 0.86 0.00 0.62 6.97 X X X X 0.85 2.364791 4459 108 0 40719 0 1.18 1.67 1.65 56925 957 0.07 56468 40 0.86 1.12 0.005783 34580 2 0.001575 63501 1 0.00 0.00 0.078329 3827 3 1.15990058 2386 28 0.62 0.76 1.49 596 9 12.44 6246 887 6.97 7.74
CRC_Monitoring_139 75 Panitumumab - end 24-Oct-13 PD 4-Oct-13 19-Jun-13 Qiagen 28611 longitudinal EGFRi 28 14.20 11.36 40.94 0.00 1 X X X 40.94 0.03 0.00 10.24 5.60 X X X 1.20 45.17 2759 2273 36.7 4724 2739 40.94 5.99 0.04 56520 20 0.01 65515 5 0.03 0.02 0 838 0 0 8780 0 0.00 0.00 16.04 8245 1575 4.44 35508 1650 10.24 8.20 4.41 260 12 6.79 494 36 5.60 1.68
CRC_Monitoring_139 75 Irinotecan - start 24-Oct-13 PD 5-Feb-14 17-Jul-13 Qiagen 23953 longitudinal EGFRi 56 17.35 13.88 59.54 0.01 1 X X X 59.54 0.04 0.01 7.56 2.27 X X X 2.10 62.13 1562 2563 56.94 2044 2703 59.54 3.67 0.05 105159 56 0.02 63097 14 0.04 0.02 0 6091 0 0.01 18430 2 0.01 0.01 2.35 6478 156 12.76 10130 1481 7.56 7.36 2.27 1809 42 2.27
CRC_Monitoring_139 75 21-Aug-13 Qiagen 25726 longitudinal EGFRi 91 37.73 30.39 56.32 0.04 1 X X X X 52.90 0.04 1.02 41.65 56.32 X X X X 2.30 45.97 1809 1539 59.82 5944 8848 52.90 9.79 0.03 49719 13 0.05 33459 18 0.04 0.01 1.68 1463 25 0.35 14029 49 1.02 0.94 45.76 2305 1945 37.54 5484 3296 41.65 5.81 53.78 165 192 58.86 736 1053 56.32 3.59
CRC_Monitoring_139 75 3-Jul-13 11.8 18-Sep-13 Qiagen 45577 longitudinal EGFRi 119 47.44 38.91 94.86 0.10 1 X X X X 94.86 0.10 4.77 37.19 57.63 X X X X 4.90 94.74 1209 21754 94.98 331 6268 94.86 0.17 0.07 52170 34 0.12 37213 43 0.10 0.04 0.07 12256 9 9.46 11371 1188 4.77 6.64 32.38 6508 3116 42 9015 6527 37.19 6.80 66.19 189 370 49.07 3599 3468 57.63 12.11
CRC_Monitoring_139 75 24-Oct-13 Qiagen 85345 longitudinal EGFRi 155 64.63 53.28 96.26 0.23 1 X X X X 96.26 0.23 7.86 81.28 80.75 X X X X 5.85 97.12 191 6437 95.4 500 10377 96.26 1.22 0.06 56475 34 0.4 33942 138 0.23 0.24 7.35 22408 1777 8.37 17896 1634 7.86 0.72 81.04 1953 8345 81.51 2042 9003 81.28 0.33 83.08 917 4503 78.42 334 1214 80.75 3.30
CRC_Monitoring_139 75 29-Nov-13 Qiagen 31490 longitudinal EGFRi 191 47.07 53.82 84.10 0.11 1 X X X X 84.10 0.11 80.81 55.34 48.74 X X X X 6.75 92.93 2389 31420 75.27 2249 6845 84.10 12.49 0.05 11947 6 0.16 12862 21 0.11 0.08 77.55 730 2522 84.06 336 1772 80.81 4.60 41.72 3377 2417 68.95 5639 12522 55.34 19.25 48.74 487 463 48.74
CRC_Monitoring_139 75 3-Jan-14 Qiagen 49563 longitudinal EGFRi 226 10.94 8.75 31.31 0.01 1 X X X X 2.06 1.11 0.01 31.31 9.28 X X X X 3.60 2.04 9971 208 2.07 6814 144 2.06 0.02 1.99 41952 850 0.22 18214 41 1.11 1.25 0.02 10317 2 0 6446 0 0.01 0.01 31.77 4762 2217 30.84 1859 829 31.31 0.66 9.28 6308 645 9.28 6308 645 9.28 0.00
CRC_Monitoring_142 60 SD 8-Feb-13 28-Dec-12 164 28-Dec-12 Qiagen 44484 Prevalence TEMECT 0 34.54 34.54 84.63 8.02 1 X X X X X 42.17 8.02 84.63 11.25 26.61 X X X X X 42.90 51.66 7728 8258 32.67 1414 686 42.17 13.43 3.7 14898 572 12.34 4846 682 8.02 6.11 90.23 702 6480 79.02 1615 6083 84.63 7.93 10.4 8280 961 12.09 31567 4343 11.25 1.20 32.87 729 357 20.35 180 46 26.61 8.85
CRC_Monitoring_142 60 PD 22-Mar-13 9-Jan-13 107.3 9-Jan-13 Qiagen 43962 longitudinal TEMECT 12 19.75 19.75 67.62 6.09 1 X X X X X 7.09 9.83 67.62 6.09 8.10 X X X X X 10.34 14389 1659 3.83 27402 1091 7.09 4.60 16.25 12037 2335 3.4 62082 2185 9.83 9.09 65.6 1993 3800 69.64 11442 26240 67.62 2.86 6.46 31136 2152 5.72 87768 5322 6.09 0.52 3.65 844 32 12.54 5049 724 8.10 6.29
CRC_Monitoring_142 60 25-Jan-13 197.4 25-Jan-13 Qiagen 41918 longitudinal TEMECT 28 50.25 50.25 61.71 42.29 1 X X X X X 61.71 52.09 46.12 49.06 42.29 X X X X X 62.55 15011 25070 60.87 659 1025 61.71 1.19 49.57 7172 7050 54.61 10178 12247 52.09 3.56 56.01 7610 9690 36.22 1592 904 46.12 13.99 51.1 9739 10177 47.01 2483 2203 49.06 2.89 43.15 1377 1045 41.43 714 505 42.29 1.22
CRC_Monitoring_142 60 20-Feb-13 150.4 20-Feb-13 Qiagen 32582 longitudinal TEMECT 54 47.55 47.55 73.31 33.27 1 X X X X X 42.76 38.06 73.31 50.38 33.27 X X X X X 48.19 3028 2816 37.33 15427 9190 42.76 7.68 45.99 6635 5649 30.12 1051 453 38.06 11.22 79.11 4753 17995 67.5 2413 5012 73.31 8.21 48.06 12957 11990 52.69 25392 28275 50.38 3.27 34.8 1040 555 31.73 910 423 33.27 2.17
CRC_Monitoring_142 60 1-Mar-13 209.4 1-Mar-13 Qiagen 25817 longitudinal TEMECT 63 37.98 37.98 51.27 23.01 1 X X X X X 51.27 23.01 38.11 37.57 39.95 X X X X X 58.27 5967 8331 44.27 11401 9057 51.27 9.90 19.26 10330 2464 26.76 2704 988 23.01 5.30 30.28 1034 449 45.94 8597 7307 38.11 11.07 38.06 10964 6738 37.08 22289 13137 37.57 0.69 31.23 1077 489 48.66 824 781 39.95 12.32
CRC_Monitoring_143 61 SD 8-Mar-13 24-Jan-13 44.5 25-Jan-13 Qiagen 48357 Prevalence TEMECT 0 51.44 51.44 78.32 1.51 1 X X X X X 78.32 43.80 68.81 1.51 64.77 X X X X X 44.30 69.63 5791 13276 87.01 1356 9082 78.32 12.29 39.19 5349 3447 48.41 2301 2159 43.80 6.52 73.71 3510 9840 63.9 2988 5289 68.81 6.94 2.06 6412 135 0.96 40144 390 1.51 0.78 67.33 719 1482 62.2 127 209 64.77 3.63
CRC_Monitoring_143 61 SD 19-Apr-13 14-Feb-13 30.3 14-Feb-13 Qiagen 10232 longitudinal TEMECT 20 3.78 3.78 11.23 0.02 1 X X X 1.64 0.04 5.98 0.02 11.23 X X X 3.24 598 20 0.04 6708 3 1.64 2.26 0 6039 0 0.08 1200 1 0.04 0.06 11.96 3437 467 0 101988 4 5.98 8.46 0 2328 0 0.03 3726 1 0.02 0.02 6.68 363 26 15.77 219 41 11.23 6.43
CRC_Monitoring_143 61 20-Feb-13 32.5 20-Feb-13 Qiagen 18877 longitudinal TEMECT 26 0.15 0.15 0.40 0.00 0 0.40 0.02 0.06 0.00 0.28 0.4 996 4 0.40 0.28 0.04 102645 41 0 75002 1 0.02 0.03 0.02 13675 3 0.09 118395 107 0.06 0.05 0 9891 0 0 441 0 0.00 0.00 0 658 0 0.56 704 4 0.28 0.40
CRC_Monitoring_143 61 8-Mar-13 48.5 4-Mar-13 Qiagen 35012 longitudinal TEMECT 38 5.79 5.79 12.10 0.00 1 X X X X 1.60 4.29 10.97 0.00 12.10 X X X X 0.03 17231 5 3.16 28918 944 1.60 2.21 2.32 6484 154 6.26 6512 435 4.29 2.79 9.42 13815 1436 12.52 24005 3435 10.97 2.19 0 11817 0 0 13867 0 0.00 0.00 13.47 456 71 10.73 1681 202 12.10 1.94
CRC_Monitoring_143 61 27-Mar-13 92.1 27-Mar-13 Qiagen 64785 longitudinal TEMECT 61 54.21 54.21 98.00 3.39 1 X X X X X 61.63 36.83 98.00 3.39 71.23 X X X X X 51.32 9839 10371 71.94 9520 24408 61.63 14.58 32.86 6914 3384 40.79 4993 3439 36.83 5.61 96.16 2496 62557 99.84 33 21036 98.00 2.60 3.76 11316 442 3.01 16198 503 3.39 0.53 74.06 2138 6103 68.4 1393 3015 71.23 4.00
CRC_Monitoring_143 61 19-Apr-13 115.6 23-Apr-13 Qiagen 98241 longitudinal TEMECT 88 68.00 68.00 98.34 8.28 1 X X X X X 81.79 64.65 98.34 8.28 86.96 X X X X X 77.85 9423 33118 85.72 7613 45681 81.79 5.56 70.58 2005 4809 58.72 8743 12435 64.65 8.39 96.69 1995 58266 99.99 2 17679 98.34 2.33 5.68 3569 215 10.88 14928 1823 8.28 3.68 83.46 353 1781 90.46 764 7246 86.96 4.95
CRC_Monitoring_144 54 SD 10-Oct-13 23-Aug-13 13.3 23-Aug-13 Qiagen 17574 Prevalence TEMECT 0 2.27 2.74 4.64 1.03 1 X X X X X 2.71 1.03 3.65 1.68 4.64 X X X X 14.60 0.01 24912 2 5.4 2573 147 2.71 3.81 0 23607 3 2.06 6759 142 1.03 1.46 0 2851 0 7.3 4380 345 3.65 5.16 3.36 18291 636 0 91293 0 1.68 2.38 0.5 791 4 8.77 208 20 4.64 5.85
CRC_Monitoring_144 54 SD 20-Nov-13 22-Oct-13 29.3 23-Oct-13 Qiagen 15894 longitudinal TEMECT 61 13.64 14.79 22.27 4.47 1 X X X X X 4.47 14.35 22.27 13.49 19.35 X X X X X 8.8 1534 148 0.14 5128 7 4.47 6.12 11.94 10368 1406 16.75 18798 3783 14.35 3.40 19.97 2136 533 24.57 1182 385 22.27 3.25 23.85 4326 1355 3.13 31048 1003 13.49 14.65 23.96 219 69 14.73 550 95 19.35 6.53
CRC_Monitoring_144 54 PD 3-Jan-14 17-Dec-13 22 18-Dec-13 Qiagen 100167 longitudinal TEMECT 117 62.69 64.78 86.24 36.66 1 X X X X X 53.84 36.66 86.24 74.03 73.13 X X X X X 48.93 1388 1330 58.75 14638 20845 53.84 6.94 35.91 4604 2580 37.41 2488 1487 36.66 1.06 90.43 502 4741 82.05 496 2268 86.24 5.93 80.17 1040 4204 67.88 2108 4455 74.03 8.69 77.45 1506 5172 68.81 1902 4197 73.13 6.11
CRC_Monitoring_144 54 13-Jan-14 25.7 27-Jan-14 Qiagen 1037212 longitudinal TEMECT 157 72.68 74.42 94.59 44.45 1 X X X X X 69.62 44.45 94.59 82.06 81.37 X X X X X 64.29 4573 8234 74.94 13756 41142 69.62 7.53 46.55 2347 2044 42.34 2319 1703 44.45 2.98 94.43 1470 24941 94.74 897 16153 94.59 0.22 80.29 658 2681 83.83 1520 7878 82.06 2.50 80.11 2652 10683 82.62 2729 12977 81.37 1.77
CRC_Monitoring_145 62 PD 3-Feb-14 19-Dec-13 80 19-Dec-13 Qiagen 11774 Prevalence TEMECT 0 1.97 0.48 1.97 0.00 1 X 0.00 0.21 0.21 0.01 1.97 X 0.00 0 9623 0 0 753 0 0.00 0.00 0.4 23635 104 0.01 17275 2 0.21 0.28 0.42 948 4 0 3368 0 0.21 0.30 0.02 18220 4 0 38835 0 0.01 0.01 1.97 947 19 1.97
CRC_Monitoring_145 62 22-Jan-14 117.9 22-Jan-14 Qiagen 111113 longitudinal TEMECT 34 1.23 2.52 10.50 0.01 1 X X X 10.50 0.74 0.01 0.11 1.23 X X X 21 5138 1366 0 552 0 10.50 14.85 0.55 32542 180 0.93 27407 258 0.74 0.27 0.02 17271 3 0 55476 0 0.01 0.01 0 21812 0 0.22 10990 24 0.11 0.16 1.04 9763 103 1.41 1047 15 1.23 0.26
CRC_Monitoring_146 72 SD 21-Aug-13 5-Jul-13 147.6 5-Jul-13 Qiagen 19981 Prevalence TEMECT 0 15.57 12.52 29.43 0.30 1 X X X X 18.20 0.30 2.23 12.42 29.43 X X X X 0.00 24.76 2082 685 11.64 6566 865 18.20 9.28 0.1 7943 4 0.5 3604 18 0.30 0.28 1.76 6101 109 2.7 1479 41 2.23 0.66 18.64 10848 2485 6.19 26773 1768 12.42 8.80 18.93 364 85 39.92 155 103 29.43 14.84
CRC_Monitoring_146 72 PD 3-Oct-13 8-Aug-13 238.1 8-Aug-13 Qiagen 16859 longitudinal TEMECT 34 40.51 35.54 48.98 15.65 1 X X X X X 48.98 15.65 37.24 31.44 44.39 X X X X X 42.37 7934 5832 55.58 764 956 48.98 9.34 13.63 34014 5370 17.66 11254 2414 15.65 2.85 38.18 5861 3619 36.29 6858 3907 37.24 1.34 32.12 15655 7407 30.75 1410 626 31.44 0.97 34.35 904 473 54.42 103 123 44.39 14.19
CRC_Monitoring_146 72 4-Sep-13 309.1 5-Sep-13 Qiagen 13415 longitudinal TEMECT 62 52.13 41.85 94.43 0.76 1 X X X X X 12.37 0.76 94.43 57.26 44.45 X X X X X 1.52 9975 154 23.21 24192 7314 12.37 15.34 1.5 42637 648 0.02 28128 7 0.76 1.05 90.7 341 3324 98.16 748 39802 94.43 5.28 64.54 7883 14349 49.97 29367 29328 57.26 10.30 35.63 365 202 53.27 973 1109 44.45 12.47
CRC_Monitoring_146 72 5-Sep-13 334.5 12-Sep-13 Qiagen 41701 longitudinal TEMECT 69 83.95 75.96 95.21 43.98 1 X X X X X 72.59 43.98 95.21 90.70 77.31 X X X X X 71.72 10420 26426 73.45 4517 12499 72.59 1.22 48.81 10558 10066 39.15 8902 5727 43.98 6.83 93.2 2124 29098 97.21 254 8849 95.21 2.84 92.52 3008 37218 88.88 5267 42108 90.70 2.57 73.15 678 1847 81.46 781 3432 77.31 5.88
CRC_Monitoring_146 72 9-Oct-13 592.3 10-Oct-13 Qiagen 41418 longitudinal TEMECT 97 61.68 59.51 76.92 45.76 1 X X X X X 58.12 50.85 45.76 65.91 76.92 X X X X X 54.99 748 914 61.24 4729 7473 58.12 4.42 44.24 4919 3902 57.46 5409 7307 50.85 9.35 50.21 3907 3940 41.31 14214 10004 45.76 6.29 75.01 7134 21412 56.8 29047 38185 65.91 12.88 77.19 375 1269 76.65 727 2386 76.92 0.38
CRC_Monitoring_147 77 SD 15-Oct-13 3-Sep-13 112.9 3-Sep-13 Qiagen 34425 Prevalence TEMECT 0 29.32 29.32 73.59 1.51 1 X X X X X 61.33 2.29 73.59 1.51 7.89 X X X X X 4.00 53.23 2698 3071 69.42 1771 4021 61.33 11.45 2.2 12974 285 2.37 7169 174 2.29 0.12 70.64 438 1054 76.54 973 3175 73.59 4.17 1.98 17275 349 1.04 52837 556 1.51 0.66 6.86 597 44 8.92 1123 110 7.89 1.46
CRC_Monitoring_147 77 PD 29-Nov-13 2-Oct-13 52.3 2-Oct-13 Qiagen 35262 longitudinal TEMECT 29 2.16 2.16 9.16 0.00 1 X X 0.00 9.16 0.01 0.93 0.70 X X 0 1296 0 0 4199 0 0.00 0.00 4.97 32640 1707 13.35 48503 7472 9.16 5.93 0.01 6694 1 0 130513 0 0.01 0.01 0.01 68249 5 1.84 101043 1899 0.93 1.29 1.39 993 14 0 671 0 0.70 0.98
CRC_Monitoring_147 77 30-Oct-13 16.6 30-Oct-13 Qiagen 24736 longitudinal TEMECT 57 2.23 2.23 6.78 0.10 1 X X X 1.79 0.10 0.27 2.20 6.78 X X X 0.23 4683 11 3.34 21540 745 1.79 2.20 0.15 21525 32 0.05 34932 16 0.10 0.07 0.06 8424 5 0.48 11049 53 0.27 0.30 2.61 33493 899 1.78 137899 2496 2.20 0.59 8.29 1393 126 5.27 1060 59 6.78 2.14
CRC_Monitoring_148 63 PD 11-Mar-13 23-Jan-13 3389 21-Jan-13 Qiagen 70062 Prevalence TEMECT 0 77.75 77.75 96.31 64.43 1 X X X X X 82.09 64.43 96.31 65.98 79.96 X X X X X 61.90 79.67 1986 7782 84.51 760 4147 82.09 3.42 64.75 1256 2307 64.11 3599 6429 64.43 0.45 93.83 134 2039 98.79 38 3099 96.31 3.51 73.04 928 2514 58.91 2861 4102 65.98 9.99 75.7 227 707 84.22 671 3581 79.96 6.02
CRC_Monitoring_148 63 11-Feb-13 3440 11-Feb-13 Qiagen 140043 longitudinal TEMECT 21 88.22 88.22 96.05 79.93 1 X X X X X 91.97 79.93 96.05 83.35 89.81 X X X X X 86.87 2112 13974 97.07 1909 63220 91.97 7.21 79.78 5268 20791 80.08 8322 33447 79.93 0.21 92.14 3750 43956 99.95 27 59304 96.05 5.52 82.05 4204 19212 84.64 12117 66777 83.35 1.83 89.92 325 2899 89.69 975 8483 89.81 0.16
CRC_Monitoring_149 63 PD 6-Mar-13 14-Jan-13 1866 14-Jan-13 Qiagen 35597 Prevalence TEMECT 0 12.78 12.78 25.45 3.94 1 X X X X X 17.92 7.97 3.94 8.65 25.45 X X X X X 9.70 23.4 442 135 12.44 5907 839 17.92 7.75 12 10512 1439 3.93 5713 234 7.97 5.71 1.53 2830 44 6.34 3647 247 3.94 3.40 13.4 12934 2001 3.89 39922 1617 8.65 6.72 21.41 958 261 29.49 526 220 25.45 5.71
CRC_Monitoring_149 63 30-Jan-13 2148 11-Feb-13 Qiagen 26031 longitudinal TEMECT 28 27.34 27.34 59.01 0.68 1 X X X X X 5.10 27.47 0.68 59.01 44.43 X X X X X 7.75 2403 202 2.45 6452 162 5.10 3.75 34.93 9215 4947 20 2288 572 27.47 10.56 0 938 0 1.35 2989 41 0.68 0.95 67.99 7499 15927 50.02 17886 17898 59.01 12.71 35.47 131 72 53.38 200 229 44.43 12.66
CRC_Monitoring_149 63 8-Mar-13 2446 8-Mar-13 Qiagen 56424 longitudinal TEMECT 53 49.34 49.34 79.48 17.89 1 X X X X X 56.96 17.89 79.48 37.72 54.64 X X X X X 65.61 7085 13519 48.31 2880 2692 56.96 12.23 24.76 11740 3864 11.01 38184 4724 17.89 9.72 72.74 957 2553 86.21 526 3288 79.48 9.52 39.6 12623 8276 35.84 53004 29609 37.72 2.66 56.47 259 336 52.81 286 320 54.64 2.59
CRC_Monitoring_150 62 3-May-13 132 4-Apr-13 Qiagen 21605 Prevalence TEMECT 0 0.78 3.76 0.01 1 X 0.01 0.02 0.09 0.01 3.76 2.30 0.02 5166 1 0 2991 0 0.01 0.01 0 9711 1 0.03 14079 4 0.02 0.02 0 2478 0 0.17 1173 2 0.09 0.12 0.01 26781 2 0 14135 0 0.01 0.01 0 219 0 7.51 382 31 3.76 5.31
CRC_Monitoring_151 45 PD 21-Jun-13 6-May-13 11 6-May-13 Qiagen 19490 Prevalence TEMECT 0 72.66 72.66 99.22 56.50 1 X X X X X 69.18 63.64 99.22 56.50 74.78 X X X X X 69.30 71.99 298 766 66.37 2649 5229 69.18 3.97 68.37 3402 7353 58.91 2033 2915 63.64 6.69 98.6 554 38970 99.83 2 1197 99.22 0.87 46.24 6774 5826 66.75 10459 20993 56.50 14.50 69.46 524 1192 80.09 224 901 74.78 7.52
CRC_Monitoring_151 45 7-Jun-13 21.6 7-Jun-13 Qiagen 60633 longitudinal TEMECT 32 84.48 84.48 89.41 81.91 1 X X X X X 89.41 82.43 86.02 82.62 81.91 X X X X X 84.95 5140 29004 93.87 3210 49145 89.41 6.31 85.07 3852 21948 79.79 7941 31355 82.43 3.73 93.43 291 4137 78.61 1395 5127 86.02 10.48 83.62 4954 25293 81.62 10189 45238 82.62 1.41 80.49 861 3551 83.32 214 1069 81.91 2.00
CRC_Monitoring_151 45 3-Jul-13 52.7 5-Jul-13 Qiagen 51833 longitudinal TEMECT 60 88.90 88.90 99.04 81.32 1 X X X X X 99.04 81.32 89.06 86.50 88.60 X X X X X 98.6 1157 81658 99.47 357 66802 99.04 0.62 82.31 4085 19002 80.33 8594 35097 81.32 1.40 89.66 296 2567 88.45 909 6959 89.06 0.86 92.43 2446 29882 80.57 7350 30475 86.50 8.39 91.81 496 5560 85.39 1380 8064 88.60 4.54
CRC_Monitoring_152 47 SD 8-May-13 11-Mar-13 19.2 14-Mar-13 Qiagen 23568 Prevalence TEMECT 0 37.39 37.39 69.56 11.72 1 X X X X X 11.72 28.06 69.56 39.75 37.88 X X X X X 9.37 1422 147 14.06 214 35 11.72 3.32 20.1 19084 4800 36.02 28729 16176 28.06 11.26 69.56 494 1129 69.56 36.04 2227 1255 43.46 3473 2670 39.75 5.25 39.61 125 82 36.14 1896 1073 37.88 2.45
CRC_Monitoring_152 47 PD 18-May-13 26-Mar-13 21.5 26-Mar-13 Qiagen 7785 longitudinal TEMECT 12 13.29 13.29 40.36 0.57 1 NA X X 0.59 0.57 11.62 40.36 NA X X 0 238 0 1.17 3283 39 0.59 0.83 1.14 93060 1075 0 39117 1 0.57 0.81 13.68 2329 369 9.56 26806 2832 11.62 2.91 27.07 1339 497 53.64 389 450 40.36 18.79
CRC_Monitoring_152 47 24-Apr-13 40 24-Apr-13 Qiagen 13265 longitudinal TEMECT 41 14.83 14.83 40.23 2.75 1 X X NA X X 40.23 3.72 2.75 12.62 X X NA X X 40.23 9044 6088 40.23 18.70 0.04 180108 75 7.39 7840 626 3.72 5.20 3.24 7310 245 2.25 12489 288 2.75 0.70 15.25 150 27 9.98 415 46 12.62 3.73
CRC_Monitoring_152 47 8-May-13 41.7 22-May-13 Qiagen 5556 longitudinal TEMECT 69 40.24 40.24 91.27 2.04 1 X X X X X 91.27 20.82 2.04 38.47 48.63 X X X X X 91.27 465 4862 91.27 6.17 6.45 76313 5260 35.18 7872 4273 20.82 20.32 2.04 11180 233 2.04 11180 233 2.04 0.00 43.44 647 497 33.49 562 283 38.47 7.04 58.58 70 99 38.68 363 229 48.63 14.07
CRC_Monitoring_152 47 20-Jun-13 119.9 20-Jun-13 Qiagen 17013 longitudinal TEMECT 98 58.79 58.79 94.21 16.54 1 X X X X X 16.54 77.20 94.21 56.60 49.39 X X X X X 19.78 726 179 13.29 9170 1406 16.54 4.59 80.8 10020 42156 73.6 10802 30114 77.20 5.09 94.21 1446 23546 94.21 1446 23546 94.21 0.00 53.44 2726 3129 59.75 3932 5836 56.60 4.46 45.82 564 477 52.96 398 448 49.39 5.05
CRC_Monitoring_153 41 PR 3-May-13 21-Mar-13 84.1 21-Mar-13 Qiagen 14536 Prevalence TEMECT 0 80.58 80.58 98.87 59.55 1 X X X X X 86.43 59.55 98.87 75.34 82.72 X X X X X 74.20 91.82 555 6227 81.03 1434 6127 86.43 7.63 61.9 2371 3856 57.2 2617 3498 59.55 3.32 100 0 1861 97.73 52 2241 98.87 1.61 78.39 1616 5862 72.28 5456 14227 75.34 4.32 84.15 42 223 81.28 409 1776 82.72 2.03
CRC_Monitoring_153 41 PR 4-Jun-13 3-May-13 176.7 3-May-13 Qiagen 25979 longitudinal TEMECT 43 71.24 71.24 90.37 54.27 1 X X X X X 88.82 60.23 90.37 62.50 54.27 X X X X X 87.29 1516 10409 90.34 3287 30732 88.82 2.16 59.03 11850 17076 61.43 16427 26165 60.23 1.70 84.53 2971 16230 96.21 456 11580 90.37 8.26 49.84 919 913 75.16 3282 9930 62.50 17.90 68.18 63 135 40.36 569 385 54.27 19.67
CRC_Monitoring_153 41 SD 27-Jun-13 28-May-13 246.9 4-Jun-13 Qiagen 36216 longitudinal TEMECT 75 57.10 57.10 66.55 43.54 1 X X X X X 58.00 43.54 50.98 66.55 66.42 X X X X X 61.97 2199 3584 54.02 8702 10225 58.00 5.62 52.07 3755 4079 35.01 7652 4122 43.54 12.06 50.98 6654 6921 50.98 57.16 5136 6854 75.94 18267 57640 66.55 13.28 66.61 1062 2119 66.22 476 933 66.42 0.28
CRC_Monitoring_153 41 PD 4-Sep-13 27-Jun-13 449 27-Jun-13 Qiagen 72514 longitudinal TEMECT 98 88.89 88.89 99.67 74.89 1 X X X X X 93.20 84.69 99.67 74.89 91.98 X X X X X 97.41 1927 72613 88.98 2895 23379 93.20 5.96 80.07 4437 17821 89.3 3131 26122 84.69 6.53 99.53 314 66598 99.81 46 24362 99.67 0.20 74.86 5894 17548 74.92 17045 50911 74.89 0.04 92.12 112 1309 91.83 64 719 91.98 0.21
CRC_Monitoring_153 41 5-Sep-13 1073 4-Sep-13 Qiagen 197007 longitudinal TEMECT 167 87.02 87.02 99.40 77.84 1 X X X X X 92.66 84.75 99.40 77.84 80.46 X X X X X 95.88 2444 56945 89.43 218 1844 92.66 4.56 81.94 6256 28388 87.56 3731 26260 84.75 3.97 99.36 357 55137 99.43 50 8660 99.40 0.05 81.2 5372 23199 74.48 9110 26591 77.84 4.75 77.22 775 2627 83.7 861 4422 80.46 4.58
CRC_Monitoring_154 57 PD 15-Mar-13 25-Jan-13 496.9 25-Jan-13 Qiagen 40465 Prevalence TEMECT 0 16.41 16.41 28.96 4.76 1 X X X X X 16.00 5.93 26.40 4.76 28.96 X X X X X 17.00 25.57 2227 765 6.43 4146 285 16.00 13.53 3.8 10355 413 8.05 7386 647 5.93 3.01 28.03 8321 3241 24.76 1191 392 26.40 2.31 4.77 16956 850 4.74 18082 899 4.76 0.02 28.25 734 289 29.67 1877 792 28.96 1.00
CRC_Monitoring_154 57 25-Feb-13 666.8 25-Feb-13 Qiagen 53501 longitudinal TEMECT 31 42.31 42.31 79.27 16.08 1 X X X X X 79.27 16.08 34.88 23.06 58.27 X X X X X 82.89 2613 12663 75.65 5154 16009 79.27 5.12 26.06 24194 8529 6.09 30544 1981 16.08 14.12 34.88 24330 13029 34.88 21.01 20209 5376 25.1 46710 15653 23.06 2.89 65.21 167 313 51.33 1319 1391 58.27 9.81
CRC_Monitoring_154 57 26-Mar-13 789.3 26-Mar-13 Qiagen 30809 longitudinal TEMECT 60 57.75 57.75 95.78 27.19 1 X X X X X 74.33 27.19 95.78 31.99 59.46 X X X X X 79.28 4224 16165 69.38 8140 18447 74.33 7.00 17.83 25822 5602 36.54 16486 9491 27.19 13.23 99.89 10 9376 91.67 352 3874 95.78 5.81 22.08 19985 5662 41.9 19594 14131 31.99 14.01 56.36 515 665 62.55 352 588 59.46 4.38
CRC_Monitoring_155 55 11-Apr-13 634.7 3-Apr-13 Qiagen 104241 Prevalence TEMECT 0 35.56 35.56 58.54 18.23 1 X X X X X 41.40 19.53 58.54 18.23 40.10 X X X X X 21.10 41.39 13735 9701 41.4 8931 6310 41.40 0.01 19.6 3415 834 19.45 5213 1259 19.53 0.11 59.25 2365 3438 57.83 3721 5102 58.54 1.00 17.32 3428 718 19.13 7533 1782 18.23 1.28 42.53 458 339 37.67 10476 6331 40.10 3.44
CRC_Monitoring_155 55 11-Apr-13 Qiagen 1081552 longitudinal TEMECT 8 63.21 63.21 94.02 42.09 1 X X X X X 52.83 42.09 94.02 74.50 52.63 X X X X X 47.6 19628 17830 58.05 19910 27547 52.83 7.39 31.69 19691 9133 52.49 15926 17594 42.09 14.71 89.9 2512 22366 98.13 290 15228 94.02 5.82 70.89 707 1722 78.11 16166 57688 74.50 5.11 60.64 5267 8114 44.62 6562 5286 52.63 11.33
CRC_Monitoring_155 55 9-May-13 1629 9-May-13 Qiagen 245753 longitudinal TEMECT 36 65.26 65.26 92.15 50.50 1 X X X X X 70.01 50.50 92.15 51.00 62.64 X X X X X 70.95 11128 27173 69.07 14622 32653 70.01 1.33 47.05 15845 14077 53.94 19711 23085 50.50 4.87 93.13 3129 42423 91.17 424 4379 92.15 1.39 53.27 4219 4809 48.73 21999 20910 51.00 3.21 66.61 1378 2749 58.67 4715 6694 62.64 5.61
CRC_Monitoring_156 55 PD 12-Jun-13 10-Apr-13 68.4 10-Apr-13 Qiagen 6089 Prevalence TEMECT 0 0.77 0.17 0.77 0.00 1 X 0.05 0.77 0.00 0.04 0.02 X 0.00 0 2828 0 0.1 1006 1 0.05 0.07 1.5 22363 338 0.03 13955 4 0.77 1.04 0 3428 0 0.00 0.06 8908 5 0.01 19886 1 0.04 0.04 0.02 4574 1 0.02
CRC_Monitoring_156 55 30-Apr-13 80.6 30-Apr-13 Qiagen 17227 longitudinal TEMECT 20 1.76 9.78 27.30 1.76 1 X X X X X 2.37 1.76 1.99 27.30 15.49 X X X X X 1.64 240 4 3.09 34947 1116 2.37 1.03 2.31 42046 993 1.2 5704 69 1.76 0.78 0.01 8784 1 3.97 5827 241 1.99 2.80 34.82 4733 2528 19.78 3841 947 27.30 10.63 15.87 212 40 15.1 641 114 15.49 0.54
CRC_Monitoring_156 55 28-May-13 104.7 28-May-13 Qiagen 19510 longitudinal TEMECT 48 16.71 24.09 64.17 1.38 1 X X X X X 1.38 16.71 64.17 6.30 31.88 X X X X X 2.76 3561 101 0 2650 0 1.38 1.95 16.16 19615 3781 17.26 36860 7688 16.71 0.78 67.63 725 1515 60.71 4341 6707 64.17 4.89 0.79 17346 139 11.8 11464 1533 6.30 7.79 23.6 136 42 40.16 149 100 31.88 11.71
CRC_Monitoring_156 55 2-Jul-13 111.5 2-Jul-13 Qiagen 18086 longitudinal TEMECT 83 38.66 45.40 68.01 34.43 1 X X X X X 40.26 38.66 68.01 34.43 45.64 X X X X X 53.57 4629 5341 26.94 949 350 40.26 18.83 30.73 14123 6264 46.58 5620 4901 38.66 11.21 68.01 3452 7339 68.01 34.51 5447 2870 34.35 1313 687 34.43 0.11 38.25 867 537 53.02 732 826 45.64 10.44
CRC_Monitoring_157 64 4-Apr-13 5 4-Apr-13 Qiagen 18012 Prevalence TEMECT 0 11.83 2.43 11.83 0.00 1 X 0.31 0.01 0.00 0.00 11.83 X 0.00 0 127 0 0.61 3074 19 0.31 0.43 0 39192 6 0.01 10803 1 0.01 0.01 0 1604 0 0 1724 0 0.00 0.00 0 26682 0 0 71782 1 0.00 0.00 12.93 202 30 10.73 233 28 11.83 1.56
Supplementary File 2G
CRC_Monitoring_158 62 SD 8-Apr-14 27-Feb-14 6.8 28-Feb-14 Qiagen 16364 Prevalence TEMECT 0 14.62 6.04 28.48 0.00 1 X X 28.48 0.76 0.00 0.01 0.93 X X 57.80 25.38 638 217 31.58 4129 1906 28.48 4.38 1.5 12371 190 0.02 20752 4 0.76 1.05 0 12160 0 0 2005 0 0.00 0.00 0 24772 0 0.01 22542 3 0.01 0.01 0.19 527 1 1.67 825 14 0.93 1.05
CRC_Monitoring_158 62 SD 20-May-14 21-Mar-14 3.11 27-Mar-14 Qiagen 6589 longitudinal TEMECT 27 0.03 1.33 6.50 0.00 1 X 0.01 0.06 6.50 0.00 0.10 X 0 227 0 0.02 5245 1 0.01 0.01 0.04 43313 17 0.07 13168 9 0.06 0.02 0 246 0 12.99 375 56 6.50 9.19 0 3476 0 0 883 0 0.00 0.00 0.2 502 1 0 342 0 0.10 0.14
CRC_Monitoring_158 62 7-May-14 2.85 7-May-14 Qiagen 9424 longitudinal TEMECT 68 5.18 3.67 10.29 0.06 1 X X X 10.29 0.06 0.10 3.22 4.69 X X 16.94 1162 237 3.63 716 27 10.29 9.41 0.07 65802 43 0.05 15695 8 0.06 0.01 0.18 550 1 0.01 7436 1 0.10 0.12 0 5795 0 6.44 218 15 3.22 4.55 1.72 171 3 7.66 2181 181 4.69 4.20
CRC_Monitoring_158 62 24-May-14 11.2 21-May-14 Qiagen 18090 longitudinal TEMECT 82 0.79 1.44 5.09 0.02 1 X X 1.50 0.08 0.54 0.02 5.09 X X 3 323 10 0 4711 0 1.50 2.12 0.09 37495 33 0.06 30493 19 0.08 0.02 1.07 1295 14 0 4361 0 0.54 0.76 0.03 6292 2 0 21120 0 0.02 0.02 10.17 433 49 0 1038 0 5.09 7.19
CRC_Monitoring_158 62 21-Jun-14 23 25-Jun-14 Qiagen 11687 longitudinal TEMECT 117 0.03 2.09 9.95 0.00 1 X 0.03 0.03 0.44 0.00 9.95 0.06 4721 3 0 566 0 0.03 0.04 0.01 13987 2 0.04 31502 13 0.03 0.02 0 675 0 0.88 112 1 0.44 0.62 0 670 0 0 3927 0 0.00 0.00 0 267 0 19.9 334 83 9.95 14.07
CRC_Monitoring_159 55 PD 3-Feb-14 16-Dec-13 262.8 17-Dec-13 Qiagen 32537 Prevalence TEMECT 0 17.83 17.83 48.01 1.88 1 X X X X X 48.01 10.41 1.88 7.18 21.66 X X X X X 8.80 39.09 8769 5628 56.92 1525 2015 48.01 12.61 4.4 10496 481 16.42 4453 875 10.41 8.50 3.75 5562 217 0.01 7124 1 1.88 2.64 12.01 4295 586 2.35 23650 570 7.18 6.83 29.57 162 68 13.74 3686 587 21.66 11.19
CRC_Monitoring_159 55 22-Jan-14 373 22-Jan-14 Qiagen 33975 longitudinal TEMECT 36 36.21 36.21 79.50 18.18 1 X X X X X 32.37 18.18 79.50 23.14 27.88 X X X X X 25.51 21562 7383 39.23 2666 1721 32.37 9.70 25.33 31473 10674 11.02 23252 2879 18.18 10.12 78.66 4009 14776 80.33 3333 13615 79.50 1.18 21.89 13786 3864 24.39 50512 16297 23.14 1.77 24.92 943 313 30.84 2119 945 27.88 4.19
CRC_Monitoring_159 55 19-Feb-14 523.4 19-Feb-14 Qiagen 19696 longitudinal TEMECT 64 45.17 45.17 77.29 27.56 1 X X X X X 27.56 34.40 77.29 45.01 41.58 X X X X X 33.35 25622 12820 21.76 15657 4355 27.56 8.20 44.96 836 683 23.84 11290 3534 34.40 14.93 64.07 4920 8772 90.5 427 4066 77.29 18.69 40.41 5201 3527 49.6 36815 36230 45.01 6.50 42.96 478 360 40.19 1765 1186 41.58 1.96
CRC_Monitoring_160 74 SD 4-Apr-14 18-Feb-14 280 18-Feb-14 Qiagen 23854 Prevalence TEMECT 0 47.45 47.45 98.39 9.83 1 X X X X NA 47.06 9.83 98.39 34.51 X X X X NA 0.00 45.64 1547 1299 48.48 2713 2553 47.06 2.01 10.53 1895 223 9.13 20561 2067 9.83 0.99 96.8 9 272 99.98 1 4724 98.39 2.25 38.69 5371 3390 30.32 10974 4776 34.51 5.92
CRC_Monitoring_160 74 20-Mar-14 370.9 20-Mar-14 Qiagen 16391 longitudinal TEMECT 30 46.71 47.06 86.38 26.53 1 X X X X X 44.93 26.53 86.38 28.99 48.49 X X X X X 44.93 2166 1767 44.93 27.5 8863 3361 25.56 30781 10567 26.53 1.37 82.39 1294 6053 90.37 3410 31985 86.38 5.64 25.05 21728 7262 32.92 2576 1264 28.99 5.56 45.78 315 266 51.2 304 319 48.49 3.83
CRC_Monitoring_160 74 18-Apr-14 659.4 17-Apr-14 Qiagen 43793 longitudinal TEMECT 58 55.61 49.58 92.96 25.46 1 X X X X X 47.67 34.09 92.96 47.73 25.46 X X X X X 47.67 1225 1116 47.67 2.60 27.92 24660 9550 40.26 17486 11785 34.09 8.73 87.24 3673 25105 98.68 637 47456 92.96 8.09 45.95 2564 2180 49.5 23593 23128 47.73 2.51 19.66 2468 604 31.25 462 210 25.46 8.20
CRC_Monitoring_161 68 SD 23-Apr-14 5-Mar-14 22 4-Mar-14 Qiagen 28577 Prevalence TEMECT 0 4.53 2.84 5.87 0.29 1 X X X 0.35 5.87 0.29 3.66 4.05 X X X 0.60 0.69 16477 115 0 13250 0 0.35 0.49 6.1 11686 757 5.64 24618 1471 5.87 0.33 0.57 4575 26 0 3097 0 0.29 0.40 5.61 5436 323 1.71 19614 342 3.66 2.76 8.1 193 17 0 980 0 4.05 5.73
CRC_Monitoring_161 68 PD 30-May-14 9-Apr-14 37.4 9-Apr-14 Qiagen 6535 longitudinal TEMECT 36 16.11 9.66 45.69 0.00 1 X X 0.00 2.19 0.00 45.69 0.44 X X 0 6986 0 0 315 0 0.00 0.00 0.07 8858 6 4.3 4204 189 2.19 2.99 0 675 0 0 1751 0 0.00 0.00 46.31 2722 2348 45.07 924 758 45.69 0.88 0.58 171 1 0.29 346 1 0.44 0.21
CRC_Monitoring_161 68 7-May-14 47.6 7-May-14 Qiagen 10376 longitudinal TEMECT 64 13.41 8.08 25.38 0.00 1 X X 0.16 14.86 0.02 25.38 0.00 X X 0.16 3810 6 0.16 19.7 7265 1782 10.01 27886 3101 14.86 6.85 0.03 3385 1 0.01 7603 1 0.02 0.01 18.17 1252 278 32.59 58515 28296 25.38 10.20 0 312 0 0 572 0 0.00 0.00
CRC_Monitoring_162 60 PD 12-Jul-13 30-May-13 7.6 30-May-13 Qiagen 35053 Prevalence TEMECT 0 9.98 8.01 14.70 0.12 1 X X X X 14.70 10.03 0.12 0.50 14.69 X X X X 27.80 17.98 4024 882 11.41 2128 274 14.70 4.65 15.9 2753 521 4.15 28604 1239 10.03 8.31 0.23 1302 3 0 3520 0 0.12 0.16 0.31 20361 63 0.68 30488 210 0.50 0.26 6.15 397 26 23.23 228 69 14.69 12.08
CRC_Monitoring_162 60 28-Jun-13 18.8 28-Jun-13 Qiagen 9673 longitudinal TEMECT 29 28.08 22.46 63.96 0.00 1 X X X 4.37 43.99 0.00 0.01 63.96 X X X 4.37 438 20 4.37 3.09 48.7 3265 3099 39.27 16477 10655 43.99 6.67 0 529 0 0 1095 0 0.00 0.00 0 1344 0 0.01 9438 1 0.01 0.01 63.96 133 236 63.96
CRC_Monitoring_162 60 26-Jul-13 24.1 26-Jul-13 Qiagen 10058 longitudinal TEMECT 57 28.00 22.48 65.95 0.37 1 X X X X 12.96 31.71 0.37 1.40 65.95 X X X X 3.25 3248 109 22.67 7073 2073 12.96 13.73 22.35 13033 3752 41.07 12735 8877 31.71 13.24 0.72 553 4 0.02 5187 1 0.37 0.49 0 16374 0 2.79 3549 102 1.40 1.97 68.97 279 620 62.92 89 151 65.95 4.28
CRC_Monitoring_163 66 SD 2-Apr-13 14-Feb-13 1.4 14-Feb-13 Qiagen 40107 Prevalence TEMECT 0 1.39 0.68 2.12 0.00 1 X X 0.13 0.52 0.00 0.65 2.12 X X 1.80 0 10704 0 0.26 2673 7 0.13 0.18 0 32265 12 1.03 22812 238 0.52 0.73 0 1668 0 0 4065 0 0.00 0.00 0.89 20599 186 0.41 30470 124 0.65 0.34 1.98 744 15 2.26 6761 156 2.12 0.20
CRC_Monitoring_163 66 15-Mar-13 1.2 15-Mar-13 Qiagen 12018 longitudinal TEMECT 29 0.00 10.63 29.75 0.00 1 X X 29.75 23.39 0.00 0.00 0.00 X X 23.78 1003 313 29.75 8.44 28.78 16048 6486 17.99 6908 1515 23.39 7.63 0 410 0 0 3204 0 0.00 0.00 0 1970 0 0 35469 1 0.00 0.00 0 733 0 0.00
CRC_Monitoring_164 53 SD 28-Mar-13 18-Feb-13 517.2 18-Feb-13 Qiagen 75478 Prevalence TEMECT 0 68.30 68.30 87.72 38.18 1 X X X X X 87.72 75.61 70.10 69.90 38.18 X X X X X 69.70 82.59 2040 9680 92.84 523 6781 87.72 7.25 79.7 1201 4709 71.51 2843 7137 75.61 5.79 71.63 4893 12356 68.57 1508 3290 70.10 2.16 76.03 2362 7491 63.76 3284 5779 69.90 8.68 38.51 2178 1364 37.85 1128 687 38.18 0.47
CRC_Monitoring_164 53 PD 17-May-13 26-Mar-13 972.2 26-Mar-13 Qiagen 143352 longitudinal TEMECT 36 0.16 0.16 0.61 0.00 0 0.00 0.15 0.03 0.03 0.61 0 96539 1 0 38176 0 0.00 0.00 0.28 89780 248 0.02 95332 18 0.15 0.18 0.01 19238 2 0.04 108300 38 0.03 0.02 0.01 100940 8 0.05 238198 122 0.03 0.03 1.05 3206 34 0.16 619 1 0.61 0.63
CRC_Monitoring_164 53 22-Apr-13 1104 22-Apr-13 Qiagen 24994 longitudinal TEMECT 63 55.57 55.57 99.99 32.18 1 X X X X X 48.19 57.16 99.99 32.18 40.34 X X X X X 42.01 7437 5387 54.37 8682 10346 48.19 8.74 66.84 6493 13086 47.48 9995 9037 57.16 13.69 99.98 2 10000 100 0 124630 99.99 0.01 24.21 4061 1297 40.14 40287 27012 32.18 11.26 48.8 1063 1013 31.88 188 88 40.34 11.96
CRC_Monitoring_164 53 22-May-13 1412 22-May-13 Qiagen 29837 longitudinal TEMECT 93 76.28 76.28 94.81 66.60 1 X X X X X 68.08 74.97 94.81 76.93 66.60 X X X X X 75.28 202 615 60.87 2186 3401 68.08 10.19 81.82 985 4433 68.12 9159 19568 74.97 9.69 89.62 2191 18913 100 0 85313 94.81 7.34 87.36 2855 19739 66.5 29044 57660 76.93 14.75 59.16 214 310 74.04 61 174 66.60 10.52
CRC_Monitoring_165 61 PD 23-Jun-14 30-Apr-14 274.2 14-May-14 Qiagen 149959 Prevalence TEMECT 0 73.99 73.99 90.03 39.53 1 X X X X X 76.23 77.07 90.03 87.11 39.53 X X X X X 25.30 68.29 6518 14037 84.16 4387 23317 76.23 11.22 70.61 2989 7180 83.52 587 2975 77.07 9.13 88.07 357 2635 91.98 1992 22845 90.03 2.76 93.21 669 9177 81 4019 17129 87.11 8.63 42.02 2583 1872 37.04 2562 1507 39.53 3.52
CRC_Monitoring_165 61 11-Jun-14 830.2 11-Jun-14 Qiagen 241336 longitudinal TEMECT 28 56.87 56.87 69.55 44.91 1 X X X X X 65.87 46.03 69.55 58.01 44.91 X X X X X 65.97 9258 17945 65.77 11790 22652 65.87 0.14 44.47 17470 13988 47.58 14419 13090 46.03 2.20 67.52 11048 22972 71.57 2062 5190 69.55 2.86 59.33 8107 11825 56.69 27966 36607 58.01 1.87 44.95 2263 1848 44.86 2485 2022 44.91 0.06
CRC_Monitoring_165 61 4-Jul-14 2207 9-Jul-14 Qiagen 241646 longitudinal TEMECT 56 72.54 72.54 96.63 50.29 1 X X X X X 76.54 69.45 96.63 69.81 50.29 X X X X X 70.23 7169 16910 82.85 7097 34279 76.54 8.92 74.11 8806 25213 64.78 12432 22862 69.45 6.60 93.3 2801 38978 99.96 18 40529 96.63 4.71 77.86 3878 13639 61.75 23058 37228 69.81 11.39 46.98 615 545 53.6 6350 7336 50.29 4.68
CRC_Monitoring_166 39 PD 10-Jul-13 15-May-13 57.5 14-May-13 Qiagen 28811 Prevalence TEMECT 0 22.58 9.12 31.71 0.00 1 X X 0.42 0.02 0.00 31.71 13.44 X X 16.60 0.84 9436 80 0 4292 0 0.42 0.59 0 27892 5 0.03 53369 14 0.02 0.02 0 1658 0 0 4443 0 0.00 0.00 25.88 6544 2285 37.54 6406 3850 31.71 8.24 19.19 1415 336 7.69 276 23 13.44 8.13
CRC_Monitoring_166 39 24-May-13 63.7 24-May-13 Qiagen 36155 longitudinal TEMECT 10 54.50 27.17 81.45 1.52 1 X X X X X 18.48 1.52 6.87 81.45 27.55 X X X X X 11.14 5465 685 25.81 7779 2706 18.48 10.37 0.03 65398 21 3.01 12148 377 1.52 2.11 3.91 4109 167 9.82 32601 3550 6.87 4.18 79.81 4664 18441 83.08 846 4153 81.45 2.31 32.29 325 155 22.8 1243 367 27.55 6.71
CRC_Monitoring_167 53 28-May-13 73 28-May-13 Qiagen 13968 Prevalence TEMECT 0 3.83 3.07 7.96 0.03 1 X X X X 7.96 2.31 0.03 2.00 3.05 X X X X 0.00 15.92 4463 845 0 4353 0 7.96 11.26 0.1 9609 8 4.52 1688 80 2.31 3.13 0 6037 0 0.05 1849 1 0.03 0.04 3.99 17713 736 0 10161 0 2.00 2.82 3.18 945 31 2.91 734 22 3.05 0.19
CRC_Monitoring_168 72 PD 17-Apr-14 3-Mar-14 421.4 3-Mar-14 Qiagen 1210353 Prevalence TEMECT 0 83.51 83.51 89.73 69.03 1 X X X X X 88.30 69.03 89.73 80.83 89.64 X X X X X 81.00 91.4 3427 36444 85.2 4746 27331 88.30 4.38 64.8 1941 3566 73.26 671 1838 69.03 5.98 93.44 1264 18008 86.02 5095 31359 89.73 5.25 82.23 1412 6534 79.43 2875 11100 80.83 1.98 88.02 1094 8037 91.25 872 9090 89.64 2.28
CRC_Monitoring_168 72 29-Apr-14 1065 30-Apr-14 Qiagen 2267703 longitudinal TEMECT 58 92.46 92.46 98.35 86.19 1 X X X X X 90.77 86.19 98.35 93.54 93.47 X X X X X 86.41 2603 16554 95.12 2613 50919 90.77 6.16 82.11 3321 15241 90.27 4182 38778 86.19 5.77 98.1 1127 58183 98.59 1215 84958 98.35 0.35 93.06 2271 30448 94.01 5804 91171 93.54 0.67 94.42 970 16403 92.52 1145 14169 93.47 1.34
CRC_Monitoring_169 63 PD 21-Nov-13 2-Oct-13 342.8 2-Oct-13 Qiagen 306598 Prevalence TEMECT 0 48.34 48.34 73.65 5.37 1 X X X X X 73.65 44.54 72.02 46.12 5.37 X X X X X 19.80 79.94 4658 18562 67.36 7054 14560 73.65 8.90 36.9 2876 1679 52.18 3543 3866 44.54 10.80 71.63 1037 2618 72.41 1639 4302 72.02 0.55 42 2233 1617 50.23 2073 2092 46.12 5.82 6.34 8009 542 4.39 87822 4035 5.37 1.38
CRC_Monitoring_169 63 9-Oct-13 Qiagen 99536 longitudinal TEMECT 7 48.49 48.49 85.05 6.25 1 X X X X X 85.05 43.70 57.62 49.82 6.25 X X X X X 80.03 3083 12352 90.07 5914 53658 85.05 7.10 45.8 16651 14071 41.6 17036 12135 43.70 2.97 49.75 6805 6737 65.49 5639 10700 57.62 11.13 55.1 8196 10059 44.53 29248 23481 49.82 7.47 7.62 2618 216 4.88 18108 930 6.25 1.94
CRC_Monitoring_169 63 6-Nov-13 794.8 6-Nov-13 Qiagen 804444 longitudinal TEMECT 35 65.55 65.55 94.77 8.55 1 X X X X X 90.06 65.41 94.77 68.96 8.55 X X X X X 88.4 4879 37176 91.71 3757 41558 90.06 2.34 62.95 5362 9109 67.87 11437 24164 65.41 3.48 90.02 4113 37093 99.51 9 1814 94.77 6.71 70.99 4292 10503 66.93 17239 34897 68.96 2.87 10.93 1280 157 6.16 34987 2297 8.55 3.37
CRC_Monitoring_169 63 5-Dec-13 1144 5-Dec-13 Qiagen 1549740 longitudinal TEMECT 64 74.26 74.26 98.98 9.34 1 X X X X X 88.46 84.11 98.98 90.42 9.34 X X X X X 83.6 4057 20676 93.32 2568 35855 88.46 6.87 82.54 4245 20064 85.68 5414 32382 84.11 2.22 97.95 1307 62319 100 0 8966 98.98 1.45 91.17 1700 17549 89.67 6692 58079 90.42 1.06 10.35 8073 932 8.32 41411 3759 9.34 1.44
CRC_Monitoring_170 74 16-Dec-13 51.6 19-Dec-13 Qiagen 29333 Prevalence TEMECT 0 0.04 0.10 0.00 0 0.00 0.09 0.00 0.00 0.10 0.00 0 6942 0 0 7114 0 0.00 0.00 0.1 24273 13 0.07 5493 4 0.09 0.02 0 1042 0 0 3483 0 0.00 0.00 0 26986 1 0 31310 0 0.00 0.00 0.19 516 1 0 477 0 0.10 0.13
Median pvalue
Sex Female 35.60 0.029
Male 11.80




CEA (ng/ml) <=5 2.80 ns
>5 18.60
RECIST (mm) [9-49.25[ 3.15 ref.
(quartiles) [49.25-81.55[ 17.10 0.06
[81.55-117[ 18.10 ns
[117-250] 33.80 0.006
GE/ml [1110-19613[ 2.40 ref.
(quartiles) [19613-40107[ 10.10 ns
[40107-137394[ 34.20 <0.001
[137394-9259908] 69.95 <0.001
Primary tumor intact No 12.45 0.002
Yes 53.20
Metastatic lesions 1 5.50 0.023
2+ 22.45
Bulky disease No 11.85 0.012
Yes 39.00
RAS wild type 15.60 ns
mutated 17.80
BRAF wild type 15.70 ns
mutated 47.40
Under treatment No 18.35 ns
Yes 14.20
Association between clinico-pathological features and
circulating DNA methylation
Supplementary File 2H
Case_ID Collection_Date Days Average marker>1%in BL Mn-M0
Best_CH3_chan














CRC_Monitoring_142 28-Dec-12 0 34.5 0.0 4-Dec-12 -24 -24 141 0 164 2.80 1 42.9
CRC_Monitoring_142 9-Jan-13 12 19.7 -14.8 x 107.3 2.80 1 42.9
CRC_Monitoring_142 25-Jan-13 28 50.3 15.7 8-Feb-13 42 14 137 -2.8 X 197.4 2.80 1 42.9
CRC_Monitoring_142 20-Feb-13 54 47.6 13.0 150.4 2.80 1 42.9
CRC_Monitoring_142 1-Mar-13 63 38.0 3.4 22-Mar-13 84 21 152 y 7.8 209.4 2.80 1 42.9
CRC_Monitoring_143 25-Jan-13 0 51.4 0.0 23-Jan-13 -2 -2 117 n 44.5 2.77 1 44.3
CRC_Monitoring_143 14-Feb-13 20 3.8 -47.7 30.3 2.77 1 44.3
CRC_Monitoring_143 20-Feb-13 26 0.2 -51.3 x 32.5 2.77 1 44.3
CRC_Monitoring_143 4-Mar-13 38 5.8 -45.7 8-Mar-13 42 4 97 -17.1 X 48.5 2.77 1 44.3
CRC_Monitoring_143 27-Mar-13 61 54.2 2.8 92.1 2.77 1 44.3
CRC_Monitoring_143 23-Apr-13 88 68.0 16.6 19-Apr-13 84 -4 119 1.7 115.6 2.77 1 44.3
CRC_Monitoring_144 23-Aug-13 0 2.3 0.0 6-Aug-13 -17 -17 97 0 13.3 4.30 1 14.6
CRC_Monitoring_144 23-Oct-13 61 13.6 11.4 x 10-Oct-13 48 -13 95 -2.1 X 29.3 4.30 1 14.6
CRC_Monitoring_144 18-Dec-13 117 62.7 60.4 20-Nov-13 89 -28 102 5.2 22 4.30 1 14.6
CRC_Monitoring_144 27-Jan-14 157 72.7 70.4 3-Jan-14 133 -24 99 y 2.1 25.7 4.30 1 14.6
CRC_Monitoring_145 19-Dec-13 0 2.0 0.0 20-Dec-13 1 1 84 0 80 1.37 0 0.0
CRC_Monitoring_145 22-Jan-14 34 1.2 -0.7 x 3-Feb-14 46 12 100 y 19 X 117.9 1.37 0 0.0
CRC_Monitoring_146 5-Jul-13 0 15.6 0.0 10-Jul-13 5 5 126 n 147.6 2.77 1 0.0
CRC_Monitoring_146 8-Aug-13 34 40.5 24.9 x 21-Aug-13 47 13 146 15.9 X 238.1 2.77 1 0.0
CRC_Monitoring_146 5-Sep-13 62 52.1 36.6 309.1 2.77 1 0.0
CRC_Monitoring_146 12-Sep-13 69 84.0 68.4 334.5 2.77 1 0.0
CRC_Monitoring_146 10-Oct-13 97 61.7 46.1 3-Oct-13 90 -7 165 31 592.3 2.77 1 0.0
CRC_Monitoring_147 3-Sep-13 0 29.3 0.0 3-Aug-13 -31 -31 133 0 112.9 2.87 1 4.0
CRC_Monitoring_147 2-Oct-13 29 2.2 -27.2 x 15-Oct-13 42 13 127 -4.5 52.3 2.87 1 4.0
CRC_Monitoring_147 30-Oct-13 57 2.2 -27.1 29-Nov-13 87 30 105 y -21.1 X 16.6 2.87 1 4.0
CRC_Monitoring_148 21-Jan-13 0 77.8 0.0 21-Jan-13 0 0 135 n 3389 1.37 0 61.9
CRC_Monitoring_148 11-Feb-13 21 88.2 10.5 x 11-Mar-13 49 28 163 y 20.7 X 3440 1.37 0 61.9
CRC_Monitoring_149 14-Jan-13 0 12.8 0.0 21-Dec-12 -24 -24 167 n 1866 1.63 0 9.7
CRC_Monitoring_149 11-Feb-13 28 27.3 14.6 x 2148 1.63 0 9.7
CRC_Monitoring_149 8-Mar-13 53 49.3 36.6 6-Mar-13 51 -2 194 y 16.2 X 2446 1.63 0 9.7
CRC_Monitoring_151 6-May-13 0 72.7 0.0 6-May-13 0 0 53 0 11 1.30 0 69.3
CRC_Monitoring_151 7-Jun-13 32 84.5 11.8 x 21-Jun-13 46 14 92 73.6 X 21.6 1.30 0 69.3
CRC_Monitoring_151 5-Jul-13 60 88.9 16.2 52.7 1.30 0 69.3
CRC_Monitoring_152 14-Mar-13 0 37.4 0.0 11-Mar-13 -3 -3 34 n 19.2 2.77 1 0.0
CRC_Monitoring_152 26-Mar-13 12 13.3 -24.1 x 21.5 2.77 1 0.0
CRC_Monitoring_152 24-Apr-13 41 14.8 -22.6 8-May-13 55 14 34 0 X 40 2.77 1 0.0
CRC_Monitoring_152 22-May-13 69 40.2 2.9 18-May-13 65 -4 45 y 32.4 41.7 2.77 1 0.0
CRC_Monitoring_152 20-Jun-13 98 58.8 21.4 119.9 2.77 1 0.0
CRC_Monitoring_153 21-Mar-13 0 80.6 0.0 12-Mar-13 -9 -9 57 n 84.1 5.43 2 74.2
CRC_Monitoring_153 3-May-13 43 71.2 -9.3 3-May-13 43 0 40 -29.8 176.7 5.43 2 74.2
CRC_Monitoring_153 4-Jun-13 75 57.1 -23.5 x 4-Jun-13 75 0 40 -29.8 X 246.9 5.43 2 74.2
CRC_Monitoring_153 27-Jun-13 98 88.9 8.3 27-Jun-13 98 0 43 -24.6 449 5.43 2 74.2
CRC_Monitoring_153 4-Sep-13 167 87.0 6.4 4-Sep-13 167 0 69 21.1 1073 5.43 2 74.2
CRC_Monitoring_154 25-Jan-13 0 16.4 0.0 29-Jan-13 4 4 105 n 496.9 1.50 0 17.0
CRC_Monitoring_154 25-Feb-13 31 42.3 25.9 x 15-Mar-13 49 18 121 y 15.2 X 666.8 1.50 0 17.0
CRC_Monitoring_154 26-Mar-13 60 57.7 41.3 789.3 1.50 0 17.0
CRC_Monitoring_155 3-Apr-13 0 35.6 0.0 8-Apr-13 5 5 107 n 634.7 2.47 0 21.1
CRC_Monitoring_155 11-Apr-13 8 63.2 27.7 x 2.47 0 21.1
CRC_Monitoring_155 9-May-13 36 65.3 29.7 1629 2.47 0 21.1
CRC_Monitoring_156 10-Apr-13 0 0.8 0.0 12-Apr-13 2 2 29 n 68.4 1.43 0 0.0
CRC_Monitoring_156 30-Apr-13 20 1.8 1.0 x 80.6 1.43 0 0.0
CRC_Monitoring_156 28-May-13 48 16.7 15.9 104.7 1.43 0 0.0
CRC_Monitoring_156 2-Jul-13 83 38.7 37.9 12-Jun-13 63 -20 36 24.1 X 111.5 1.43 0 0.0
CRC_Monitoring_158 28-Feb-14 0 14.6 0.0 10-Feb-14 -18 -18 29 n 6.8 1.63 1 57.8
CRC_Monitoring_158 27-Mar-14 27 0.0 -14.6 x 8-Apr-14 39 12 26 -10.3 X 3.11 1.63 1 57.8
CRC_Monitoring_158 7-May-14 68 5.2 -9.4 2.85 1.63 1 57.8
CRC_Monitoring_158 21-May-14 82 0.8 -13.8 20-May-14 81 -1 32 10.3 11.2 1.63 1 57.8
CRC_Monitoring_158 25-Jun-14 117 0.0 -14.6 23 1.63 1 57.8
CRC_Monitoring_159 17-Dec-13 0 17.8 0.0 18-Dec-13 1 1 172 n 262.8 1.40 0 8.8
CRC_Monitoring_159 22-Jan-14 36 36.2 18.4 x 3-Feb-14 48 12 198 y 15.1 X 373 1.40 0 8.8
CRC_Monitoring_159 19-Feb-14 64 45.2 27.3 523.4 1.40 0 8.8
CRC_Monitoring_160 18-Feb-14 0 47.4 0.0 5-Feb-14 -13 -13 107 n 280 10.63 1 0.0
CRC_Monitoring_160 20-Mar-14 30 46.7 -0.7 x 370.9 10.63 1 0.0
CRC_Monitoring_160 17-Apr-14 58 55.6 8.2 4-Apr-14 45 -13 126 17.8 X 659.4 10.63 1 0.0
CRC_Monitoring_161 4-Mar-14 0 4.5 0.0 26-Feb-14 -6 -6 29 n 22 2.83 1 0.6
CRC_Monitoring_161 9-Apr-14 36 16.1 11.6 23-Apr-14 50 14 24 -17.2 X 37.4 2.83 1 0.6
CRC_Monitoring_161 7-May-14 64 13.4 8.9 x 30-May-14 87 23 31 y 6.9 47.6 2.83 1 0.6
CRC_Monitoring_162 30-May-13 0 10.0 0.0 2-May-13 -28 -28 79 n 7.6 1.40 0 27.8
CRC_Monitoring_162 28-Jun-13 29 28.1 18.1 x 18.8 1.40 0 27.8
CRC_Monitoring_162 26-Jul-13 57 28.0 18.0 12-Jul-13 43 -14 108 36.7 X 24.1 1.40 0 27.8
CRC_Monitoring_163 14-Feb-13 0 1.4 0.0 23-Jan-13 -22 -22 190 n 1.4 4.00 1 1.8
CRC_Monitoring_163 15-Mar-13 29 0.0 -1.4 x 2-Apr-13 47 18 194 2.1 X 1.2 4.00 1 1.8
CRC_Monitoring_164 18-Feb-13 0 68.3 0.0 20-Feb-13 2 2 142 n 517.2 2.80 1 69.7
CRC_Monitoring_164 26-Mar-13 36 0.2 -68.1 x 28-Mar-13 38 2 140 -1.4 X 972.2 2.80 1 69.7
CRC_Monitoring_164 22-Apr-13 63 55.6 -12.7 1104 2.80 1 69.7
CRC_Monitoring_164 22-May-13 93 76.3 8.0 17-May-13 88 -5 152 y 7 1412 2.80 1 69.7
CRC_Monitoring_165 14-May-14 0 74.0 0.0 14-May-14 0 0 147 274.2 1.30 0 25.3
CRC_Monitoring_165 11-Jun-14 28 56.9 -17.1 x 23-Jun-14 40 12 176 19.7 X 830.2 1.30 0 25.3
CRC_Monitoring_165 9-Jul-14 56 72.5 -1.5 n 2207 1.30 0 25.3
CRC_Monitoring_166 14-May-13 0 22.6 0.0 23-May-13 9 9 48 57.5 1.57 0 16.6
CRC_Monitoring_166 24-May-13 10 54.5 31.9 x 10-Jul-13 57 47 79 64.6 X 63.7 1.57 0 16.6
CRC_Monitoring_168 3-Mar-14 0 83.5 0.0 5-Feb-14 -26 -26 85 421.4 1.40 0 81.0
CRC_Monitoring_168 30-Apr-14 58 92.5 9.0 x 17-Apr-14 45 -13 117 y 37.6 X 1065 1.40 0 81.0
CRC_Monitoring_169 2-Oct-13 0 48.3 0.0 4-Oct-13 2 2 108 n 342.8 1.40 0 19.8
CRC_Monitoring_169 9-Oct-13 7 48.5 0.1 x 1.40 0 19.8
CRC_Monitoring_169 6-Nov-13 35 65.6 17.2 794.8 1.40 0 19.8
CRC_Monitoring_169 5-Dec-13 64 74.3 25.9 21-Nov-13 50 -14 135 y 25 X 1144 1.40 0 19.8
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Marker Discovery (From microarrays on tissue, new data and publically 
available dataset): 
Identification of markers: 
Cell bank (GSE86078; N=149) 
Normal Mucosa (GSE32146; N=20) 
Blood controls (GSE41169; N=34) 
In-silico Validation: 
Test set (GSE72752; N=63) 
Validation set (TCGA COREAD; N=446 / GSE48684; N=41) 
Tissue validation:  
Normal / matched cohort (N=32) 
Plasma matched cohort (N=51) 
 
cfDNA assessment: 
Prevalence assessment  
§ Aging cohort, self-declared healthy (N=50) 
§ mCRC cohort (N=135) 
§ Longitudinal cohort – baselines (N=47) 
Longitudinal assessment: 
§ Conventional chemotherapies (N=12) 
§ Targeted therapy (N=6) 
§ Clinical trial with temozolomide (N=29) 
 
All Cohorts and numbers are also reported in Figure 1. 
Assay carried out 
by core lab or 
investigator’s lab?  
All experiments were carried out in the investigator’s laboratory. All DNA 
extraction and subsequent molecular characterization were carried out at the 
Department of Oncology of the Univesity of Turin.” 
 
Sample Description 
Samples used Description and annotation of samples can be found in supplementary data 
1A for the microarray analyses and in supplementary data 1E for the tissue 
and cfDNA samples. 
Volume or mass of 
sample processed. 
Concerning the FFPE samples: 
§ the normal / tumor matched samples were macrodissected and a piece of 
FFPE block (~9mm3) was sent to the laboratory for extraction. 
§ the plasma matched tissues were remaining DNA samples extracted from 
two 10um slides (without tumour cellularity control) extracted using the QIA 
FFPE tissue kit (Qiagen). 
 
Concerning the cfDNA: One or two 6ml vacutainer tubes were collected 
from each timepoint of the CRC cohorts. Blood were processed within six 
hours as previously described (two steps centrifugation), and aliquoted into 
1ml cryovials which were stored at -80°C until DNA extraction. These 
samples being used for collaborative project one milliliter of plasma was 
available for the current study. 
Microdissection or 
macrodissection. 
the normal / tumor matched samples were macrodissected. 
While FFPE tissue DNA (plasma matched tumours) were obtained through a 
previous project in which only the tumor extension was controlled without 
further dissection. 
 Processing procedure 
If frozen—how 
and how quickly? 





Fixation was performed in Paraformaldehyde 4%.Since tissue samples were 
retrieved from multiple collection center across Italie, it was not possible to 




- FFPE block were from archival tissue bank and have been stored 
between at room temperature in darkness up to 13 years prior 
processing (average=6 years). Cut of the block was performed prior to 
DNA extraction. 
- Plasma samples were kept at -80°C prior to extraction up to 8 years 
(average = 4 years). 
Nucleic acid extraction 
Quantification—
instrument/method. 
- FFPE tissue DNA were quantified using Nanodrop system. 
-  Circulating DNA were quantified by genome equivalent evaluated by 
qPCR using the LINE1 assay previously described in Siravegna et al. 









DNA were from FFPE tissue origin or from cell free circulating DNA. DNA 
were stored without further modifications prior to their bisulfite conversion 







Template were bisulfite converted as mentioned in material and methods 
using the EZ methylation Gold kit from Zymo Research according to 
manufacturers’ procedure except for the elution step which was carried out in 
twice 20ul for cfDNA and in twice 40ul for tissue DNA. 
Manufacturer of 
reagents used and 
catalogue number 
- Qiagen - QIAamp DNA FFPE Tissue Kit - Cat No./ID: 56404 
- Qiagen - QIAamp Circulating Nucleic Acid Kit - Cat No./ID: 55114 
- Promega - Maxwell® RSC ccfDNA Plasma Kit - Cat No./ID:AS1480 
- Zymo Research - EZ DNA Methylation-Gold™ Kit - Cat No./ID: 
D5006  
Reaction volume - Bisulfite conversion was carried out as follow: 
§FFPE DNA :  input : 250ng  output: 2x40ul 
§cfDNA :  input: 20ul output: 2x20ul 
 
- 1st PCR amplification: 
FFPE and cfDNA :  input : 2ul of bisulfite converted DNA per reaction
 final volume: 20ul 
 
- 2nd amplification (EmPCR): 
FFPE :   Input : 3.5ul of 1st amplification (diluted at 1/20000)  final 
volume: 20ul (+70ul oil) 
cfDNA :  Input : 3.5ul of 1st amplification (diluted at 1/6000)  final 
volume: 20ul (+70ul oil) 
  
dPCR target information 











PCR product(s) on the bisulfite transformed sense chain 
      Forward primer: GTGGATAGGATGGAAGTTT 
      Reverse primer: CCCCCCCCACCTCCCTAC 
 
 
No PCR product should be generated. 
PCR product(s) on the bisulfite transformed antisense chain 
      Forward primer: GTGGATAGGATGGAAGTTT 
      Reverse primer: CCCCCCCCACCTCCCTAC 
1. Chromosome 6 (len: 96) 
 133241282                                                   CCCAC 
            CCCACCTCCC TACACAAATA CAAAACTACC AACAACACAA CACACACTCC 




PCR product(s) on the bisulfite transformed sense chain 
      Forward primer: GGGTTGGTGTAGGTTTGTT 
      Reverse primer: CTCCCCCCTTACTTTCTCACATACACACAA 
1. Chromosome 11 (len: 106) 
 105610527                     GG GTTGGTGTAG GTTTGTTGGG GGATGTTGGT 
            TGATGTGAGT TGGAGAGTGT GTGTGGTGGT TGTGGTGTTA GTGTTTGTGT 
            GTATGTGAGA AAGTAAGGGG TGAG                              
105610633 
PCR product(s) on the bisulfite transformed antisense chain 
      Forward primer: GGGTTGGTGTAGGTTTGTT 
      Reverse primer: CTCCCCCCTTACTTTCTCACATACACACAA 
No PCR product should be generated. 
 
- ITGA4: 
PCR product(s) on the bisulfite transformed sense chain 
      Forward primer: GGGGAAGAAAGTTTTAAGAGATGAG 
      Reverse primer: TCCTCTTCCCTCTCTCCT 
No PCR product should be generated. 
PCR product(s) on the bisulfite transformed antisense chain 
      Forward primer: GGGGAAGAAAGTTTTAAGAGATGAG 
      Reverse primer: TCCTCTTCCCTCTCTCCT 
1. Chromosome 2 (len: 76) 
 181457503           T CCTCTTCCCT CTCTCCTTCC TTTAACCCAC TAACACCAAA 




PCR product(s) on the bisulfite transformed sense chain 
      Forward primer: GGATTGGTGGGAGTTGGAAATATTAGA 
      Reverse primer: ACCTAAATACCACTCCCTACCTATAAAAT 
1. Chromosome 17 (len: 103) 
  45262097      GGATTG GTGGGTGTTG GAAATATTAG AGGTGTTGGT GTTTGTGATG 
            TTGTTGTTTT TGTGATGTTT TTGTTGTGAT TTTATAGGTA GGGAGTTGTA 
            TTTAGGT                                                 
45262200 
PCR product(s) on the bisulfite transformed antisense chain 
      Forward primer: GGATTGGTGGGAGTTGGAAATATTAGA 
      Reverse primer: ACCTAAATACCACTCCCTACCTATAAAAT 
No PCR product should be generated. 
- MSC: 
PCR product(s) on the bisulfite transformed sense chain 
      Forward primer: AGGGTTTAGTAGTAGAGTGTAAGT 
      Reverse primer: AAACACCCAAAACAAACTAATCT 
No PCR product should be generated. 
PCR product(s) on the bisulfite transformed antisense chain 
      Forward primer: AGGGTTTAGTAGTAGAGTGTAAGT 
      Reverse primer: AAACACCCAAAACAAACTAATCT 
1. Chromosome 8 (len: 122) 
  71843764                                          AAA CACCCAAAAC 
            AAACTAATCT TAAACCTAAA AAAAACTTTA CTCAACACAC ACATCCAAAC 
            ACACTCACAA ACATTAACCA CATTCCACTA CAACTACTTA CACTCTACAA 











- EYA4 amplicon: 
SEQUENCE 5'- CCC ACC TCC CTA CAC AAA TAC AAA ACT ACC AAC AAC ACA ACA 
CAC ACT CCA ACC ATT CCC AAC TTC CAC ACA AAA CTT CCA TCC TAT CCA C -3' 
COMPLEMENT 5'- GTG GAT AGG ATG GAA GTT TTG TGT GGA AGT TGG GAA TGG 
TTG GAG TGT GTG TTG TGT TGT TGG TAG TTT TGT ATT TGT GTA GGG AGG TGG G 
-3' 
LENGTH 91 
GC CONTENT 45.1 % 
MELT TEMP 71 ºC 
MOLECULAR WEIGHT 27328.8 g/mole 




- GRIA4 amplicon: 
SEQUENCE 5'- GGG TTG GTG TAG GTT TGT TGG GGG ATG TTG GTT GAT GTG AGT 
TGG AGA GTG TGT GTG GTG GTT GTG GTG TTA GTG TTT GTG TGT ATG TGA GAA 
AGT AAG GGG TGA G -3' 
COMPLEMENT 5'- CTC ACC CCT TAC TTT CTC ACA TAC ACA CAA ACA CTA ACA 
CCA CAA CCA CCA CAC ACA CTC TCC AAC TCA CAT CAA CCA ACA TCC CCC AAC 
AAA CCT ACA CCA ACC C -3' 
LENGTH 106 
GC CONTENT 48.1 % 
MELT TEMP 71.9 ºC 
MOLECULAR WEIGHT 33593.6 g/mole 




- ITGA4 amplicon: 
SEQUENCE 5'- TCC TCT TCC CTC TCT CCT TCC TTT AAC CCA CTA ACA CCA AAC 
ACA CTA CAC CTC ATC TCT TAA AAC ATT CTT CCC C -3' 
COMPLEMENT 5'- GGG GAA GAA TGT TTT AAG AGA TGA GGT GTA GTG TGT TTG 
GTG TTA GTG GGT TAA AGG AAG GAG AGA GGG AAG AGG A -3' 
LENGTH 76 
GC CONTENT 44.7 % 
MELT TEMP 69.8 ºC 
MOLECULAR WEIGHT 22717.8 g/mole 
EXTINCTION COEFFICIENT 669200 L/(mole·cm) 
nmole/OD260: 1.49 
µg/OD260: 33.95 
- MAP3K14-AS1 amplicon: 
SEQUENCE 5'- GGA TTG GTG GGT GTT GGA AAT ATT AGA GGT GTT GGT GTT TGT 
GAT GTT GTT GTT TTT GTG ATG TTT TTG TTG TGA TTT TAT AGG TAG GGA GTT 
GTA TTT AGG T -3' 
COMPLEMENT 5'- ACC TAA ATA CAA CTC CCT ACC TAT AAA ATC ACA ACA AAA 
ACA TCA CAA AAA CAA CAA CAT CAC AAA CAC CAA CAC CTC TAA TAT TTC CAA 
CAC CCA CCA ATC C -3' 
LENGTH 103 
GC CONTENT 35.9 % 
MELT TEMP 70 ºC 
MOLECULAR WEIGHT 32339.9 g/mole 




- MSC amplicon: 
SEQUENCE 5'- AAA CAC CCA AAA CAA ACT AAT CTT AAA CCT AAA AAA AAC TTT 
ACT CAA CAC ACA CAT CCA AAC ACA CTC ACA AAC ATT AAC CAC ATT CCA CTA 
CAA CTA CTT ACA CTC TAC AAC TAA ACC CT -3' 
COMPLEMENT 5'- AGG GTT TAG TTG TAG AGT GTA AGT AGT TGT AGT GGA ATG 
TGG TTA ATG TTT GTG AGT GTG TTT GGA TGT GTG TGT TGA GTA AAG TTT TTT 
TTA GGT TTA AGA TTA GTT TGT TTT GGG TGT TT -3' 
LENGTH 122 
GC CONTENT 33.6 % 
MELT TEMP 70.6 ºC 
MOLECULAR WEIGHT 36957.2 g/mole 

















































All primers and probes were ordered through IDT. 
Purification 
method 
Primers were ordered desalted while probes were purified with HLPC and 
modified with fluorescent dye at 5’ (/5Alex647N/ for methylated probe ; 





- Mg concentrations: 
- C9orf50:   1.5mM 
- EYA4:    2 mM 
- GRIA4:   1.5 mM 
- ITGA4:   2.5 mM 
- MAP3K14-AS1:  2.5 mM 
- MSC:   1.5 mM 
- SEPT9:   1 mM 
- Tm: 
- C9orf50:   50°C 
- EYA4:    54°C 
- GRIA4:   62°C 
- ITGA4:   50°C 
- MAP3K14-AS1:  50°C 
- MSC:   58°C 
- SEPT9:   56°C 
Plates/tubes 
Catalogue No and 
manufacturer 
-1 1st amplification: 8-tube strips for qPCR with individually attached, optically 
clear, flat caps (VWR – Cat No: 211-0338) 





- 1st amplification: 
94°C 2 min 
----- ϴ ---- 
94°C 30 sec 
Tm 15 sec  Tm:see above 
72°C 15 sec 
-- go to ϴ -- x39 
72°C 5 min 
- EmPCR amplification: 
94.0 2 min 
-----  ---- 
94.0 10 sec 
68.0 50 sec 
70.0 80 sec 
-- go to  -- x3 
-----  ---- 
94.0 10 sec 
65.0 50 sec 
70.0 80 sec 
-- go to  -- x3 
-----  ---- 
94.0 10 sec 
62.0 50 sec 
70.0 80 sec 
-- go to  -- x3 
-----  ---- 
94.0 10 sec 
59.0 50 sec 
70.0 80 sec 
-- go to  -- x50 
70.0 2 min 
Reaction setup Buffer, Magnesium and Taq are from Platinum® Taq DNA Polymerase (ref. 
Thermo Fisher 10966018) 
dNTP are from dNTP Set (100 mM) (ref. Thermo Fisher 10297018) 
 
- 1st amplification: 
Buffer:  1X 
Mg:   See above 
dNTP:  300nM 
primers:  200nM 
Taq:   0.75 unit 
Template :  2 ul (variable concentration) 
H2O:   qsp 20 ul 
 
- EmPCR (Ref: Diehl 2006, Nat methods): 
Buffer:  1X 
Mg:   5 mM 
dNTPs: 200uM  
Tag 2:  8 uM 
Tag1:   50 nM 
Beads:  6.107 
Taq Platinum: 2 units 
DNA:  ~25 pg 





Amplification performed on a Bio-rad C1000 thermocycler. 
Reading was performed on a BD – Accuri C6 flow cytometer. 
Optimization data 
for the assay 
E Y A 4
























Equation Y = 0.9924*X - 1.972
R square 0.9934
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Equation Y = 0.9565*X - 1.775
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Equation Y = 1.033*X - 0.1825
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Equation Y = 1.014*X - 0.03156
 M S C
























Equation Y = 1.023*X + 0.3947
R square 0.9985
 
Limit of detection 
of calibration 
control. 
The Limit of detection using calibration control (artificial DNA) was down to: 
§ EYA4: 0.18% 
§ GRIA4: 0.18% 
§ ITGA4: 0.09% 
§ MAP3K14-AS1: 0.18% 
§ MSC: 0.09% 
Mean copies per 
partition 
The average number of events over all tissue samples assessed were: 
- EYA4: 9767 events  
- GRIA4: 5995 events \ 
- ITGA4: 4603 events  
- MAP3K14-AS1: 9308 events 
- MSC: 7846 events 
 
The average number of events over all cfDNA samples assessed were: 
- EYA4: 18939 events  
- GRIA4: 11401 events \ 
- ITGA4: 3677 events  
- MAP3K14-AS1: 15963 events 
- MSC: 16584 events 
In the prevalence dataset only comparing normal self-declared healthy samples 
(H) from cancer samples (C): 
- EYA4: H= 8560 events – C= 20594 
- GRIA4: H= 4464 events – C= 12562 
- ITGA4: H= 2590 events – C= 3855 
- MAP3K14-AS1: H= 4715 events – C= 17798 








Non amplified samples were amplified a 3rd time and in case of failure were 
annotated as NA. 
Replicates with more than 20% variation in cfDNA were re-amplified.  
Results of no-
template controls 
No-template control had to show less than 100 cumulated events (Methylated 






For each graph: R5 Unmethylated events; R4 Methylated Events; R6 Empty 
Beads. 
- Fully methylated sample: 
 - Intermediate methylation: (37.1%) 
 




Percentage of methylation was calculated on the number of events obtained in 
the methylated gate (R4) / number of cumulated events (events in methylated 








Replication was performed at the 1st amplification stage. 
i.e. 1 plasma / tissue sample  1 DNA  1 BisDNA  2 1st PCR /assay  
 2 EmPCR /assay  2 well in FACs. 





average standard deviation [± SD] on all assessed samples: 
- In tissue DNA: 
§ EYA4: 4.36 % [± 2.84] 
§ GRIA4: 3.72 % [± 3.08] 
§ ITGA4: 2.97 % [± 2.47] 
§ MAP3K14-AS1: 3.24 % [± 3.14] 
§ MSC: 5.61 [± 4.67] 
- In cfDNA: 
§ EYA4: 3.29 % [± 4.24] 
§ GRIA4: 4.07 % [± 4.78] 
§ ITGA4: 3.72 % [± 4.70] 
§ MAP3K14-AS1: 3.05 % [± 4.19] 
§ MSC: 2.90 % [± 4.26] 
Limit of blank 
E Y A 4





















P o is s o n -fitte d
F a lse  p o s itive
G R IA 4






















P o is s o n -fitte d
F a lse  p o s itive
IT G A 4





















F a lse  p o s itive
P o is s o n -fitte d
M A P K 3 1 4 -A S 1




















F a lse  p o s itive
P o is s o n -fitte d
M S C






















P o is s o n -fitte d
F a lse  p o s itive
 
The limit of blank was calculated using the negative template samples which 
displayed some output and on five ultramer samples corresponding to the fully 
unmethylated template. Since the distribution of the false events does not always 
follow a Poisson distribution, an empirical estimate for the 95% upper 
confidence limit of the data was estimated (as applied in Taly et al. Clin Chem 
2013): 





EYA4 28 3.6 5 6 
GRIA4 30 1.7 3 3 
ITGA4 27 1.5 2 3 
MAP3K14-AS1 29 1.9 3 3 
MSC 30 2.4 3 4 
 
 
Suplementary File 4A 
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TCGA COREAD - Data
Stratification based on threshold
 PPV=1 (9 / 17 loci)
 NPV > 0.5 (6 / 9 loci)
Methylation independent assay design
5 genes














«Liquid biopsy» assessable regions




gene seqnames start end threshold NPV PPV
DAB1 chr1 58715539 58715553 0.42 0.500 0.997
SPAG6 chr10 22634432 22634439 0.31 0.495 1.000
KIAA1217 chr10 23983496 23983498 0.15 0.683 0.990
TLX1 chr10 102893980 102894120 0.38 0.600 1.000
INA chr10 105036701 105036727 0.40 0.425 1.000
NELL1-A chr11 20690720 20690807 0.27 0.829 0.974
NELL1-B chr11 20691126 20691161 0.40 0.672 0.990
MIR129-2 chr11 43602845 43602879 0.36 0.592 1.000
GRIA4 chr11 105481317 105481322 0.26 0.714 1.000
DDX25 chr11 125774082 125774092 0.51 0.402 0.973
TM6SF1 chr15 83776269 83776420 0.27 0.543 0.997
BNC1 chr15 83952345 83952420 0.35 0.632 0.995
SALL1 chr16 51185001 51185082 0.38 0.542 1.000
C17orf46* chr17 43339223 43339328 0.26 0.584 1.000
LOC100133991* chr17 43339497 43339589 0.21 0.549 1.000
CLIP4-A chr2 29338077 29338121 0.50 0.735 0.978
CLIP4-B chr2 29338113 29338258 0.52 0.706 0.978
OTX1-A chr2 63281069 63281139 0.20 0.409 1.000
OTX1-B chr2 63283967 63284066 0.11 0.405 1.000
OTX1-C chr2 63284066 63284132 0.13 0.415 0.997
CNRIP1 chr2 68546467 68546579 0.31 0.732 0.990
ITGA4 chr2 182322268 182322279 0.28 0.833 1.000
THBD chr20 23029287 23029298 0.49 0.433 1.000
SLC32A1 chr20 37353096 37353126 0.45 0.423 0.997
TRH chr3 129693489 129693586 0.42 0.657 0.997
PEX5L chr3 179754603 179754613 0.41 0.412 0.992
TMEM155 chr4 122686453 122686493 0.40 0.579 0.997
MARCH11 chr5 16180033 16180076 0.47 0.254 1.000
SPOCK1 chr5 136834464 136834492 0.45 0.463 0.997
UBD chr6 29521751 29521756 0.41 0.662 1.000
EYA4 chr6 133562461 133562492 0.23 0.714 1.000
SND1-A chr7 127672473 127672564 0.30 0.977 0.995
SND1-B chr7 127672564 127672658 0.34 0.977 0.995
FAM115A chr7 143579665 143579698 0.53 0.652 1.000
NEFM chr8 24772350 24772435 0.37 0.258 0.983
PLAG1 chr8 57069907 57070013 0.36 0.652 0.995
ADHFE1 chr8 67344665 67344720 0.46 0.714 1.000
TCF24 chr8 67874178 67874206 0.17 0.484 0.997
MSC chr8 72756058 72756155 0.35 0.662 1.000






TCGA COREAD - Data
Stratification based on threshold
 PPV=1 (10 / 15 loci)












Within a region §
N=73
«Liquid biopsy» assessable regions




seqnames start end threshold NPV PPV
SPAG6 chr10 22634432 22634439 0.312 0.495 1.000
KIAA1217 chr10 23983496 23983498 0.148 0.683 0.990
GRIA4 chr11 105481317 105481322 0.258 0.714 1.000
C17orf46* chr17 43339223 43339328 0.262 0.584 1.000
LOC100133991* chr17 43339497 43339589 0.208 0.549 1.000
OTX1-A chr2 63283967 63284066 0.114 0.405 1.000
OTX1-B chr2 63284066 63284132 0.126 0.415 0.997
NXPH2 chr2 139537824 139537845 0.382 0.662 1.000
ITGA4 chr2 182322268 182322279 0.275 0.833 1.000
COL25A1 chr4 110223795 110223830 0.240 0.600 1.000
MARCH11 chr5 16180033 16180055 0.304 0.409 1.000
UBD-A chr6 29521138 29521143 0.360 0.563 1.000
UBD-B chr6 29521568 29521595 0.282 0.672 1.000
EYA4 chr6 133562479 133562492 0.199 0.738 1.000
SND1-A chr7 127672169 127672235 0.095 0.657 0.997
SND1-B chr7 127672473 127672564 0.304 0.977 0.995
ADHFE1 chr8 67344665 67344720 0.461 0.714 1.000
TCF24 chr8 67874178 67874206 0.169 0.484 0.997
* same gene locus MAP3K14-AS1
§ Loss of MSC region due to presence of
only one significant DMP
Supplementary File 5B
Supplementary File 6A 
 
Region Assessed: Hg19: chr17: 75369484-75369657 
Overlapping Probes: cg20275528; cg12783819 
Exclusion criteria: DMP too far away >150bp. 
  
ROC Analysis based on GSE42752: 
 
Supplementary File 6B  
 
Region Assessed: Hg19:chr12:65514979-65515037 (assessed by Roperch et al. BMC Cancer 2013) 
Overlapping Probes: cg03509412; cg19427610; cg26733786. 
Exclusion criteria: differential methylation value below the 0.8 beta-value threshold; threshold established in GSE42752 above the 
0.35 cut-off. 
  
ROC Analysis based on GSE42752: 
 
Supplementary File 6C  
  
Region Assessed: Hg19:chr7:24323761-24323856 (assessed by Roperch et al. BMC Cancer 2013) 
Overlapping Probes: cg24885417; cg00355281; cg15929698; cg16964348; cg25884711. 
Exclusion criteria: positivity in blood (GSE41169) and multiple positive normal healthy and normal peritumoural tissue samples 
(yielding a specificity <1 in the validation cohort). 
ROC Analysis based on GSE42752: 
 
Supplementary File 7
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Supplementary File 11
